id	sid	tid	token	lemma	pos
fnp-5892	1	1	adult	adult	NOUN
fnp-5892	1	2	glioblastoma	glioblastoma	NOUN
fnp-5892	1	3	with	with	ADP
fnp-5892	1	4	lynch	lynch	PROPN
fnp-5892	1	5	syndrome	syndrome	PROPN
fnp-5892	1	6	-	-	PUNCT
fnp-5892	1	7	associated	associate	VERB
fnp-5892	1	8	mismatch	mismatch	NOUN
fnp-5892	1	9	repair	repair	NOUN
fnp-5892	1	10	deficiency	deficiency	NOUN
fnp-5892	1	11	forms	form	VERB
fnp-5892	1	12	a	a	DET
fnp-5892	1	13	distinct	distinct	ADJ
fnp-5892	1	14	high	high	ADJ
fnp-5892	1	15	-	-	PUNCT
fnp-5892	1	16	risk	risk	NOUN
fnp-5892	1	17	molecular	molecular	ADJ
fnp-5892	1	18	subgroup	subgroup	NOUN
fnp-5892	1	19	feel	feel	VERB
fnp-5892	1	20	free	free	ADJ
fnp-5892	1	21	to	to	PART
fnp-5892	1	22	add	add	VERB
fnp-5892	1	23	comments	comment	NOUN
fnp-5892	1	24	by	by	ADP
fnp-5892	1	25	clicking	click	VERB
fnp-5892	1	26	these	these	DET
fnp-5892	1	27	icons	icon	NOUN
fnp-5892	1	28	on	on	ADP
fnp-5892	1	29	the	the	DET
fnp-5892	1	30	sidebar	sidebar	NOUN
fnp-5892	1	31	free	free	ADJ
fnp-5892	1	32	neuropathology	neuropathology	PROPN
fnp-5892	1	33	5:32	5:32	PROPN
fnp-5892	1	34	(	(	PUNCT
fnp-5892	1	35	2024	2024	NUM
fnp-5892	1	36	)	)	PUNCT
fnp-5892	1	37	original	original	ADJ
fnp-5892	1	38	paper	paper	NOUN
fnp-5892	1	39	adult	adult	NOUN
fnp-5892	1	40	glioblastoma	glioblastoma	NOUN
fnp-5892	1	41	with	with	ADP
fnp-5892	1	42	lynch	lynch	PROPN
fnp-5892	1	43	syndrome	syndrome	PROPN
fnp-5892	1	44	-	-	PUNCT
fnp-5892	1	45	associated	associate	VERB
fnp-5892	1	46	mismatch	mismatch	NOUN
fnp-5892	1	47	repair	repair	NOUN
fnp-5892	1	48	deficiency	deficiency	NOUN
fnp-5892	1	49	forms	form	VERB
fnp-5892	1	50	a	a	DET
fnp-5892	1	51	distinct	distinct	ADJ
fnp-5892	1	52	high	high	ADJ
fnp-5892	1	53	-	-	PUNCT
fnp-5892	1	54	risk	risk	NOUN
fnp-5892	1	55	molecular	molecular	ADJ
fnp-5892	1	56	subgroup	subgroup	NOUN
fnp-5892	1	57	maria	maria	PROPN
fnp-5892	1	58	-	-	PUNCT
fnp-5892	1	59	magdalena	magdalena	PROPN
fnp-5892	1	60	georgescu	georgescu	PROPN
fnp-5892	1	61	neuromarkers	neuromarkers	PROPN
fnp-5892	1	62	,	,	PUNCT
fnp-5892	1	63	houston	houston	PROPN
fnp-5892	1	64	,	,	PUNCT
fnp-5892	1	65	texas	texas	PROPN
fnp-5892	1	66	,	,	PUNCT
fnp-5892	1	67	usa	usa	PROPN
fnp-5892	1	68	corresponding	corresponding	PROPN
fnp-5892	1	69	author	author	NOUN
fnp-5892	1	70	:	:	PUNCT
fnp-5892	1	71	maria	maria	PROPN
fnp-5892	1	72	-	-	PUNCT
fnp-5892	1	73	magdalena	magdalena	PROPN
fnp-5892	1	74	georgescu	georgescu	PROPN
fnp-5892	1	75	·	·	PUNCT
fnp-5892	1	76	neuromarkers	neuromarker	NOUN
fnp-5892	1	77	·	·	PUNCT
fnp-5892	1	78	6907	6907	NUM
fnp-5892	1	79	academy	academy	PROPN
fnp-5892	1	80	street	street	PROPN
fnp-5892	1	81	,	,	PUNCT
fnp-5892	1	82	77025	77025	NUM
fnp-5892	1	83	·	·	PUNCT
fnp-5892	2	1	houston	houston	PROPN
fnp-5892	2	2	·	·	PUNCT
fnp-5892	2	3	texas	texas	PROPN
fnp-5892	2	4	·	·	PUNCT
fnp-5892	2	5	usa	usa	PROPN
fnp-5892	2	6	mmgeorgescu@yahoo.com	mmgeorgescu@yahoo.com	PROPN
fnp-5892	2	7	additional	additional	ADJ
fnp-5892	2	8	resources	resource	NOUN
fnp-5892	2	9	and	and	CCONJ
fnp-5892	2	10	electronic	electronic	ADJ
fnp-5892	2	11	supplementary	supplementary	ADJ
fnp-5892	2	12	material	material	NOUN
fnp-5892	2	13	:	:	PUNCT
fnp-5892	2	14	supplementary	supplementary	ADJ
fnp-5892	2	15	material	material	NOUN
fnp-5892	2	16	submitted	submit	VERB
fnp-5892	2	17	:	:	PUNCT
fnp-5892	2	18	17	17	NUM
fnp-5892	2	19	september	september	PROPN
fnp-5892	2	20	2024	2024	NUM
fnp-5892	2	21	accepted	accept	VERB
fnp-5892	2	22	:	:	PUNCT
fnp-5892	2	23	17	17	NUM
fnp-5892	2	24	november	november	PROPN
fnp-5892	2	25	2024	2024	NUM
fnp-5892	2	26	copyedited	copyedit	VERB
fnp-5892	2	27	by	by	ADP
fnp-5892	2	28	:	:	PUNCT
fnp-5892	2	29	joão	joão	PROPN
fnp-5892	2	30	gama	gama	PROPN
fnp-5892	2	31	published	publish	VERB
fnp-5892	2	32	:	:	PUNCT
fnp-5892	2	33	10	10	NUM
fnp-5892	2	34	december	december	PROPN
fnp-5892	2	35	2024	2024	NUM
fnp-5892	2	36	https://doi.org/10.17879/freeneuropathology-2024-5892	https://doi.org/10.17879/freeneuropathology-2024-5892	NOUN
fnp-5892	2	37	keywords	keyword	NOUN
fnp-5892	2	38	:	:	PUNCT
fnp-5892	2	39	glioblastoma	glioblastoma	NOUN
fnp-5892	2	40	,	,	PUNCT
fnp-5892	2	41	mmr	mmr	NOUN
fnp-5892	2	42	deficiency	deficiency	NOUN
fnp-5892	2	43	,	,	PUNCT
fnp-5892	2	44	lynch	lynch	PROPN
fnp-5892	2	45	syndrome	syndrome	PROPN
fnp-5892	2	46	,	,	PUNCT
fnp-5892	2	47	tp53	tp53	PROPN
fnp-5892	2	48	,	,	PUNCT
fnp-5892	2	49	pik3ca	pik3ca	PROPN
fnp-5892	2	50	,	,	PUNCT
fnp-5892	2	51	chromatin	chromatin	NOUN
fnp-5892	2	52	remodeling	remodeling	NOUN
fnp-5892	2	53	genes	gene	NOUN
fnp-5892	2	54	,	,	PUNCT
fnp-5892	2	55	multinucleated	multinucleate	VERB
fnp-5892	2	56	giant	giant	ADJ
fnp-5892	2	57	cells	cell	NOUN
fnp-5892	2	58	,	,	PUNCT
fnp-5892	2	59	p53	p53	NOUN
fnp-5892	2	60	immuno	immuno	NOUN
fnp-5892	2	61	-	-	PUNCT
fnp-5892	2	62	histochemistry	histochemistry	NOUN
fnp-5892	2	63	,	,	PUNCT
fnp-5892	2	64	immune	immune	ADJ
fnp-5892	2	65	checkpoint	checkpoint	NOUN
fnp-5892	2	66	inhibitors	inhibitor	NOUN
fnp-5892	2	67	,	,	PUNCT
fnp-5892	2	68	ipilimumab	ipilimumab	ADV
fnp-5892	2	69	,	,	PUNCT
fnp-5892	2	70	nivolumab	nivolumab	ADP
fnp-5892	2	71	abstract	abstract	ADJ
fnp-5892	2	72	glioblastoma	glioblastoma	NOUN
fnp-5892	2	73	is	be	AUX
fnp-5892	2	74	the	the	DET
fnp-5892	2	75	most	most	ADV
fnp-5892	2	76	frequent	frequent	ADJ
fnp-5892	2	77	and	and	CCONJ
fnp-5892	2	78	malignant	malignant	ADJ
fnp-5892	2	79	primary	primary	ADJ
fnp-5892	2	80	brain	brain	NOUN
fnp-5892	2	81	tumor	tumor	NOUN
fnp-5892	2	82	.	.	PUNCT
fnp-5892	3	1	although	although	SCONJ
fnp-5892	3	2	the	the	DET
fnp-5892	3	3	survival	survival	NOUN
fnp-5892	3	4	is	be	AUX
fnp-5892	3	5	generally	generally	ADV
fnp-5892	3	6	dismal	dismal	ADJ
fnp-5892	3	7	for	for	ADP
fnp-5892	3	8	glioblastoma	glioblastoma	NOUN
fnp-5892	3	9	patients	patient	NOUN
fnp-5892	3	10	,	,	PUNCT
fnp-5892	3	11	risk	risk	NOUN
fnp-5892	3	12	stratification	stratification	NOUN
fnp-5892	3	13	and	and	CCONJ
fnp-5892	3	14	the	the	DET
fnp-5892	3	15	identification	identification	NOUN
fnp-5892	3	16	of	of	ADP
fnp-5892	3	17	high	high	ADJ
fnp-5892	3	18	-	-	PUNCT
fnp-5892	3	19	risk	risk	NOUN
fnp-5892	3	20	subgroups	subgroup	NOUN
fnp-5892	3	21	is	be	AUX
fnp-5892	3	22	important	important	ADJ
fnp-5892	3	23	for	for	ADP
fnp-5892	3	24	prompt	prompt	ADJ
fnp-5892	3	25	and	and	CCONJ
fnp-5892	3	26	aggressive	aggressive	ADJ
fnp-5892	3	27	management	management	NOUN
fnp-5892	3	28	.	.	PUNCT
fnp-5892	4	1	the	the	DET
fnp-5892	4	2	g1	g1	NOUN
fnp-5892	4	3	–	–	PUNCT
fnp-5892	4	4	g7	g7	PROPN
fnp-5892	4	5	molecular	molecular	ADJ
fnp-5892	4	6	subgroup	subgroup	NOUN
fnp-5892	4	7	classification	classification	NOUN
fnp-5892	4	8	based	base	VERB
fnp-5892	4	9	on	on	ADP
fnp-5892	4	10	the	the	DET
fnp-5892	4	11	mapk	mapk	NOUN
fnp-5892	4	12	pathway	pathway	NOUN
fnp-5892	4	13	activation	activation	NOUN
fnp-5892	4	14	has	have	AUX
fnp-5892	4	15	offered	offer	VERB
fnp-5892	4	16	for	for	ADP
fnp-5892	4	17	the	the	DET
fnp-5892	4	18	first	first	ADJ
fnp-5892	4	19	time	time	NOUN
fnp-5892	4	20	a	a	DET
fnp-5892	4	21	non	non	ADJ
fnp-5892	4	22	-	-	ADJ
fnp-5892	4	23	redundant	redundant	ADJ
fnp-5892	4	24	,	,	PUNCT
fnp-5892	4	25	all	all	PRON
fnp-5892	4	26	-	-	PUNCT
fnp-5892	4	27	inclusive	inclusive	ADJ
fnp-5892	4	28	classification	classification	NOUN
fnp-5892	4	29	of	of	ADP
fnp-5892	4	30	adult	adult	NOUN
fnp-5892	4	31	glioblastoma	glioblastoma	NOUN
fnp-5892	4	32	.	.	PUNCT
fnp-5892	5	1	five	five	NUM
fnp-5892	5	2	patients	patient	NOUN
fnp-5892	5	3	from	from	ADP
fnp-5892	5	4	the	the	DET
fnp-5892	5	5	large	large	ADJ
fnp-5892	5	6	,	,	PUNCT
fnp-5892	5	7	218	218	NUM
fnp-5892	5	8	-	-	PUNCT
fnp-5892	5	9	patient	patient	NOUN
fnp-5892	5	10	,	,	PUNCT
fnp-5892	5	11	prospective	prospective	ADJ
fnp-5892	5	12	cohort	cohort	NOUN
fnp-5892	5	13	showed	show	VERB
fnp-5892	5	14	germline	germline	NOUN
fnp-5892	5	15	mutations	mutation	NOUN
fnp-5892	5	16	in	in	ADP
fnp-5892	5	17	mismatch	mismatch	ADJ
fnp-5892	5	18	repair	repair	NOUN
fnp-5892	5	19	(	(	PUNCT
fnp-5892	5	20	mmr	mmr	PROPN
fnp-5892	5	21	)	)	PUNCT
fnp-5892	5	22	genes	gene	NOUN
fnp-5892	5	23	(	(	PUNCT
fnp-5892	5	24	lynch	lynch	PROPN
fnp-5892	5	25	syndrome	syndrome	PROPN
fnp-5892	5	26	)	)	PUNCT
fnp-5892	5	27	and	and	CCONJ
fnp-5892	5	28	a	a	DET
fnp-5892	5	29	significantly	significantly	ADV
fnp-5892	5	30	worse	bad	ADJ
fnp-5892	5	31	median	median	ADJ
fnp-5892	5	32	survival	survival	NOUN
fnp-5892	5	33	of	of	ADP
fnp-5892	5	34	3.25	3.25	NUM
fnp-5892	5	35	months	month	NOUN
fnp-5892	5	36	post	post	ADJ
fnp-5892	5	37	-	-	NOUN
fnp-5892	5	38	surgery	surgery	NOUN
fnp-5892	5	39	than	than	ADP
fnp-5892	5	40	those	those	PRON
fnp-5892	5	41	from	from	ADP
fnp-5892	5	42	the	the	DET
fnp-5892	5	43	g1	g1	PROPN
fnp-5892	5	44	/	/	SYM
fnp-5892	5	45	egfr	egfr	NOUN
fnp-5892	5	46	and	and	CCONJ
fnp-5892	5	47	g3	g3	PROPN
fnp-5892	5	48	/	/	SYM
fnp-5892	5	49	nf1	nf1	NOUN
fnp-5892	5	50	major	major	ADJ
fnp-5892	5	51	subgroups	subgroup	NOUN
fnp-5892	5	52	,	,	PUNCT
fnp-5892	5	53	or	or	CCONJ
fnp-5892	5	54	from	from	ADP
fnp-5892	5	55	the	the	DET
fnp-5892	5	56	rest	rest	NOUN
fnp-5892	5	57	of	of	ADP
fnp-5892	5	58	the	the	DET
fnp-5892	5	59	cohort	cohort	NOUN
fnp-5892	5	60	adjusted	adjust	VERB
fnp-5892	5	61	for	for	ADP
fnp-5892	5	62	age	age	NOUN
fnp-5892	5	63	.	.	PUNCT
fnp-5892	6	1	these	these	DET
fnp-5892	6	2	rare	rare	ADJ
fnp-5892	6	3	tumors	tumor	NOUN
fnp-5892	6	4	were	be	AUX
fnp-5892	6	5	assigned	assign	VERB
fnp-5892	6	6	to	to	ADP
fnp-5892	6	7	a	a	DET
fnp-5892	6	8	new	new	ADJ
fnp-5892	6	9	subgroup	subgroup	NOUN
fnp-5892	6	10	,	,	PUNCT
fnp-5892	6	11	g3	g3	PROPN
fnp-5892	6	12	/	/	SYM
fnp-5892	6	13	mmr	mmr	PROPN
fnp-5892	6	14	,	,	PUNCT
fnp-5892	6	15	a	a	DET
fnp-5892	6	16	g3	g3	PROPN
fnp-5892	6	17	/	/	SYM
fnp-5892	6	18	nf1	nf1	NOUN
fnp-5892	6	19	subgroup	subgroup	NOUN
fnp-5892	6	20	spin	spin	NOUN
fnp-5892	6	21	-	-	PUNCT
fnp-5892	6	22	off	off	NOUN
fnp-5892	6	23	,	,	PUNCT
fnp-5892	6	24	as	as	SCONJ
fnp-5892	6	25	they	they	PRON
fnp-5892	6	26	generally	generally	ADV
fnp-5892	6	27	show	show	VERB
fnp-5892	6	28	genomic	genomic	ADJ
fnp-5892	6	29	alterations	alteration	NOUN
fnp-5892	6	30	leading	lead	VERB
fnp-5892	6	31	to	to	ADP
fnp-5892	6	32	ras	ras	NOUN
fnp-5892	6	33	activation	activation	NOUN
fnp-5892	6	34	,	,	PUNCT
fnp-5892	6	35	such	such	ADJ
fnp-5892	6	36	as	as	ADP
fnp-5892	6	37	nf1	nf1	NOUN
fnp-5892	6	38	and	and	CCONJ
fnp-5892	6	39	ptpn11	ptpn11	NOUN
fnp-5892	6	40	mutations	mutation	NOUN
fnp-5892	6	41	.	.	PUNCT
fnp-5892	7	1	an	an	DET
fnp-5892	7	2	integrated	integrated	ADJ
fnp-5892	7	3	clinical	clinical	ADJ
fnp-5892	7	4	,	,	PUNCT
fnp-5892	7	5	histologic	histologic	ADJ
fnp-5892	7	6	and	and	CCONJ
fnp-5892	7	7	molecular	molecular	ADJ
fnp-5892	7	8	analysis	analysis	NOUN
fnp-5892	7	9	of	of	ADP
fnp-5892	7	10	the	the	DET
fnp-5892	7	11	g3	g3	PROPN
fnp-5892	7	12	/	/	SYM
fnp-5892	7	13	mmr	mmr	PROPN
fnp-5892	7	14	tumors	tumor	NOUN
fnp-5892	7	15	showed	show	VERB
fnp-5892	7	16	distinct	distinct	ADJ
fnp-5892	7	17	characteristics	characteristic	NOUN
fnp-5892	7	18	as	as	SCONJ
fnp-5892	7	19	compared	compare	VERB
fnp-5892	7	20	to	to	ADP
fnp-5892	7	21	other	other	ADJ
fnp-5892	7	22	glioblastomas	glioblastoma	NOUN
fnp-5892	7	23	,	,	PUNCT
fnp-5892	7	24	including	include	VERB
fnp-5892	7	25	those	those	PRON
fnp-5892	7	26	with	with	ADP
fnp-5892	7	27	iatrogenic	iatrogenic	ADJ
fnp-5892	7	28	high	high	ADJ
fnp-5892	7	29	tumor	tumor	NOUN
fnp-5892	7	30	mutation	mutation	NOUN
fnp-5892	7	31	burden	burden	NOUN
fnp-5892	7	32	(	(	PUNCT
fnp-5892	7	33	tmb	tmb	NOUN
fnp-5892	7	34	)	)	PUNCT
fnp-5892	7	35	,	,	PUNCT
fnp-5892	7	36	warranting	warrant	VERB
fnp-5892	7	37	a	a	DET
fnp-5892	7	38	separate	separate	ADJ
fnp-5892	7	39	subgroup	subgroup	NOUN
fnp-5892	7	40	.	.	PUNCT
fnp-5892	8	1	prior	prior	ADJ
fnp-5892	8	2	history	history	NOUN
fnp-5892	8	3	of	of	ADP
fnp-5892	8	4	cancer	cancer	NOUN
fnp-5892	8	5	,	,	PUNCT
fnp-5892	8	6	midline	midline	NOUN
fnp-5892	8	7	location	location	NOUN
fnp-5892	8	8	or	or	CCONJ
fnp-5892	8	9	multifocality	multifocality	NOUN
fnp-5892	8	10	,	,	PUNCT
fnp-5892	8	11	presence	presence	NOUN
fnp-5892	8	12	of	of	ADP
fnp-5892	8	13	multinucleated	multinucleate	VERB
fnp-5892	8	14	giant	giant	ADJ
fnp-5892	8	15	cells	cell	NOUN
fnp-5892	8	16	(	(	PUNCT
fnp-5892	8	17	mgcs	mgcs	NOUN
fnp-5892	8	18	)	)	PUNCT
fnp-5892	8	19	,	,	PUNCT
fnp-5892	8	20	positive	positive	ADJ
fnp-5892	8	21	p53	p53	NOUN
fnp-5892	8	22	and	and	CCONJ
fnp-5892	8	23	mmr	mmr	PROPN
fnp-5892	8	24	immunohistochemistry	immunohistochemistry	NOUN
fnp-5892	8	25	,	,	PUNCT
fnp-5892	8	26	and	and	CCONJ
fnp-5892	8	27	specific	specific	ADJ
fnp-5892	8	28	molecular	molecular	ADJ
fnp-5892	8	29	characteristics	characteristic	NOUN
fnp-5892	8	30	,	,	PUNCT
fnp-5892	8	31	including	include	VERB
fnp-5892	8	32	high	high	ADJ
fnp-5892	8	33	tmb	tmb	PROPN
fnp-5892	8	34	,	,	PUNCT
fnp-5892	8	35	msh2	msh2	NOUN
fnp-5892	8	36	/	/	SYM
fnp-5892	8	37	msh6	msh6	NOUN
fnp-5892	8	38	alterations	alteration	NOUN
fnp-5892	8	39	,	,	PUNCT
fnp-5892	8	40	biallelic	biallelic	NOUN
fnp-5892	8	41	tp53	tp53	PROPN
fnp-5892	8	42	arg	arg	NOUN
fnp-5892	8	43	mutations	mutation	NOUN
fnp-5892	8	44	and	and	CCONJ
fnp-5892	8	45	co	co	VERB
fnp-5892	8	46	-	-	ADJ
fnp-5892	8	47	occurring	occurring	ADJ
fnp-5892	8	48	pik3ca	pik3ca	NUM
fnp-5892	8	49	p.r88q	p.r88q	ADJ
fnp-5892	8	50	and	and	CCONJ
fnp-5892	8	51	pten	pten	VERB
fnp-5892	8	52	alterations	alteration	NOUN
fnp-5892	8	53	,	,	PUNCT
fnp-5892	8	54	alert	alert	ADJ
fnp-5892	8	55	to	to	ADP
fnp-5892	8	56	this	this	DET
fnp-5892	8	57	high	high	ADJ
fnp-5892	8	58	-	-	PUNCT
fnp-5892	8	59	risk	risk	NOUN
fnp-5892	8	60	g3	g3	NOUN
fnp-5892	8	61	/	/	SYM
fnp-5892	8	62	mmr	mmr	PROPN
fnp-5892	8	63	subgroup	subgroup	NOUN
fnp-5892	8	64	.	.	PUNCT
fnp-5892	9	1	the	the	DET
fnp-5892	9	2	mgcs	mgcs	PROPN
fnp-5892	9	3	and	and	CCONJ
fnp-5892	9	4	p53	p53	NOUN
fnp-5892	9	5	immunohistochemistry	immunohistochemistry	NOUN
fnp-5892	9	6	analysis	analysis	NOUN
fnp-5892	9	7	in	in	ADP
fnp-5892	9	8	g1	g1	NOUN
fnp-5892	9	9	–	–	PUNCT
fnp-5892	9	10	g7	g7	PROPN
fnp-5892	9	11	subgroups	subgroup	NOUN
fnp-5892	9	12	showed	show	VERB
fnp-5892	9	13	that	that	SCONJ
fnp-5892	9	14	one	one	NUM
fnp-5892	9	15	in	in	ADP
fnp-5892	9	16	7	7	NUM
fnp-5892	9	17	tumors	tumor	NOUN
fnp-5892	9	18	with	with	ADP
fnp-5892	9	19	these	these	DET
fnp-5892	9	20	characteristics	characteristic	NOUN
fnp-5892	9	21	is	be	AUX
fnp-5892	9	22	a	a	DET
fnp-5892	9	23	g3	g3	PROPN
fnp-5892	9	24	/	/	SYM
fnp-5892	9	25	mmr	mmr	PROPN
fnp-5892	9	26	glioblastoma	glioblastoma	NOUN
fnp-5892	9	27	.	.	PUNCT
fnp-5892	10	1	the	the	DET
fnp-5892	10	2	fda	fda	PROPN
fnp-5892	10	3	-	-	PUNCT
fnp-5892	10	4	approved	approve	VERB
fnp-5892	10	5	first	first	ADJ
fnp-5892	10	6	-	-	PUNCT
fnp-5892	10	7	line	line	NOUN
fnp-5892	10	8	therapy	therapy	NOUN
fnp-5892	10	9	for	for	ADP
fnp-5892	10	10	many	many	ADJ
fnp-5892	10	11	advanced	advanced	ADJ
fnp-5892	10	12	solid	solid	ADJ
fnp-5892	10	13	tumors	tumor	NOUN
fnp-5892	10	14	consists	consist	VERB
fnp-5892	10	15	of	of	ADP
fnp-5892	10	16	nivolumab	nivolumab	NOUN
fnp-5892	10	17	-	-	PUNCT
fnp-5892	10	18	ipilimumab	ipilimumab	NOUN
fnp-5892	10	19	immune	immune	ADJ
fnp-5892	10	20	checkpoint	checkpoint	NOUN
fnp-5892	10	21	inhibitors	inhibitor	NOUN
fnp-5892	10	22	.	.	PUNCT
fnp-5892	11	1	one	one	NUM
fnp-5892	11	2	g3	g3	NOUN
fnp-5892	11	3	/	/	SYM
fnp-5892	11	4	mmr	mmr	PROPN
fnp-5892	11	5	patient	patient	NOUN
fnp-5892	11	6	received	receive	VERB
fnp-5892	11	7	this	this	DET
fnp-5892	11	8	regimen	regiman	NOUN
fnp-5892	11	9	and	and	CCONJ
fnp-5892	11	10	survived	survive	VERB
fnp-5892	11	11	much	much	ADV
fnp-5892	11	12	longer	long	ADJ
fnp-5892	11	13	than	than	ADP
fnp-5892	11	14	the	the	DET
fnp-5892	11	15	rest	rest	NOUN
fnp-5892	11	16	,	,	PUNCT
fnp-5892	11	17	setting	set	VERB
fnp-5892	11	18	a	a	DET
fnp-5892	11	19	proof	proof	NOUN
fnp-5892	11	20	-	-	PUNCT
fnp-5892	11	21	of	of	ADP
fnp-5892	11	22	-	-	PUNCT
fnp-5892	11	23	principle	principle	NOUN
fnp-5892	11	24	example	example	NOUN
fnp-5892	11	25	for	for	ADP
fnp-5892	11	26	the	the	DET
fnp-5892	11	27	treatment	treatment	NOUN
fnp-5892	11	28	of	of	ADP
fnp-5892	11	29	these	these	DET
fnp-5892	11	30	very	very	ADV
fnp-5892	11	31	aggressive	aggressive	ADJ
fnp-5892	11	32	g3	g3	NOUN
fnp-5892	11	33	/	/	SYM
fnp-5892	11	34	mmr	mmr	PROPN
fnp-5892	11	35	glioblastomas	glioblastoma	NOUN
fnp-5892	11	36	.	.	PUNCT
fnp-5892	12	1	introduction	introduction	NOUN
fnp-5892	12	2	glioblastoma	glioblastoma	NOUN
fnp-5892	12	3	is	be	AUX
fnp-5892	12	4	the	the	DET
fnp-5892	12	5	most	most	ADV
fnp-5892	12	6	frequent	frequent	ADJ
fnp-5892	12	7	and	and	CCONJ
fnp-5892	12	8	deadly	deadly	ADJ
fnp-5892	12	9	primary	primary	ADJ
fnp-5892	12	10	brain	brain	NOUN
fnp-5892	12	11	tumor	tumor	NOUN
fnp-5892	13	1	[	[	X
fnp-5892	13	2	1	1	NUM
fnp-5892	13	3	]	]	PUNCT
fnp-5892	13	4	,	,	PUNCT
fnp-5892	13	5	assigned	assign	VERB
fnp-5892	13	6	by	by	ADP
fnp-5892	13	7	the	the	DET
fnp-5892	13	8	world	world	PROPN
fnp-5892	13	9	health	health	PROPN
fnp-5892	13	10	organization	organization	NOUN
fnp-5892	13	11	(	(	PUNCT
fnp-5892	13	12	who	who	PRON
fnp-5892	13	13	)	)	PUNCT
fnp-5892	13	14	classification	classification	NOUN
fnp-5892	13	15	of	of	ADP
fnp-5892	13	16	central	central	ADJ
fnp-5892	13	17	nervous	nervous	ADJ
fnp-5892	13	18	system	system	NOUN
fnp-5892	13	19	tumors	tumor	NOUN
fnp-5892	13	20	the	the	DET
fnp-5892	13	21	highest	high	ADJ
fnp-5892	13	22	tumor	tumor	NOUN
fnp-5892	13	23	grade	grade	NOUN
fnp-5892	13	24	,	,	PUNCT
fnp-5892	13	25	who	who	PRON
fnp-5892	13	26	grade	grade	VERB
fnp-5892	13	27	4	4	NUM
fnp-5892	13	28	[	[	X
fnp-5892	13	29	2	2	NUM
fnp-5892	13	30	]	]	PUNCT
fnp-5892	13	31	.	.	PUNCT
fnp-5892	14	1	its	its	PRON
fnp-5892	14	2	dismal	dismal	ADJ
fnp-5892	14	3	prognosis	prognosis	NOUN
fnp-5892	14	4	is	be	AUX
fnp-5892	14	5	mainly	mainly	ADV
fnp-5892	14	6	due	due	ADJ
fnp-5892	14	7	to	to	ADP
fnp-5892	14	8	diffuse	diffuse	VERB
fnp-5892	14	9	brain	brain	NOUN
fnp-5892	14	10	invasion	invasion	NOUN
fnp-5892	14	11	,	,	PUNCT
fnp-5892	14	12	tumor	tumor	NOUN
fnp-5892	14	13	heterogeneity	heterogeneity	NOUN
fnp-5892	14	14	,	,	PUNCT
fnp-5892	14	15	but	but	CCONJ
fnp-5892	14	16	also	also	ADV
fnp-5892	14	17	activation	activation	NOUN
fnp-5892	14	18	of	of	ADP
fnp-5892	14	19	pathways	pathway	NOUN
fnp-5892	14	20	that	that	PRON
fnp-5892	14	21	impart	impart	VERB
fnp-5892	14	22	resistance	resistance	NOUN
fnp-5892	14	23	to	to	ADP
fnp-5892	14	24	therapy	therapy	NOUN
fnp-5892	14	25	.	.	PUNCT
fnp-5892	15	1	virtually	virtually	ADV
fnp-5892	15	2	all	all	DET
fnp-5892	15	3	glioblastomas	glioblastoma	NOUN
fnp-5892	15	4	show	show	VERB
fnp-5892	15	5	activation	activation	NOUN
fnp-5892	15	6	of	of	ADP
fnp-5892	15	7	the	the	DET
fnp-5892	15	8	extracellular	extracellular	ADJ
fnp-5892	15	9	signal	signal	NOUN
fnp-5892	15	10	-	-	PUNCT
fnp-5892	15	11	regulated	regulate	VERB
fnp-5892	15	12	kinase	kinase	NOUN
fnp-5892	15	13	 	 	SPACE
fnp-5892	15	14	/	/	SYM
fnp-5892	15	15	 	 	SPACE
fnp-5892	15	16	mitogen	mitogen	NOUN
fnp-5892	15	17	-	-	PUNCT
fnp-5892	15	18	activated	activate	VERB
fnp-5892	15	19	protein	protein	NOUN
fnp-5892	15	20	kinase	kinase	NOUN
fnp-5892	15	21	(	(	PUNCT
fnp-5892	15	22	erk	erk	PROPN
fnp-5892	15	23	/	/	SYM
fnp-5892	15	24	mapk	mapk	NOUN
fnp-5892	15	25	)	)	PUNCT
fnp-5892	15	26	and	and	CCONJ
fnp-5892	15	27	phosphatidyl	phosphatidyl	NOUN
fnp-5892	15	28	-	-	PUNCT
fnp-5892	15	29	inositol	inositol	ADJ
fnp-5892	15	30	3	3	NUM
fnp-5892	15	31	-	-	SYM
fnp-5892	15	32	oh	oh	INTJ
fnp-5892	15	33	kinase	kinase	NOUN
fnp-5892	15	34	(	(	PUNCT
fnp-5892	15	35	pi3k	pi3k	NOUN
fnp-5892	15	36	)	)	PUNCT
fnp-5892	15	37	canonical	canonical	ADJ
fnp-5892	15	38	growth	growth	NOUN
fnp-5892	15	39	pathways	pathway	NOUN
fnp-5892	16	1	[	[	X
fnp-5892	16	2	3–5	3–5	X
fnp-5892	16	3	]	]	PUNCT
fnp-5892	16	4	.	.	PUNCT
fnp-5892	17	1	non	non	ADJ
fnp-5892	17	2	-	-	ADJ
fnp-5892	17	3	redundant	redundant	ADJ
fnp-5892	17	4	molecular	molecular	ADJ
fnp-5892	17	5	alterations	alteration	NOUN
fnp-5892	17	6	in	in	ADP
fnp-5892	17	7	the	the	DET
fnp-5892	17	8	upstream	upstream	ADJ
fnp-5892	17	9	mediators	mediator	NOUN
fnp-5892	17	10	of	of	ADP
fnp-5892	17	11	the	the	DET
fnp-5892	17	12	erk	erk	PROPN
fnp-5892	17	13	/	/	SYM
fnp-5892	17	14	mapk	mapk	NOUN
fnp-5892	17	15	pathway	pathway	NOUN
fnp-5892	17	16	,	,	PUNCT
fnp-5892	17	17	including	include	VERB
fnp-5892	17	18	the	the	DET
fnp-5892	17	19	receptor	receptor	NOUN
fnp-5892	17	20	tyrosine	tyrosine	NOUN
fnp-5892	17	21	kinases	kinase	NOUN
fnp-5892	17	22	(	(	PUNCT
fnp-5892	17	23	rtks	rtks	NOUN
fnp-5892	17	24	)	)	PUNCT
fnp-5892	17	25	triggering	trigger	VERB
fnp-5892	17	26	pathway	pathway	NOUN
fnp-5892	17	27	activation	activation	NOUN
fnp-5892	17	28	,	,	PUNCT
fnp-5892	17	29	allowed	allow	VERB
fnp-5892	17	30	an	an	DET
fnp-5892	17	31	all	all	ADV
fnp-5892	17	32	-	-	PUNCT
fnp-5892	17	33	inclusive	inclusive	ADJ
fnp-5892	17	34	molecular	molecular	ADJ
fnp-5892	17	35	classification	classification	NOUN
fnp-5892	17	36	of	of	ADP
fnp-5892	17	37	glioblastoma	glioblastoma	NOUN
fnp-5892	17	38	into	into	ADP
fnp-5892	17	39	7	7	NUM
fnp-5892	17	40	subgroups	subgroup	NOUN
fnp-5892	17	41	[	[	X
fnp-5892	17	42	4,5	4,5	NUM
fnp-5892	17	43	]	]	PUNCT
fnp-5892	17	44	.	.	PUNCT
fnp-5892	18	1	these	these	DET
fnp-5892	18	2	subgroups	subgroup	NOUN
fnp-5892	18	3	,	,	PUNCT
fnp-5892	18	4	termed	term	VERB
fnp-5892	18	5	after	after	SCONJ
fnp-5892	18	6	the	the	DET
fnp-5892	18	7	most	most	ADV
fnp-5892	18	8	upstream	upstream	ADJ
fnp-5892	18	9	gene	gene	NOUN
fnp-5892	18	10	showing	show	VERB
fnp-5892	18	11	activating	activate	VERB
fnp-5892	18	12	rtk	rtk	PROPN
fnp-5892	18	13	or	or	CCONJ
fnp-5892	18	14	mapk	mapk	NOUN
fnp-5892	18	15	effector	effector	NOUN
fnp-5892	18	16	alterations	alteration	NOUN
fnp-5892	18	17	are	be	AUX
fnp-5892	18	18	:	:	PUNCT
fnp-5892	18	19	g1	g1	X
fnp-5892	18	20	/	/	SYM
fnp-5892	18	21	egfr	egfr	NOUN
fnp-5892	18	22	,	,	PUNCT
fnp-5892	18	23	g2	g2	PROPN
fnp-5892	18	24	/	/	SYM
fnp-5892	18	25	fgfr3	fgfr3	PROPN
fnp-5892	18	26	,	,	PUNCT
fnp-5892	18	27	g3	g3	PROPN
fnp-5892	18	28	/	/	SYM
fnp-5892	18	29	nf1	nf1	NOUN
fnp-5892	18	30	,	,	PUNCT
fnp-5892	18	31	g4	g4	NOUN
fnp-5892	18	32	/	/	SYM
fnp-5892	18	33	raf	raf	NOUN
fnp-5892	18	34	,	,	PUNCT
fnp-5892	18	35	g5	g5	NOUN
fnp-5892	18	36	/	/	SYM
fnp-5892	18	37	pdgfra	pdgfra	NOUN
fnp-5892	18	38	,	,	PUNCT
fnp-5892	18	39	g6	g6	ADJ
fnp-5892	18	40	/	/	SYM
fnp-5892	18	41	multi	multi	ADJ
fnp-5892	18	42	-	-	NOUN
fnp-5892	18	43	rtk	rtk	ADJ
fnp-5892	18	44	,	,	PUNCT
fnp-5892	18	45	and	and	CCONJ
fnp-5892	18	46	g7	g7	PROPN
fnp-5892	18	47	/	/	SYM
fnp-5892	18	48	other	other	ADJ
fnp-5892	18	49	,	,	PUNCT
fnp-5892	18	50	the	the	DET
fnp-5892	18	51	latter	latter	ADJ
fnp-5892	18	52	showing	show	VERB
fnp-5892	18	53	dominant	dominant	ADJ
fnp-5892	18	54	pi3k	pi3k	NOUN
fnp-5892	18	55	pathway	pathway	NOUN
fnp-5892	18	56	activation	activation	NOUN
fnp-5892	18	57	[	[	X
fnp-5892	18	58	4,5	4,5	NUM
fnp-5892	18	59	]	]	PUNCT
fnp-5892	18	60	.	.	PUNCT
fnp-5892	19	1	of	of	ADP
fnp-5892	19	2	these	these	PRON
fnp-5892	19	3	,	,	PUNCT
fnp-5892	19	4	the	the	DET
fnp-5892	19	5	g1	g1	PROPN
fnp-5892	19	6	/	/	SYM
fnp-5892	19	7	egfr	egfr	NOUN
fnp-5892	19	8	,	,	PUNCT
fnp-5892	19	9	g3	g3	PROPN
fnp-5892	19	10	/	/	SYM
fnp-5892	19	11	nf1	nf1	NOUN
fnp-5892	19	12	and	and	CCONJ
fnp-5892	19	13	g7	g7	PROPN
fnp-5892	19	14	/	/	SYM
fnp-5892	19	15	other	other	ADJ
fnp-5892	19	16	are	be	AUX
fnp-5892	19	17	major	major	ADJ
fnp-5892	19	18	subgroups	subgroup	NOUN
fnp-5892	19	19	,	,	PUNCT
fnp-5892	19	20	containing	contain	VERB
fnp-5892	19	21	together	together	ADV
fnp-5892	19	22	approximately	approximately	ADV
fnp-5892	19	23	three	three	NUM
fnp-5892	19	24	quarters	quarter	NOUN
fnp-5892	19	25	of	of	ADP
fnp-5892	19	26	all	all	DET
fnp-5892	19	27	glioblastoma	glioblastoma	NOUN
fnp-5892	19	28	cases	case	NOUN
fnp-5892	19	29	,	,	PUNCT
fnp-5892	19	30	and	and	CCONJ
fnp-5892	19	31	showing	show	VERB
fnp-5892	19	32	distinct	distinct	ADJ
fnp-5892	19	33	risk	risk	NOUN
fnp-5892	19	34	stratification	stratification	NOUN
fnp-5892	19	35	,	,	PUNCT
fnp-5892	19	36	with	with	ADP
fnp-5892	19	37	overall	overall	ADJ
fnp-5892	19	38	poor	poor	ADJ
fnp-5892	19	39	prognosis	prognosis	NOUN
fnp-5892	19	40	for	for	ADP
fnp-5892	19	41	the	the	DET
fnp-5892	19	42	g7	g7	PROPN
fnp-5892	19	43	/	/	SYM
fnp-5892	19	44	other	other	ADJ
fnp-5892	19	45	subgroup	subgroup	NOUN
fnp-5892	19	46	[	[	X
fnp-5892	19	47	5	5	NUM
fnp-5892	19	48	]	]	PUNCT
fnp-5892	19	49	.	.	PUNCT
fnp-5892	20	1	the	the	DET
fnp-5892	20	2	treatment	treatment	NOUN
fnp-5892	20	3	of	of	ADP
fnp-5892	20	4	glioblastoma	glioblastoma	NOUN
fnp-5892	20	5	relies	rely	VERB
fnp-5892	20	6	on	on	ADP
fnp-5892	20	7	surgical	surgical	ADJ
fnp-5892	20	8	resection	resection	NOUN
fnp-5892	20	9	,	,	PUNCT
fnp-5892	20	10	the	the	DET
fnp-5892	20	11	extent	extent	NOUN
fnp-5892	20	12	of	of	ADP
fnp-5892	20	13	which	which	PRON
fnp-5892	20	14	correlates	correlate	VERB
fnp-5892	20	15	to	to	ADP
fnp-5892	20	16	the	the	DET
fnp-5892	20	17	survival	survival	NOUN
fnp-5892	20	18	benefit	benefit	NOUN
fnp-5892	20	19	[	[	X
fnp-5892	20	20	6	6	NUM
fnp-5892	20	21	]	]	PUNCT
fnp-5892	20	22	.	.	PUNCT
fnp-5892	21	1	subsequent	subsequent	ADJ
fnp-5892	21	2	radiation	radiation	NOUN
fnp-5892	21	3	and	and	CCONJ
fnp-5892	21	4	temozolomide	temozolomide	NOUN
fnp-5892	21	5	(	(	PUNCT
fnp-5892	21	6	tmz	tmz	NOUN
fnp-5892	21	7	)	)	PUNCT
fnp-5892	21	8	chemotherapy	chemotherapy	NOUN
fnp-5892	21	9	represent	represent	VERB
fnp-5892	21	10	the	the	DET
fnp-5892	21	11	standard	standard	ADJ
fnp-5892	21	12	adjuvant	adjuvant	ADJ
fnp-5892	21	13	regimen	regiman	NOUN
fnp-5892	21	14	for	for	ADP
fnp-5892	21	15	the	the	DET
fnp-5892	21	16	past	past	ADJ
fnp-5892	21	17	20	20	NUM
fnp-5892	21	18	years	year	NOUN
fnp-5892	21	19	[	[	X
fnp-5892	21	20	7	7	NUM
fnp-5892	21	21	]	]	PUNCT
fnp-5892	21	22	,	,	PUNCT
fnp-5892	21	23	with	with	SCONJ
fnp-5892	21	24	few	few	ADJ
fnp-5892	21	25	recent	recent	ADJ
fnp-5892	21	26	trials	trial	NOUN
fnp-5892	21	27	proven	prove	VERB
fnp-5892	21	28	beneficial	beneficial	ADJ
fnp-5892	21	29	for	for	ADP
fnp-5892	21	30	the	the	DET
fnp-5892	21	31	younger	young	ADJ
fnp-5892	21	32	glioblastoma	glioblastoma	NOUN
fnp-5892	21	33	patient	patient	ADJ
fnp-5892	21	34	population	population	NOUN
fnp-5892	22	1	[	[	X
fnp-5892	22	2	8	8	NUM
fnp-5892	22	3	]	]	PUNCT
fnp-5892	22	4	.	.	PUNCT
fnp-5892	23	1	beside	beside	ADP
fnp-5892	23	2	risk	risk	NOUN
fnp-5892	23	3	stratification	stratification	NOUN
fnp-5892	23	4	,	,	PUNCT
fnp-5892	23	5	the	the	DET
fnp-5892	23	6	aim	aim	NOUN
fnp-5892	23	7	of	of	ADP
fnp-5892	23	8	the	the	DET
fnp-5892	23	9	g1	g1	NOUN
fnp-5892	23	10	–	–	PUNCT
fnp-5892	23	11	g7	g7	PROPN
fnp-5892	23	12	molecular	molecular	ADJ
fnp-5892	23	13	subgroup	subgroup	NOUN
fnp-5892	23	14	classification	classification	NOUN
fnp-5892	23	15	is	be	AUX
fnp-5892	23	16	to	to	PART
fnp-5892	23	17	identify	identify	VERB
fnp-5892	23	18	subgroups	subgroup	NOUN
fnp-5892	23	19	benefiting	benefit	VERB
fnp-5892	23	20	of	of	ADP
fnp-5892	23	21	specific	specific	ADJ
fnp-5892	23	22	targeted	target	VERB
fnp-5892	23	23	therapy	therapy	NOUN
fnp-5892	23	24	[	[	X
fnp-5892	23	25	5	5	NUM
fnp-5892	23	26	]	]	PUNCT
fnp-5892	23	27	.	.	PUNCT
fnp-5892	24	1	for	for	ADP
fnp-5892	24	2	example	example	NOUN
fnp-5892	24	3	,	,	PUNCT
fnp-5892	24	4	the	the	DET
fnp-5892	24	5	g6	g6	PROPN
fnp-5892	24	6	/	/	SYM
fnp-5892	24	7	multi	multi	ADJ
fnp-5892	24	8	-	-	ADJ
fnp-5892	24	9	rtk	rtk	PROPN
fnp-5892	24	10	has	have	AUX
fnp-5892	24	11	been	be	AUX
fnp-5892	24	12	analyzed	analyze	VERB
fnp-5892	24	13	in	in	ADP
fnp-5892	24	14	detail	detail	NOUN
fnp-5892	24	15	and	and	CCONJ
fnp-5892	24	16	shows	show	VERB
fnp-5892	24	17	rtk	rtk	PROPN
fnp-5892	24	18	gene	gene	NOUN
fnp-5892	24	19	fusions	fusion	NOUN
fnp-5892	24	20	for	for	ADP
fnp-5892	24	21	which	which	PRON
fnp-5892	24	22	addition	addition	NOUN
fnp-5892	24	23	of	of	ADP
fnp-5892	24	24	specific	specific	ADJ
fnp-5892	24	25	rtk	rtk	NOUN
fnp-5892	24	26	inhibitors	inhibitor	NOUN
fnp-5892	24	27	improves	improve	VERB
fnp-5892	24	28	survival	survival	NOUN
fnp-5892	24	29	[	[	X
fnp-5892	24	30	5,9,10	5,9,10	NUM
fnp-5892	24	31	]	]	PUNCT
fnp-5892	24	32	.	.	PUNCT
fnp-5892	25	1	a	a	DET
fnp-5892	25	2	very	very	ADV
fnp-5892	25	3	small	small	ADJ
fnp-5892	25	4	but	but	CCONJ
fnp-5892	25	5	significant	significant	ADJ
fnp-5892	25	6	subgroup	subgroup	NOUN
fnp-5892	25	7	of	of	ADP
fnp-5892	25	8	glioblastomas	glioblastoma	NOUN
fnp-5892	25	9	that	that	PRON
fnp-5892	25	10	harbor	harbor	VERB
fnp-5892	25	11	germline	germline	NOUN
fnp-5892	25	12	mismatch	mismatch	PROPN
fnp-5892	25	13	repair	repair	PROPN
fnp-5892	25	14	(	(	PUNCT
fnp-5892	25	15	mmr	mmr	PROPN
fnp-5892	25	16	)	)	PUNCT
fnp-5892	25	17	gene	gene	NOUN
fnp-5892	25	18	deficiency	deficiency	NOUN
fnp-5892	25	19	consistent	consistent	ADJ
fnp-5892	25	20	with	with	ADP
fnp-5892	25	21	lynch	lynch	PROPN
fnp-5892	25	22	syndrome	syndrome	PROPN
fnp-5892	25	23	has	have	AUX
fnp-5892	25	24	been	be	AUX
fnp-5892	25	25	identified	identify	VERB
fnp-5892	25	26	in	in	ADP
fnp-5892	25	27	a	a	DET
fnp-5892	25	28	previous	previous	ADJ
fnp-5892	25	29	study	study	NOUN
fnp-5892	25	30	[	[	X
fnp-5892	25	31	5	5	NUM
fnp-5892	25	32	]	]	PUNCT
fnp-5892	25	33	.	.	PUNCT
fnp-5892	26	1	this	this	DET
fnp-5892	26	2	subgroup	subgroup	NOUN
fnp-5892	26	3	has	have	AUX
fnp-5892	26	4	been	be	AUX
fnp-5892	26	5	termed	term	VERB
fnp-5892	26	6	g3	g3	PROPN
fnp-5892	26	7	/	/	SYM
fnp-5892	26	8	mmr	mmr	PROPN
fnp-5892	26	9	,	,	PUNCT
fnp-5892	26	10	as	as	SCONJ
fnp-5892	26	11	ras	ras	NOUN
fnp-5892	26	12	activation	activation	NOUN
fnp-5892	26	13	appears	appear	VERB
fnp-5892	26	14	to	to	PART
fnp-5892	26	15	be	be	AUX
fnp-5892	26	16	dominant	dominant	ADJ
fnp-5892	26	17	in	in	ADP
fnp-5892	26	18	these	these	DET
fnp-5892	26	19	tumors	tumor	NOUN
fnp-5892	26	20	,	,	PUNCT
fnp-5892	26	21	similarly	similarly	ADV
fnp-5892	26	22	to	to	ADP
fnp-5892	26	23	the	the	DET
fnp-5892	26	24	g3	g3	PROPN
fnp-5892	26	25	/	/	SYM
fnp-5892	26	26	nf1	nf1	NOUN
fnp-5892	26	27	tumors	tumor	NOUN
fnp-5892	26	28	.	.	PUNCT
fnp-5892	27	1	lynch	lynch	PROPN
fnp-5892	27	2	syndrome	syndrome	PROPN
fnp-5892	27	3	is	be	AUX
fnp-5892	27	4	a	a	DET
fnp-5892	27	5	cancer	cancer	NOUN
fnp-5892	27	6	predisposition	predisposition	NOUN
fnp-5892	27	7	syndrome	syndrome	NOUN
fnp-5892	27	8	caused	cause	VERB
fnp-5892	27	9	by	by	ADP
fnp-5892	27	10	germline	germline	NOUN
fnp-5892	27	11	pathogenic	pathogenic	ADJ
fnp-5892	27	12	alterations	alteration	NOUN
fnp-5892	27	13	in	in	ADP
fnp-5892	27	14	the	the	DET
fnp-5892	27	15	mmr	mmr	PROPN
fnp-5892	27	16	genes	gene	NOUN
fnp-5892	27	17	mlh1	mlh1	PROPN
fnp-5892	27	18	,	,	PUNCT
fnp-5892	27	19	pms2	pms2	NOUN
fnp-5892	27	20	,	,	PUNCT
fnp-5892	27	21	msh2	msh2	NOUN
fnp-5892	27	22	and	and	CCONJ
fnp-5892	27	23	msh6	msh6	NOUN
fnp-5892	27	24	,	,	PUNCT
fnp-5892	27	25	in	in	ADP
fnp-5892	27	26	which	which	PRON
fnp-5892	27	27	various	various	ADJ
fnp-5892	27	28	types	type	NOUN
fnp-5892	27	29	of	of	ADP
fnp-5892	27	30	tumors	tumor	NOUN
fnp-5892	27	31	,	,	PUNCT
fnp-5892	27	32	the	the	DET
fnp-5892	27	33	most	most	ADV
fnp-5892	27	34	prevalent	prevalent	ADJ
fnp-5892	27	35	being	be	AUX
fnp-5892	27	36	colorectal	colorectal	ADJ
fnp-5892	27	37	carcinoma	carcinoma	NOUN
fnp-5892	27	38	(	(	PUNCT
fnp-5892	27	39	crc	crc	NOUN
fnp-5892	27	40	)	)	PUNCT
fnp-5892	27	41	,	,	PUNCT
fnp-5892	27	42	arise	arise	VERB
fnp-5892	27	43	by	by	ADP
fnp-5892	27	44	inactivation	inactivation	NOUN
fnp-5892	27	45	of	of	ADP
fnp-5892	27	46	the	the	DET
fnp-5892	27	47	second	second	ADJ
fnp-5892	27	48	mmr	mmr	PROPN
fnp-5892	27	49	allele	allele	NOUN
fnp-5892	27	50	and	and	CCONJ
fnp-5892	27	51	a	a	DET
fnp-5892	27	52	subsequent	subsequent	ADJ
fnp-5892	27	53	high	high	ADJ
fnp-5892	27	54	rate	rate	NOUN
fnp-5892	27	55	of	of	ADP
fnp-5892	27	56	repair	repair	NOUN
fnp-5892	27	57	errors	error	NOUN
fnp-5892	27	58	during	during	ADP
fnp-5892	27	59	dna	dna	NOUN
fnp-5892	27	60	replication	replication	NOUN
fnp-5892	27	61	[	[	X
fnp-5892	27	62	11	11	NUM
fnp-5892	27	63	]	]	PUNCT
fnp-5892	27	64	.	.	PUNCT
fnp-5892	28	1	this	this	DET
fnp-5892	28	2	mmr	mmr	PROPN
fnp-5892	28	3	deficiency	deficiency	NOUN
fnp-5892	28	4	is	be	AUX
fnp-5892	28	5	reflected	reflect	VERB
fnp-5892	28	6	in	in	ADP
fnp-5892	28	7	a	a	DET
fnp-5892	28	8	high	high	ADJ
fnp-5892	28	9	tumor	tumor	NOUN
fnp-5892	28	10	mutation	mutation	NOUN
fnp-5892	28	11	burden	burden	NOUN
fnp-5892	28	12	(	(	PUNCT
fnp-5892	28	13	tmb	tmb	NOUN
fnp-5892	28	14	)	)	PUNCT
fnp-5892	28	15	that	that	PRON
fnp-5892	28	16	has	have	AUX
fnp-5892	28	17	been	be	AUX
fnp-5892	28	18	shown	show	VERB
fnp-5892	28	19	to	to	PART
fnp-5892	28	20	benefit	benefit	VERB
fnp-5892	28	21	from	from	ADP
fnp-5892	28	22	immune	immune	ADJ
fnp-5892	28	23	checkpoint	checkpoint	NOUN
fnp-5892	28	24	inhibitors	inhibitor	NOUN
fnp-5892	28	25	[	[	X
fnp-5892	28	26	12	12	NUM
fnp-5892	28	27	]	]	PUNCT
fnp-5892	28	28	.	.	PUNCT
fnp-5892	29	1	the	the	DET
fnp-5892	29	2	current	current	ADJ
fnp-5892	29	3	study	study	NOUN
fnp-5892	29	4	focuses	focus	VERB
fnp-5892	29	5	on	on	ADP
fnp-5892	29	6	the	the	DET
fnp-5892	29	7	clinical	clinical	ADJ
fnp-5892	29	8	,	,	PUNCT
fnp-5892	29	9	histologic	histologic	ADJ
fnp-5892	29	10	and	and	CCONJ
fnp-5892	29	11	molecular	molecular	ADJ
fnp-5892	29	12	characterization	characterization	NOUN
fnp-5892	29	13	of	of	ADP
fnp-5892	29	14	the	the	DET
fnp-5892	29	15	g3	g3	PROPN
fnp-5892	29	16	/	/	SYM
fnp-5892	29	17	mmr	mmr	PROPN
fnp-5892	29	18	subgroup	subgroup	NOUN
fnp-5892	29	19	in	in	ADP
fnp-5892	29	20	comparison	comparison	NOUN
fnp-5892	29	21	to	to	ADP
fnp-5892	29	22	other	other	ADJ
fnp-5892	29	23	glioblastoma	glioblastoma	NOUN
fnp-5892	29	24	cases	case	NOUN
fnp-5892	29	25	from	from	ADP
fnp-5892	29	26	the	the	DET
fnp-5892	29	27	same	same	ADJ
fnp-5892	29	28	cohort	cohort	NOUN
fnp-5892	29	29	,	,	PUNCT
fnp-5892	29	30	including	include	VERB
fnp-5892	29	31	cases	case	NOUN
fnp-5892	29	32	with	with	ADP
fnp-5892	29	33	high	high	ADJ
fnp-5892	29	34	tmb	tmb	NOUN
fnp-5892	29	35	due	due	ADP
fnp-5892	29	36	to	to	ADP
fnp-5892	29	37	tmz	tmz	NOUN
fnp-5892	29	38	therapy	therapy	NOUN
fnp-5892	29	39	.	.	PUNCT
fnp-5892	30	1	it	it	PRON
fnp-5892	30	2	shows	show	VERB
fnp-5892	30	3	the	the	DET
fnp-5892	30	4	distinct	distinct	ADJ
fnp-5892	30	5	characteristics	characteristic	NOUN
fnp-5892	30	6	of	of	ADP
fnp-5892	30	7	g3	g3	PROPN
fnp-5892	30	8	/	/	SYM
fnp-5892	30	9	mmr	mmr	PROPN
fnp-5892	30	10	tumors	tumor	NOUN
fnp-5892	30	11	occurring	occur	VERB
fnp-5892	30	12	in	in	ADP
fnp-5892	30	13	older	old	ADJ
fnp-5892	30	14	adults	adult	NOUN
fnp-5892	30	15	,	,	PUNCT
fnp-5892	30	16	similar	similar	ADJ
fnp-5892	30	17	to	to	ADP
fnp-5892	30	18	most	most	ADJ
fnp-5892	30	19	glioblastoma	glioblastoma	NOUN
fnp-5892	30	20	cases	case	NOUN
fnp-5892	30	21	,	,	PUNCT
fnp-5892	30	22	and	and	CCONJ
fnp-5892	30	23	reviews	review	VERB
fnp-5892	30	24	few	few	ADJ
fnp-5892	30	25	additional	additional	ADJ
fnp-5892	30	26	adult	adult	NOUN
fnp-5892	30	27	cases	case	NOUN
fnp-5892	30	28	from	from	ADP
fnp-5892	30	29	the	the	DET
fnp-5892	30	30	literature	literature	NOUN
fnp-5892	31	1	[	[	X
fnp-5892	31	2	13,14	13,14	NUM
fnp-5892	31	3	]	]	PUNCT
fnp-5892	31	4	,	,	PUNCT
fnp-5892	31	5	delineating	delineate	VERB
fnp-5892	31	6	diagnostic	diagnostic	ADJ
fnp-5892	31	7	guidelines	guideline	NOUN
fnp-5892	31	8	for	for	ADP
fnp-5892	31	9	the	the	DET
fnp-5892	31	10	identification	identification	NOUN
fnp-5892	31	11	of	of	ADP
fnp-5892	31	12	these	these	DET
fnp-5892	31	13	rare	rare	ADJ
fnp-5892	31	14	cases	case	NOUN
fnp-5892	31	15	.	.	PUNCT
fnp-5892	32	1	importantly	importantly	ADV
fnp-5892	32	2	,	,	PUNCT
fnp-5892	32	3	this	this	PRON
fnp-5892	32	4	is	be	AUX
fnp-5892	32	5	the	the	DET
fnp-5892	32	6	first	first	ADJ
fnp-5892	32	7	study	study	NOUN
fnp-5892	32	8	showing	show	VERB
fnp-5892	32	9	survival	survival	NOUN
fnp-5892	32	10	advantage	advantage	NOUN
fnp-5892	32	11	in	in	ADP
fnp-5892	32	12	adult	adult	NOUN
fnp-5892	32	13	g3	g3	NOUN
fnp-5892	32	14	/	/	SYM
fnp-5892	32	15	mmr	mmr	PROPN
fnp-5892	32	16	glioblastoma	glioblastoma	NOUN
fnp-5892	32	17	by	by	ADP
fnp-5892	32	18	addition	addition	NOUN
fnp-5892	32	19	of	of	ADP
fnp-5892	32	20	the	the	DET
fnp-5892	32	21	dual	dual	ADJ
fnp-5892	32	22	nivolumab	nivolumab	NOUN
fnp-5892	32	23	-	-	PUNCT
fnp-5892	32	24	ipilimumab	ipilimumab	NOUN
fnp-5892	32	25	regimen	regiman	NOUN
fnp-5892	32	26	of	of	ADP
fnp-5892	32	27	immune	immune	ADJ
fnp-5892	32	28	checkpoint	checkpoint	NOUN
fnp-5892	32	29	inhibitors	inhibitor	NOUN
fnp-5892	32	30	to	to	ADP
fnp-5892	32	31	the	the	DET
fnp-5892	32	32	standard	standard	ADJ
fnp-5892	32	33	adjuvant	adjuvant	ADJ
fnp-5892	32	34	regimen	regiman	NOUN
fnp-5892	32	35	.	.	PUNCT
fnp-5892	33	1	methods	method	NOUN
fnp-5892	33	2	tumor	tumor	NOUN
fnp-5892	33	3	specimens	specimen	NOUN
fnp-5892	33	4	,	,	PUNCT
fnp-5892	33	5	histology	histology	NOUN
fnp-5892	33	6	and	and	CCONJ
fnp-5892	33	7	immunohistochemistry	immunohistochemistry	NOUN
fnp-5892	33	8	(	(	PUNCT
fnp-5892	33	9	ihc	ihc	PROPN
fnp-5892	33	10	)	)	PUNCT
fnp-5892	33	11	.	.	PUNCT
fnp-5892	34	1	surgical	surgical	ADJ
fnp-5892	34	2	specimens	specimen	NOUN
fnp-5892	34	3	were	be	AUX
fnp-5892	34	4	obtained	obtain	VERB
fnp-5892	34	5	from	from	ADP
fnp-5892	34	6	patients	patient	NOUN
fnp-5892	34	7	,	,	PUNCT
fnp-5892	34	8	as	as	SCONJ
fnp-5892	34	9	previously	previously	ADV
fnp-5892	34	10	described	describe	VERB
fnp-5892	34	11	[	[	X
fnp-5892	34	12	15–17	15–17	NUM
fnp-5892	34	13	]	]	PUNCT
fnp-5892	34	14	.	.	PUNCT
fnp-5892	35	1	formalin	formalin	NOUN
fnp-5892	35	2	-	-	PUNCT
fnp-5892	35	3	fixed	fix	VERB
fnp-5892	35	4	paraffin	paraffin	NOUN
fnp-5892	35	5	-	-	PUNCT
fnp-5892	35	6	embedded	embed	VERB
fnp-5892	35	7	(	(	PUNCT
fnp-5892	35	8	ffpe	ffpe	NOUN
fnp-5892	35	9	)	)	PUNCT
fnp-5892	35	10	sections	section	NOUN
fnp-5892	35	11	from	from	ADP
fnp-5892	35	12	glioblastoma	glioblastoma	NOUN
fnp-5892	35	13	biopsies	biopsy	NOUN
fnp-5892	35	14	or	or	CCONJ
fnp-5892	35	15	surgical	surgical	ADJ
fnp-5892	35	16	resections	resection	NOUN
fnp-5892	35	17	were	be	AUX
fnp-5892	35	18	stained	stain	VERB
fnp-5892	35	19	with	with	ADP
fnp-5892	35	20	hematoxylin	hematoxylin	NOUN
fnp-5892	35	21	and	and	CCONJ
fnp-5892	35	22	eosin	eosin	NOUN
fnp-5892	35	23	(	(	PUNCT
fnp-5892	35	24	h&e	h&e	PROPN
fnp-5892	35	25	)	)	PUNCT
fnp-5892	35	26	or	or	CCONJ
fnp-5892	35	27	various	various	ADJ
fnp-5892	35	28	antibodies	antibody	NOUN
fnp-5892	35	29	for	for	ADP
fnp-5892	35	30	protein	protein	NOUN
fnp-5892	35	31	expression	expression	NOUN
fnp-5892	35	32	by	by	ADP
fnp-5892	35	33	ihc	ihc	PROPN
fnp-5892	35	34	:	:	PUNCT
fnp-5892	35	35	p53	p53	NOUN
fnp-5892	35	36	(	(	PUNCT
fnp-5892	35	37	do-7	do-7	NOUN
fnp-5892	35	38	)	)	PUNCT
fnp-5892	35	39	,	,	PUNCT
fnp-5892	35	40	p16	p16	NOUN
fnp-5892	35	41	(	(	PUNCT
fnp-5892	35	42	e6h4	e6h4	NOUN
fnp-5892	35	43	)	)	PUNCT
fnp-5892	35	44	,	,	PUNCT
fnp-5892	35	45	ki-67	ki-67	X
fnp-5892	35	46	(	(	PUNCT
fnp-5892	35	47	30	30	NUM
fnp-5892	35	48	-	-	SYM
fnp-5892	35	49	9	9	NUM
fnp-5892	35	50	)	)	PUNCT
fnp-5892	35	51	,	,	PUNCT
fnp-5892	35	52	mlh1	mlh1	PROPN
fnp-5892	35	53	(	(	PUNCT
fnp-5892	35	54	m1	m1	PROPN
fnp-5892	35	55	)	)	PUNCT
fnp-5892	35	56	,	,	PUNCT
fnp-5892	35	57	pms2	pms2	NOUN
fnp-5892	35	58	(	(	PUNCT
fnp-5892	35	59	a16	a16	PROPN
fnp-5892	35	60	-	-	PUNCT
fnp-5892	35	61	4	4	NUM
fnp-5892	35	62	)	)	PUNCT
fnp-5892	35	63	,	,	PUNCT
fnp-5892	35	64	msh2	msh2	NOUN
fnp-5892	35	65	(	(	PUNCT
fnp-5892	35	66	g219	g219	PROPN
fnp-5892	35	67	)	)	PUNCT
fnp-5892	35	68	and	and	CCONJ
fnp-5892	35	69	msh6	msh6	NOUN
fnp-5892	35	70	(	(	PUNCT
fnp-5892	35	71	sp93	sp93	PROPN
fnp-5892	35	72	)	)	PUNCT
fnp-5892	35	73	(	(	PUNCT
fnp-5892	35	74	roche	roche	X
fnp-5892	35	75	 	 	SPACE
fnp-5892	35	76	/	/	SYM
fnp-5892	35	77	 	 	SPACE
fnp-5892	35	78	ventana	ventana	PROPN
fnp-5892	35	79	medical	medical	PROPN
fnp-5892	35	80	systems	systems	PROPN
fnp-5892	35	81	inc	inc	PROPN
fnp-5892	35	82	.	.	PROPN
fnp-5892	35	83	,	,	PUNCT
fnp-5892	35	84	tucson	tucson	PROPN
fnp-5892	35	85	,	,	PUNCT
fnp-5892	35	86	az	az	PROPN
fnp-5892	35	87	)	)	PUNCT
fnp-5892	35	88	,	,	PUNCT
fnp-5892	35	89	and	and	CCONJ
fnp-5892	35	90	gfap	gfap	PROPN
fnp-5892	35	91	(	(	PUNCT
fnp-5892	35	92	ep672y	ep672y	PROPN
fnp-5892	35	93	)	)	PUNCT
fnp-5892	35	94	(	(	PUNCT
fnp-5892	35	95	ventana	ventana	PROPN
fnp-5892	35	96	 	 	SPACE
fnp-5892	35	97	/	/	SYM
fnp-5892	35	98	 	 	SPACE
fnp-5892	35	99	cell	cell	NOUN
fnp-5892	35	100	marque	marque	NOUN
fnp-5892	35	101	,	,	PUNCT
fnp-5892	35	102	rocklin	rocklin	PROPN
fnp-5892	35	103	,	,	PUNCT
fnp-5892	35	104	ca	ca	NOUN
fnp-5892	35	105	)	)	PUNCT
fnp-5892	35	106	,	,	PUNCT
fnp-5892	35	107	as	as	SCONJ
fnp-5892	35	108	described	describe	VERB
fnp-5892	35	109	[	[	X
fnp-5892	35	110	5,16	5,16	NUM
fnp-5892	35	111	]	]	PUNCT
fnp-5892	35	112	.	.	PUNCT
fnp-5892	36	1	images	image	NOUN
fnp-5892	36	2	were	be	AUX
fnp-5892	36	3	acquired	acquire	VERB
fnp-5892	36	4	with	with	ADP
fnp-5892	36	5	nikon	nikon	PROPN
fnp-5892	36	6	eclipse	eclipse	NOUN
fnp-5892	36	7	ci	ci	NOUN
fnp-5892	36	8	microscope	microscope	NOUN
fnp-5892	36	9	equipped	equip	VERB
fnp-5892	36	10	with	with	ADP
fnp-5892	36	11	nikon	nikon	PROPN
fnp-5892	36	12	digital	digital	ADJ
fnp-5892	36	13	sight	sight	NOUN
fnp-5892	36	14	ds	ds	ADJ
fnp-5892	36	15	-	-	ADJ
fnp-5892	36	16	fi2	fi2	ADJ
fnp-5892	36	17	camera	camera	NOUN
fnp-5892	36	18	(	(	PUNCT
fnp-5892	36	19	nikon	nikon	PROPN
fnp-5892	36	20	instruments	instruments	PROPN
fnp-5892	36	21	inc	inc	PROPN
fnp-5892	36	22	.	.	PROPN
fnp-5892	36	23	,	,	PUNCT
fnp-5892	36	24	melville	melville	PROPN
fnp-5892	36	25	,	,	PUNCT
fnp-5892	36	26	ny	ny	PROPN
fnp-5892	36	27	)	)	PUNCT
fnp-5892	37	1	[	[	X
fnp-5892	37	2	4	4	NUM
fnp-5892	37	3	]	]	PUNCT
fnp-5892	37	4	.	.	PUNCT
fnp-5892	38	1	an	an	DET
fnp-5892	38	2	integrated	integrate	VERB
fnp-5892	38	3	histologic	histologic	ADJ
fnp-5892	38	4	and	and	CCONJ
fnp-5892	38	5	molecular	molecular	ADJ
fnp-5892	38	6	diagnosis	diagnosis	NOUN
fnp-5892	38	7	,	,	PUNCT
fnp-5892	38	8	according	accord	VERB
fnp-5892	38	9	to	to	ADP
fnp-5892	38	10	the	the	DET
fnp-5892	38	11	most	most	ADV
fnp-5892	38	12	recent	recent	ADJ
fnp-5892	38	13	who	who	PRON
fnp-5892	38	14	guidelines	guideline	VERB
fnp-5892	38	15	[	[	X
fnp-5892	38	16	2	2	NUM
fnp-5892	38	17	]	]	PUNCT
fnp-5892	38	18	was	be	AUX
fnp-5892	38	19	obtained	obtain	VERB
fnp-5892	38	20	for	for	ADP
fnp-5892	38	21	all	all	DET
fnp-5892	38	22	cases	case	NOUN
fnp-5892	38	23	,	,	PUNCT
fnp-5892	38	24	prior	prior	ADV
fnp-5892	38	25	to	to	ADP
fnp-5892	38	26	classifying	classify	VERB
fnp-5892	38	27	them	they	PRON
fnp-5892	38	28	in	in	ADP
fnp-5892	38	29	the	the	DET
fnp-5892	38	30	g1	g1	NOUN
fnp-5892	38	31	–	–	PUNCT
fnp-5892	38	32	g7	g7	PROPN
fnp-5892	38	33	molecular	molecular	ADJ
fnp-5892	38	34	subgroups	subgroup	NOUN
fnp-5892	38	35	[	[	X
fnp-5892	38	36	4,5	4,5	NUM
fnp-5892	38	37	]	]	PUNCT
fnp-5892	38	38	.	.	PUNCT
fnp-5892	39	1	next	next	ADJ
fnp-5892	39	2	generation	generation	NOUN
fnp-5892	39	3	sequencing	sequence	VERB
fnp-5892	39	4	(	(	PUNCT
fnp-5892	39	5	ngs	ng	NOUN
fnp-5892	39	6	)	)	PUNCT
fnp-5892	39	7	,	,	PUNCT
fnp-5892	39	8	copy	copy	VERB
fnp-5892	39	9	number	number	NOUN
fnp-5892	39	10	variation	variation	NOUN
fnp-5892	39	11	(	(	PUNCT
fnp-5892	39	12	cnv	cnv	NOUN
fnp-5892	39	13	)	)	PUNCT
fnp-5892	39	14	,	,	PUNCT
fnp-5892	39	15	and	and	CCONJ
fnp-5892	39	16	transcriptomics	transcriptomic	NOUN
fnp-5892	39	17	.	.	PUNCT
fnp-5892	40	1	the	the	DET
fnp-5892	40	2	dna	dna	PROPN
fnp-5892	40	3	and	and	CCONJ
fnp-5892	40	4	rna	rna	NOUN
fnp-5892	40	5	ngs	ng	NOUN
fnp-5892	40	6	analyses	analysis	NOUN
fnp-5892	40	7	were	be	AUX
fnp-5892	40	8	performed	perform	VERB
fnp-5892	40	9	from	from	ADP
fnp-5892	40	10	ffpe	ffpe	NOUN
fnp-5892	40	11	samples	sample	NOUN
fnp-5892	40	12	by	by	ADP
fnp-5892	40	13	using	use	VERB
fnp-5892	40	14	the	the	DET
fnp-5892	40	15	xt-648	xt-648	NOUN
fnp-5892	40	16	-	-	PUNCT
fnp-5892	40	17	gene	gene	NOUN
fnp-5892	40	18	panel	panel	NOUN
fnp-5892	40	19	(	(	PUNCT
fnp-5892	40	20	tempus	tempus	PROPN
fnp-5892	40	21	labs	labs	PROPN
fnp-5892	40	22	,	,	PUNCT
fnp-5892	40	23	chicago	chicago	PROPN
fnp-5892	40	24	,	,	PUNCT
fnp-5892	40	25	il	il	PROPN
fnp-5892	40	26	)	)	PUNCT
fnp-5892	40	27	,	,	PUNCT
fnp-5892	40	28	as	as	SCONJ
fnp-5892	40	29	previously	previously	ADV
fnp-5892	40	30	described	describe	VERB
fnp-5892	40	31	[	[	PRON
fnp-5892	40	32	15,17,18	15,17,18	NUM
fnp-5892	40	33	]	]	X
fnp-5892	40	34	.	.	PUNCT
fnp-5892	41	1	for	for	ADP
fnp-5892	41	2	each	each	DET
fnp-5892	41	3	case	case	NOUN
fnp-5892	41	4	,	,	PUNCT
fnp-5892	41	5	the	the	DET
fnp-5892	41	6	same	same	ADJ
fnp-5892	41	7	ffpe	ffpe	NOUN
fnp-5892	41	8	block	block	NOUN
fnp-5892	41	9	was	be	AUX
fnp-5892	41	10	used	use	VERB
fnp-5892	41	11	for	for	ADP
fnp-5892	41	12	dna	dna	PROPN
fnp-5892	41	13	and	and	CCONJ
fnp-5892	41	14	rna	rna	NOUN
fnp-5892	41	15	extraction	extraction	NOUN
fnp-5892	41	16	to	to	PART
fnp-5892	41	17	allow	allow	VERB
fnp-5892	41	18	direct	direct	ADJ
fnp-5892	41	19	comparison	comparison	NOUN
fnp-5892	41	20	of	of	ADP
fnp-5892	41	21	results	result	NOUN
fnp-5892	41	22	.	.	PUNCT
fnp-5892	42	1	variant	variant	NOUN
fnp-5892	42	2	and	and	CCONJ
fnp-5892	42	3	cnv	cnv	NOUN
fnp-5892	42	4	assessment	assessment	NOUN
fnp-5892	42	5	and	and	CCONJ
fnp-5892	42	6	interpretation	interpretation	NOUN
fnp-5892	42	7	,	,	PUNCT
fnp-5892	42	8	and	and	CCONJ
fnp-5892	42	9	the	the	DET
fnp-5892	42	10	rna	rna	NOUN
fnp-5892	42	11	expression	expression	NOUN
fnp-5892	42	12	analysis	analysis	NOUN
fnp-5892	42	13	were	be	AUX
fnp-5892	42	14	performed	perform	VERB
fnp-5892	42	15	as	as	SCONJ
fnp-5892	42	16	extensively	extensively	ADV
fnp-5892	42	17	described	describe	VERB
fnp-5892	42	18	elsewhere	elsewhere	ADV
fnp-5892	43	1	[	[	X
fnp-5892	43	2	15,18	15,18	NUM
fnp-5892	43	3	]	]	PUNCT
fnp-5892	43	4	.	.	PUNCT
fnp-5892	44	1	assessment	assessment	NOUN
fnp-5892	44	2	of	of	ADP
fnp-5892	44	3	mutation	mutation	NOUN
fnp-5892	44	4	germline	germline	NOUN
fnp-5892	44	5	origin	origin	NOUN
fnp-5892	44	6	.	.	PUNCT
fnp-5892	45	1	genetic	genetic	ADJ
fnp-5892	45	2	testing	testing	NOUN
fnp-5892	45	3	from	from	ADP
fnp-5892	45	4	blood	blood	NOUN
fnp-5892	45	5	was	be	AUX
fnp-5892	45	6	performed	perform	VERB
fnp-5892	45	7	for	for	ADP
fnp-5892	45	8	patient	patient	ADJ
fnp-5892	45	9	f70	f70	PROPN
fnp-5892	45	10	.	.	PUNCT
fnp-5892	46	1	for	for	ADP
fnp-5892	46	2	patients	patient	NOUN
fnp-5892	46	3	m62	m62	PROPN
fnp-5892	46	4	,	,	PUNCT
fnp-5892	46	5	m68	m68	PROPN
fnp-5892	46	6	and	and	CCONJ
fnp-5892	46	7	m72	m72	PROPN
fnp-5892	46	8	,	,	PUNCT
fnp-5892	46	9	the	the	DET
fnp-5892	46	10	germline	germline	NOUN
fnp-5892	46	11	origin	origin	NOUN
fnp-5892	46	12	was	be	AUX
fnp-5892	46	13	inferred	infer	VERB
fnp-5892	46	14	by	by	ADP
fnp-5892	46	15	comparing	compare	VERB
fnp-5892	46	16	the	the	DET
fnp-5892	46	17	variant	variant	ADJ
fnp-5892	46	18	allele	allele	NOUN
fnp-5892	46	19	fraction	fraction	NOUN
fnp-5892	46	20	(	(	PUNCT
fnp-5892	46	21	vaf	vaf	NOUN
fnp-5892	46	22	)	)	PUNCT
fnp-5892	46	23	for	for	ADP
fnp-5892	46	24	the	the	DET
fnp-5892	46	25	mmr	mmr	PROPN
fnp-5892	46	26	mutations	mutation	NOUN
fnp-5892	46	27	and	and	CCONJ
fnp-5892	46	28	the	the	DET
fnp-5892	46	29	vaf	vaf	NOUN
fnp-5892	46	30	for	for	ADP
fnp-5892	46	31	somatic	somatic	ADJ
fnp-5892	46	32	heterozygous	heterozygous	ADJ
fnp-5892	46	33	mutations	mutation	NOUN
fnp-5892	46	34	(	(	PUNCT
fnp-5892	46	35	e.g.	e.g.	ADV
fnp-5892	46	36	pten	pten	VERB
fnp-5892	46	37	,	,	PUNCT
fnp-5892	46	38	pik3ca	pik3ca	PROPN
fnp-5892	46	39	,	,	PUNCT
fnp-5892	46	40	tp53	tp53	PROPN
fnp-5892	46	41	)	)	PUNCT
fnp-5892	46	42	,	,	PUNCT
fnp-5892	46	43	in	in	ADP
fnp-5892	46	44	parallel	parallel	NOUN
fnp-5892	46	45	with	with	ADP
fnp-5892	46	46	cnv	cnv	PROPN
fnp-5892	46	47	analysis	analysis	NOUN
fnp-5892	46	48	.	.	PUNCT
fnp-5892	47	1	a	a	DET
fnp-5892	47	2	clear	clear	ADJ
fnp-5892	47	3	distinction	distinction	NOUN
fnp-5892	47	4	between	between	ADP
fnp-5892	47	5	the	the	DET
fnp-5892	47	6	vaf	vaf	NOUN
fnp-5892	47	7	in	in	ADP
fnp-5892	47	8	the	the	DET
fnp-5892	47	9	germline	germline	NOUN
fnp-5892	47	10	versus	versus	ADP
fnp-5892	47	11	somatic	somatic	ADJ
fnp-5892	47	12	range	range	NOUN
fnp-5892	47	13	was	be	AUX
fnp-5892	47	14	present	present	ADJ
fnp-5892	47	15	in	in	ADP
fnp-5892	47	16	each	each	PRON
fnp-5892	47	17	of	of	ADP
fnp-5892	47	18	these	these	DET
fnp-5892	47	19	cases	case	NOUN
fnp-5892	47	20	(	(	PUNCT
fnp-5892	47	21	see	see	VERB
fnp-5892	47	22	suppl	suppl	ADJ
fnp-5892	47	23	.	.	PUNCT
fnp-5892	47	24	table	table	NOUN
fnp-5892	47	25	 	 	SPACE
fnp-5892	47	26	s1	s1	NOUN
fnp-5892	47	27	)	)	PUNCT
fnp-5892	47	28	.	.	PUNCT
fnp-5892	48	1	when	when	SCONJ
fnp-5892	48	2	possible	possible	ADJ
fnp-5892	48	3	,	,	PUNCT
fnp-5892	48	4	this	this	DET
fnp-5892	48	5	method	method	NOUN
fnp-5892	48	6	was	be	AUX
fnp-5892	48	7	extended	extend	VERB
fnp-5892	48	8	to	to	ADP
fnp-5892	48	9	the	the	DET
fnp-5892	48	10	rest	rest	NOUN
fnp-5892	48	11	of	of	ADP
fnp-5892	48	12	mmr	mmr	PROPN
fnp-5892	48	13	mutations	mutation	NOUN
fnp-5892	48	14	from	from	ADP
fnp-5892	48	15	tumors	tumor	NOUN
fnp-5892	48	16	not	not	PART
fnp-5892	48	17	mapping	map	VERB
fnp-5892	48	18	to	to	ADP
fnp-5892	48	19	the	the	DET
fnp-5892	48	20	g3	g3	PROPN
fnp-5892	48	21	/	/	SYM
fnp-5892	48	22	mmr	mmr	PROPN
fnp-5892	48	23	subgroup	subgroup	NOUN
fnp-5892	48	24	(	(	PUNCT
fnp-5892	48	25	see	see	VERB
fnp-5892	48	26	suppl	suppl	ADJ
fnp-5892	48	27	.	.	PUNCT
fnp-5892	48	28	table	table	NOUN
fnp-5892	48	29	 	 	SPACE
fnp-5892	48	30	s2	s2	PROPN
fnp-5892	48	31	)	)	PUNCT
fnp-5892	48	32	.	.	PUNCT
fnp-5892	49	1	this	this	DET
fnp-5892	49	2	assessment	assessment	NOUN
fnp-5892	49	3	based	base	VERB
fnp-5892	49	4	on	on	ADP
fnp-5892	49	5	vaf	vaf	PROPN
fnp-5892	49	6	showed	show	VERB
fnp-5892	49	7	reliable	reliable	ADJ
fnp-5892	49	8	somatic	somatic	NOUN
fnp-5892	49	9	versus	versus	ADP
fnp-5892	49	10	germline	germline	NOUN
fnp-5892	49	11	prediction	prediction	NOUN
fnp-5892	49	12	on	on	ADP
fnp-5892	49	13	the	the	DET
fnp-5892	49	14	ngs	ng	NOUN
fnp-5892	49	15	platform	platform	NOUN
fnp-5892	49	16	used	use	VERB
fnp-5892	49	17	in	in	ADP
fnp-5892	49	18	the	the	DET
fnp-5892	49	19	cases	case	NOUN
fnp-5892	49	20	for	for	ADP
fnp-5892	49	21	which	which	PRON
fnp-5892	49	22	genetic	genetic	ADJ
fnp-5892	49	23	testing	testing	NOUN
fnp-5892	49	24	was	be	AUX
fnp-5892	49	25	performed	perform	VERB
fnp-5892	49	26	in	in	ADP
fnp-5892	49	27	parallel	parallel	NOUN
fnp-5892	49	28	[	[	X
fnp-5892	49	29	15,17–19	15,17–19	NOUN
fnp-5892	49	30	]	]	PUNCT
fnp-5892	49	31	.	.	PUNCT
fnp-5892	50	1	statistical	statistical	ADJ
fnp-5892	50	2	analysis	analysis	NOUN
fnp-5892	50	3	.	.	PUNCT
fnp-5892	51	1	survival	survival	PROPN
fnp-5892	51	2	kaplan	kaplan	PROPN
fnp-5892	51	3	-	-	PROPN
fnp-5892	51	4	meyer	meyer	PROPN
fnp-5892	51	5	curves	curve	NOUN
fnp-5892	51	6	were	be	AUX
fnp-5892	51	7	analyzed	analyze	VERB
fnp-5892	51	8	by	by	ADP
fnp-5892	51	9	log	log	NOUN
fnp-5892	51	10	-	-	PUNCT
fnp-5892	51	11	rank	rank	NOUN
fnp-5892	51	12	(	(	PUNCT
fnp-5892	51	13	mantel	mantel	NOUN
fnp-5892	51	14	-	-	PUNCT
fnp-5892	51	15	cox	cox	NOUN
fnp-5892	51	16	)	)	PUNCT
fnp-5892	51	17	and	and	CCONJ
fnp-5892	51	18	gehan	gehan	NOUN
fnp-5892	51	19	-	-	PUNCT
fnp-5892	51	20	breslow	breslow	NOUN
fnp-5892	51	21	-	-	PUNCT
fnp-5892	51	22	wilcoxon	wilcoxon	ADJ
fnp-5892	51	23	tests	test	NOUN
fnp-5892	51	24	for	for	ADP
fnp-5892	51	25	statistical	statistical	ADJ
fnp-5892	51	26	significance	significance	NOUN
fnp-5892	51	27	,	,	PUNCT
fnp-5892	51	28	as	as	SCONJ
fnp-5892	51	29	described	describe	VERB
fnp-5892	51	30	[	[	X
fnp-5892	51	31	4,5	4,5	NUM
fnp-5892	51	32	]	]	PUNCT
fnp-5892	51	33	.	.	PUNCT
fnp-5892	52	1	parametric	parametric	PROPN
fnp-5892	52	2	unpaired	unpaired	ADJ
fnp-5892	52	3	t	t	NOUN
fnp-5892	52	4	-	-	PUNCT
fnp-5892	52	5	test	test	NOUN
fnp-5892	52	6	with	with	ADP
fnp-5892	52	7	welch	welch	PROPN
fnp-5892	52	8	’s	’s	PART
fnp-5892	52	9	correction	correction	NOUN
fnp-5892	52	10	was	be	AUX
fnp-5892	52	11	performed	perform	VERB
fnp-5892	52	12	by	by	ADP
fnp-5892	52	13	using	use	VERB
fnp-5892	52	14	graphpad	graphpad	NOUN
fnp-5892	52	15	prism	prism	NOUN
fnp-5892	52	16	(	(	PUNCT
fnp-5892	52	17	version	version	NOUN
fnp-5892	52	18	10.2.3	10.2.3	NUM
fnp-5892	52	19	,	,	PUNCT
fnp-5892	52	20	graphpad	graphpad	NOUN
fnp-5892	52	21	software	software	NOUN
fnp-5892	52	22	,	,	PUNCT
fnp-5892	52	23	la	la	PROPN
fnp-5892	52	24	jolla	jolla	PROPN
fnp-5892	52	25	,	,	PUNCT
fnp-5892	52	26	ca	ca	NOUN
fnp-5892	52	27	)	)	PUNCT
fnp-5892	52	28	.	.	PUNCT
fnp-5892	53	1	statistical	statistical	ADJ
fnp-5892	53	2	significance	significance	NOUN
fnp-5892	53	3	was	be	AUX
fnp-5892	53	4	considered	consider	VERB
fnp-5892	53	5	for	for	ADP
fnp-5892	53	6	p	p	X
fnp-5892	53	7	 	 	SPACE
fnp-5892	53	8	<	<	X
fnp-5892	53	9	 	 	SPACE
fnp-5892	53	10	0.05	0.05	NUM
fnp-5892	53	11	,	,	PUNCT
fnp-5892	53	12	and	and	CCONJ
fnp-5892	53	13	confidence	confidence	NOUN
fnp-5892	53	14	intervals	interval	NOUN
fnp-5892	53	15	were	be	AUX
fnp-5892	53	16	95	95	NUM
fnp-5892	53	17	 	 	SPACE
fnp-5892	53	18	%	%	NOUN
fnp-5892	53	19	for	for	ADP
fnp-5892	53	20	all	all	DET
fnp-5892	53	21	tests	test	NOUN
fnp-5892	53	22	.	.	PUNCT
fnp-5892	54	1	data	datum	NOUN
fnp-5892	54	2	were	be	AUX
fnp-5892	54	3	analyzed	analyze	VERB
fnp-5892	54	4	and	and	CCONJ
fnp-5892	54	5	plotted	plot	VERB
fnp-5892	54	6	by	by	ADP
fnp-5892	54	7	using	use	VERB
fnp-5892	54	8	microsoft	microsoft	PROPN
fnp-5892	54	9	excel	excel	PROPN
fnp-5892	54	10	(	(	PUNCT
fnp-5892	54	11	microsoft	microsoft	PROPN
fnp-5892	54	12	corp	corp	PROPN
fnp-5892	54	13	.	.	PROPN
fnp-5892	54	14	,	,	PUNCT
fnp-5892	54	15	redmond	redmond	PROPN
fnp-5892	54	16	,	,	PUNCT
fnp-5892	54	17	wa	wa	NOUN
fnp-5892	54	18	)	)	PUNCT
fnp-5892	54	19	,	,	PUNCT
fnp-5892	54	20	and	and	CCONJ
fnp-5892	54	21	graphpad	graphpad	NOUN
fnp-5892	54	22	prism	prism	NOUN
fnp-5892	54	23	.	.	PUNCT
fnp-5892	55	1	results	result	VERB
fnp-5892	55	2	dismal	dismal	ADJ
fnp-5892	55	3	prognosis	prognosis	NOUN
fnp-5892	55	4	of	of	ADP
fnp-5892	55	5	g3	g3	PROPN
fnp-5892	55	6	/	/	SYM
fnp-5892	55	7	mmr	mmr	PROPN
fnp-5892	55	8	glioblastoma	glioblastoma	NOUN
fnp-5892	55	9	patients	patient	NOUN
fnp-5892	55	10	:	:	PUNCT
fnp-5892	55	11	treatment	treatment	NOUN
fnp-5892	55	12	of	of	ADP
fnp-5892	55	13	one	one	NUM
fnp-5892	55	14	patient	patient	NOUN
fnp-5892	55	15	with	with	ADP
fnp-5892	55	16	nivolumab	nivolumab	NOUN
fnp-5892	55	17	-	-	PUNCT
fnp-5892	55	18	ipilimumab	ipilimumab	NOUN
fnp-5892	55	19	immune	immune	ADJ
fnp-5892	55	20	checkpoint	checkpoint	NOUN
fnp-5892	55	21	inhibitors	inhibitor	NOUN
fnp-5892	55	22	improves	improve	VERB
fnp-5892	55	23	outcome	outcome	NOUN
fnp-5892	55	24	.	.	PUNCT
fnp-5892	56	1	in	in	ADP
fnp-5892	56	2	a	a	DET
fnp-5892	56	3	prospectively	prospectively	ADV
fnp-5892	56	4	assembled	assemble	VERB
fnp-5892	56	5	cohort	cohort	NOUN
fnp-5892	56	6	of	of	ADP
fnp-5892	56	7	218	218	NUM
fnp-5892	56	8	glioblastoma	glioblastoma	NOUN
fnp-5892	56	9	patients	patient	NOUN
fnp-5892	56	10	where	where	SCONJ
fnp-5892	56	11	all	all	DET
fnp-5892	56	12	the	the	DET
fnp-5892	56	13	tumors	tumor	NOUN
fnp-5892	56	14	were	be	AUX
fnp-5892	56	15	subjected	subject	VERB
fnp-5892	56	16	to	to	ADP
fnp-5892	56	17	dna	dna	PROPN
fnp-5892	56	18	and	and	CCONJ
fnp-5892	56	19	rna	rna	NOUN
fnp-5892	56	20	ngs	ng	NOUN
fnp-5892	56	21	,	,	PUNCT
fnp-5892	56	22	and	and	CCONJ
fnp-5892	56	23	classified	classify	VERB
fnp-5892	56	24	in	in	ADP
fnp-5892	56	25	molecular	molecular	ADJ
fnp-5892	56	26	subgroups	subgroup	NOUN
fnp-5892	56	27	according	accord	VERB
fnp-5892	56	28	to	to	ADP
fnp-5892	56	29	the	the	DET
fnp-5892	56	30	mapk	mapk	NOUN
fnp-5892	56	31	-	-	PUNCT
fnp-5892	56	32	based	base	VERB
fnp-5892	56	33	g1	g1	NOUN
fnp-5892	56	34	–	–	PUNCT
fnp-5892	56	35	g7	g7	PROPN
fnp-5892	56	36	subgroup	subgroup	NOUN
fnp-5892	56	37	classification	classification	NOUN
fnp-5892	56	38	[	[	X
fnp-5892	56	39	4,5	4,5	NUM
fnp-5892	56	40	]	]	PUNCT
fnp-5892	56	41	,	,	PUNCT
fnp-5892	56	42	five	five	NUM
fnp-5892	56	43	cases	case	NOUN
fnp-5892	56	44	with	with	ADP
fnp-5892	56	45	germline	germline	NOUN
fnp-5892	56	46	mutations	mutation	NOUN
fnp-5892	56	47	in	in	ADP
fnp-5892	56	48	mmr	mmr	PROPN
fnp-5892	56	49	genes	gene	NOUN
fnp-5892	56	50	stood	stand	VERB
fnp-5892	56	51	apart	apart	ADV
fnp-5892	56	52	as	as	ADP
fnp-5892	56	53	a	a	DET
fnp-5892	56	54	separate	separate	ADJ
fnp-5892	56	55	subset	subset	NOUN
fnp-5892	56	56	,	,	PUNCT
fnp-5892	56	57	g3	g3	PROPN
fnp-5892	56	58	/	/	SYM
fnp-5892	56	59	mmr	mmr	PROPN
fnp-5892	56	60	(	(	PUNCT
fnp-5892	56	61	fig	fig	NOUN
fnp-5892	56	62	.	.	PUNCT
fnp-5892	56	63	 	 	SPACE
fnp-5892	56	64	1a	1a	NOUN
fnp-5892	56	65	)	)	PUNCT
fnp-5892	56	66	.	.	PUNCT
fnp-5892	57	1	the	the	DET
fnp-5892	57	2	g3	g3	PROPN
fnp-5892	57	3	/	/	SYM
fnp-5892	57	4	mmr	mmr	PROPN
fnp-5892	57	5	subgroup	subgroup	PROPN
fnp-5892	57	6	represented	represent	VERB
fnp-5892	57	7	approximately	approximately	ADV
fnp-5892	57	8	2	2	NUM
fnp-5892	57	9	 	 	SPACE
fnp-5892	57	10	%	%	NOUN
fnp-5892	57	11	of	of	ADP
fnp-5892	57	12	the	the	DET
fnp-5892	57	13	glioblastoma	glioblastoma	NOUN
fnp-5892	57	14	cohort	cohort	NOUN
fnp-5892	57	15	,	,	PUNCT
fnp-5892	57	16	and	and	CCONJ
fnp-5892	57	17	showed	show	VERB
fnp-5892	57	18	distinctive	distinctive	ADJ
fnp-5892	57	19	clinical	clinical	ADJ
fnp-5892	57	20	,	,	PUNCT
fnp-5892	57	21	histologic	histologic	ADJ
fnp-5892	57	22	and	and	CCONJ
fnp-5892	57	23	molecular	molecular	ADJ
fnp-5892	57	24	characteristics	characteristic	NOUN
fnp-5892	57	25	,	,	PUNCT
fnp-5892	57	26	summarized	summarize	VERB
fnp-5892	57	27	in	in	ADP
fnp-5892	57	28	table	table	NOUN
fnp-5892	57	29	 	 	SPACE
fnp-5892	57	30	1	1	NUM
fnp-5892	57	31	.	.	PUNCT
fnp-5892	58	1	the	the	DET
fnp-5892	58	2	g3	g3	PROPN
fnp-5892	58	3	/	/	SYM
fnp-5892	58	4	mmr	mmr	PROPN
fnp-5892	58	5	patients	patient	NOUN
fnp-5892	58	6	frequently	frequently	ADV
fnp-5892	58	7	had	have	VERB
fnp-5892	58	8	a	a	DET
fnp-5892	58	9	clinical	clinical	ADJ
fnp-5892	58	10	history	history	NOUN
fnp-5892	58	11	of	of	ADP
fnp-5892	58	12	prior	prior	ADJ
fnp-5892	58	13	cancers	cancer	NOUN
fnp-5892	58	14	,	,	PUNCT
fnp-5892	58	15	sometimes	sometimes	ADV
fnp-5892	58	16	with	with	ADP
fnp-5892	58	17	multiple	multiple	ADJ
fnp-5892	58	18	different	different	ADJ
fnp-5892	58	19	malignancies	malignancy	NOUN
fnp-5892	58	20	,	,	PUNCT
fnp-5892	58	21	the	the	DET
fnp-5892	58	22	most	most	ADV
fnp-5892	58	23	commonly	commonly	ADV
fnp-5892	58	24	reported	report	VERB
fnp-5892	58	25	being	be	AUX
fnp-5892	58	26	crc	crc	NOUN
fnp-5892	58	27	in	in	ADP
fnp-5892	58	28	two	two	NUM
fnp-5892	58	29	of	of	ADP
fnp-5892	58	30	the	the	DET
fnp-5892	58	31	five	five	NUM
fnp-5892	58	32	patients	patient	NOUN
fnp-5892	58	33	.	.	PUNCT
fnp-5892	59	1	skin	skin	NOUN
fnp-5892	59	2	cancer	cancer	NOUN
fnp-5892	59	3	,	,	PUNCT
fnp-5892	59	4	either	either	CCONJ
fnp-5892	59	5	melanoma	melanoma	NOUN
fnp-5892	59	6	or	or	CCONJ
fnp-5892	59	7	basal	basal	ADJ
fnp-5892	59	8	cell	cell	NOUN
fnp-5892	59	9	carcinoma	carcinoma	NOUN
fnp-5892	59	10	,	,	PUNCT
fnp-5892	59	11	was	be	AUX
fnp-5892	59	12	also	also	ADV
fnp-5892	59	13	relatively	relatively	ADV
fnp-5892	59	14	common	common	ADJ
fnp-5892	59	15	in	in	ADP
fnp-5892	59	16	these	these	DET
fnp-5892	59	17	patients	patient	NOUN
fnp-5892	59	18	,	,	PUNCT
fnp-5892	59	19	and	and	CCONJ
fnp-5892	59	20	lymphoma	lymphoma	NOUN
fnp-5892	59	21	and	and	CCONJ
fnp-5892	59	22	thyroid	thyroid	VERB
fnp-5892	59	23	carcinoma	carcinoma	NOUN
fnp-5892	59	24	less	less	ADV
fnp-5892	59	25	common	common	ADJ
fnp-5892	59	26	(	(	PUNCT
fnp-5892	59	27	table	table	NOUN
fnp-5892	59	28	 	 	SPACE
fnp-5892	59	29	1	1	NUM
fnp-5892	59	30	)	)	PUNCT
fnp-5892	59	31	.	.	PUNCT
fnp-5892	60	1	figure	figure	VERB
fnp-5892	60	2	1	1	NUM
fnp-5892	60	3	:	:	PUNCT
fnp-5892	60	4	location	location	NOUN
fnp-5892	60	5	of	of	ADP
fnp-5892	60	6	g3	g3	PROPN
fnp-5892	60	7	/	/	SYM
fnp-5892	60	8	mmr	mmr	PROPN
fnp-5892	60	9	molecular	molecular	ADJ
fnp-5892	60	10	subgroup	subgroup	NOUN
fnp-5892	60	11	tumors	tumor	NOUN
fnp-5892	60	12	a.	a.	NOUN
fnp-5892	60	13	pie	pie	PROPN
fnp-5892	60	14	chart	chart	NOUN
fnp-5892	60	15	distribution	distribution	NOUN
fnp-5892	60	16	(	(	PUNCT
fnp-5892	60	17	%	%	INTJ
fnp-5892	60	18	)	)	PUNCT
fnp-5892	60	19	of	of	ADP
fnp-5892	60	20	218	218	NUM
fnp-5892	60	21	prospective	prospective	ADJ
fnp-5892	60	22	glioblastoma	glioblastoma	NOUN
fnp-5892	60	23	cases	case	NOUN
fnp-5892	60	24	in	in	ADP
fnp-5892	60	25	g1	g1	NOUN
fnp-5892	60	26	–	–	PUNCT
fnp-5892	60	27	g7	g7	PROPN
fnp-5892	60	28	molecular	molecular	ADJ
fnp-5892	60	29	subgroups	subgroup	NOUN
fnp-5892	60	30	.	.	PUNCT
fnp-5892	61	1	purple	purple	ADJ
fnp-5892	61	2	arrow	arrow	NOUN
fnp-5892	61	3	shows	show	VERB
fnp-5892	61	4	the	the	DET
fnp-5892	61	5	g3	g3	PROPN
fnp-5892	61	6	/	/	SYM
fnp-5892	61	7	mmr	mmr	PROPN
fnp-5892	61	8	subgroup	subgroup	NOUN
fnp-5892	61	9	.	.	PUNCT
fnp-5892	62	1	gbm	gbm	NOUN
fnp-5892	62	2	,	,	PUNCT
fnp-5892	62	3	glioblastoma	glioblastoma	NOUN
fnp-5892	62	4	;	;	PUNCT
fnp-5892	62	5	egfr↑	egfr↑	ADJ
fnp-5892	62	6	,	,	PUNCT
fnp-5892	62	7	egfr	egfr	NOUN
fnp-5892	62	8	-	-	PUNCT
fnp-5892	62	9	amplified	amplify	VERB
fnp-5892	62	10	;	;	PUNCT
fnp-5892	62	11	egfrm	egfrm	NOUN
fnp-5892	62	12	,	,	PUNCT
fnp-5892	62	13	egfr	egfr	NOUN
fnp-5892	62	14	-	-	PUNCT
fnp-5892	62	15	mutated	mutate	VERB
fnp-5892	62	16	.	.	PUNCT
fnp-5892	63	1	b.	b.	PROPN
fnp-5892	63	2	regional	regional	ADJ
fnp-5892	63	3	distribution	distribution	NOUN
fnp-5892	63	4	of	of	ADP
fnp-5892	63	5	the	the	DET
fnp-5892	63	6	glioblastomas	glioblastoma	NOUN
fnp-5892	63	7	from	from	ADP
fnp-5892	63	8	the	the	DET
fnp-5892	63	9	g3	g3	PROPN
fnp-5892	63	10	/	/	SYM
fnp-5892	63	11	mmr	mmr	PROPN
fnp-5892	63	12	,	,	PUNCT
fnp-5892	63	13	as	as	SCONJ
fnp-5892	63	14	compared	compare	VERB
fnp-5892	63	15	to	to	ADP
fnp-5892	63	16	the	the	DET
fnp-5892	63	17	rest	rest	NOUN
fnp-5892	63	18	of	of	ADP
fnp-5892	63	19	the	the	DET
fnp-5892	63	20	cohort	cohort	NOUN
fnp-5892	63	21	(	(	PUNCT
fnp-5892	63	22	gbm	gbm	PROPN
fnp-5892	63	23	)	)	PUNCT
fnp-5892	63	24	.	.	PUNCT
fnp-5892	64	1	cc	cc	PROPN
fnp-5892	64	2	,	,	PUNCT
fnp-5892	64	3	corpus	corpus	NOUN
fnp-5892	64	4	callosum	callosum	NOUN
fnp-5892	64	5	.	.	PUNCT
fnp-5892	65	1	c.	c.	PROPN
fnp-5892	65	2	selected	select	VERB
fnp-5892	65	3	mri	mri	NOUN
fnp-5892	65	4	images	image	NOUN
fnp-5892	65	5	showing	show	VERB
fnp-5892	65	6	multifocality	multifocality	NOUN
fnp-5892	65	7	(	(	PUNCT
fnp-5892	65	8	red	red	ADJ
fnp-5892	65	9	arrows	arrow	NOUN
fnp-5892	65	10	)	)	PUNCT
fnp-5892	65	11	and	and	CCONJ
fnp-5892	65	12	brainstem	brainstem	NOUN
fnp-5892	65	13	infiltration	infiltration	NOUN
fnp-5892	65	14	(	(	PUNCT
fnp-5892	65	15	blue	blue	ADJ
fnp-5892	65	16	arrow	arrow	NOUN
fnp-5892	65	17	)	)	PUNCT
fnp-5892	65	18	in	in	ADP
fnp-5892	65	19	three	three	NUM
fnp-5892	65	20	g3	g3	PROPN
fnp-5892	65	21	/	/	SYM
fnp-5892	65	22	mmr	mmr	PROPN
fnp-5892	65	23	cases	case	NOUN
fnp-5892	65	24	.	.	PUNCT
fnp-5892	66	1	*	*	PUNCT
fnp-5892	66	2	gbm	gbm	PROPN
fnp-5892	66	3	-	-	ADJ
fnp-5892	66	4	mmr	mmr	PROPN
fnp-5892	66	5	n=213	n=213	PROPN
fnp-5892	66	6	1(192	1(192	NUM
fnp-5892	66	7	)	)	PUNCT
fnp-5892	66	8	g3	g3	PROPN
fnp-5892	66	9	/	/	SYM
fnp-5892	66	10	mmr	mmr	PROPN
fnp-5892	66	11	n=5	n=5	PROPN
fnp-5892	66	12	m62	m62	PROPN
fnp-5892	66	13	m68	m68	PROPN
fnp-5892	66	14	f70	f70	PROPN
fnp-5892	66	15	f72	f72	PROPN
fnp-5892	66	16	f79	f79	NOUN
fnp-5892	66	17	median	median	ADJ
fnp-5892	66	18	age	age	NOUN
fnp-5892	66	19	:	:	PUNCT
fnp-5892	66	20	years	year	NOUN
fnp-5892	66	21	65	65	NUM
fnp-5892	66	22	1	1	NUM
fnp-5892	66	23	(	(	PUNCT
fnp-5892	66	24	66	66	NUM
fnp-5892	66	25	)	)	PUNCT
fnp-5892	66	26	70	70	NUM
fnp-5892	66	27	62	62	NUM
fnp-5892	66	28	68	68	NUM
fnp-5892	66	29	70	70	NUM
fnp-5892	66	30	72	72	NUM
fnp-5892	66	31	79	79	NUM
fnp-5892	66	32	sex	sex	NOUN
fnp-5892	66	33	m	m	NOUN
fnp-5892	66	34	:	:	PUNCT
fnp-5892	66	35	f	f	PROPN
fnp-5892	66	36	ratio	ratio	NOUN
fnp-5892	66	37	1.5	1.5	NUM
fnp-5892	66	38	 	 	SPACE
fnp-5892	66	39	:	:	PUNCT
fnp-5892	66	40	 	 	SPACE
fnp-5892	66	41	1	1	NUM
fnp-5892	66	42	4	4	NUM
fnp-5892	66	43	 	 	SPACE
fnp-5892	66	44	:	:	PUNCT
fnp-5892	66	45	 	 	SPACE
fnp-5892	66	46	1	1	NUM
fnp-5892	66	47	male	male	ADJ
fnp-5892	66	48	male	male	ADJ
fnp-5892	66	49	female	female	ADJ
fnp-5892	66	50	male	male	ADJ
fnp-5892	66	51	male	male	ADJ
fnp-5892	66	52	race	race	NOUN
fnp-5892	66	53	w	w	NOUN
fnp-5892	66	54	:	:	PUNCT
fnp-5892	66	55	h	h	NOUN
fnp-5892	66	56	ratio	ratio	NOUN
fnp-5892	66	57	53	53	NUM
fnp-5892	66	58	 	 	SPACE
fnp-5892	66	59	:	:	PUNCT
fnp-5892	66	60	 	 	SPACE
fnp-5892	66	61	1	1	NUM
fnp-5892	66	62	4	4	NUM
fnp-5892	66	63	 	 	SPACE
fnp-5892	66	64	:	:	PUNCT
fnp-5892	66	65	 	 	SPACE
fnp-5892	66	66	1	1	NUM
fnp-5892	66	67	white	white	ADJ
fnp-5892	66	68	hispanic	hispanic	ADJ
fnp-5892	66	69	white	white	PROPN
fnp-5892	66	70	white	white	PROPN
fnp-5892	66	71	white	white	ADJ
fnp-5892	66	72	history	history	NOUN
fnp-5892	66	73	of	of	ADP
fnp-5892	66	74	prior	prior	ADJ
fnp-5892	66	75	cancer	cancer	NOUN
fnp-5892	66	76	nd	nd	ADV
fnp-5892	66	77	60	60	NUM
fnp-5892	66	78	 	 	SPACE
fnp-5892	66	79	%	%	NOUN
fnp-5892	67	1	no	no	INTJ
fnp-5892	67	2	no	no	DET
fnp-5892	67	3	crc	crc	NOUN
fnp-5892	67	4	bcc	bcc	PROPN
fnp-5892	67	5	,	,	PUNCT
fnp-5892	67	6	lymphoma	lymphoma	VERB
fnp-5892	67	7	melanoma	melanoma	PROPN
fnp-5892	67	8	,	,	PUNCT
fnp-5892	67	9	crc	crc	NOUN
fnp-5892	67	10	,	,	PUNCT
fnp-5892	67	11	thyroid	thyroid	VERB
fnp-5892	67	12	2location	2location	NUM
fnp-5892	67	13	22	22	NUM
fnp-5892	67	14	 	 	SPACE
fnp-5892	67	15	%	%	NOUN
fnp-5892	67	16	midline	midline	NOUN
fnp-5892	67	17	40	40	NUM
fnp-5892	67	18	 	 	SPACE
fnp-5892	67	19	%	%	NOUN
fnp-5892	67	20	midline	midline	NOUN
fnp-5892	67	21	r	r	NOUN
fnp-5892	67	22	bg	bg	NOUN
fnp-5892	67	23	l	l	NOUN
fnp-5892	67	24	frontal	frontal	ADJ
fnp-5892	67	25	r	r	NOUN
fnp-5892	67	26	temporal	temporal	ADJ
fnp-5892	67	27	l	l	NOUN
fnp-5892	67	28	bg	bg	NOUN
fnp-5892	67	29	r	r	NOUN
fnp-5892	67	30	frontal	frontal	ADJ
fnp-5892	67	31	2midline	2midline	NUM
fnp-5892	67	32	/	/	SYM
fnp-5892	67	33	crosses	crosse	NOUN
fnp-5892	67	34	midline	midline	VERB
fnp-5892	67	35	22	22	NUM
fnp-5892	67	36	 	 	SPACE
fnp-5892	67	37	%	%	NOUN
fnp-5892	68	1	60	60	NUM
fnp-5892	68	2	 	 	SPACE
fnp-5892	68	3	%	%	INTJ
fnp-5892	69	1	yes	yes	INTJ
fnp-5892	70	1	no	no	INTJ
fnp-5892	71	1	no	no	INTJ
fnp-5892	72	1	yes	yes	INTJ
fnp-5892	73	1	yes	yes	INTJ
fnp-5892	73	2	2multifocal	2multifocal	NUM
fnp-5892	73	3	nd	nd	NUM
fnp-5892	73	4	60	60	NUM
fnp-5892	73	5	 	 	SPACE
fnp-5892	73	6	%	%	NOUN
fnp-5892	74	1	yes	yes	INTJ
fnp-5892	75	1	yes	yes	INTJ
fnp-5892	76	1	no	no	INTJ
fnp-5892	77	1	yes	yes	INTJ
fnp-5892	77	2	no	no	DET
fnp-5892	77	3	2tumor	2tumor	NUM
fnp-5892	77	4	size	size	NOUN
fnp-5892	77	5	:	:	PUNCT
fnp-5892	77	6	cm	cm	NOUN
fnp-5892	77	7	variable	variable	NOUN
fnp-5892	78	1	large	large	ADJ
fnp-5892	78	2	4.9	4.9	NUM
fnp-5892	78	3	x	x	SYM
fnp-5892	78	4	4.3	4.3	NUM
fnp-5892	78	5	x	x	SYM
fnp-5892	78	6	4.2	4.2	NUM
fnp-5892	78	7	4.3	4.3	NUM
fnp-5892	78	8	x	x	SYM
fnp-5892	78	9	4.1	4.1	NUM
fnp-5892	78	10	x	x	SYM
fnp-5892	78	11	3.1	3.1	NUM
fnp-5892	78	12	7.7	7.7	NUM
fnp-5892	78	13	2.8	2.8	NUM
fnp-5892	78	14	x	x	SYM
fnp-5892	78	15	1.8	1.8	NUM
fnp-5892	78	16	7	7	NUM
fnp-5892	78	17	x	x	SYM
fnp-5892	78	18	5	5	NUM
fnp-5892	78	19	3survival	3survival	NUM
fnp-5892	78	20	:	:	PUNCT
fnp-5892	78	21	months	month	NOUN
fnp-5892	78	22	91	91	NUM
fnp-5892	78	23	(	(	PUNCT
fnp-5892	78	24	8)	8)	NUM
fnp-5892	78	25	3.25	3.25	NUM
fnp-5892	78	26	2	2	NUM
fnp-5892	78	27	3.25	3.25	NUM
fnp-5892	78	28	10	10	NUM
fnp-5892	78	29	1.7	1.7	NUM
fnp-5892	78	30	4.5	4.5	NUM
fnp-5892	78	31	surgery	surgery	NOUN
fnp-5892	78	32	24	24	NUM
fnp-5892	78	33	 	 	SPACE
fnp-5892	78	34	%	%	NOUN
fnp-5892	78	35	biopsy	biopsy	NOUN
fnp-5892	78	36	40	40	NUM
fnp-5892	78	37	 	 	SPACE
fnp-5892	78	38	%	%	NOUN
fnp-5892	78	39	biopsy	biopsy	NOUN
fnp-5892	78	40	biopsy	biopsy	PROPN
fnp-5892	78	41	str	str	PROPN
fnp-5892	78	42	str	str	PROPN
fnp-5892	78	43	biopsy	biopsy	PROPN
fnp-5892	78	44	gtr	gtr	NOUN
fnp-5892	78	45	adjuvant	adjuvant	ADJ
fnp-5892	78	46	treatment	treatment	PROPN
fnp-5892	78	47	none	none	NOUN
fnp-5892	78	48	rt	rt	PROPN
fnp-5892	78	49	/	/	SYM
fnp-5892	78	50	icpi4	icpi4	PROPN
fnp-5892	78	51	rt	rt	PROPN
fnp-5892	78	52	/	/	SYM
fnp-5892	78	53	tmz	tmz	PROPN
fnp-5892	78	54	/	/	SYM
fnp-5892	78	55	icpi	icpi	PROPN
fnp-5892	78	56	none	none	NOUN
fnp-5892	78	57	rt	rt	PROPN
fnp-5892	78	58	/	/	SYM
fnp-5892	78	59	tmz	tmz	PROPN
fnp-5892	78	60	mgmt	mgmt	PROPN
fnp-5892	78	61	promoter	promoter	PROPN
fnp-5892	78	62	methylation	methylation	NOUN
fnp-5892	78	63	negative	negative	ADJ
fnp-5892	78	64	positive	positive	ADJ
fnp-5892	78	65	nd	nd	ADV
fnp-5892	78	66	positive	positive	ADJ
fnp-5892	78	67	nd	nd	NOUN
fnp-5892	78	68	5histologic	5histologic	NUM
fnp-5892	78	69	clusters	cluster	NOUN
fnp-5892	78	70	all	all	PRON
fnp-5892	78	71	5	5	NUM
fnp-5892	78	72	#	#	SYM
fnp-5892	78	73	3	3	NUM
fnp-5892	78	74	and	and	CCONJ
fnp-5892	78	75	#	#	SYM
fnp-5892	78	76	5	5	NUM
fnp-5892	78	77	mix	mix	NOUN
fnp-5892	78	78	#	#	SYM
fnp-5892	78	79	3	3	NUM
fnp-5892	78	80	 	 	SPACE
fnp-5892	78	81	+	+	NOUN
fnp-5892	78	82	 	 	SPACE
fnp-5892	78	83	#	#	SYM
fnp-5892	78	84	5	5	NUM
fnp-5892	78	85	#	#	SYM
fnp-5892	78	86	3	3	NUM
fnp-5892	78	87	/	/	SYM
fnp-5892	78	88	ana	ana	NOUN
fnp-5892	78	89	mix	mix	NOUN
fnp-5892	78	90	#	#	SYM
fnp-5892	78	91	3	3	NUM
fnp-5892	78	92	 	 	SPACE
fnp-5892	78	93	+	+	NOUN
fnp-5892	78	94	 	 	SPACE
fnp-5892	78	95	#	#	SYM
fnp-5892	78	96	5	5	NUM
fnp-5892	78	97	#	#	SYM
fnp-5892	78	98	5	5	NUM
fnp-5892	78	99	/	/	SYM
fnp-5892	78	100	epi	epi	NOUN
fnp-5892	78	101	mix	mix	NOUN
fnp-5892	78	102	#	#	SYM
fnp-5892	78	103	3	3	NUM
fnp-5892	78	104	 	 	SPACE
fnp-5892	78	105	+	+	NOUN
fnp-5892	78	106	 	 	SPACE
fnp-5892	78	107	#	#	SYM
fnp-5892	78	108	5	5	NUM
fnp-5892	78	109	multinucleated	multinucleate	VERB
fnp-5892	78	110	giant	giant	ADJ
fnp-5892	78	111	cells	cell	NOUN
fnp-5892	78	112	18	18	NUM
fnp-5892	78	113	 	 	SPACE
fnp-5892	78	114	%	%	NOUN
fnp-5892	78	115	100	100	NUM
fnp-5892	78	116	 	 	SPACE
fnp-5892	78	117	%	%	INTJ
fnp-5892	79	1	yes	yes	INTJ
fnp-5892	80	1	yes	yes	INTJ
fnp-5892	80	2	yes	yes	INTJ
fnp-5892	80	3	giant	giant	ADJ
fnp-5892	80	4	cell	cell	NOUN
fnp-5892	80	5	gbm	gbm	NOUN
fnp-5892	81	1	yes	yes	INTJ
fnp-5892	81	2	mmr	mmr	PROPN
fnp-5892	81	3	ihc	ihc	PROPN
fnp-5892	81	4	retained	retain	VERB
fnp-5892	81	5	loss	loss	NOUN
fnp-5892	81	6	msh2	msh2	NOUN
fnp-5892	81	7	/	/	PUNCT
fnp-5892	81	8	msh6	msh6	NOUN
fnp-5892	81	9	msh6	msh6	NOUN
fnp-5892	81	10	msh2	msh2	PROPN
fnp-5892	81	11	/	/	PUNCT
fnp-5892	81	12	msh6	msh6	PROPN
fnp-5892	82	1	nd	nd	INTJ
fnp-5892	82	2	msh2	msh2	NOUN
fnp-5892	82	3	/	/	SYM
fnp-5892	82	4	msh6	msh6	PROPN
fnp-5892	82	5	germline	germline	NOUN
fnp-5892	82	6	mutation	mutation	NOUN
fnp-5892	82	7	no	no	DET
fnp-5892	82	8	msh2/6	msh2/6	PROPN
fnp-5892	82	9	msh2	msh2	NOUN
fnp-5892	82	10	/	/	SYM
fnp-5892	82	11	msh6	msh6	NOUN
fnp-5892	82	12	msh6	msh6	NOUN
fnp-5892	82	13	msh6	msh6	PROPN
fnp-5892	82	14	msh2	msh2	PROPN
fnp-5892	82	15	msh6	msh6	NOUN
fnp-5892	82	16	msh2	msh2	PROPN
fnp-5892	82	17	/	/	PUNCT
fnp-5892	82	18	msh6	msh6	PROPN
fnp-5892	82	19	detected	detect	VERB
fnp-5892	82	20	at	at	ADP
fnp-5892	82	21	gbm	gbm	PROPN
fnp-5892	82	22	workup	workup	PROPN
fnp-5892	82	23	na	na	ADP
fnp-5892	82	24	80	80	NUM
fnp-5892	82	25	 	 	SPACE
fnp-5892	82	26	%	%	NOUN
fnp-5892	83	1	yes	yes	INTJ
fnp-5892	84	1	yes	yes	INTJ
fnp-5892	84	2	prior	prior	ADV
fnp-5892	85	1	yes	yes	INTJ
fnp-5892	85	2	yes	yes	INTJ
fnp-5892	85	3	tmb	tmb	NOUN
fnp-5892	85	4	:	:	PUNCT
fnp-5892	85	5	mutations	mutation	NOUN
fnp-5892	85	6	/	/	SYM
fnp-5892	85	7	mb	mb	ADP
fnp-5892	85	8	4.3	4.3	NUM
fnp-5892	85	9	 	 	SPACE
fnp-5892	85	10	±	±	NOUN
fnp-5892	85	11	 	 	SPACE
fnp-5892	85	12	0.1	0.1	NUM
fnp-5892	85	13	24.3	24.3	NUM
fnp-5892	85	14	 	 	SPACE
fnp-5892	85	15	±	±	NOUN
fnp-5892	85	16	 	 	SPACE
fnp-5892	85	17	5.1	5.1	NUM
fnp-5892	85	18	9	9	NUM
fnp-5892	85	19	29.5	29.5	NUM
fnp-5892	85	20	38.9	38.9	NUM
fnp-5892	85	21	17.6	17.6	NUM
fnp-5892	85	22	26.3	26.3	NUM
fnp-5892	85	23	msi	msi	NOUN
fnp-5892	85	24	status	status	PROPN
fnp-5892	85	25	stable	stable	ADJ
fnp-5892	85	26	mixed	mixed	ADJ
fnp-5892	85	27	stable	stable	ADJ
fnp-5892	85	28	stable	stable	ADJ
fnp-5892	85	29	high	high	ADJ
fnp-5892	85	30	nd	nd	ADP
fnp-5892	85	31	stable	stable	ADJ
fnp-5892	85	32	6dna	6dna	NUM
fnp-5892	85	33	mutation	mutation	NOUN
fnp-5892	85	34	signature	signature	NOUN
fnp-5892	85	35	none	none	NOUN
fnp-5892	85	36	mmr	mmr	PROPN
fnp-5892	85	37	mmr	mmr	PROPN
fnp-5892	85	38	mmr	mmr	PROPN
fnp-5892	85	39	mmr	mmr	PROPN
fnp-5892	85	40	mmr	mmr	PROPN
fnp-5892	85	41	mmr	mmr	PROPN
fnp-5892	85	42	table	table	NOUN
fnp-5892	85	43	1	1	NUM
fnp-5892	85	44	:	:	PUNCT
fnp-5892	85	45	demographic	demographic	ADJ
fnp-5892	85	46	,	,	PUNCT
fnp-5892	85	47	clinical	clinical	ADJ
fnp-5892	85	48	,	,	PUNCT
fnp-5892	85	49	radiologic	radiologic	ADJ
fnp-5892	85	50	,	,	PUNCT
fnp-5892	85	51	histologic	histologic	ADJ
fnp-5892	85	52	and	and	CCONJ
fnp-5892	85	53	molecular	molecular	ADJ
fnp-5892	85	54	characteristics	characteristic	NOUN
fnp-5892	85	55	of	of	ADP
fnp-5892	85	56	g3	g3	PROPN
fnp-5892	85	57	/	/	SYM
fnp-5892	85	58	mmr	mmr	PROPN
fnp-5892	85	59	patients	patient	NOUN
fnp-5892	85	60	.	.	PUNCT
fnp-5892	86	1	gbm	gbm	NOUN
fnp-5892	86	2	,	,	PUNCT
fnp-5892	86	3	glioblastoma	glioblastoma	NOUN
fnp-5892	86	4	;	;	PUNCT
fnp-5892	86	5	m	m	NOUN
fnp-5892	86	6	,	,	PUNCT
fnp-5892	86	7	male	male	NOUN
fnp-5892	86	8	;	;	PUNCT
fnp-5892	86	9	f	f	X
fnp-5892	86	10	,	,	PUNCT
fnp-5892	86	11	female	female	NOUN
fnp-5892	86	12	;	;	PUNCT
fnp-5892	86	13	w	w	NOUN
fnp-5892	86	14	,	,	PUNCT
fnp-5892	86	15	white	white	ADJ
fnp-5892	86	16	 	 	SPACE
fnp-5892	86	17	/	/	SYM
fnp-5892	86	18	 	 	SPACE
fnp-5892	86	19	caucasian	caucasian	PROPN
fnp-5892	86	20	;	;	PUNCT
fnp-5892	86	21	h	h	NOUN
fnp-5892	86	22	,	,	PUNCT
fnp-5892	86	23	hispanic	hispanic	ADJ
fnp-5892	86	24	;	;	PUNCT
fnp-5892	86	25	r	r	X
fnp-5892	86	26	,	,	PUNCT
fnp-5892	86	27	right	right	ADJ
fnp-5892	86	28	;	;	PUNCT
fnp-5892	86	29	l	l	NOUN
fnp-5892	86	30	,	,	PUNCT
fnp-5892	86	31	left	leave	VERB
fnp-5892	86	32	;	;	PUNCT
fnp-5892	86	33	bg	bg	PROPN
fnp-5892	86	34	,	,	PUNCT
fnp-5892	86	35	basal	basal	ADJ
fnp-5892	86	36	ganglia	ganglia	NOUN
fnp-5892	86	37	;	;	PUNCT
fnp-5892	86	38	crc	crc	NOUN
fnp-5892	86	39	,	,	PUNCT
fnp-5892	86	40	colorectal	colorectal	ADJ
fnp-5892	86	41	cancer	cancer	NOUN
fnp-5892	86	42	;	;	PUNCT
fnp-5892	86	43	bcc	bcc	PROPN
fnp-5892	86	44	,	,	PUNCT
fnp-5892	86	45	basal	basal	ADJ
fnp-5892	86	46	cell	cell	NOUN
fnp-5892	86	47	carcinoma	carcinoma	NOUN
fnp-5892	86	48	;	;	PUNCT
fnp-5892	86	49	gtr	gtr	NOUN
fnp-5892	86	50	,	,	PUNCT
fnp-5892	86	51	gross	gross	ADJ
fnp-5892	86	52	total	total	ADJ
fnp-5892	86	53	resection	resection	NOUN
fnp-5892	86	54	;	;	PUNCT
fnp-5892	86	55	str	str	NUM
fnp-5892	86	56	,	,	PUNCT
fnp-5892	86	57	subtotal	subtotal	ADJ
fnp-5892	86	58	resection	resection	NOUN
fnp-5892	86	59	;	;	PUNCT
fnp-5892	86	60	rt	rt	PROPN
fnp-5892	86	61	/	/	SYM
fnp-5892	86	62	tmz	tmz	PROPN
fnp-5892	86	63	,	,	PUNCT
fnp-5892	86	64	radiation	radiation	NOUN
fnp-5892	86	65	 	 	SPACE
fnp-5892	86	66	/	/	SYM
fnp-5892	86	67	 	 	SPACE
fnp-5892	86	68	temozolomide	temozolomide	NOUN
fnp-5892	86	69	adjuvant	adjuvant	ADJ
fnp-5892	86	70	therapy	therapy	NOUN
fnp-5892	86	71	;	;	PUNCT
fnp-5892	86	72	icpi	icpi	NOUN
fnp-5892	86	73	,	,	PUNCT
fnp-5892	86	74	immune	immune	ADJ
fnp-5892	86	75	checkpoint	checkpoint	NOUN
fnp-5892	86	76	inhibitors	inhibitor	NOUN
fnp-5892	86	77	;	;	PUNCT
fnp-5892	86	78	nd	nd	NUM
fnp-5892	86	79	,	,	PUNCT
fnp-5892	86	80	not	not	PART
fnp-5892	86	81	determined	determine	VERB
fnp-5892	86	82	;	;	PUNCT
fnp-5892	86	83	na	na	PART
fnp-5892	86	84	,	,	PUNCT
fnp-5892	86	85	not	not	PART
fnp-5892	86	86	applicable	applicable	ADJ
fnp-5892	86	87	.	.	PUNCT
fnp-5892	87	1	*	*	PUNCT
fnp-5892	87	2	gbm	gbm	NOUN
fnp-5892	87	3	cohort	cohort	NOUN
fnp-5892	87	4	without	without	ADP
fnp-5892	87	5	the	the	DET
fnp-5892	87	6	g3	g3	PROPN
fnp-5892	87	7	/	/	SYM
fnp-5892	87	8	mmr	mmr	PROPN
fnp-5892	87	9	cases	case	NOUN
fnp-5892	87	10	.	.	PUNCT
fnp-5892	88	1	1numbers	1numbers	NUM
fnp-5892	88	2	in	in	ADP
fnp-5892	88	3	parenthesis	parenthesis	NOUN
fnp-5892	88	4	apply	apply	VERB
fnp-5892	88	5	to	to	ADP
fnp-5892	88	6	the	the	DET
fnp-5892	88	7	age	age	NOUN
fnp-5892	88	8	-	-	PUNCT
fnp-5892	88	9	corrected	correct	VERB
fnp-5892	88	10	cohort	cohort	NOUN
fnp-5892	88	11	excluding	exclude	VERB
fnp-5892	88	12	less	less	ADJ
fnp-5892	88	13	-	-	PUNCT
fnp-5892	88	14	than-50	than-50	NUM
fnp-5892	88	15	year	year	NOUN
fnp-5892	88	16	-	-	PUNCT
fnp-5892	88	17	old	old	ADJ
fnp-5892	88	18	patients	patient	NOUN
fnp-5892	88	19	.	.	PUNCT
fnp-5892	89	1	2parameters	2parameter	NOUN
fnp-5892	89	2	determined	determine	VERB
fnp-5892	89	3	by	by	ADP
fnp-5892	89	4	pre	pre	ADJ
fnp-5892	89	5	-	-	ADJ
fnp-5892	89	6	operative	operative	ADJ
fnp-5892	89	7	mri	mri	NOUN
fnp-5892	89	8	.	.	PUNCT
fnp-5892	89	9	size	size	NOUN
fnp-5892	89	10	of	of	ADP
fnp-5892	89	11	enhancement	enhancement	NOUN
fnp-5892	89	12	measurements	measurement	NOUN
fnp-5892	89	13	:	:	PUNCT
fnp-5892	89	14	m62	m62	PROPN
fnp-5892	89	15	,	,	PUNCT
fnp-5892	89	16	the	the	DET
fnp-5892	89	17	whole	whole	ADJ
fnp-5892	89	18	enhancing	enhance	VERB
fnp-5892	89	19	area	area	NOUN
fnp-5892	89	20	;	;	PUNCT
fnp-5892	89	21	m68	m68	PROPN
fnp-5892	89	22	and	and	CCONJ
fnp-5892	89	23	m72	m72	PROPN
fnp-5892	89	24	,	,	PUNCT
fnp-5892	89	25	the	the	DET
fnp-5892	89	26	largest	large	ADJ
fnp-5892	89	27	focus	focus	NOUN
fnp-5892	89	28	.	.	PUNCT
fnp-5892	90	1	3median	3median	ADJ
fnp-5892	90	2	survival	survival	NOUN
fnp-5892	90	3	is	be	AUX
fnp-5892	90	4	indicated	indicate	VERB
fnp-5892	90	5	for	for	ADP
fnp-5892	90	6	the	the	DET
fnp-5892	90	7	g3	g3	PROPN
fnp-5892	90	8	/	/	SYM
fnp-5892	90	9	mmr	mmr	PROPN
fnp-5892	90	10	subgroup	subgroup	NOUN
fnp-5892	90	11	and	and	CCONJ
fnp-5892	90	12	for	for	ADP
fnp-5892	90	13	the	the	DET
fnp-5892	90	14	rest	rest	NOUN
fnp-5892	90	15	of	of	ADP
fnp-5892	90	16	the	the	DET
fnp-5892	90	17	cohort	cohort	NOUN
fnp-5892	90	18	(	(	PUNCT
fnp-5892	90	19	gbm	gbm	PROPN
fnp-5892	90	20	–	–	PUNCT
fnp-5892	90	21	mmr	mmr	PROPN
fnp-5892	90	22	)	)	PUNCT
fnp-5892	90	23	with	with	ADP
fnp-5892	90	24	or	or	CCONJ
fnp-5892	90	25	without	without	ADP
fnp-5892	90	26	age	age	NOUN
fnp-5892	90	27	correction	correction	NOUN
fnp-5892	90	28	.	.	PUNCT
fnp-5892	91	1	4rt	4rt	ADJ
fnp-5892	91	2	/	/	SYM
fnp-5892	91	3	icpi	icpi	NOUN
fnp-5892	91	4	for	for	ADP
fnp-5892	91	5	patient	patient	ADJ
fnp-5892	91	6	m68	m68	PROPN
fnp-5892	91	7	was	be	AUX
fnp-5892	91	8	started	start	VERB
fnp-5892	91	9	1.5	1.5	NUM
fnp-5892	91	10	months	month	NOUN
fnp-5892	91	11	post	post	ADJ
fnp-5892	91	12	-	-	ADJ
fnp-5892	91	13	surgery	surgery	NOUN
fnp-5892	91	14	and	and	CCONJ
fnp-5892	91	15	stopped	stop	VERB
fnp-5892	91	16	3	3	NUM
fnp-5892	91	17	weeks	week	NOUN
fnp-5892	91	18	later	later	ADV
fnp-5892	91	19	as	as	SCONJ
fnp-5892	91	20	the	the	DET
fnp-5892	91	21	tumor	tumor	NOUN
fnp-5892	91	22	progressed	progress	VERB
fnp-5892	91	23	during	during	ADP
fnp-5892	91	24	therapy	therapy	NOUN
fnp-5892	91	25	.	.	PUNCT
fnp-5892	92	1	5histologic	5histologic	NUM
fnp-5892	92	2	clusters	cluster	NOUN
fnp-5892	92	3	include	include	VERB
fnp-5892	92	4	the	the	DET
fnp-5892	92	5	#	#	SYM
fnp-5892	92	6	3	3	NUM
fnp-5892	92	7	/	/	SYM
fnp-5892	92	8	ana	ana	PROPN
fnp-5892	92	9	(	(	PUNCT
fnp-5892	92	10	anaplastic	anaplastic	ADJ
fnp-5892	92	11	)	)	PUNCT
fnp-5892	92	12	and	and	CCONJ
fnp-5892	92	13	#	#	SYM
fnp-5892	92	14	5	5	NUM
fnp-5892	92	15	/	/	SYM
fnp-5892	92	16	epi	epi	NOUN
fnp-5892	92	17	(	(	PUNCT
fnp-5892	92	18	epithelioid	epithelioid	NOUN
fnp-5892	92	19	)	)	PUNCT
fnp-5892	92	20	clusters	cluster	NOUN
fnp-5892	92	21	.	.	PUNCT
fnp-5892	93	1	6the	6the	PROPN
fnp-5892	93	2	mmr	mmr	PROPN
fnp-5892	93	3	-	-	PUNCT
fnp-5892	93	4	type	type	ADJ
fnp-5892	93	5	dna	dna	PROPN
fnp-5892	93	6	mutation	mutation	NOUN
fnp-5892	93	7	signature	signature	NOUN
fnp-5892	93	8	consists	consist	VERB
fnp-5892	93	9	in	in	ADP
fnp-5892	93	10	a	a	DET
fnp-5892	93	11	predominance	predominance	NOUN
fnp-5892	93	12	of	of	ADP
fnp-5892	93	13	c	c	NOUN
fnp-5892	93	14	:	:	PUNCT
fnp-5892	93	15	g	g	NOUN
fnp-5892	93	16	to	to	ADP
fnp-5892	93	17	t	t	PROPN
fnp-5892	93	18	:	:	PUNCT
fnp-5892	93	19	a	a	DET
fnp-5892	93	20	transitions	transition	NOUN
fnp-5892	93	21	.	.	PUNCT
fnp-5892	94	1	the	the	DET
fnp-5892	94	2	survival	survival	NOUN
fnp-5892	94	3	in	in	ADP
fnp-5892	94	4	glioblastoma	glioblastoma	NOUN
fnp-5892	94	5	depends	depend	VERB
fnp-5892	94	6	on	on	ADP
fnp-5892	94	7	many	many	ADJ
fnp-5892	94	8	factors	factor	NOUN
fnp-5892	94	9	,	,	PUNCT
fnp-5892	94	10	and	and	CCONJ
fnp-5892	94	11	these	these	PRON
fnp-5892	94	12	include	include	VERB
fnp-5892	94	13	tumor	tumor	NOUN
fnp-5892	94	14	location	location	NOUN
fnp-5892	94	15	and	and	CCONJ
fnp-5892	94	16	subsequent	subsequent	ADJ
fnp-5892	94	17	extent	extent	NOUN
fnp-5892	94	18	of	of	ADP
fnp-5892	94	19	surgical	surgical	ADJ
fnp-5892	94	20	resection	resection	NOUN
fnp-5892	94	21	,	,	PUNCT
fnp-5892	94	22	age	age	NOUN
fnp-5892	94	23	and	and	CCONJ
fnp-5892	94	24	comorbidities	comorbiditie	NOUN
fnp-5892	94	25	,	,	PUNCT
fnp-5892	94	26	accessibility	accessibility	NOUN
fnp-5892	94	27	to	to	ADP
fnp-5892	94	28	and	and	CCONJ
fnp-5892	94	29	effectiveness	effectiveness	NOUN
fnp-5892	94	30	of	of	ADP
fnp-5892	94	31	adjuvant	adjuvant	ADJ
fnp-5892	94	32	treatment	treatment	NOUN
fnp-5892	94	33	[	[	X
fnp-5892	94	34	20,21	20,21	NUM
fnp-5892	94	35	]	]	PUNCT
fnp-5892	94	36	.	.	PUNCT
fnp-5892	95	1	the	the	DET
fnp-5892	95	2	intrinsic	intrinsic	ADJ
fnp-5892	95	3	aggressivity	aggressivity	NOUN
fnp-5892	95	4	of	of	ADP
fnp-5892	95	5	the	the	DET
fnp-5892	95	6	tumor	tumor	NOUN
fnp-5892	95	7	may	may	AUX
fnp-5892	95	8	also	also	ADV
fnp-5892	95	9	influence	influence	VERB
fnp-5892	95	10	survival	survival	NOUN
fnp-5892	95	11	[	[	X
fnp-5892	95	12	5,21	5,21	X
fnp-5892	95	13	]	]	PUNCT
fnp-5892	95	14	.	.	PUNCT
fnp-5892	96	1	the	the	DET
fnp-5892	96	2	location	location	NOUN
fnp-5892	96	3	of	of	ADP
fnp-5892	96	4	the	the	DET
fnp-5892	96	5	tumors	tumor	NOUN
fnp-5892	96	6	varied	varied	ADJ
fnp-5892	96	7	,	,	PUNCT
fnp-5892	96	8	with	with	ADP
fnp-5892	96	9	a	a	DET
fnp-5892	96	10	high	high	ADJ
fnp-5892	96	11	percentage	percentage	NOUN
fnp-5892	96	12	of	of	ADP
fnp-5892	96	13	tumors	tumor	NOUN
fnp-5892	96	14	showing	show	VERB
fnp-5892	96	15	midline	midline	NOUN
fnp-5892	96	16	location	location	NOUN
fnp-5892	96	17	and	and	CCONJ
fnp-5892	96	18	multifocality	multifocality	NOUN
fnp-5892	96	19	,	,	PUNCT
fnp-5892	96	20	the	the	DET
fnp-5892	96	21	latter	latter	ADJ
fnp-5892	96	22	often	often	ADV
fnp-5892	96	23	interpreted	interpret	VERB
fnp-5892	96	24	as	as	ADP
fnp-5892	96	25	metastatic	metastatic	ADJ
fnp-5892	96	26	disease	disease	NOUN
fnp-5892	96	27	(	(	PUNCT
fnp-5892	96	28	table	table	NOUN
fnp-5892	96	29	 	 	SPACE
fnp-5892	96	30	1	1	NUM
fnp-5892	96	31	,	,	PUNCT
fnp-5892	96	32	fig	fig	NOUN
fnp-5892	96	33	.	.	PUNCT
fnp-5892	96	34	 	 	SPACE
fnp-5892	96	35	1b	1b	NUM
fnp-5892	96	36	–	–	PUNCT
fnp-5892	96	37	c	c	NOUN
fnp-5892	96	38	)	)	PUNCT
fnp-5892	96	39	.	.	PUNCT
fnp-5892	97	1	the	the	DET
fnp-5892	97	2	two	two	NUM
fnp-5892	97	3	multifocal	multifocal	ADJ
fnp-5892	97	4	tumors	tumor	NOUN
fnp-5892	97	5	located	locate	VERB
fnp-5892	97	6	in	in	ADP
fnp-5892	97	7	the	the	DET
fnp-5892	97	8	midline	midline	NOUN
fnp-5892	97	9	that	that	PRON
fnp-5892	97	10	were	be	AUX
fnp-5892	97	11	only	only	ADV
fnp-5892	97	12	biopsied	biopsie	VERB
fnp-5892	97	13	associated	associate	VERB
fnp-5892	97	14	with	with	ADP
fnp-5892	97	15	the	the	DET
fnp-5892	97	16	worst	bad	ADJ
fnp-5892	97	17	survival	survival	NOUN
fnp-5892	97	18	in	in	ADP
fnp-5892	97	19	patients	patient	NOUN
fnp-5892	97	20	m62	m62	PROPN
fnp-5892	97	21	and	and	CCONJ
fnp-5892	97	22	m72	m72	PROPN
fnp-5892	97	23	(	(	PUNCT
fnp-5892	97	24	table	table	NOUN
fnp-5892	97	25	 	 	SPACE
fnp-5892	97	26	1	1	NUM
fnp-5892	97	27	,	,	PUNCT
fnp-5892	97	28	fig	fig	NOUN
fnp-5892	97	29	.	.	PUNCT
fnp-5892	97	30	 	 	SPACE
fnp-5892	97	31	1c	1c	NOUN
fnp-5892	97	32	)	)	PUNCT
fnp-5892	97	33	.	.	PUNCT
fnp-5892	98	1	patient	patient	PROPN
fnp-5892	98	2	m79	m79	PROPN
fnp-5892	98	3	,	,	PUNCT
fnp-5892	98	4	with	with	ADP
fnp-5892	98	5	peripherally	peripherally	ADV
fnp-5892	98	6	located	locate	VERB
fnp-5892	98	7	tumor	tumor	NOUN
fnp-5892	98	8	crossing	cross	VERB
fnp-5892	98	9	the	the	DET
fnp-5892	98	10	midline	midline	NOUN
fnp-5892	98	11	,	,	PUNCT
fnp-5892	98	12	and	and	CCONJ
fnp-5892	98	13	receiving	receive	VERB
fnp-5892	98	14	gross	gross	ADJ
fnp-5892	98	15	total	total	ADJ
fnp-5892	98	16	resection	resection	NOUN
fnp-5892	98	17	and	and	CCONJ
fnp-5892	98	18	standard	standard	ADJ
fnp-5892	98	19	radiation	radiation	NOUN
fnp-5892	98	20	-	-	PUNCT
fnp-5892	98	21	tmz	tmz	NOUN
fnp-5892	98	22	adjuvant	adjuvant	PROPN
fnp-5892	98	23	therapy	therapy	NOUN
fnp-5892	98	24	,	,	PUNCT
fnp-5892	98	25	marginally	marginally	ADV
fnp-5892	98	26	survived	survive	VERB
fnp-5892	98	27	longer	long	ADV
fnp-5892	98	28	.	.	PUNCT
fnp-5892	99	1	patient	patient	PROPN
fnp-5892	99	2	m68	m68	PROPN
fnp-5892	99	3	underwent	undergo	VERB
fnp-5892	99	4	subtotal	subtotal	ADJ
fnp-5892	99	5	resection	resection	NOUN
fnp-5892	99	6	of	of	ADP
fnp-5892	99	7	the	the	DET
fnp-5892	99	8	larger	large	ADJ
fnp-5892	99	9	right	right	ADJ
fnp-5892	99	10	frontal	frontal	ADJ
fnp-5892	99	11	focus	focus	NOUN
fnp-5892	99	12	(	(	PUNCT
fnp-5892	99	13	fig	fig	NOUN
fnp-5892	99	14	.	.	PUNCT
fnp-5892	99	15	 	 	SPACE
fnp-5892	99	16	1c	1c	NOUN
fnp-5892	99	17	)	)	PUNCT
fnp-5892	99	18	,	,	PUNCT
fnp-5892	99	19	and	and	CCONJ
fnp-5892	99	20	had	have	AUX
fnp-5892	99	21	slow	slow	ADJ
fnp-5892	99	22	post	post	ADJ
fnp-5892	99	23	-	-	ADJ
fnp-5892	99	24	surgical	surgical	ADJ
fnp-5892	99	25	recovery	recovery	NOUN
fnp-5892	99	26	,	,	PUNCT
fnp-5892	99	27	during	during	ADP
fnp-5892	99	28	which	which	PRON
fnp-5892	99	29	the	the	DET
fnp-5892	99	30	residual	residual	ADJ
fnp-5892	99	31	tumor	tumor	NOUN
fnp-5892	99	32	focus	focus	NOUN
fnp-5892	99	33	progressed	progress	VERB
fnp-5892	99	34	.	.	PUNCT
fnp-5892	100	1	the	the	DET
fnp-5892	100	2	radiation	radiation	NOUN
fnp-5892	100	3	and	and	CCONJ
fnp-5892	100	4	immune	immune	ADJ
fnp-5892	100	5	checkpoint	checkpoint	NOUN
fnp-5892	100	6	inhibitor	inhibitor	NOUN
fnp-5892	100	7	therapy	therapy	NOUN
fnp-5892	100	8	with	with	ADP
fnp-5892	100	9	pembrolizumab	pembrolizumab	NOUN
fnp-5892	100	10	was	be	AUX
fnp-5892	100	11	initiated	initiate	VERB
fnp-5892	100	12	1.5	1.5	NUM
fnp-5892	100	13	months	month	NOUN
fnp-5892	100	14	post	post	ADJ
fnp-5892	100	15	-	-	ADJ
fnp-5892	100	16	surgery	surgery	NOUN
fnp-5892	100	17	and	and	CCONJ
fnp-5892	100	18	did	do	AUX
fnp-5892	100	19	not	not	PART
fnp-5892	100	20	stop	stop	VERB
fnp-5892	100	21	tumor	tumor	NOUN
fnp-5892	100	22	growth	growth	NOUN
fnp-5892	100	23	,	,	PUNCT
fnp-5892	100	24	being	be	AUX
fnp-5892	100	25	aborted	abort	VERB
fnp-5892	100	26	after	after	ADP
fnp-5892	100	27	3	3	NUM
fnp-5892	100	28	weeks	week	NOUN
fnp-5892	100	29	.	.	PUNCT
fnp-5892	101	1	the	the	DET
fnp-5892	101	2	median	median	ADJ
fnp-5892	101	3	survival	survival	NOUN
fnp-5892	101	4	calculated	calculate	VERB
fnp-5892	101	5	from	from	ADP
fnp-5892	101	6	the	the	DET
fnp-5892	101	7	date	date	NOUN
fnp-5892	101	8	of	of	ADP
fnp-5892	101	9	the	the	DET
fnp-5892	101	10	surgery	surgery	NOUN
fnp-5892	101	11	was	be	AUX
fnp-5892	101	12	3.25	3.25	NUM
fnp-5892	101	13	months	month	NOUN
fnp-5892	101	14	for	for	ADP
fnp-5892	101	15	the	the	DET
fnp-5892	101	16	g3	g3	PROPN
fnp-5892	101	17	/	/	SYM
fnp-5892	101	18	mmr	mmr	PROPN
fnp-5892	101	19	subgroup	subgroup	NOUN
fnp-5892	101	20	patients	patient	NOUN
fnp-5892	101	21	,	,	PUNCT
fnp-5892	101	22	and	and	CCONJ
fnp-5892	101	23	9	9	NUM
fnp-5892	101	24	months	month	NOUN
fnp-5892	101	25	for	for	ADP
fnp-5892	101	26	the	the	DET
fnp-5892	101	27	rest	rest	NOUN
fnp-5892	101	28	of	of	ADP
fnp-5892	101	29	the	the	DET
fnp-5892	101	30	cohort	cohort	NOUN
fnp-5892	101	31	(	(	PUNCT
fnp-5892	101	32	table	table	NOUN
fnp-5892	101	33	 	 	SPACE
fnp-5892	101	34	1	1	NUM
fnp-5892	101	35	)	)	PUNCT
fnp-5892	101	36	.	.	PUNCT
fnp-5892	102	1	the	the	DET
fnp-5892	102	2	survival	survival	NOUN
fnp-5892	102	3	was	be	AUX
fnp-5892	102	4	equally	equally	ADV
fnp-5892	102	5	dismal	dismal	ADJ
fnp-5892	102	6	for	for	ADP
fnp-5892	102	7	four	four	NUM
fnp-5892	102	8	out	out	ADP
fnp-5892	102	9	of	of	ADP
fnp-5892	102	10	the	the	DET
fnp-5892	102	11	5	5	NUM
fnp-5892	102	12	g3	g3	PROPN
fnp-5892	102	13	/	/	SYM
fnp-5892	102	14	mmr	mmr	PROPN
fnp-5892	102	15	patients	patient	NOUN
fnp-5892	102	16	,	,	PUNCT
fnp-5892	102	17	within	within	ADP
fnp-5892	102	18	a	a	DET
fnp-5892	102	19	range	range	NOUN
fnp-5892	102	20	between	between	ADP
fnp-5892	102	21	1.7	1.7	NUM
fnp-5892	102	22	and	and	CCONJ
fnp-5892	102	23	4.5	4.5	NUM
fnp-5892	102	24	months	month	NOUN
fnp-5892	102	25	,	,	PUNCT
fnp-5892	102	26	with	with	ADP
fnp-5892	102	27	only	only	ADV
fnp-5892	102	28	f70	f70	PROPN
fnp-5892	102	29	surviving	survive	VERB
fnp-5892	102	30	to	to	ADP
fnp-5892	102	31	10	10	NUM
fnp-5892	102	32	months	month	NOUN
fnp-5892	102	33	.	.	PUNCT
fnp-5892	103	1	the	the	DET
fnp-5892	103	2	age	age	NOUN
fnp-5892	103	3	range	range	NOUN
fnp-5892	103	4	between	between	ADP
fnp-5892	103	5	62	62	NUM
fnp-5892	103	6	and	and	CCONJ
fnp-5892	103	7	79	79	NUM
fnp-5892	103	8	years	year	NOUN
fnp-5892	103	9	within	within	ADP
fnp-5892	103	10	the	the	DET
fnp-5892	103	11	g3	g3	PROPN
fnp-5892	103	12	/	/	SYM
fnp-5892	103	13	mmr	mmr	PROPN
fnp-5892	103	14	subgroup	subgroup	NOUN
fnp-5892	103	15	did	do	AUX
fnp-5892	103	16	not	not	PART
fnp-5892	103	17	appear	appear	VERB
fnp-5892	103	18	to	to	PART
fnp-5892	103	19	influence	influence	VERB
fnp-5892	103	20	the	the	DET
fnp-5892	103	21	survival	survival	NOUN
fnp-5892	103	22	,	,	PUNCT
fnp-5892	103	23	as	as	SCONJ
fnp-5892	103	24	patients	patient	NOUN
fnp-5892	103	25	in	in	ADP
fnp-5892	103	26	their	their	PRON
fnp-5892	103	27	60s	60	NOUN
fnp-5892	103	28	or	or	CCONJ
fnp-5892	103	29	70s	70	NOUN
fnp-5892	103	30	performed	perform	VERB
fnp-5892	103	31	the	the	DET
fnp-5892	103	32	same	same	ADJ
fnp-5892	103	33	in	in	ADP
fnp-5892	103	34	this	this	DET
fnp-5892	103	35	subgroup	subgroup	NOUN
fnp-5892	103	36	(	(	PUNCT
fnp-5892	103	37	table	table	NOUN
fnp-5892	103	38	 	 	SPACE
fnp-5892	103	39	1	1	NUM
fnp-5892	103	40	)	)	PUNCT
fnp-5892	103	41	.	.	PUNCT
fnp-5892	104	1	however	however	ADV
fnp-5892	104	2	,	,	PUNCT
fnp-5892	104	3	age	age	NOUN
fnp-5892	104	4	-	-	PUNCT
fnp-5892	104	5	adjusted	adjust	VERB
fnp-5892	104	6	survival	survival	NOUN
fnp-5892	104	7	showed	show	VERB
fnp-5892	104	8	a	a	DET
fnp-5892	104	9	highly	highly	ADV
fnp-5892	104	10	significant	significant	ADJ
fnp-5892	104	11	difference	difference	NOUN
fnp-5892	104	12	between	between	ADP
fnp-5892	104	13	patients	patient	NOUN
fnp-5892	104	14	older	old	ADJ
fnp-5892	104	15	or	or	CCONJ
fnp-5892	104	16	younger	young	ADJ
fnp-5892	104	17	than	than	ADP
fnp-5892	104	18	50	50	NUM
fnp-5892	104	19	years	year	NOUN
fnp-5892	104	20	in	in	ADP
fnp-5892	104	21	the	the	DET
fnp-5892	104	22	rest	rest	NOUN
fnp-5892	104	23	of	of	ADP
fnp-5892	104	24	the	the	DET
fnp-5892	104	25	cohort	cohort	NOUN
fnp-5892	104	26	,	,	PUNCT
fnp-5892	104	27	with	with	ADP
fnp-5892	104	28	8	8	NUM
fnp-5892	104	29	versus	versus	ADP
fnp-5892	104	30	20	20	NUM
fnp-5892	104	31	months	month	NOUN
fnp-5892	104	32	median	median	ADJ
fnp-5892	104	33	survival	survival	NOUN
fnp-5892	104	34	values	value	NOUN
fnp-5892	104	35	,	,	PUNCT
fnp-5892	104	36	respectively	respectively	ADV
fnp-5892	104	37	(	(	PUNCT
fnp-5892	104	38	fig	fig	NOUN
fnp-5892	104	39	.	.	PUNCT
fnp-5892	104	40	 	 	SPACE
fnp-5892	104	41	2a	2a	NUM
fnp-5892	104	42	)	)	PUNCT
fnp-5892	104	43	.	.	PUNCT
fnp-5892	105	1	the	the	DET
fnp-5892	105	2	median	median	ADJ
fnp-5892	105	3	age	age	NOUN
fnp-5892	105	4	of	of	ADP
fnp-5892	105	5	the	the	DET
fnp-5892	105	6	g3	g3	PROPN
fnp-5892	105	7	/	/	SYM
fnp-5892	105	8	mmr	mmr	PROPN
fnp-5892	105	9	patients	patient	NOUN
fnp-5892	105	10	was	be	AUX
fnp-5892	105	11	comparable	comparable	ADJ
fnp-5892	105	12	to	to	ADP
fnp-5892	105	13	the	the	DET
fnp-5892	105	14	≥	≥	NUM
fnp-5892	105	15	  	  	SPACE
fnp-5892	105	16	50	50	NUM
fnp-5892	105	17	-	-	PUNCT
fnp-5892	105	18	years	year	NOUN
fnp-5892	105	19	age	age	NOUN
fnp-5892	105	20	-	-	PUNCT
fnp-5892	105	21	adjusted	adjust	VERB
fnp-5892	105	22	cohort	cohort	NOUN
fnp-5892	105	23	,	,	PUNCT
fnp-5892	105	24	but	but	CCONJ
fnp-5892	105	25	the	the	DET
fnp-5892	105	26	median	median	ADJ
fnp-5892	105	27	survival	survival	NOUN
fnp-5892	105	28	was	be	AUX
fnp-5892	105	29	significantly	significantly	ADV
fnp-5892	105	30	lower	low	ADJ
fnp-5892	105	31	,	,	PUNCT
fnp-5892	105	32	at	at	ADP
fnp-5892	105	33	3.25	3.25	NUM
fnp-5892	105	34	months	month	NOUN
fnp-5892	105	35	versus	versus	ADP
fnp-5892	105	36	8	8	NUM
fnp-5892	105	37	months	month	NOUN
fnp-5892	105	38	,	,	PUNCT
fnp-5892	105	39	respectively	respectively	ADV
fnp-5892	105	40	(	(	PUNCT
fnp-5892	105	41	fig	fig	NOUN
fnp-5892	105	42	.	.	PUNCT
fnp-5892	105	43	 	 	SPACE
fnp-5892	105	44	2a	2a	NUM
fnp-5892	105	45	)	)	PUNCT
fnp-5892	105	46	.	.	PUNCT
fnp-5892	106	1	compared	compare	VERB
fnp-5892	106	2	to	to	ADP
fnp-5892	106	3	the	the	DET
fnp-5892	106	4	three	three	NUM
fnp-5892	106	5	major	major	ADJ
fnp-5892	106	6	glioblastoma	glioblastoma	NOUN
fnp-5892	106	7	subgroups	subgroup	NOUN
fnp-5892	106	8	,	,	PUNCT
fnp-5892	106	9	a	a	DET
fnp-5892	106	10	statistically	statistically	ADV
fnp-5892	106	11	significant	significant	ADJ
fnp-5892	106	12	difference	difference	NOUN
fnp-5892	106	13	was	be	AUX
fnp-5892	106	14	apparent	apparent	ADJ
fnp-5892	106	15	between	between	ADP
fnp-5892	106	16	g3	g3	PROPN
fnp-5892	106	17	/	/	SYM
fnp-5892	106	18	mmr	mmr	PROPN
fnp-5892	106	19	patients	patient	NOUN
fnp-5892	106	20	and	and	CCONJ
fnp-5892	106	21	the	the	DET
fnp-5892	106	22	g1	g1	PROPN
fnp-5892	106	23	/	/	SYM
fnp-5892	106	24	egfr	egfr	NOUN
fnp-5892	106	25	and	and	CCONJ
fnp-5892	106	26	g3	g3	PROPN
fnp-5892	106	27	/	/	SYM
fnp-5892	106	28	nf1	nf1	NOUN
fnp-5892	106	29	subgroup	subgroup	NOUN
fnp-5892	106	30	patients	patient	NOUN
fnp-5892	106	31	that	that	PRON
fnp-5892	106	32	showed	show	VERB
fnp-5892	106	33	11.3and	11.3and	NUM
fnp-5892	106	34	8.5	8.5	NUM
fnp-5892	106	35	-	-	PUNCT
fnp-5892	106	36	month	month	NOUN
fnp-5892	106	37	median	median	ADJ
fnp-5892	106	38	survival	survival	NOUN
fnp-5892	106	39	,	,	PUNCT
fnp-5892	106	40	respectively	respectively	ADV
fnp-5892	106	41	,	,	PUNCT
fnp-5892	106	42	but	but	CCONJ
fnp-5892	106	43	not	not	PART
fnp-5892	106	44	the	the	DET
fnp-5892	106	45	g7	g7	PROPN
fnp-5892	106	46	/	/	SYM
fnp-5892	106	47	other	other	ADJ
fnp-5892	106	48	subgroup	subgroup	NOUN
fnp-5892	106	49	patients	patient	NOUN
fnp-5892	106	50	that	that	PRON
fnp-5892	106	51	showed	show	VERB
fnp-5892	106	52	a	a	DET
fnp-5892	106	53	lower	low	ADJ
fnp-5892	106	54	median	median	ADJ
fnp-5892	106	55	survival	survival	NOUN
fnp-5892	106	56	of	of	ADP
fnp-5892	106	57	7	7	NUM
fnp-5892	106	58	months	month	NOUN
fnp-5892	106	59	(	(	PUNCT
fnp-5892	106	60	fig	fig	NOUN
fnp-5892	106	61	.	.	PUNCT
fnp-5892	106	62	 	 	SPACE
fnp-5892	106	63	2b	2b	NOUN
fnp-5892	106	64	)	)	PUNCT
fnp-5892	106	65	.	.	PUNCT
fnp-5892	107	1	figure	figure	VERB
fnp-5892	107	2	2	2	NUM
fnp-5892	107	3	:	:	PUNCT
fnp-5892	107	4	survival	survival	NOUN
fnp-5892	107	5	of	of	ADP
fnp-5892	107	6	g3	g3	PROPN
fnp-5892	107	7	/	/	SYM
fnp-5892	107	8	mmr	mmr	PROPN
fnp-5892	107	9	subgroup	subgroup	NOUN
fnp-5892	107	10	patients	patient	NOUN
fnp-5892	107	11	a	a	PROPN
fnp-5892	107	12	-	-	PUNCT
fnp-5892	107	13	b.	b.	NOUN
fnp-5892	107	14	survival	survival	NOUN
fnp-5892	107	15	curves	curve	NOUN
fnp-5892	107	16	for	for	ADP
fnp-5892	107	17	g3	g3	PROPN
fnp-5892	107	18	/	/	SYM
fnp-5892	107	19	mmr	mmr	PROPN
fnp-5892	107	20	patients	patient	NOUN
fnp-5892	107	21	in	in	ADP
fnp-5892	107	22	comparison	comparison	NOUN
fnp-5892	107	23	to	to	ADP
fnp-5892	107	24	patients	patient	NOUN
fnp-5892	107	25	from	from	ADP
fnp-5892	107	26	the	the	DET
fnp-5892	107	27	rest	rest	NOUN
fnp-5892	107	28	of	of	ADP
fnp-5892	107	29	the	the	DET
fnp-5892	107	30	cohort	cohort	NOUN
fnp-5892	107	31	:	:	PUNCT
fnp-5892	107	32	older	old	ADJ
fnp-5892	107	33	than	than	ADP
fnp-5892	107	34	50	50	NUM
fnp-5892	107	35	years	year	NOUN
fnp-5892	107	36	(	(	PUNCT
fnp-5892	107	37	≥50	≥50	X
fnp-5892	107	38	yo	yo	NOUN
fnp-5892	107	39	)	)	PUNCT
fnp-5892	107	40	or	or	CCONJ
fnp-5892	107	41	younger	young	ADJ
fnp-5892	107	42	than	than	ADP
fnp-5892	107	43	50	50	NUM
fnp-5892	107	44	years	year	NOUN
fnp-5892	107	45	(	(	PUNCT
fnp-5892	107	46	<	<	X
fnp-5892	107	47	 	 	SPACE
fnp-5892	107	48	50	50	NUM
fnp-5892	107	49	yo	yo	NOUN
fnp-5892	107	50	)	)	PUNCT
fnp-5892	107	51	(	(	PUNCT
fnp-5892	107	52	a	a	NOUN
fnp-5892	107	53	)	)	PUNCT
fnp-5892	107	54	,	,	PUNCT
fnp-5892	107	55	and	and	CCONJ
fnp-5892	107	56	from	from	ADP
fnp-5892	107	57	other	other	ADJ
fnp-5892	107	58	g1	g1	NOUN
fnp-5892	107	59	–	–	PUNCT
fnp-5892	107	60	g7	g7	PROPN
fnp-5892	107	61	subgroups	subgroup	NOUN
fnp-5892	107	62	(	(	PUNCT
fnp-5892	107	63	b	b	NOUN
fnp-5892	107	64	)	)	PUNCT
fnp-5892	107	65	.	.	PUNCT
fnp-5892	108	1	statistical	statistical	ADJ
fnp-5892	108	2	significance	significance	NOUN
fnp-5892	108	3	:	:	PUNCT
fnp-5892	108	4	*	*	X
fnp-5892	108	5	,	,	PUNCT
fnp-5892	108	6	p	p	X
fnp-5892	108	7	 	 	SPACE
fnp-5892	108	8	<	<	X
fnp-5892	108	9	 	 	SPACE
fnp-5892	108	10	0.05	0.05	NUM
fnp-5892	108	11	;	;	PUNCT
fnp-5892	108	12	*	*	PUNCT
fnp-5892	108	13	*	*	PUNCT
fnp-5892	108	14	,	,	PUNCT
fnp-5892	108	15	p	p	X
fnp-5892	108	16	 	 	SPACE
fnp-5892	108	17	<	<	X
fnp-5892	108	18	 	 	SPACE
fnp-5892	108	19	0.01	0.01	NUM
fnp-5892	108	20	;	;	PUNCT
fnp-5892	108	21	*	*	PUNCT
fnp-5892	108	22	*	*	PUNCT
fnp-5892	108	23	*	*	PUNCT
fnp-5892	108	24	,	,	PUNCT
fnp-5892	108	25	p	p	X
fnp-5892	108	26	 	 	SPACE
fnp-5892	108	27	<	<	X
fnp-5892	108	28	 	 	SPACE
fnp-5892	108	29	0.001	0.001	NUM
fnp-5892	108	30	.	.	PUNCT
fnp-5892	109	1	n	n	CCONJ
fnp-5892	109	2	,	,	PUNCT
fnp-5892	109	3	number	number	NOUN
fnp-5892	109	4	of	of	ADP
fnp-5892	109	5	deaths	death	NOUN
fnp-5892	109	6	;	;	PUNCT
fnp-5892	109	7	n	n	CCONJ
fnp-5892	109	8	,	,	PUNCT
fnp-5892	109	9	number	number	NOUN
fnp-5892	109	10	of	of	ADP
fnp-5892	109	11	patients	patient	NOUN
fnp-5892	109	12	in	in	ADP
fnp-5892	109	13	follow	follow	NOUN
fnp-5892	109	14	-	-	PUNCT
fnp-5892	109	15	up	up	NOUN
fnp-5892	109	16	.	.	PUNCT
fnp-5892	110	1	the	the	DET
fnp-5892	110	2	median	median	ADJ
fnp-5892	110	3	survival	survival	NOUN
fnp-5892	110	4	in	in	ADP
fnp-5892	110	5	months	month	NOUN
fnp-5892	110	6	,	,	PUNCT
fnp-5892	110	7	and	and	CCONJ
fnp-5892	110	8	the	the	DET
fnp-5892	110	9	median	median	ADJ
fnp-5892	110	10	age	age	NOUN
fnp-5892	110	11	in	in	ADP
fnp-5892	110	12	years	year	NOUN
fnp-5892	110	13	,	,	PUNCT
fnp-5892	110	14	are	be	AUX
fnp-5892	110	15	indicated	indicate	VERB
fnp-5892	110	16	.	.	PUNCT
fnp-5892	111	1	c.	c.	NOUN
fnp-5892	111	2	timeline	timeline	NOUN
fnp-5892	111	3	of	of	ADP
fnp-5892	111	4	disease	disease	NOUN
fnp-5892	111	5	progression	progression	NOUN
fnp-5892	111	6	and	and	CCONJ
fnp-5892	111	7	treatment	treatment	NOUN
fnp-5892	111	8	for	for	ADP
fnp-5892	111	9	the	the	DET
fnp-5892	111	10	g3	g3	PROPN
fnp-5892	111	11	/	/	SYM
fnp-5892	111	12	mmr	mmr	PROPN
fnp-5892	111	13	patient	patient	PROPN
fnp-5892	111	14	f70	f70	PROPN
fnp-5892	111	15	.	.	PUNCT
fnp-5892	112	1	gbm	gbm	PROPN
fnp-5892	112	2	,	,	PUNCT
fnp-5892	112	3	glioblastoma	glioblastoma	NOUN
fnp-5892	112	4	;	;	PUNCT
fnp-5892	112	5	str	str	NUM
fnp-5892	112	6	,	,	PUNCT
fnp-5892	112	7	subtotal	subtotal	ADJ
fnp-5892	112	8	resection	resection	NOUN
fnp-5892	112	9	;	;	PUNCT
fnp-5892	112	10	icpi	icpi	NOUN
fnp-5892	112	11	,	,	PUNCT
fnp-5892	112	12	immune	immune	ADJ
fnp-5892	112	13	checkpoint	checkpoint	NOUN
fnp-5892	112	14	inhibitors	inhibitor	NOUN
fnp-5892	112	15	.	.	PUNCT
fnp-5892	113	1	d.	d.	NOUN
fnp-5892	113	2	expression	expression	NOUN
fnp-5892	113	3	of	of	ADP
fnp-5892	113	4	the	the	DET
fnp-5892	113	5	ctla4	ctla4	NOUN
fnp-5892	113	6	,	,	PUNCT
fnp-5892	113	7	pd	pd	PROPN
fnp-5892	113	8	-	-	PUNCT
fnp-5892	113	9	l1	l1	PROPN
fnp-5892	113	10	,	,	PUNCT
fnp-5892	113	11	pd-1	pd-1	ADJ
fnp-5892	113	12	and	and	CCONJ
fnp-5892	113	13	ido1	ido1	PROPN
fnp-5892	113	14	immune	immune	ADJ
fnp-5892	113	15	therapy	therapy	NOUN
fnp-5892	113	16	response	response	NOUN
fnp-5892	113	17	targets	target	NOUN
fnp-5892	113	18	in	in	ADP
fnp-5892	113	19	the	the	DET
fnp-5892	113	20	5	5	NUM
fnp-5892	113	21	g3	g3	PROPN
fnp-5892	113	22	/	/	SYM
fnp-5892	113	23	mmr	mmr	PROPN
fnp-5892	113	24	tumors	tumor	NOUN
fnp-5892	113	25	.	.	PUNCT
fnp-5892	114	1	levels	level	NOUN
fnp-5892	114	2	were	be	AUX
fnp-5892	114	3	normalized	normalize	VERB
fnp-5892	114	4	to	to	ADP
fnp-5892	114	5	the	the	DET
fnp-5892	114	6	lower	low	ADJ
fnp-5892	114	7	expression	expression	NOUN
fnp-5892	114	8	values	value	NOUN
fnp-5892	114	9	for	for	ADP
fnp-5892	114	10	the	the	DET
fnp-5892	114	11	respective	respective	ADJ
fnp-5892	114	12	immune	immune	ADJ
fnp-5892	114	13	target	target	NOUN
fnp-5892	114	14	.	.	PUNCT
fnp-5892	115	1	note	note	VERB
fnp-5892	115	2	very	very	ADV
fnp-5892	115	3	high	high	ADJ
fnp-5892	115	4	and	and	CCONJ
fnp-5892	115	5	high	high	ADJ
fnp-5892	115	6	expression	expression	NOUN
fnp-5892	115	7	levels	level	NOUN
fnp-5892	115	8	for	for	ADP
fnp-5892	115	9	ido1	ido1	NOUN
fnp-5892	115	10	and	and	CCONJ
fnp-5892	115	11	ctla4	ctla4	PROPN
fnp-5892	115	12	,	,	PUNCT
fnp-5892	115	13	respectively	respectively	ADV
fnp-5892	115	14	,	,	PUNCT
fnp-5892	115	15	in	in	ADP
fnp-5892	115	16	m62	m62	PROPN
fnp-5892	115	17	and	and	CCONJ
fnp-5892	115	18	m72	m72	ADJ
fnp-5892	115	19	tumors	tumor	NOUN
fnp-5892	115	20	.	.	PUNCT
fnp-5892	116	1	f70	f70	PROPN
fnp-5892	116	2	was	be	AUX
fnp-5892	116	3	the	the	DET
fnp-5892	116	4	only	only	ADJ
fnp-5892	116	5	patient	patient	NOUN
fnp-5892	116	6	from	from	ADP
fnp-5892	116	7	the	the	DET
fnp-5892	116	8	g3	g3	PROPN
fnp-5892	116	9	/	/	SYM
fnp-5892	116	10	mmr	mmr	PROPN
fnp-5892	116	11	subgroup	subgroup	NOUN
fnp-5892	116	12	with	with	ADP
fnp-5892	116	13	significantly	significantly	ADV
fnp-5892	116	14	longer	long	ADJ
fnp-5892	116	15	survival	survival	NOUN
fnp-5892	116	16	to	to	ADP
fnp-5892	116	17	10	10	NUM
fnp-5892	116	18	months	month	NOUN
fnp-5892	116	19	(	(	PUNCT
fnp-5892	116	20	table	table	NOUN
fnp-5892	116	21	 	 	SPACE
fnp-5892	116	22	1	1	NUM
fnp-5892	116	23	,	,	PUNCT
fnp-5892	116	24	fig	fig	NOUN
fnp-5892	116	25	.	.	PUNCT
fnp-5892	116	26	 	 	SPACE
fnp-5892	116	27	2c	2c	NUM
fnp-5892	116	28	)	)	PUNCT
fnp-5892	116	29	.	.	PUNCT
fnp-5892	117	1	she	she	PRON
fnp-5892	117	2	had	have	VERB
fnp-5892	117	3	family	family	NOUN
fnp-5892	117	4	history	history	NOUN
fnp-5892	117	5	of	of	ADP
fnp-5892	117	6	first	first	ADJ
fnp-5892	117	7	-	-	PUNCT
fnp-5892	117	8	degree	degree	NOUN
fnp-5892	117	9	cousin	cousin	NOUN
fnp-5892	117	10	with	with	ADP
fnp-5892	117	11	glioblastoma	glioblastoma	NOUN
fnp-5892	117	12	,	,	PUNCT
fnp-5892	117	13	and	and	CCONJ
fnp-5892	117	14	history	history	NOUN
fnp-5892	117	15	of	of	ADP
fnp-5892	117	16	colorectal	colorectal	ADJ
fnp-5892	117	17	cancer	cancer	NOUN
fnp-5892	117	18	10	10	NUM
fnp-5892	117	19	years	year	NOUN
fnp-5892	117	20	prior	prior	ADV
fnp-5892	117	21	,	,	PUNCT
fnp-5892	117	22	status	status	NOUN
fnp-5892	117	23	post	post	NOUN
fnp-5892	117	24	resection	resection	NOUN
fnp-5892	117	25	and	and	CCONJ
fnp-5892	117	26	5	5	NUM
fnp-5892	117	27	-	-	PUNCT
fnp-5892	117	28	flurouracil	flurouracil	NOUN
fnp-5892	117	29	chemotherapy	chemotherapy	NOUN
fnp-5892	117	30	.	.	PUNCT
fnp-5892	118	1	she	she	PRON
fnp-5892	118	2	presented	present	VERB
fnp-5892	118	3	with	with	ADP
fnp-5892	118	4	dizziness	dizziness	NOUN
fnp-5892	118	5	,	,	PUNCT
fnp-5892	118	6	unsteady	unsteady	ADJ
fnp-5892	118	7	gait	gait	NOUN
fnp-5892	118	8	,	,	PUNCT
fnp-5892	118	9	sleepiness	sleepiness	NOUN
fnp-5892	118	10	and	and	CCONJ
fnp-5892	118	11	confusion	confusion	NOUN
fnp-5892	118	12	and	and	CCONJ
fnp-5892	118	13	received	receive	VERB
fnp-5892	118	14	subtotal	subtotal	ADJ
fnp-5892	118	15	resection	resection	NOUN
fnp-5892	118	16	of	of	ADP
fnp-5892	118	17	the	the	DET
fnp-5892	118	18	7.7	7.7	NUM
fnp-5892	118	19	 	 	SPACE
fnp-5892	118	20	cm	cm	NOUN
fnp-5892	118	21	,	,	PUNCT
fnp-5892	118	22	right	right	ADJ
fnp-5892	118	23	temporal	temporal	ADJ
fnp-5892	118	24	lobe	lobe	ADJ
fnp-5892	118	25	glioblastoma	glioblastoma	NOUN
fnp-5892	118	26	,	,	PUNCT
fnp-5892	118	27	leaving	leave	VERB
fnp-5892	118	28	residual	residual	ADJ
fnp-5892	118	29	enhancing	enhancing	NOUN
fnp-5892	118	30	and	and	CCONJ
fnp-5892	118	31	non	non	ADJ
fnp-5892	118	32	-	-	ADJ
fnp-5892	118	33	enhancing	enhancing	ADJ
fnp-5892	118	34	tumor	tumor	NOUN
fnp-5892	118	35	in	in	ADP
fnp-5892	118	36	the	the	DET
fnp-5892	118	37	anterior	anterior	ADJ
fnp-5892	118	38	mesial	mesial	ADJ
fnp-5892	118	39	temporal	temporal	ADJ
fnp-5892	118	40	region	region	NOUN
fnp-5892	118	41	.	.	PUNCT
fnp-5892	119	1	surgery	surgery	NOUN
fnp-5892	119	2	was	be	AUX
fnp-5892	119	3	followed	follow	VERB
fnp-5892	119	4	by	by	ADP
fnp-5892	119	5	the	the	DET
fnp-5892	119	6	standard	standard	ADJ
fnp-5892	119	7	radiation	radiation	NOUN
fnp-5892	119	8	-	-	PUNCT
fnp-5892	119	9	tmz	tmz	NOUN
fnp-5892	119	10	regimen	regiman	NOUN
fnp-5892	119	11	consisting	consist	VERB
fnp-5892	119	12	of	of	ADP
fnp-5892	119	13	radiation	radiation	NOUN
fnp-5892	119	14	with	with	ADP
fnp-5892	119	15	concurrent	concurrent	ADJ
fnp-5892	119	16	tmz	tmz	NOUN
fnp-5892	119	17	.	.	PUNCT
fnp-5892	120	1	a	a	DET
fnp-5892	120	2	regimen	regimen	NOUN
fnp-5892	120	3	of	of	ADP
fnp-5892	120	4	immune	immune	ADJ
fnp-5892	120	5	checkpoint	checkpoint	NOUN
fnp-5892	120	6	inhibitors	inhibitor	NOUN
fnp-5892	120	7	consisting	consist	VERB
fnp-5892	120	8	of	of	ADP
fnp-5892	120	9	combination	combination	NOUN
fnp-5892	120	10	nivolumab	nivolumab	NOUN
fnp-5892	120	11	-	-	PUNCT
fnp-5892	120	12	ipilimumab	ipilimumab	NOUN
fnp-5892	120	13	(	(	PUNCT
fnp-5892	120	14	opdivo	opdivo	NOUN
fnp-5892	120	15	-	-	PUNCT
fnp-5892	120	16	yervoy	yervoy	NOUN
fnp-5892	120	17	)	)	PUNCT
fnp-5892	120	18	,	,	PUNCT
fnp-5892	120	19	in	in	ADP
fnp-5892	120	20	the	the	DET
fnp-5892	120	21	dosing	dosing	NOUN
fnp-5892	120	22	and	and	CCONJ
fnp-5892	120	23	schedule	schedule	NOUN
fnp-5892	120	24	as	as	ADP
fnp-5892	120	25	for	for	ADP
fnp-5892	120	26	metastatic	metastatic	ADJ
fnp-5892	120	27	non	non	ADJ
fnp-5892	120	28	-	-	ADJ
fnp-5892	120	29	small	small	ADJ
fnp-5892	120	30	cell	cell	NOUN
fnp-5892	120	31	lung	lung	NOUN
fnp-5892	120	32	cancer	cancer	NOUN
fnp-5892	120	33	(	(	PUNCT
fnp-5892	120	34	nsclc	nsclc	NOUN
fnp-5892	120	35	)	)	PUNCT
fnp-5892	121	1	[	[	X
fnp-5892	121	2	22	22	NUM
fnp-5892	121	3	]	]	PUNCT
fnp-5892	121	4	,	,	PUNCT
fnp-5892	121	5	was	be	AUX
fnp-5892	121	6	then	then	ADV
fnp-5892	121	7	added	add	VERB
fnp-5892	121	8	for	for	ADP
fnp-5892	121	9	the	the	DET
fnp-5892	121	10	following	follow	VERB
fnp-5892	121	11	4	4	NUM
fnp-5892	121	12	months	month	NOUN
fnp-5892	121	13	and	and	CCONJ
fnp-5892	121	14	interrupted	interrupt	VERB
fnp-5892	121	15	when	when	SCONJ
fnp-5892	121	16	the	the	DET
fnp-5892	121	17	patient	patient	NOUN
fnp-5892	121	18	showed	show	VERB
fnp-5892	121	19	decline	decline	NOUN
fnp-5892	121	20	of	of	ADP
fnp-5892	121	21	cognitive	cognitive	ADJ
fnp-5892	121	22	skills	skill	NOUN
fnp-5892	121	23	.	.	PUNCT
fnp-5892	122	1	the	the	DET
fnp-5892	122	2	patient	patient	NOUN
fnp-5892	122	3	survived	survive	VERB
fnp-5892	122	4	an	an	DET
fnp-5892	122	5	additional	additional	ADJ
fnp-5892	122	6	4	4	NUM
fnp-5892	122	7	months	month	NOUN
fnp-5892	122	8	post	post	NOUN
fnp-5892	122	9	-	-	NOUN
fnp-5892	122	10	therapy	therapy	NOUN
fnp-5892	122	11	.	.	PUNCT
fnp-5892	123	1	the	the	DET
fnp-5892	123	2	gene	gene	NOUN
fnp-5892	123	3	expression	expression	NOUN
fnp-5892	123	4	for	for	ADP
fnp-5892	123	5	various	various	ADJ
fnp-5892	123	6	immune	immune	ADJ
fnp-5892	123	7	checkpoint	checkpoint	NOUN
fnp-5892	123	8	inhibitor	inhibitor	NOUN
fnp-5892	123	9	targets	target	NOUN
fnp-5892	123	10	is	be	AUX
fnp-5892	123	11	one	one	NUM
fnp-5892	123	12	of	of	ADP
fnp-5892	123	13	the	the	DET
fnp-5892	123	14	modalities	modality	NOUN
fnp-5892	123	15	used	use	VERB
fnp-5892	123	16	for	for	ADP
fnp-5892	123	17	assessing	assess	VERB
fnp-5892	123	18	immune	immune	ADJ
fnp-5892	123	19	checkpoint	checkpoint	NOUN
fnp-5892	123	20	inhibitor	inhibitor	NOUN
fnp-5892	123	21	therapies	therapy	NOUN
fnp-5892	123	22	[	[	X
fnp-5892	123	23	23	23	NUM
fnp-5892	123	24	]	]	PUNCT
fnp-5892	123	25	.	.	PUNCT
fnp-5892	124	1	the	the	DET
fnp-5892	124	2	expression	expression	NOUN
fnp-5892	124	3	of	of	ADP
fnp-5892	124	4	ctla4	ctla4	PROPN
fnp-5892	124	5	,	,	PUNCT
fnp-5892	124	6	the	the	DET
fnp-5892	124	7	cd274	cd274	PROPN
fnp-5892	124	8	/	/	SYM
fnp-5892	124	9	pd	pd	PROPN
fnp-5892	124	10	-	-	PROPN
fnp-5892	124	11	l1	l1	PROPN
fnp-5892	124	12	and	and	CCONJ
fnp-5892	124	13	pdcd1	pdcd1	PROPN
fnp-5892	124	14	/	/	SYM
fnp-5892	124	15	pd-1	pd-1	ADJ
fnp-5892	124	16	interactors	interactor	NOUN
fnp-5892	124	17	,	,	PUNCT
fnp-5892	124	18	and	and	CCONJ
fnp-5892	124	19	ido1	ido1	PROPN
fnp-5892	124	20	,	,	PUNCT
fnp-5892	124	21	a	a	DET
fnp-5892	124	22	negative	negative	ADJ
fnp-5892	124	23	immunomodulator	immunomodulator	NOUN
fnp-5892	124	24	in	in	ADP
fnp-5892	124	25	glioblastoma	glioblastoma	NOUN
fnp-5892	124	26	[	[	X
fnp-5892	124	27	24,25	24,25	NUM
fnp-5892	124	28	]	]	PUNCT
fnp-5892	124	29	,	,	PUNCT
fnp-5892	124	30	showed	show	VERB
fnp-5892	124	31	variable	variable	ADJ
fnp-5892	124	32	levels	level	NOUN
fnp-5892	124	33	in	in	ADP
fnp-5892	124	34	the	the	DET
fnp-5892	124	35	g3	g3	PROPN
fnp-5892	124	36	/	/	SYM
fnp-5892	124	37	mmr	mmr	PROPN
fnp-5892	124	38	tumors	tumor	NOUN
fnp-5892	124	39	(	(	PUNCT
fnp-5892	124	40	fig	fig	NOUN
fnp-5892	124	41	.	.	PUNCT
fnp-5892	124	42	 	 	SPACE
fnp-5892	124	43	2d	2d	NOUN
fnp-5892	124	44	)	)	PUNCT
fnp-5892	124	45	.	.	PUNCT
fnp-5892	125	1	all	all	DET
fnp-5892	125	2	markers	marker	NOUN
fnp-5892	125	3	were	be	AUX
fnp-5892	125	4	low	low	ADJ
fnp-5892	125	5	in	in	ADP
fnp-5892	125	6	the	the	DET
fnp-5892	125	7	m68	m68	PROPN
fnp-5892	125	8	tumor	tumor	NOUN
fnp-5892	125	9	.	.	PUNCT
fnp-5892	126	1	ido1	ido1	PROPN
fnp-5892	126	2	showed	show	VERB
fnp-5892	126	3	very	very	ADV
fnp-5892	126	4	high	high	ADJ
fnp-5892	126	5	levels	level	NOUN
fnp-5892	126	6	in	in	ADP
fnp-5892	126	7	the	the	DET
fnp-5892	126	8	m62	m62	PROPN
fnp-5892	126	9	and	and	CCONJ
fnp-5892	126	10	m72	m72	ADJ
fnp-5892	126	11	tumors	tumor	NOUN
fnp-5892	126	12	and	and	CCONJ
fnp-5892	126	13	low	low	ADJ
fnp-5892	126	14	levels	level	NOUN
fnp-5892	126	15	in	in	ADP
fnp-5892	126	16	the	the	DET
fnp-5892	126	17	rest	rest	NOUN
fnp-5892	126	18	.	.	PUNCT
fnp-5892	127	1	the	the	DET
fnp-5892	127	2	ctla4	ctla4	NOUN
fnp-5892	127	3	levels	level	NOUN
fnp-5892	127	4	were	be	AUX
fnp-5892	127	5	also	also	ADV
fnp-5892	127	6	slightly	slightly	ADV
fnp-5892	127	7	elevated	elevate	VERB
fnp-5892	127	8	in	in	ADP
fnp-5892	127	9	the	the	DET
fnp-5892	127	10	m62	m62	PROPN
fnp-5892	127	11	and	and	CCONJ
fnp-5892	127	12	m72	m72	ADJ
fnp-5892	127	13	tumors	tumor	NOUN
fnp-5892	127	14	.	.	PUNCT
fnp-5892	128	1	the	the	DET
fnp-5892	128	2	pd	pd	PROPN
fnp-5892	128	3	-	-	PROPN
fnp-5892	128	4	l1	l1	PROPN
fnp-5892	128	5	and	and	CCONJ
fnp-5892	128	6	pd-1	pd-1	ADJ
fnp-5892	128	7	levels	level	NOUN
fnp-5892	128	8	were	be	AUX
fnp-5892	128	9	variable	variable	ADJ
fnp-5892	128	10	,	,	PUNCT
fnp-5892	128	11	with	with	ADP
fnp-5892	128	12	at	at	ADV
fnp-5892	128	13	least	least	ADV
fnp-5892	128	14	one	one	NUM
fnp-5892	128	15	slightly	slightly	ADV
fnp-5892	128	16	elevated	elevate	VERB
fnp-5892	128	17	in	in	ADP
fnp-5892	128	18	the	the	DET
fnp-5892	128	19	m62	m62	PROPN
fnp-5892	128	20	,	,	PUNCT
fnp-5892	128	21	m72	m72	NOUN
fnp-5892	128	22	and	and	CCONJ
fnp-5892	128	23	m79	m79	NOUN
fnp-5892	128	24	cases	case	NOUN
fnp-5892	128	25	.	.	PUNCT
fnp-5892	129	1	mmr	mmr	PROPN
fnp-5892	129	2	glioblastoma	glioblastoma	NOUN
fnp-5892	129	3	shows	show	NOUN
fnp-5892	129	4	multinucleated	multinucleate	VERB
fnp-5892	129	5	giant	giant	ADJ
fnp-5892	129	6	cells	cell	NOUN
fnp-5892	129	7	(	(	PUNCT
fnp-5892	129	8	mgcs	mgcs	NOUN
fnp-5892	129	9	)	)	PUNCT
fnp-5892	129	10	and	and	CCONJ
fnp-5892	129	11	ihc	ihc	PROPN
fnp-5892	129	12	compatible	compatible	ADJ
fnp-5892	129	13	with	with	ADP
fnp-5892	129	14	p53	p53	NOUN
fnp-5892	129	15	mutation	mutation	NOUN
fnp-5892	129	16	and	and	CCONJ
fnp-5892	129	17	mmr	mmr	NOUN
fnp-5892	129	18	deficiency	deficiency	NOUN
fnp-5892	129	19	.	.	PUNCT
fnp-5892	130	1	histologic	histologic	ADJ
fnp-5892	130	2	examination	examination	NOUN
fnp-5892	130	3	of	of	ADP
fnp-5892	130	4	the	the	DET
fnp-5892	130	5	g3	g3	PROPN
fnp-5892	130	6	/	/	SYM
fnp-5892	130	7	mmr	mmr	PROPN
fnp-5892	130	8	tumors	tumor	NOUN
fnp-5892	130	9	showed	show	VERB
fnp-5892	130	10	presence	presence	NOUN
fnp-5892	130	11	of	of	ADP
fnp-5892	130	12	mgcs	mgcs	NOUN
fnp-5892	130	13	in	in	ADP
fnp-5892	130	14	all	all	DET
fnp-5892	130	15	cases	case	NOUN
fnp-5892	130	16	(	(	PUNCT
fnp-5892	130	17	table	table	NOUN
fnp-5892	130	18	 	 	SPACE
fnp-5892	130	19	1	1	NUM
fnp-5892	130	20	,	,	PUNCT
fnp-5892	130	21	fig	fig	NOUN
fnp-5892	130	22	.	.	PUNCT
fnp-5892	130	23	 	 	SPACE
fnp-5892	130	24	3	3	NUM
fnp-5892	130	25	)	)	PUNCT
fnp-5892	130	26	.	.	PUNCT
fnp-5892	131	1	however	however	ADV
fnp-5892	131	2	,	,	PUNCT
fnp-5892	131	3	except	except	SCONJ
fnp-5892	131	4	for	for	ADP
fnp-5892	131	5	case	case	NOUN
fnp-5892	131	6	m72	m72	NOUN
fnp-5892	131	7	that	that	PRON
fnp-5892	131	8	was	be	AUX
fnp-5892	131	9	diagnosed	diagnose	VERB
fnp-5892	131	10	as	as	ADP
fnp-5892	131	11	giant	giant	ADJ
fnp-5892	131	12	cell	cell	NOUN
fnp-5892	131	13	glioblastoma	glioblastoma	NOUN
fnp-5892	131	14	,	,	PUNCT
fnp-5892	131	15	the	the	DET
fnp-5892	131	16	mgcs	mgcs	NOUN
fnp-5892	131	17	were	be	AUX
fnp-5892	131	18	either	either	CCONJ
fnp-5892	131	19	scattered	scatter	VERB
fnp-5892	131	20	or	or	CCONJ
fnp-5892	131	21	focal	focal	ADJ
fnp-5892	131	22	in	in	ADP
fnp-5892	131	23	the	the	DET
fnp-5892	131	24	other	other	ADJ
fnp-5892	131	25	cases	case	NOUN
fnp-5892	131	26	and	and	CCONJ
fnp-5892	131	27	admixed	admix	VERB
fnp-5892	131	28	with	with	ADP
fnp-5892	131	29	neoplastic	neoplastic	ADJ
fnp-5892	131	30	cells	cell	NOUN
fnp-5892	131	31	with	with	ADP
fnp-5892	131	32	high	high	ADJ
fnp-5892	131	33	-	-	PUNCT
fnp-5892	131	34	grade	grade	NOUN
fnp-5892	131	35	neuroendocrine	neuroendocrine	NOUN
fnp-5892	131	36	(	(	PUNCT
fnp-5892	131	37	hgne	hgne	NOUN
fnp-5892	131	38	)	)	PUNCT
fnp-5892	131	39	or	or	CCONJ
fnp-5892	131	40	gemistocytic	gemistocytic	ADJ
fnp-5892	131	41	morphology	morphology	NOUN
fnp-5892	131	42	,	,	PUNCT
fnp-5892	131	43	which	which	PRON
fnp-5892	131	44	were	be	AUX
fnp-5892	131	45	the	the	DET
fnp-5892	131	46	predominant	predominant	ADJ
fnp-5892	131	47	histologic	histologic	NOUN
fnp-5892	131	48	patterns	pattern	NOUN
fnp-5892	131	49	.	.	PUNCT
fnp-5892	132	1	moreover	moreover	ADV
fnp-5892	132	2	,	,	PUNCT
fnp-5892	132	3	myxoid	myxoid	ADJ
fnp-5892	132	4	extracellular	extracellular	ADJ
fnp-5892	132	5	matrix	matrix	NOUN
fnp-5892	132	6	,	,	PUNCT
fnp-5892	132	7	a	a	DET
fnp-5892	132	8	feature	feature	NOUN
fnp-5892	132	9	present	present	ADJ
fnp-5892	132	10	in	in	ADP
fnp-5892	132	11	many	many	ADJ
fnp-5892	132	12	tumors	tumor	NOUN
fnp-5892	132	13	with	with	ADP
fnp-5892	132	14	hgne	hgne	NOUN
fnp-5892	132	15	morphology	morphology	NOUN
fnp-5892	132	16	from	from	ADP
fnp-5892	132	17	the	the	DET
fnp-5892	132	18	g7	g7	PROPN
fnp-5892	132	19	 	 	SPACE
fnp-5892	132	20	/	/	SYM
fnp-5892	132	21	 	 	SPACE
fnp-5892	132	22	other	other	ADJ
fnp-5892	132	23	molecular	molecular	ADJ
fnp-5892	132	24	subgroup	subgroup	NOUN
fnp-5892	132	25	[	[	X
fnp-5892	132	26	4	4	NUM
fnp-5892	132	27	]	]	PUNCT
fnp-5892	132	28	,	,	PUNCT
fnp-5892	132	29	was	be	AUX
fnp-5892	132	30	present	present	ADJ
fnp-5892	132	31	in	in	ADP
fnp-5892	132	32	three	three	NUM
fnp-5892	132	33	cases	case	NOUN
fnp-5892	132	34	,	,	PUNCT
fnp-5892	132	35	m62	m62	PROPN
fnp-5892	132	36	,	,	PUNCT
fnp-5892	132	37	m68	m68	PROPN
fnp-5892	132	38	and	and	CCONJ
fnp-5892	132	39	f70	f70	PROPN
fnp-5892	132	40	.	.	PUNCT
fnp-5892	133	1	the	the	DET
fnp-5892	133	2	gfap	gfap	ADJ
fnp-5892	133	3	expression	expression	NOUN
fnp-5892	133	4	was	be	AUX
fnp-5892	133	5	variable	variable	ADJ
fnp-5892	133	6	,	,	PUNCT
fnp-5892	133	7	being	be	AUX
fnp-5892	133	8	lost	lose	VERB
fnp-5892	133	9	in	in	ADP
fnp-5892	133	10	subsets	subset	NOUN
fnp-5892	133	11	of	of	ADP
fnp-5892	133	12	neoplastic	neoplastic	ADJ
fnp-5892	133	13	cells	cell	NOUN
fnp-5892	133	14	,	,	PUNCT
fnp-5892	133	15	in	in	ADP
fnp-5892	133	16	correlation	correlation	NOUN
fnp-5892	133	17	with	with	ADP
fnp-5892	133	18	the	the	DET
fnp-5892	133	19	hgne	hgne	NOUN
fnp-5892	133	20	morphology	morphology	NOUN
fnp-5892	134	1	[	[	X
fnp-5892	134	2	4	4	NUM
fnp-5892	134	3	]	]	PUNCT
fnp-5892	134	4	.	.	PUNCT
fnp-5892	135	1	figure	figure	VERB
fnp-5892	135	2	3	3	NUM
fnp-5892	135	3	:	:	PUNCT
fnp-5892	135	4	histology	histology	NOUN
fnp-5892	135	5	and	and	CCONJ
fnp-5892	135	6	ihc	ihc	PROPN
fnp-5892	135	7	of	of	ADP
fnp-5892	135	8	g3	g3	PROPN
fnp-5892	135	9	/	/	SYM
fnp-5892	135	10	mmr	mmr	PROPN
fnp-5892	135	11	molecular	molecular	ADJ
fnp-5892	135	12	subgroup	subgroup	PROPN
fnp-5892	135	13	tumors	tumor	NOUN
fnp-5892	135	14	h&e	h&e	PROPN
fnp-5892	135	15	panels	panel	NOUN
fnp-5892	135	16	showing	show	VERB
fnp-5892	135	17	tumor	tumor	NOUN
fnp-5892	135	18	morphology	morphology	NOUN
fnp-5892	135	19	with	with	ADP
fnp-5892	135	20	presence	presence	NOUN
fnp-5892	135	21	of	of	ADP
fnp-5892	135	22	mgcs	mgcs	NOUN
fnp-5892	135	23	for	for	ADP
fnp-5892	135	24	all	all	DET
fnp-5892	135	25	5	5	NUM
fnp-5892	135	26	cases	case	NOUN
fnp-5892	135	27	,	,	PUNCT
fnp-5892	135	28	as	as	SCONJ
fnp-5892	135	29	indicated	indicate	VERB
fnp-5892	135	30	in	in	ADP
fnp-5892	135	31	the	the	DET
fnp-5892	135	32	upper	upper	ADJ
fnp-5892	135	33	left	left	NOUN
fnp-5892	135	34	corner	corner	NOUN
fnp-5892	135	35	.	.	PUNCT
fnp-5892	136	1	ihc	ihc	PROPN
fnp-5892	136	2	with	with	ADP
fnp-5892	136	3	color	color	NOUN
fnp-5892	136	4	-	-	PUNCT
fnp-5892	136	5	coded	code	VERB
fnp-5892	136	6	antibodies	antibody	NOUN
fnp-5892	136	7	:	:	PUNCT
fnp-5892	136	8	yellow	yellow	ADJ
fnp-5892	136	9	for	for	ADP
fnp-5892	136	10	mmr	mmr	PROPN
fnp-5892	136	11	,	,	PUNCT
fnp-5892	136	12	green	green	ADJ
fnp-5892	136	13	for	for	ADP
fnp-5892	136	14	gfap	gfap	ADJ
fnp-5892	136	15	,	,	PUNCT
fnp-5892	136	16	blue	blue	NOUN
fnp-5892	136	17	for	for	ADP
fnp-5892	136	18	p53	p53	NOUN
fnp-5892	136	19	,	,	PUNCT
fnp-5892	136	20	and	and	CCONJ
fnp-5892	136	21	pink	pink	ADJ
fnp-5892	136	22	for	for	ADP
fnp-5892	136	23	p16	p16	NOUN
fnp-5892	136	24	.	.	PUNCT
fnp-5892	137	1	the	the	DET
fnp-5892	137	2	mmr	mmr	PROPN
fnp-5892	137	3	ihc	ihc	PROPN
fnp-5892	137	4	is	be	AUX
fnp-5892	137	5	shown	show	VERB
fnp-5892	137	6	only	only	ADV
fnp-5892	137	7	for	for	ADP
fnp-5892	137	8	the	the	DET
fnp-5892	137	9	f70	f70	PROPN
fnp-5892	137	10	case	case	NOUN
fnp-5892	137	11	and	and	CCONJ
fnp-5892	137	12	is	be	AUX
fnp-5892	137	13	representative	representative	ADJ
fnp-5892	137	14	for	for	ADP
fnp-5892	137	15	the	the	DET
fnp-5892	137	16	other	other	ADJ
fnp-5892	137	17	g3	g3	PROPN
fnp-5892	137	18	/	/	SYM
fnp-5892	137	19	mmr	mmr	PROPN
fnp-5892	137	20	cases	case	NOUN
fnp-5892	137	21	.	.	PUNCT
fnp-5892	138	1	all	all	DET
fnp-5892	138	2	panels	panel	NOUN
fnp-5892	138	3	are	be	AUX
fnp-5892	138	4	shown	show	VERB
fnp-5892	138	5	at	at	ADP
fnp-5892	138	6	200x	200x	NUM
fnp-5892	138	7	magnification	magnification	NOUN
fnp-5892	138	8	,	,	PUNCT
fnp-5892	138	9	and	and	CCONJ
fnp-5892	138	10	the	the	DET
fnp-5892	138	11	scale	scale	NOUN
fnp-5892	138	12	bars	bar	NOUN
fnp-5892	138	13	are	be	AUX
fnp-5892	138	14	all	all	ADV
fnp-5892	138	15	the	the	DET
fnp-5892	138	16	same	same	ADJ
fnp-5892	138	17	,	,	PUNCT
fnp-5892	138	18	at	at	ADP
fnp-5892	138	19	100	100	NUM
fnp-5892	138	20	μm	μm	NOUN
fnp-5892	138	21	.	.	PUNCT
fnp-5892	139	1	note	note	VERB
fnp-5892	139	2	gigantic	gigantic	ADJ
fnp-5892	139	3	cells	cell	NOUN
fnp-5892	139	4	in	in	ADP
fnp-5892	139	5	the	the	DET
fnp-5892	139	6	m72	m72	ADJ
fnp-5892	139	7	tumor	tumor	NOUN
fnp-5892	139	8	,	,	PUNCT
fnp-5892	139	9	the	the	DET
fnp-5892	139	10	only	only	ADJ
fnp-5892	139	11	of	of	ADP
fnp-5892	139	12	the	the	DET
fnp-5892	139	13	5	5	NUM
fnp-5892	139	14	g3	g3	PROPN
fnp-5892	139	15	/	/	SYM
fnp-5892	139	16	mmr	mmr	PROPN
fnp-5892	139	17	tumors	tumor	NOUN
fnp-5892	139	18	diagnosed	diagnose	VERB
fnp-5892	139	19	as	as	ADP
fnp-5892	139	20	giant	giant	ADJ
fnp-5892	139	21	cell	cell	NOUN
fnp-5892	139	22	glioblastoma	glioblastoma	NOUN
fnp-5892	139	23	.	.	PUNCT
fnp-5892	140	1	ihc	ihc	PROPN
fnp-5892	140	2	for	for	ADP
fnp-5892	140	3	the	the	DET
fnp-5892	140	4	mmr	mmr	PROPN
fnp-5892	140	5	proteins	protein	NOUN
fnp-5892	140	6	mlh1	mlh1	PROPN
fnp-5892	140	7	,	,	PUNCT
fnp-5892	140	8	pms2	pms2	NOUN
fnp-5892	140	9	,	,	PUNCT
fnp-5892	140	10	msh2	msh2	NOUN
fnp-5892	140	11	and	and	CCONJ
fnp-5892	140	12	msh6	msh6	NOUN
fnp-5892	140	13	consistently	consistently	ADV
fnp-5892	140	14	showed	show	VERB
fnp-5892	140	15	preserved	preserve	VERB
fnp-5892	140	16	nuclear	nuclear	ADJ
fnp-5892	140	17	staining	stain	VERB
fnp-5892	140	18	for	for	ADP
fnp-5892	140	19	the	the	DET
fnp-5892	140	20	mlh1	mlh1	PROPN
fnp-5892	140	21	-	-	PUNCT
fnp-5892	140	22	pms2	pms2	PROPN
fnp-5892	140	23	pair	pair	NOUN
fnp-5892	140	24	and	and	CCONJ
fnp-5892	140	25	loss	loss	NOUN
fnp-5892	140	26	of	of	ADP
fnp-5892	140	27	nuclear	nuclear	ADJ
fnp-5892	140	28	staining	stain	VERB
fnp-5892	140	29	for	for	ADP
fnp-5892	140	30	the	the	DET
fnp-5892	140	31	msh2	msh2	NOUN
fnp-5892	140	32	-	-	PUNCT
fnp-5892	140	33	msh6	msh6	NOUN
fnp-5892	140	34	pair	pair	NOUN
fnp-5892	140	35	,	,	PUNCT
fnp-5892	140	36	or	or	CCONJ
fnp-5892	140	37	just	just	ADV
fnp-5892	140	38	msh6	msh6	VERB
fnp-5892	140	39	for	for	ADP
fnp-5892	140	40	m68	m68	PROPN
fnp-5892	140	41	(	(	PUNCT
fnp-5892	140	42	table	table	NOUN
fnp-5892	140	43	 	 	SPACE
fnp-5892	140	44	1	1	NUM
fnp-5892	140	45	,	,	PUNCT
fnp-5892	140	46	fig	fig	NOUN
fnp-5892	140	47	.	.	PUNCT
fnp-5892	140	48	 	 	SPACE
fnp-5892	140	49	3	3	NUM
fnp-5892	140	50	)	)	PUNCT
fnp-5892	140	51	.	.	PUNCT
fnp-5892	141	1	ngs	ng	NOUN
fnp-5892	141	2	confirmed	confirm	VERB
fnp-5892	141	3	germline	germline	NOUN
fnp-5892	141	4	msh2	msh2	PROPN
fnp-5892	141	5	or	or	CCONJ
fnp-5892	141	6	msh6	msh6	NOUN
fnp-5892	141	7	alterations	alteration	NOUN
fnp-5892	141	8	,	,	PUNCT
fnp-5892	141	9	showing	show	VERB
fnp-5892	141	10	perfect	perfect	ADJ
fnp-5892	141	11	correlation	correlation	NOUN
fnp-5892	141	12	with	with	ADP
fnp-5892	141	13	mmr	mmr	PROPN
fnp-5892	141	14	ihc	ihc	PROPN
fnp-5892	141	15	.	.	PUNCT
fnp-5892	142	1	importantly	importantly	ADV
fnp-5892	142	2	,	,	PUNCT
fnp-5892	142	3	the	the	DET
fnp-5892	142	4	combined	combined	ADJ
fnp-5892	142	5	ihc	ihc	PROPN
fnp-5892	142	6	and	and	CCONJ
fnp-5892	142	7	ngs	ng	NOUN
fnp-5892	142	8	workup	workup	PROPN
fnp-5892	142	9	revealed	reveal	VERB
fnp-5892	142	10	the	the	DET
fnp-5892	142	11	mmr	mmr	PROPN
fnp-5892	142	12	deficiency	deficiency	NOUN
fnp-5892	142	13	for	for	ADP
fnp-5892	142	14	the	the	DET
fnp-5892	142	15	first	first	ADJ
fnp-5892	142	16	time	time	NOUN
fnp-5892	142	17	in	in	ADP
fnp-5892	142	18	4	4	NUM
fnp-5892	142	19	of	of	ADP
fnp-5892	142	20	5	5	NUM
fnp-5892	142	21	patients	patient	NOUN
fnp-5892	142	22	,	,	PUNCT
fnp-5892	142	23	including	include	VERB
fnp-5892	142	24	in	in	ADP
fnp-5892	142	25	patients	patient	NOUN
fnp-5892	142	26	with	with	ADP
fnp-5892	142	27	prior	prior	ADJ
fnp-5892	142	28	history	history	NOUN
fnp-5892	142	29	of	of	ADP
fnp-5892	142	30	cancer	cancer	NOUN
fnp-5892	142	31	(	(	PUNCT
fnp-5892	142	32	table	table	NOUN
fnp-5892	142	33	 	 	SPACE
fnp-5892	142	34	1	1	NUM
fnp-5892	142	35	)	)	PUNCT
fnp-5892	142	36	,	,	PUNCT
fnp-5892	142	37	underscoring	underscore	VERB
fnp-5892	142	38	the	the	DET
fnp-5892	142	39	importance	importance	NOUN
fnp-5892	142	40	of	of	ADP
fnp-5892	142	41	combined	combined	ADJ
fnp-5892	142	42	ihc	ihc	PROPN
fnp-5892	142	43	and	and	CCONJ
fnp-5892	142	44	ngs	ng	NOUN
fnp-5892	142	45	workup	workup	VERB
fnp-5892	142	46	for	for	ADP
fnp-5892	142	47	glioblastoma	glioblastoma	NOUN
fnp-5892	142	48	.	.	PUNCT
fnp-5892	143	1	all	all	DET
fnp-5892	143	2	the	the	DET
fnp-5892	143	3	tumors	tumor	NOUN
fnp-5892	143	4	showed	show	VERB
fnp-5892	143	5	diffuse	diffuse	ADJ
fnp-5892	143	6	nuclear	nuclear	ADJ
fnp-5892	143	7	p53	p53	NOUN
fnp-5892	143	8	immunostaining	immunostaining	NOUN
fnp-5892	143	9	,	,	PUNCT
fnp-5892	143	10	suggestive	suggestive	ADJ
fnp-5892	143	11	of	of	ADP
fnp-5892	143	12	tp53	tp53	PROPN
fnp-5892	143	13	mutation	mutation	NOUN
fnp-5892	143	14	.	.	PUNCT
fnp-5892	144	1	the	the	DET
fnp-5892	144	2	ki-67	ki-67	ADJ
fnp-5892	144	3	proliferation	proliferation	NOUN
fnp-5892	144	4	index	index	NOUN
fnp-5892	144	5	was	be	AUX
fnp-5892	144	6	variable	variable	ADJ
fnp-5892	144	7	,	,	PUNCT
fnp-5892	144	8	showing	show	VERB
fnp-5892	144	9	moderate	moderate	ADJ
fnp-5892	144	10	elevation	elevation	NOUN
fnp-5892	144	11	of	of	ADP
fnp-5892	144	12	approximately	approximately	ADV
fnp-5892	144	13	20	20	NUM
fnp-5892	144	14	 	 	SPACE
fnp-5892	144	15	%	%	NOUN
fnp-5892	144	16	in	in	ADP
fnp-5892	144	17	m62	m62	PROPN
fnp-5892	144	18	and	and	CCONJ
fnp-5892	144	19	m79	m79	NOUN
fnp-5892	144	20	tumors	tumor	NOUN
fnp-5892	144	21	and	and	CCONJ
fnp-5892	144	22	high	high	ADJ
fnp-5892	144	23	rate	rate	NOUN
fnp-5892	144	24	of	of	ADP
fnp-5892	144	25	approximately	approximately	ADV
fnp-5892	144	26	50	50	NUM
fnp-5892	144	27	 	 	SPACE
fnp-5892	144	28	%	%	NOUN
fnp-5892	144	29	in	in	ADP
fnp-5892	144	30	the	the	DET
fnp-5892	144	31	m68	m68	PROPN
fnp-5892	144	32	and	and	CCONJ
fnp-5892	144	33	f70	f70	PROPN
fnp-5892	144	34	tumors	tumor	NOUN
fnp-5892	144	35	.	.	PUNCT
fnp-5892	145	1	ihc	ihc	PROPN
fnp-5892	145	2	with	with	ADP
fnp-5892	145	3	p16	p16	NOUN
fnp-5892	145	4	antibody	antibody	NOUN
fnp-5892	145	5	,	,	PUNCT
fnp-5892	145	6	performed	perform	VERB
fnp-5892	145	7	in	in	ADP
fnp-5892	145	8	the	the	DET
fnp-5892	145	9	m62	m62	PROPN
fnp-5892	145	10	,	,	PUNCT
fnp-5892	145	11	m68	m68	PROPN
fnp-5892	145	12	and	and	CCONJ
fnp-5892	145	13	m79	m79	NOUN
fnp-5892	145	14	tumors	tumor	NOUN
fnp-5892	145	15	,	,	PUNCT
fnp-5892	145	16	showed	show	VERB
fnp-5892	145	17	a	a	DET
fnp-5892	145	18	different	different	ADJ
fnp-5892	145	19	expression	expression	NOUN
fnp-5892	145	20	pattern	pattern	NOUN
fnp-5892	145	21	for	for	ADP
fnp-5892	145	22	each	each	DET
fnp-5892	145	23	case	case	NOUN
fnp-5892	145	24	(	(	PUNCT
fnp-5892	145	25	fig	fig	NOUN
fnp-5892	145	26	.	.	PUNCT
fnp-5892	145	27	 	 	SPACE
fnp-5892	145	28	3	3	NUM
fnp-5892	145	29	)	)	PUNCT
fnp-5892	145	30	.	.	PUNCT
fnp-5892	146	1	this	this	PRON
fnp-5892	146	2	ranged	range	VERB
fnp-5892	146	3	between	between	ADP
fnp-5892	146	4	strong	strong	ADJ
fnp-5892	146	5	expression	expression	NOUN
fnp-5892	146	6	for	for	ADP
fnp-5892	146	7	m79	m79	NOUN
fnp-5892	146	8	,	,	PUNCT
fnp-5892	146	9	lack	lack	NOUN
fnp-5892	146	10	of	of	ADP
fnp-5892	146	11	expression	expression	NOUN
fnp-5892	146	12	for	for	ADP
fnp-5892	146	13	m68	m68	PROPN
fnp-5892	146	14	,	,	PUNCT
fnp-5892	146	15	and	and	CCONJ
fnp-5892	146	16	mixed	mixed	ADJ
fnp-5892	146	17	expression	expression	NOUN
fnp-5892	146	18	for	for	ADP
fnp-5892	146	19	m62	m62	PROPN
fnp-5892	146	20	,	,	PUNCT
fnp-5892	146	21	correlating	correlate	VERB
fnp-5892	146	22	with	with	ADP
fnp-5892	146	23	the	the	DET
fnp-5892	146	24	intact	intact	ADJ
fnp-5892	146	25	,	,	PUNCT
fnp-5892	146	26	deleted	delete	VERB
fnp-5892	146	27	,	,	PUNCT
fnp-5892	146	28	and	and	CCONJ
fnp-5892	146	29	mutant	mutant	ADJ
fnp-5892	146	30	status	status	NOUN
fnp-5892	146	31	of	of	ADP
fnp-5892	146	32	the	the	DET
fnp-5892	146	33	cdkn2a	cdkn2a	PROPN
fnp-5892	146	34	gene	gene	NOUN
fnp-5892	146	35	,	,	PUNCT
fnp-5892	146	36	respectively	respectively	ADV
fnp-5892	146	37	(	(	PUNCT
fnp-5892	146	38	suppl	suppl	ADJ
fnp-5892	146	39	table	table	NOUN
fnp-5892	146	40	 	 	SPACE
fnp-5892	146	41	s1	s1	NOUN
fnp-5892	146	42	)	)	PUNCT
fnp-5892	146	43	.	.	PUNCT
fnp-5892	147	1	mgc	mgc	PROPN
fnp-5892	147	2	histology	histology	PROPN
fnp-5892	147	3	associates	associate	NOUN
fnp-5892	147	4	with	with	ADP
fnp-5892	147	5	tp53	tp53	PROPN
fnp-5892	147	6	mutation	mutation	NOUN
fnp-5892	147	7	in	in	ADP
fnp-5892	147	8	multiple	multiple	ADJ
fnp-5892	147	9	glioblastoma	glioblastoma	NOUN
fnp-5892	147	10	subgroups	subgroup	NOUN
fnp-5892	147	11	.	.	PUNCT
fnp-5892	148	1	the	the	DET
fnp-5892	148	2	morphologic	morphologic	ADJ
fnp-5892	148	3	classification	classification	NOUN
fnp-5892	148	4	of	of	ADP
fnp-5892	148	5	glioblastoma	glioblastoma	NOUN
fnp-5892	148	6	in	in	ADP
fnp-5892	148	7	12	12	NUM
fnp-5892	148	8	patterns	pattern	NOUN
fnp-5892	148	9	assigned	assign	VERB
fnp-5892	148	10	to	to	ADP
fnp-5892	148	11	5	5	NUM
fnp-5892	148	12	histologic	histologic	ADJ
fnp-5892	148	13	clusters	cluster	NOUN
fnp-5892	148	14	,	,	PUNCT
fnp-5892	148	15	#	#	SYM
fnp-5892	148	16	1	1	NUM
fnp-5892	148	17	/	/	SYM
fnp-5892	148	18	astrocytic	astrocytic	ADJ
fnp-5892	148	19	(	(	PUNCT
fnp-5892	148	20	previously	previously	ADV
fnp-5892	148	21	called	call	VERB
fnp-5892	148	22	egfr	egfr	NOUN
fnp-5892	148	23	-	-	PUNCT
fnp-5892	148	24	like	like	ADJ
fnp-5892	148	25	)	)	PUNCT
fnp-5892	148	26	,	,	PUNCT
fnp-5892	148	27	#	#	SYM
fnp-5892	148	28	2	2	NUM
fnp-5892	148	29	/	/	SYM
fnp-5892	148	30	small	small	ADJ
fnp-5892	148	31	neuronal	neuronal	ADJ
fnp-5892	148	32	,	,	PUNCT
fnp-5892	148	33	#	#	SYM
fnp-5892	148	34	3	3	NUM
fnp-5892	148	35	/	/	SYM
fnp-5892	148	36	anaplastic	anaplastic	ADJ
fnp-5892	148	37	,	,	PUNCT
fnp-5892	148	38	#	#	SYM
fnp-5892	148	39	4	4	NUM
fnp-5892	148	40	/	/	SYM
fnp-5892	148	41	spindle	spindle	NOUN
fnp-5892	148	42	and	and	CCONJ
fnp-5892	148	43	#	#	SYM
fnp-5892	148	44	5	5	NUM
fnp-5892	148	45	/	/	SYM
fnp-5892	148	46	epithelioid	epithelioid	NOUN
fnp-5892	148	47	,	,	PUNCT
fnp-5892	148	48	has	have	AUX
fnp-5892	148	49	been	be	AUX
fnp-5892	148	50	previously	previously	ADV
fnp-5892	148	51	described	describe	VERB
fnp-5892	148	52	[	[	PUNCT
fnp-5892	148	53	4	4	NUM
fnp-5892	148	54	]	]	PUNCT
fnp-5892	148	55	.	.	PUNCT
fnp-5892	149	1	histologic	histologic	ADJ
fnp-5892	149	2	examination	examination	NOUN
fnp-5892	149	3	of	of	ADP
fnp-5892	149	4	the	the	DET
fnp-5892	149	5	entire	entire	ADJ
fnp-5892	149	6	cohort	cohort	NOUN
fnp-5892	149	7	showed	show	VERB
fnp-5892	149	8	that	that	SCONJ
fnp-5892	149	9	mgcs	mgcs	PROPN
fnp-5892	149	10	were	be	AUX
fnp-5892	149	11	also	also	ADV
fnp-5892	149	12	present	present	ADJ
fnp-5892	149	13	in	in	ADP
fnp-5892	149	14	tumors	tumor	NOUN
fnp-5892	149	15	from	from	ADP
fnp-5892	149	16	other	other	ADJ
fnp-5892	149	17	molecular	molecular	ADJ
fnp-5892	149	18	subgroups	subgroup	NOUN
fnp-5892	149	19	,	,	PUNCT
fnp-5892	149	20	making	make	VERB
fnp-5892	149	21	up	up	ADP
fnp-5892	149	22	approximately	approximately	ADV
fnp-5892	149	23	one	one	NUM
fnp-5892	149	24	fifth	fifth	ADJ
fnp-5892	149	25	(	(	PUNCT
fnp-5892	149	26	18	18	NUM
fnp-5892	149	27	 	 	SPACE
fnp-5892	149	28	%	%	NOUN
fnp-5892	149	29	)	)	PUNCT
fnp-5892	149	30	of	of	ADP
fnp-5892	149	31	the	the	DET
fnp-5892	149	32	total	total	ADJ
fnp-5892	149	33	glioblastoma	glioblastoma	NOUN
fnp-5892	149	34	cases	case	NOUN
fnp-5892	149	35	other	other	ADJ
fnp-5892	149	36	than	than	ADP
fnp-5892	149	37	g3	g3	PROPN
fnp-5892	149	38	/	/	SYM
fnp-5892	149	39	mmr	mmr	PROPN
fnp-5892	149	40	ones	one	NOUN
fnp-5892	149	41	(	(	PUNCT
fnp-5892	149	42	fig	fig	NOUN
fnp-5892	149	43	.	.	PUNCT
fnp-5892	149	44	 	 	SPACE
fnp-5892	149	45	4a	4a	NOUN
fnp-5892	149	46	)	)	PUNCT
fnp-5892	149	47	.	.	PUNCT
fnp-5892	150	1	tumors	tumor	NOUN
fnp-5892	150	2	containing	contain	VERB
fnp-5892	150	3	scattered	scatter	VERB
fnp-5892	150	4	mgcs	mgcs	NOUN
fnp-5892	150	5	resembling	resemble	VERB
fnp-5892	150	6	the	the	DET
fnp-5892	150	7	g3	g3	PROPN
fnp-5892	150	8	/	/	SYM
fnp-5892	150	9	mmr	mmr	PROPN
fnp-5892	150	10	tumors	tumor	NOUN
fnp-5892	150	11	were	be	AUX
fnp-5892	150	12	especially	especially	ADV
fnp-5892	150	13	enriched	enrich	VERB
fnp-5892	150	14	in	in	ADP
fnp-5892	150	15	the	the	DET
fnp-5892	150	16	g1	g1	PROPN
fnp-5892	150	17	/	/	SYM
fnp-5892	150	18	egfr	egfr	ADJ
fnp-5892	150	19	-	-	PUNCT
fnp-5892	150	20	mutant	mutant	NOUN
fnp-5892	150	21	subgroup	subgroup	NOUN
fnp-5892	150	22	(	(	PUNCT
fnp-5892	150	23	50	50	NUM
fnp-5892	150	24	 	 	SPACE
fnp-5892	150	25	%	%	NOUN
fnp-5892	150	26	)	)	PUNCT
fnp-5892	150	27	,	,	PUNCT
fnp-5892	150	28	and	and	CCONJ
fnp-5892	150	29	less	less	ADJ
fnp-5892	150	30	in	in	ADP
fnp-5892	150	31	the	the	DET
fnp-5892	150	32	g6	g6	ADJ
fnp-5892	150	33	/	/	SYM
fnp-5892	150	34	multi	multi	ADJ
fnp-5892	150	35	-	-	ADJ
fnp-5892	150	36	rtk	rtk	X
fnp-5892	150	37	(	(	PUNCT
fnp-5892	150	38	25	25	NUM
fnp-5892	150	39	 	 	SPACE
fnp-5892	150	40	%	%	NOUN
fnp-5892	150	41	)	)	PUNCT
fnp-5892	150	42	,	,	PUNCT
fnp-5892	150	43	g7	g7	PROPN
fnp-5892	150	44	/	/	SYM
fnp-5892	150	45	other	other	ADJ
fnp-5892	150	46	(	(	PUNCT
fnp-5892	150	47	24	24	NUM
fnp-5892	150	48	 	 	SPACE
fnp-5892	150	49	%	%	NOUN
fnp-5892	150	50	)	)	PUNCT
fnp-5892	150	51	,	,	PUNCT
fnp-5892	150	52	g3	g3	PROPN
fnp-5892	150	53	/	/	SYM
fnp-5892	150	54	nf1	nf1	NOUN
fnp-5892	150	55	(	(	PUNCT
fnp-5892	150	56	20	20	NUM
fnp-5892	150	57	 	 	SPACE
fnp-5892	150	58	%	%	NOUN
fnp-5892	150	59	)	)	PUNCT
fnp-5892	150	60	and	and	CCONJ
fnp-5892	150	61	g5	g5	NOUN
fnp-5892	150	62	/	/	SYM
fnp-5892	150	63	pdgfra	pdgfra	NOUN
fnp-5892	150	64	(	(	PUNCT
fnp-5892	150	65	20	20	NUM
fnp-5892	150	66	 	 	SPACE
fnp-5892	150	67	%	%	NOUN
fnp-5892	150	68	)	)	PUNCT
fnp-5892	150	69	subgroups	subgroup	NOUN
fnp-5892	150	70	,	,	PUNCT
fnp-5892	150	71	with	with	ADP
fnp-5892	150	72	the	the	DET
fnp-5892	150	73	major	major	ADJ
fnp-5892	150	74	g1	g1	NOUN
fnp-5892	150	75	/	/	SYM
fnp-5892	150	76	egfr	egfr	NOUN
fnp-5892	150	77	-	-	PUNCT
fnp-5892	150	78	amplified	amplify	VERB
fnp-5892	150	79	subgroup	subgroup	NOUN
fnp-5892	150	80	showing	show	VERB
fnp-5892	150	81	only	only	ADV
fnp-5892	150	82	few	few	ADJ
fnp-5892	150	83	cases	case	NOUN
fnp-5892	150	84	(	(	PUNCT
fnp-5892	150	85	8	8	NUM
fnp-5892	150	86	 	 	SPACE
fnp-5892	150	87	%	%	NOUN
fnp-5892	150	88	)	)	PUNCT
fnp-5892	150	89	.	.	PUNCT
fnp-5892	151	1	in	in	ADP
fnp-5892	151	2	total	total	ADJ
fnp-5892	151	3	,	,	PUNCT
fnp-5892	151	4	43	43	NUM
fnp-5892	151	5	primary	primary	ADJ
fnp-5892	151	6	glioblastoma	glioblastoma	NOUN
fnp-5892	151	7	cases	case	NOUN
fnp-5892	151	8	featured	feature	VERB
fnp-5892	151	9	mgcs	mgcs	NOUN
fnp-5892	151	10	,	,	PUNCT
fnp-5892	151	11	with	with	ADP
fnp-5892	151	12	the	the	DET
fnp-5892	151	13	g7	g7	PROPN
fnp-5892	151	14	/	/	SYM
fnp-5892	151	15	other	other	ADJ
fnp-5892	151	16	and	and	CCONJ
fnp-5892	151	17	g3	g3	PROPN
fnp-5892	151	18	/	/	SYM
fnp-5892	151	19	nf1	nf1	NOUN
fnp-5892	151	20	subgroups	subgroup	NOUN
fnp-5892	151	21	contributing	contribute	VERB
fnp-5892	151	22	10	10	NUM
fnp-5892	151	23	cases	case	NOUN
fnp-5892	151	24	each	each	PRON
fnp-5892	151	25	,	,	PUNCT
fnp-5892	151	26	and	and	CCONJ
fnp-5892	151	27	the	the	DET
fnp-5892	151	28	g3	g3	PROPN
fnp-5892	151	29	/	/	SYM
fnp-5892	151	30	mmr	mmr	PROPN
fnp-5892	151	31	subgroup	subgroup	NOUN
fnp-5892	151	32	,	,	PUNCT
fnp-5892	151	33	g1	g1	X
fnp-5892	151	34	/	/	SYM
fnp-5892	151	35	egfr	egfr	NOUN
fnp-5892	151	36	-	-	PUNCT
fnp-5892	151	37	amplified	amplify	VERB
fnp-5892	151	38	,	,	PUNCT
fnp-5892	151	39	g1	g1	X
fnp-5892	151	40	/	/	SYM
fnp-5892	151	41	egfr	egfr	ADJ
fnp-5892	151	42	-	-	PUNCT
fnp-5892	151	43	mutant	mutant	NOUN
fnp-5892	151	44	and	and	CCONJ
fnp-5892	151	45	g6	g6	ADJ
fnp-5892	151	46	/	/	SYM
fnp-5892	151	47	multi	multi	ADJ
fnp-5892	151	48	-	-	ADJ
fnp-5892	151	49	rtk	rtk	ADJ
fnp-5892	151	50	subgroups	subgroup	NOUN
fnp-5892	151	51	contributing	contribute	VERB
fnp-5892	151	52	5	5	NUM
fnp-5892	151	53	cases	case	NOUN
fnp-5892	151	54	each	each	DET
fnp-5892	151	55	(	(	PUNCT
fnp-5892	151	56	fig	fig	NOUN
fnp-5892	151	57	.	.	PUNCT
fnp-5892	151	58	 	 	SPACE
fnp-5892	151	59	4b	4b	PROPN
fnp-5892	151	60	)	)	PUNCT
fnp-5892	151	61	.	.	PUNCT
fnp-5892	152	1	these	these	DET
fnp-5892	152	2	data	datum	NOUN
fnp-5892	152	3	indicated	indicate	VERB
fnp-5892	152	4	that	that	SCONJ
fnp-5892	152	5	the	the	DET
fnp-5892	152	6	presence	presence	NOUN
fnp-5892	152	7	mgcs	mgcs	NOUN
fnp-5892	152	8	in	in	ADP
fnp-5892	152	9	a	a	DET
fnp-5892	152	10	tumor	tumor	NOUN
fnp-5892	152	11	is	be	AUX
fnp-5892	152	12	not	not	PART
fnp-5892	152	13	specific	specific	ADJ
fnp-5892	152	14	for	for	ADP
fnp-5892	152	15	the	the	DET
fnp-5892	152	16	g3	g3	PROPN
fnp-5892	152	17	/	/	SYM
fnp-5892	152	18	mmr	mmr	PROPN
fnp-5892	152	19	subgroup	subgroup	PROPN
fnp-5892	152	20	.	.	PUNCT
fnp-5892	153	1	figure	figure	VERB
fnp-5892	153	2	4	4	NUM
fnp-5892	153	3	:	:	PUNCT
fnp-5892	153	4	mgcs	mgcs	NOUN
fnp-5892	153	5	in	in	ADP
fnp-5892	153	6	glioblastoma	glioblastoma	NOUN
fnp-5892	153	7	:	:	PUNCT
fnp-5892	153	8	distribution	distribution	NOUN
fnp-5892	153	9	in	in	ADP
fnp-5892	153	10	g1	g1	NOUN
fnp-5892	153	11	–	–	PUNCT
fnp-5892	153	12	g7	g7	PROPN
fnp-5892	153	13	molecular	molecular	ADJ
fnp-5892	153	14	subgroups	subgroup	NOUN
fnp-5892	153	15	,	,	PUNCT
fnp-5892	153	16	histologic	histologic	ADJ
fnp-5892	153	17	profiles	profile	NOUN
fnp-5892	153	18	,	,	PUNCT
fnp-5892	153	19	and	and	CCONJ
fnp-5892	153	20	p53	p53	NOUN
fnp-5892	153	21	pathway	pathway	NOUN
fnp-5892	153	22	mutations	mutation	NOUN
fnp-5892	153	23	a.	a.	NOUN
fnp-5892	153	24	incidence	incidence	NOUN
fnp-5892	153	25	of	of	ADP
fnp-5892	153	26	cases	case	NOUN
fnp-5892	153	27	with	with	ADP
fnp-5892	153	28	mgcs	mgcs	NOUN
fnp-5892	153	29	in	in	ADP
fnp-5892	153	30	the	the	DET
fnp-5892	153	31	g1	g1	PROPN
fnp-5892	153	32	–	–	PUNCT
fnp-5892	153	33	g7	g7	PROPN
fnp-5892	153	34	glioblastoma	glioblastoma	NOUN
fnp-5892	153	35	subgroups	subgroup	NOUN
fnp-5892	153	36	.	.	PUNCT
fnp-5892	154	1	gbm	gbm	NOUN
fnp-5892	154	2	,	,	PUNCT
fnp-5892	154	3	glioblastoma	glioblastoma	NOUN
fnp-5892	154	4	;	;	PUNCT
fnp-5892	154	5	egfr↑	egfr↑	ADJ
fnp-5892	154	6	,	,	PUNCT
fnp-5892	154	7	egfr	egfr	NOUN
fnp-5892	154	8	-	-	PUNCT
fnp-5892	154	9	amplified	amplify	VERB
fnp-5892	154	10	;	;	PUNCT
fnp-5892	154	11	egfrm	egfrm	NOUN
fnp-5892	154	12	,	,	PUNCT
fnp-5892	154	13	egfr	egfr	NOUN
fnp-5892	154	14	-	-	PUNCT
fnp-5892	154	15	mutated	mutate	VERB
fnp-5892	154	16	;	;	PUNCT
fnp-5892	154	17	total	total	ADJ
fnp-5892	154	18	gbm	gbm	PROPN
fnp-5892	154	19	-	-	PUNCT
fnp-5892	154	20	mmr	mmr	PROPN
fnp-5892	154	21	,	,	PUNCT
fnp-5892	154	22	gbm	gbm	PROPN
fnp-5892	154	23	cases	case	NOUN
fnp-5892	154	24	without	without	ADP
fnp-5892	154	25	the	the	DET
fnp-5892	154	26	g3	g3	PROPN
fnp-5892	154	27	/	/	SYM
fnp-5892	154	28	mmr	mmr	PROPN
fnp-5892	154	29	cases	case	NOUN
fnp-5892	154	30	.	.	PUNCT
fnp-5892	155	1	b.	b.	NOUN
fnp-5892	155	2	pie	pie	NOUN
fnp-5892	155	3	-	-	PUNCT
fnp-5892	155	4	chart	chart	NOUN
fnp-5892	155	5	distribution	distribution	NOUN
fnp-5892	155	6	(	(	PUNCT
fnp-5892	155	7	%	%	INTJ
fnp-5892	155	8	)	)	PUNCT
fnp-5892	155	9	of	of	ADP
fnp-5892	155	10	the	the	DET
fnp-5892	155	11	43	43	NUM
fnp-5892	155	12	cases	case	NOUN
fnp-5892	155	13	with	with	ADP
fnp-5892	155	14	mgcs	mgcs	NOUN
fnp-5892	155	15	in	in	ADP
fnp-5892	155	16	g1	g1	PROPN
fnp-5892	155	17	–	–	PUNCT
fnp-5892	155	18	g7	g7	PROPN
fnp-5892	155	19	molecular	molecular	ADJ
fnp-5892	155	20	subgroups	subgroup	NOUN
fnp-5892	155	21	.	.	PUNCT
fnp-5892	156	1	c.	c.	NOUN
fnp-5892	156	2	distribution	distribution	NOUN
fnp-5892	156	3	of	of	ADP
fnp-5892	156	4	the	the	DET
fnp-5892	156	5	43	43	NUM
fnp-5892	156	6	cases	case	NOUN
fnp-5892	156	7	with	with	ADP
fnp-5892	156	8	mgcs	mgcs	NOUN
fnp-5892	156	9	into	into	ADP
fnp-5892	156	10	histologic	histologic	ADJ
fnp-5892	156	11	clusters	cluster	NOUN
fnp-5892	156	12	in	in	ADP
fnp-5892	156	13	the	the	DET
fnp-5892	156	14	g1	g1	NOUN
fnp-5892	156	15	–	–	PUNCT
fnp-5892	156	16	g7	g7	PROPN
fnp-5892	156	17	molecular	molecular	ADJ
fnp-5892	156	18	subgroups	subgroup	NOUN
fnp-5892	156	19	(	(	PUNCT
fnp-5892	156	20	upper	upper	ADJ
fnp-5892	156	21	bar	bar	NOUN
fnp-5892	156	22	graph	graph	NOUN
fnp-5892	156	23	)	)	PUNCT
fnp-5892	156	24	,	,	PUNCT
fnp-5892	156	25	or	or	CCONJ
fnp-5892	156	26	as	as	ADP
fnp-5892	156	27	%	%	NOUN
fnp-5892	156	28	(	(	PUNCT
fnp-5892	156	29	lower	low	ADJ
fnp-5892	156	30	pie	pie	NOUN
fnp-5892	156	31	chart	chart	NOUN
fnp-5892	156	32	)	)	PUNCT
fnp-5892	156	33	.	.	PUNCT
fnp-5892	157	1	#	#	X
fnp-5892	157	2	,	,	PUNCT
fnp-5892	157	3	number	number	NOUN
fnp-5892	157	4	of	of	ADP
fnp-5892	157	5	cases	case	NOUN
fnp-5892	157	6	;	;	PUNCT
fnp-5892	157	7	ana	ana	PROPN
fnp-5892	157	8	,	,	PUNCT
fnp-5892	157	9	anaplastic	anaplastic	ADJ
fnp-5892	157	10	;	;	PUNCT
fnp-5892	157	11	epi	epi	X
fnp-5892	157	12	,	,	PUNCT
fnp-5892	157	13	epithelioid	epithelioid	PROPN
fnp-5892	157	14	.	.	PUNCT
fnp-5892	158	1	d.	d.	PROPN
fnp-5892	158	2	distribution	distribution	NOUN
fnp-5892	158	3	of	of	ADP
fnp-5892	158	4	p53	p53	NOUN
fnp-5892	158	5	pathway	pathway	NOUN
fnp-5892	158	6	alterations	alteration	NOUN
fnp-5892	158	7	in	in	ADP
fnp-5892	158	8	the	the	DET
fnp-5892	158	9	43	43	NUM
fnp-5892	158	10	tumors	tumor	NOUN
fnp-5892	158	11	containing	contain	VERB
fnp-5892	158	12	mgcs	mgcs	NOUN
fnp-5892	158	13	.	.	PUNCT
fnp-5892	159	1	tp53	tp53	PROPN
fnp-5892	159	2	/	/	SYM
fnp-5892	159	3	ihc+	ihc+	PROPN
fnp-5892	159	4	and	and	CCONJ
fnp-5892	159	5	tp53	tp53	PROPN
fnp-5892	159	6	/	/	SYM
fnp-5892	159	7	ihc-	ihc-	PROPN
fnp-5892	159	8	,	,	PUNCT
fnp-5892	159	9	mgc	mgc	NOUN
fnp-5892	159	10	cases	case	NOUN
fnp-5892	159	11	with	with	ADP
fnp-5892	159	12	tp53	tp53	PROPN
fnp-5892	159	13	mutations	mutation	NOUN
fnp-5892	159	14	and	and	CCONJ
fnp-5892	159	15	positive	positive	ADJ
fnp-5892	159	16	or	or	CCONJ
fnp-5892	159	17	negative	negative	ADJ
fnp-5892	159	18	p53	p53	NOUN
fnp-5892	159	19	ihc	ihc	PROPN
fnp-5892	159	20	,	,	PUNCT
fnp-5892	159	21	respectively	respectively	ADV
fnp-5892	159	22	;	;	PUNCT
fnp-5892	159	23	other	other	ADJ
fnp-5892	159	24	(	(	PUNCT
fnp-5892	159	25	than	than	ADP
fnp-5892	159	26	tp53	tp53	PROPN
fnp-5892	159	27	or	or	CCONJ
fnp-5892	159	28	mdm2/4	mdm2/4	NOUN
fnp-5892	159	29	)	)	PUNCT
fnp-5892	159	30	alterations	alteration	NOUN
fnp-5892	159	31	include	include	VERB
fnp-5892	159	32	one	one	NUM
fnp-5892	159	33	case	case	NOUN
fnp-5892	159	34	each	each	PRON
fnp-5892	159	35	with	with	ADP
fnp-5892	159	36	rpl5	rpl5	NOUN
fnp-5892	159	37	and	and	CCONJ
fnp-5892	159	38	ebf1	ebf1	NOUN
fnp-5892	159	39	mutations	mutation	NOUN
fnp-5892	159	40	.	.	PUNCT
fnp-5892	160	1	e.	e.	PROPN
fnp-5892	160	2	bar	bar	PROPN
fnp-5892	160	3	graph	graph	NOUN
fnp-5892	160	4	showing	show	VERB
fnp-5892	160	5	the	the	DET
fnp-5892	160	6	%	%	NOUN
fnp-5892	160	7	of	of	ADP
fnp-5892	160	8	cases	case	NOUN
fnp-5892	160	9	with	with	ADP
fnp-5892	160	10	or	or	CCONJ
fnp-5892	160	11	without	without	ADP
fnp-5892	160	12	mgcs	mgcs	NOUN
fnp-5892	160	13	from	from	ADP
fnp-5892	160	14	the	the	DET
fnp-5892	160	15	total	total	ADJ
fnp-5892	160	16	gbm	gbm	NOUN
fnp-5892	160	17	cases	case	NOUN
fnp-5892	160	18	with	with	ADP
fnp-5892	160	19	tp53	tp53	PROPN
fnp-5892	160	20	mutations	mutation	NOUN
fnp-5892	160	21	(	(	PUNCT
fnp-5892	160	22	n	n	CCONJ
fnp-5892	160	23	)	)	PUNCT
fnp-5892	160	24	and	and	CCONJ
fnp-5892	160	25	per	per	ADP
fnp-5892	160	26	g1	g1	NOUN
fnp-5892	160	27	–	–	PUNCT
fnp-5892	160	28	g7	g7	PROPN
fnp-5892	160	29	molecular	molecular	ADJ
fnp-5892	160	30	subgroup	subgroup	NOUN
fnp-5892	160	31	.	.	PUNCT
fnp-5892	161	1	total	total	PROPN
fnp-5892	161	2	gmb	gmb	PROPN
fnp-5892	161	3	-	-	PUNCT
fnp-5892	161	4	mmr	mmr	PROPN
fnp-5892	161	5	,	,	PUNCT
fnp-5892	161	6	tp53	tp53	PROPN
fnp-5892	161	7	-	-	PUNCT
fnp-5892	161	8	mutant	mutant	ADJ
fnp-5892	161	9	cases	case	NOUN
fnp-5892	161	10	without	without	ADP
fnp-5892	161	11	the	the	DET
fnp-5892	161	12	g3	g3	PROPN
fnp-5892	161	13	/	/	SYM
fnp-5892	161	14	mmr	mmr	PROPN
fnp-5892	161	15	cases	case	NOUN
fnp-5892	161	16	.	.	PUNCT
fnp-5892	162	1	note	note	VERB
fnp-5892	162	2	that	that	SCONJ
fnp-5892	162	3	overall	overall	ADJ
fnp-5892	162	4	,	,	PUNCT
fnp-5892	162	5	only	only	ADV
fnp-5892	162	6	45	45	NUM
fnp-5892	162	7	 	 	SPACE
fnp-5892	162	8	%	%	NOUN
fnp-5892	162	9	of	of	ADP
fnp-5892	162	10	the	the	DET
fnp-5892	162	11	tp53	tp53	PROPN
fnp-5892	162	12	-	-	PUNCT
fnp-5892	162	13	mutant	mutant	ADJ
fnp-5892	162	14	tumors	tumor	NOUN
fnp-5892	162	15	contain	contain	VERB
fnp-5892	162	16	mgcs	mgcs	NOUN
fnp-5892	162	17	.	.	PUNCT
fnp-5892	163	1	f.	f.	PROPN
fnp-5892	163	2	bar	bar	PROPN
fnp-5892	163	3	graph	graph	NOUN
fnp-5892	163	4	showing	show	VERB
fnp-5892	163	5	the	the	DET
fnp-5892	163	6	number	number	NOUN
fnp-5892	163	7	of	of	ADP
fnp-5892	163	8	allelic	allelic	ADJ
fnp-5892	163	9	tp53	tp53	PROPN
fnp-5892	163	10	mutations	mutation	NOUN
fnp-5892	163	11	.	.	PUNCT
fnp-5892	164	1	gbm	gbm	PROPN
fnp-5892	164	2	,	,	PUNCT
fnp-5892	164	3	tp53	tp53	PROPN
fnp-5892	164	4	-	-	PUNCT
fnp-5892	164	5	mutant	mutant	ADJ
fnp-5892	164	6	glioblastoma	glioblastoma	NOUN
fnp-5892	164	7	cases	case	NOUN
fnp-5892	164	8	without	without	ADP
fnp-5892	164	9	the	the	DET
fnp-5892	164	10	g3	g3	PROPN
fnp-5892	164	11	/	/	SYM
fnp-5892	164	12	mmr	mmr	PROPN
fnp-5892	164	13	cases	case	NOUN
fnp-5892	164	14	.	.	PUNCT
fnp-5892	165	1	examination	examination	NOUN
fnp-5892	165	2	of	of	ADP
fnp-5892	165	3	the	the	DET
fnp-5892	165	4	associated	associated	ADJ
fnp-5892	165	5	morphologies	morphology	NOUN
fnp-5892	165	6	in	in	ADP
fnp-5892	165	7	these	these	DET
fnp-5892	165	8	cases	case	NOUN
fnp-5892	165	9	revealed	reveal	VERB
fnp-5892	165	10	that	that	SCONJ
fnp-5892	165	11	they	they	PRON
fnp-5892	165	12	either	either	CCONJ
fnp-5892	165	13	fell	fall	VERB
fnp-5892	165	14	into	into	ADP
fnp-5892	165	15	the	the	DET
fnp-5892	165	16	#	#	SYM
fnp-5892	165	17	3	3	NUM
fnp-5892	165	18	/	/	SYM
fnp-5892	165	19	anaplastic	anaplastic	ADJ
fnp-5892	165	20	,	,	PUNCT
fnp-5892	165	21	#	#	SYM
fnp-5892	165	22	5	5	NUM
fnp-5892	165	23	/	/	SYM
fnp-5892	165	24	epithelioid	epithelioid	NOUN
fnp-5892	165	25	,	,	PUNCT
fnp-5892	165	26	mixed	mixed	ADJ
fnp-5892	165	27	anaplastic	anaplastic	ADJ
fnp-5892	165	28	/	/	SYM
fnp-5892	165	29	epithelioid	epithelioid	NOUN
fnp-5892	165	30	or	or	CCONJ
fnp-5892	165	31	mixed	mixed	ADJ
fnp-5892	165	32	spindle	spindle	NOUN
fnp-5892	165	33	/	/	SYM
fnp-5892	165	34	epithelioid	epithelioid	NOUN
fnp-5892	165	35	clusters	cluster	NOUN
fnp-5892	165	36	,	,	PUNCT
fnp-5892	165	37	indicating	indicate	VERB
fnp-5892	165	38	that	that	SCONJ
fnp-5892	165	39	anaplastic	anaplastic	ADJ
fnp-5892	165	40	and	and	CCONJ
fnp-5892	165	41	epithelioid	epithelioid	NOUN
fnp-5892	165	42	morphologies	morphology	NOUN
fnp-5892	165	43	are	be	AUX
fnp-5892	165	44	dominant	dominant	ADJ
fnp-5892	165	45	in	in	ADP
fnp-5892	165	46	the	the	DET
fnp-5892	165	47	cases	case	NOUN
fnp-5892	165	48	with	with	ADP
fnp-5892	165	49	mgcs	mgcs	PROPN
fnp-5892	165	50	(	(	PUNCT
fnp-5892	165	51	fig	fig	NOUN
fnp-5892	165	52	.	.	PUNCT
fnp-5892	165	53	 	 	SPACE
fnp-5892	165	54	4c	4c	NOUN
fnp-5892	165	55	)	)	PUNCT
fnp-5892	165	56	.	.	PUNCT
fnp-5892	166	1	moreover	moreover	ADV
fnp-5892	166	2	,	,	PUNCT
fnp-5892	166	3	the	the	DET
fnp-5892	166	4	mixed	mixed	ADJ
fnp-5892	166	5	spindle	spindle	NOUN
fnp-5892	166	6	/	/	SYM
fnp-5892	166	7	epithelioid	epithelioid	NOUN
fnp-5892	166	8	morphology	morphology	NOUN
fnp-5892	166	9	was	be	AUX
fnp-5892	166	10	limited	limit	VERB
fnp-5892	166	11	to	to	ADP
fnp-5892	166	12	g3	g3	PROPN
fnp-5892	166	13	/	/	SYM
fnp-5892	166	14	nf1	nf1	NOUN
fnp-5892	166	15	subgroup	subgroup	NOUN
fnp-5892	166	16	tumors	tumor	NOUN
fnp-5892	166	17	that	that	PRON
fnp-5892	166	18	may	may	AUX
fnp-5892	166	19	show	show	VERB
fnp-5892	166	20	a	a	DET
fnp-5892	166	21	sega	sega	NOUN
fnp-5892	166	22	-	-	PUNCT
fnp-5892	166	23	like	like	ADJ
fnp-5892	166	24	histologic	histologic	NOUN
fnp-5892	166	25	profile	profile	NOUN
fnp-5892	166	26	[	[	X
fnp-5892	166	27	16	16	NUM
fnp-5892	166	28	]	]	PUNCT
fnp-5892	166	29	.	.	PUNCT
fnp-5892	167	1	other	other	ADJ
fnp-5892	167	2	than	than	ADP
fnp-5892	167	3	this	this	DET
fnp-5892	167	4	sega	sega	NOUN
fnp-5892	167	5	-	-	PUNCT
fnp-5892	167	6	like	like	ADJ
fnp-5892	167	7	morphology	morphology	NOUN
fnp-5892	167	8	that	that	PRON
fnp-5892	167	9	was	be	AUX
fnp-5892	167	10	noted	note	VERB
fnp-5892	167	11	only	only	ADV
fnp-5892	167	12	in	in	ADP
fnp-5892	167	13	the	the	DET
fnp-5892	167	14	g3	g3	PROPN
fnp-5892	167	15	/	/	SYM
fnp-5892	167	16	nf1	nf1	NOUN
fnp-5892	167	17	subgroup	subgroup	NOUN
fnp-5892	167	18	,	,	PUNCT
fnp-5892	167	19	and	and	CCONJ
fnp-5892	167	20	the	the	DET
fnp-5892	167	21	giant	giant	ADJ
fnp-5892	167	22	cell	cell	NOUN
fnp-5892	167	23	glioblastoma	glioblastoma	NOUN
fnp-5892	167	24	case	case	NOUN
fnp-5892	167	25	m72	m72	ADJ
fnp-5892	167	26	that	that	PRON
fnp-5892	167	27	was	be	AUX
fnp-5892	167	28	unique	unique	ADJ
fnp-5892	167	29	to	to	ADP
fnp-5892	167	30	the	the	DET
fnp-5892	167	31	cohort	cohort	NOUN
fnp-5892	167	32	,	,	PUNCT
fnp-5892	167	33	the	the	DET
fnp-5892	167	34	other	other	ADJ
fnp-5892	167	35	cases	case	NOUN
fnp-5892	167	36	showed	show	VERB
fnp-5892	167	37	scattered	scatter	VERB
fnp-5892	167	38	mgcs	mgcs	NOUN
fnp-5892	167	39	,	,	PUNCT
fnp-5892	167	40	significantly	significantly	ADV
fnp-5892	167	41	smaller	small	ADJ
fnp-5892	167	42	than	than	ADP
fnp-5892	167	43	in	in	ADP
fnp-5892	167	44	the	the	DET
fnp-5892	167	45	m72	m72	ADJ
fnp-5892	167	46	case	case	NOUN
fnp-5892	167	47	(	(	PUNCT
fnp-5892	167	48	fig	fig	NOUN
fnp-5892	167	49	.	.	PUNCT
fnp-5892	167	50	 	 	SPACE
fnp-5892	167	51	3	3	NUM
fnp-5892	167	52	)	)	PUNCT
fnp-5892	167	53	,	,	PUNCT
fnp-5892	167	54	regardless	regardless	ADV
fnp-5892	167	55	of	of	ADP
fnp-5892	167	56	the	the	DET
fnp-5892	167	57	molecular	molecular	ADJ
fnp-5892	167	58	subgroup	subgroup	NOUN
fnp-5892	167	59	.	.	PUNCT
fnp-5892	168	1	no	no	DET
fnp-5892	168	2	giant	giant	ADJ
fnp-5892	168	3	cells	cell	NOUN
fnp-5892	168	4	were	be	AUX
fnp-5892	168	5	recorded	record	VERB
fnp-5892	168	6	in	in	ADP
fnp-5892	168	7	cases	case	NOUN
fnp-5892	168	8	from	from	ADP
fnp-5892	168	9	the	the	DET
fnp-5892	168	10	minor	minor	ADJ
fnp-5892	168	11	subgroups	subgroup	NOUN
fnp-5892	168	12	g2	g2	PROPN
fnp-5892	168	13	/	/	SYM
fnp-5892	168	14	fgfr3	fgfr3	PROPN
fnp-5892	168	15	and	and	CCONJ
fnp-5892	168	16	g4	g4	NOUN
fnp-5892	168	17	/	/	SYM
fnp-5892	168	18	raf	raf	NOUN
fnp-5892	168	19	,	,	PUNCT
fnp-5892	168	20	and	and	CCONJ
fnp-5892	168	21	only	only	ADV
fnp-5892	168	22	5	5	NUM
fnp-5892	168	23	cases	case	NOUN
fnp-5892	168	24	mapped	map	VERB
fnp-5892	168	25	to	to	ADP
fnp-5892	168	26	the	the	DET
fnp-5892	168	27	largest	large	ADJ
fnp-5892	168	28	molecular	molecular	ADJ
fnp-5892	168	29	subgroup	subgroup	NOUN
fnp-5892	168	30	g1	g1	NOUN
fnp-5892	168	31	/	/	SYM
fnp-5892	168	32	egfr	egfr	NOUN
fnp-5892	168	33	-	-	PUNCT
fnp-5892	168	34	amplified	amplify	VERB
fnp-5892	168	35	,	,	PUNCT
fnp-5892	168	36	as	as	SCONJ
fnp-5892	168	37	these	these	DET
fnp-5892	168	38	three	three	NUM
fnp-5892	168	39	subgroups	subgroup	NOUN
fnp-5892	168	40	predominantly	predominantly	ADV
fnp-5892	168	41	display	display	VERB
fnp-5892	168	42	morphologies	morphology	NOUN
fnp-5892	168	43	in	in	ADP
fnp-5892	168	44	the	the	DET
fnp-5892	168	45	#	#	SYM
fnp-5892	168	46	1	1	NUM
fnp-5892	168	47	/	/	SYM
fnp-5892	168	48	astrocytic	astrocytic	ADJ
fnp-5892	168	49	or	or	CCONJ
fnp-5892	168	50	#	#	SYM
fnp-5892	168	51	2	2	NUM
fnp-5892	168	52	/	/	SYM
fnp-5892	168	53	small	small	ADJ
fnp-5892	168	54	neuronal	neuronal	ADJ
fnp-5892	168	55	clusters	cluster	NOUN
fnp-5892	168	56	that	that	PRON
fnp-5892	168	57	were	be	AUX
fnp-5892	168	58	virtually	virtually	ADV
fnp-5892	168	59	exclusive	exclusive	ADJ
fnp-5892	168	60	of	of	ADP
fnp-5892	168	61	mgcs	mgcs	NOUN
fnp-5892	168	62	.	.	PUNCT
fnp-5892	169	1	all	all	DET
fnp-5892	169	2	the	the	DET
fnp-5892	169	3	cases	case	NOUN
fnp-5892	169	4	in	in	ADP
fnp-5892	169	5	the	the	DET
fnp-5892	169	6	g3	g3	PROPN
fnp-5892	169	7	/	/	SYM
fnp-5892	169	8	mmr	mmr	PROPN
fnp-5892	169	9	subgroup	subgroup	PROPN
fnp-5892	169	10	showed	show	VERB
fnp-5892	169	11	ihc	ihc	PROPN
fnp-5892	169	12	positive	positive	ADJ
fnp-5892	169	13	for	for	ADP
fnp-5892	169	14	p53	p53	NOUN
fnp-5892	169	15	(	(	PUNCT
fnp-5892	169	16	fig	fig	NOUN
fnp-5892	169	17	.	.	PUNCT
fnp-5892	169	18	 	 	SPACE
fnp-5892	169	19	3	3	NUM
fnp-5892	169	20	and	and	CCONJ
fnp-5892	169	21	4d	4d	NUM
fnp-5892	169	22	)	)	PUNCT
fnp-5892	169	23	,	,	PUNCT
fnp-5892	169	24	and	and	CCONJ
fnp-5892	169	25	carried	carry	VERB
fnp-5892	169	26	tp53	tp53	PROPN
fnp-5892	169	27	mutations	mutation	NOUN
fnp-5892	169	28	(	(	PUNCT
fnp-5892	169	29	suppl	suppl	ADJ
fnp-5892	169	30	.	.	PUNCT
fnp-5892	169	31	table	table	NOUN
fnp-5892	169	32	 	 	SPACE
fnp-5892	169	33	s1	s1	NOUN
fnp-5892	169	34	)	)	PUNCT
fnp-5892	169	35	.	.	PUNCT
fnp-5892	170	1	analysis	analysis	NOUN
fnp-5892	170	2	of	of	ADP
fnp-5892	170	3	the	the	DET
fnp-5892	170	4	other	other	ADJ
fnp-5892	170	5	cases	case	NOUN
fnp-5892	170	6	with	with	ADP
fnp-5892	170	7	mgcs	mgcs	NOUN
fnp-5892	170	8	showed	show	VERB
fnp-5892	170	9	that	that	SCONJ
fnp-5892	170	10	the	the	DET
fnp-5892	170	11	large	large	ADJ
fnp-5892	170	12	majority	majority	NOUN
fnp-5892	170	13	also	also	ADV
fnp-5892	170	14	showed	show	VERB
fnp-5892	170	15	p53	p53	NOUN
fnp-5892	170	16	ihc	ihc	PROPN
fnp-5892	170	17	positivity	positivity	NOUN
fnp-5892	170	18	and	and	CCONJ
fnp-5892	170	19	carried	carry	VERB
fnp-5892	170	20	tp53	tp53	PROPN
fnp-5892	170	21	mutations	mutation	NOUN
fnp-5892	170	22	,	,	PUNCT
fnp-5892	170	23	regardless	regardless	ADV
fnp-5892	170	24	of	of	ADP
fnp-5892	170	25	the	the	DET
fnp-5892	170	26	molecular	molecular	ADJ
fnp-5892	170	27	subgroup	subgroup	NOUN
fnp-5892	170	28	(	(	PUNCT
fnp-5892	170	29	fig	fig	NOUN
fnp-5892	170	30	.	.	PUNCT
fnp-5892	170	31	 	 	SPACE
fnp-5892	170	32	4d	4d	NUM
fnp-5892	170	33	)	)	PUNCT
fnp-5892	170	34	.	.	PUNCT
fnp-5892	171	1	one	one	NUM
fnp-5892	171	2	tumor	tumor	NOUN
fnp-5892	171	3	occurring	occur	VERB
fnp-5892	171	4	in	in	ADP
fnp-5892	171	5	a	a	DET
fnp-5892	171	6	patient	patient	NOUN
fnp-5892	171	7	with	with	ADP
fnp-5892	171	8	li	li	ADJ
fnp-5892	171	9	-	-	ADJ
fnp-5892	171	10	fraumeni	fraumeni	ADJ
fnp-5892	171	11	syndrome	syndrome	NOUN
fnp-5892	171	12	showed	show	VERB
fnp-5892	171	13	frameshift	frameshift	ADJ
fnp-5892	171	14	mutation	mutation	NOUN
fnp-5892	171	15	in	in	ADP
fnp-5892	171	16	the	the	DET
fnp-5892	171	17	beginning	beginning	NOUN
fnp-5892	171	18	of	of	ADP
fnp-5892	171	19	tp53	tp53	PROPN
fnp-5892	171	20	gene	gene	NOUN
fnp-5892	171	21	with	with	ADP
fnp-5892	171	22	lack	lack	NOUN
fnp-5892	171	23	of	of	ADP
fnp-5892	171	24	p53	p53	NOUN
fnp-5892	171	25	protein	protein	NOUN
fnp-5892	171	26	expression	expression	NOUN
fnp-5892	171	27	,	,	PUNCT
fnp-5892	171	28	and	and	CCONJ
fnp-5892	171	29	another	another	DET
fnp-5892	171	30	12	12	NUM
fnp-5892	171	31	 	 	SPACE
fnp-5892	171	32	%	%	NOUN
fnp-5892	171	33	of	of	ADP
fnp-5892	171	34	cases	case	NOUN
fnp-5892	171	35	with	with	ADP
fnp-5892	171	36	mgcs	mgcs	NOUN
fnp-5892	171	37	showed	show	VERB
fnp-5892	171	38	alterations	alteration	NOUN
fnp-5892	171	39	in	in	ADP
fnp-5892	171	40	mediators	mediator	NOUN
fnp-5892	171	41	of	of	ADP
fnp-5892	171	42	the	the	DET
fnp-5892	171	43	p53	p53	NOUN
fnp-5892	171	44	pathway	pathway	NOUN
fnp-5892	171	45	,	,	PUNCT
fnp-5892	171	46	such	such	ADJ
fnp-5892	171	47	as	as	ADP
fnp-5892	171	48	mdm2	mdm2	PROPN
fnp-5892	171	49	,	,	PUNCT
fnp-5892	171	50	mdm4	mdm4	PROPN
fnp-5892	171	51	,	,	PUNCT
fnp-5892	171	52	rpl5	rpl5	NOUN
fnp-5892	171	53	or	or	CCONJ
fnp-5892	171	54	ebf1	ebf1	NOUN
fnp-5892	172	1	[	[	X
fnp-5892	172	2	5,26,27	5,26,27	NUM
fnp-5892	172	3	]	]	PUNCT
fnp-5892	172	4	(	(	PUNCT
fnp-5892	172	5	fig	fig	NOUN
fnp-5892	172	6	.	.	PUNCT
fnp-5892	172	7	 	 	SPACE
fnp-5892	172	8	4d	4d	NUM
fnp-5892	172	9	)	)	PUNCT
fnp-5892	172	10	.	.	PUNCT
fnp-5892	173	1	only	only	ADV
fnp-5892	173	2	7	7	NUM
fnp-5892	173	3	 	 	SPACE
fnp-5892	173	4	%	%	NOUN
fnp-5892	173	5	of	of	ADP
fnp-5892	173	6	the	the	DET
fnp-5892	173	7	cases	case	NOUN
fnp-5892	173	8	with	with	ADP
fnp-5892	173	9	mgcs	mgcs	NOUN
fnp-5892	173	10	did	do	AUX
fnp-5892	173	11	not	not	PART
fnp-5892	173	12	show	show	VERB
fnp-5892	173	13	alterations	alteration	NOUN
fnp-5892	173	14	in	in	ADP
fnp-5892	173	15	the	the	DET
fnp-5892	173	16	p53	p53	NOUN
fnp-5892	173	17	pathway	pathway	NOUN
fnp-5892	173	18	,	,	PUNCT
fnp-5892	173	19	and	and	CCONJ
fnp-5892	173	20	they	they	PRON
fnp-5892	173	21	all	all	PRON
fnp-5892	173	22	clustered	cluster	VERB
fnp-5892	173	23	in	in	ADP
fnp-5892	173	24	the	the	DET
fnp-5892	173	25	g3	g3	PROPN
fnp-5892	173	26	/	/	SYM
fnp-5892	173	27	nf1	nf1	NOUN
fnp-5892	173	28	subgroup	subgroup	NOUN
fnp-5892	173	29	.	.	PUNCT
fnp-5892	174	1	in	in	ADP
fnp-5892	174	2	total	total	NOUN
fnp-5892	174	3	,	,	PUNCT
fnp-5892	174	4	approximately	approximately	ADV
fnp-5892	174	5	one	one	NUM
fnp-5892	174	6	fifth	fifth	ADJ
fnp-5892	174	7	(	(	PUNCT
fnp-5892	174	8	21.3	21.3	NUM
fnp-5892	174	9	 	 	SPACE
fnp-5892	174	10	%	%	NOUN
fnp-5892	174	11	)	)	PUNCT
fnp-5892	174	12	of	of	ADP
fnp-5892	174	13	the	the	DET
fnp-5892	174	14	cases	case	NOUN
fnp-5892	174	15	with	with	ADP
fnp-5892	174	16	mgcs	mgcs	NOUN
fnp-5892	174	17	were	be	AUX
fnp-5892	174	18	negative	negative	ADJ
fnp-5892	174	19	for	for	ADP
fnp-5892	174	20	p53	p53	NOUN
fnp-5892	174	21	ihc	ihc	PROPN
fnp-5892	174	22	(	(	PUNCT
fnp-5892	174	23	fig	fig	NOUN
fnp-5892	174	24	.	.	PUNCT
fnp-5892	174	25	 	 	SPACE
fnp-5892	174	26	4d	4d	NUM
fnp-5892	174	27	,	,	PUNCT
fnp-5892	174	28	pie	pie	NOUN
fnp-5892	174	29	chart	chart	NOUN
fnp-5892	174	30	)	)	PUNCT
fnp-5892	174	31	.	.	PUNCT
fnp-5892	175	1	examination	examination	NOUN
fnp-5892	175	2	of	of	ADP
fnp-5892	175	3	the	the	DET
fnp-5892	175	4	tp53	tp53	PROPN
fnp-5892	175	5	mutations	mutation	NOUN
fnp-5892	175	6	in	in	ADP
fnp-5892	175	7	the	the	DET
fnp-5892	175	8	glioblastoma	glioblastoma	NOUN
fnp-5892	175	9	cohort	cohort	NOUN
fnp-5892	175	10	showed	show	VERB
fnp-5892	175	11	some	some	DET
fnp-5892	175	12	distinctive	distinctive	ADJ
fnp-5892	175	13	features	feature	NOUN
fnp-5892	175	14	of	of	ADP
fnp-5892	175	15	the	the	DET
fnp-5892	175	16	g3	g3	PROPN
fnp-5892	175	17	/	/	SYM
fnp-5892	175	18	mmr	mmr	PROPN
fnp-5892	175	19	cases	case	NOUN
fnp-5892	175	20	.	.	PUNCT
fnp-5892	176	1	whereas	whereas	SCONJ
fnp-5892	176	2	all	all	DET
fnp-5892	176	3	the	the	DET
fnp-5892	176	4	cases	case	NOUN
fnp-5892	176	5	in	in	ADP
fnp-5892	176	6	the	the	DET
fnp-5892	176	7	g3	g3	PROPN
fnp-5892	176	8	/	/	SYM
fnp-5892	176	9	mmr	mmr	PROPN
fnp-5892	176	10	subgroup	subgroup	NOUN
fnp-5892	176	11	showed	show	VERB
fnp-5892	176	12	tp53	tp53	PROPN
fnp-5892	176	13	mutations	mutation	NOUN
fnp-5892	176	14	and	and	CCONJ
fnp-5892	176	15	mgcs	mgcs	NOUN
fnp-5892	176	16	,	,	PUNCT
fnp-5892	176	17	only	only	ADV
fnp-5892	176	18	approximately	approximately	ADV
fnp-5892	176	19	half	half	NOUN
fnp-5892	176	20	of	of	ADP
fnp-5892	176	21	the	the	DET
fnp-5892	176	22	cases	case	NOUN
fnp-5892	176	23	with	with	ADP
fnp-5892	176	24	tp53	tp53	PROPN
fnp-5892	176	25	mutations	mutation	NOUN
fnp-5892	176	26	from	from	ADP
fnp-5892	176	27	other	other	ADJ
fnp-5892	176	28	molecular	molecular	ADJ
fnp-5892	176	29	subgroups	subgroup	NOUN
fnp-5892	176	30	showed	show	VERB
fnp-5892	176	31	an	an	DET
fnp-5892	176	32	mgc	mgc	NOUN
fnp-5892	176	33	phenotype	phenotype	NOUN
fnp-5892	176	34	,	,	PUNCT
fnp-5892	176	35	except	except	SCONJ
fnp-5892	176	36	for	for	ADP
fnp-5892	176	37	the	the	DET
fnp-5892	176	38	g1	g1	NOUN
fnp-5892	176	39	/	/	SYM
fnp-5892	176	40	egfr	egfr	ADJ
fnp-5892	176	41	-	-	PUNCT
fnp-5892	176	42	mutant	mutant	NOUN
fnp-5892	176	43	subgroup	subgroup	NOUN
fnp-5892	176	44	that	that	PRON
fnp-5892	176	45	showed	show	VERB
fnp-5892	176	46	83	83	NUM
fnp-5892	176	47	 	 	SPACE
fnp-5892	176	48	%	%	NOUN
fnp-5892	176	49	of	of	ADP
fnp-5892	176	50	tp53	tp53	PROPN
fnp-5892	176	51	mutant	mutant	ADJ
fnp-5892	176	52	cases	case	NOUN
fnp-5892	176	53	displaying	display	VERB
fnp-5892	176	54	an	an	DET
fnp-5892	176	55	mgcs	mgcs	NOUN
fnp-5892	176	56	(	(	PUNCT
fnp-5892	176	57	fig	fig	NOUN
fnp-5892	176	58	.	.	PUNCT
fnp-5892	176	59	 	 	SPACE
fnp-5892	176	60	4e	4e	NOUN
fnp-5892	176	61	)	)	PUNCT
fnp-5892	176	62	.	.	PUNCT
fnp-5892	177	1	overall	overall	ADV
fnp-5892	177	2	,	,	PUNCT
fnp-5892	177	3	the	the	DET
fnp-5892	177	4	g3	g3	PROPN
fnp-5892	177	5	/	/	SYM
fnp-5892	177	6	mmr	mmr	PROPN
fnp-5892	177	7	cases	case	NOUN
fnp-5892	177	8	represented	represent	VERB
fnp-5892	177	9	one	one	NUM
fnp-5892	177	10	seventh	seventh	ADJ
fnp-5892	177	11	(	(	PUNCT
fnp-5892	177	12	14.3	14.3	NUM
fnp-5892	177	13	 	 	SPACE
fnp-5892	177	14	%	%	NOUN
fnp-5892	177	15	)	)	PUNCT
fnp-5892	177	16	of	of	ADP
fnp-5892	177	17	the	the	DET
fnp-5892	177	18	cases	case	NOUN
fnp-5892	177	19	showing	show	VERB
fnp-5892	177	20	both	both	PRON
fnp-5892	177	21	mgcs	mgcs	NOUN
fnp-5892	177	22	and	and	CCONJ
fnp-5892	177	23	p53	p53	NOUN
fnp-5892	177	24	immunopositivity	immunopositivity	NOUN
fnp-5892	177	25	.	.	PUNCT
fnp-5892	178	1	a	a	DET
fnp-5892	178	2	major	major	ADJ
fnp-5892	178	3	difference	difference	NOUN
fnp-5892	178	4	also	also	ADV
fnp-5892	178	5	consisted	consist	VERB
fnp-5892	178	6	in	in	ADP
fnp-5892	178	7	the	the	DET
fnp-5892	178	8	number	number	NOUN
fnp-5892	178	9	of	of	ADP
fnp-5892	178	10	the	the	DET
fnp-5892	178	11	tp53	tp53	PROPN
fnp-5892	178	12	mutations	mutation	NOUN
fnp-5892	178	13	:	:	PUNCT
fnp-5892	178	14	whereas	whereas	SCONJ
fnp-5892	178	15	in	in	ADP
fnp-5892	178	16	g3	g3	PROPN
fnp-5892	178	17	/	/	SYM
fnp-5892	178	18	mmr	mmr	PROPN
fnp-5892	178	19	cases	case	NOUN
fnp-5892	178	20	,	,	PUNCT
fnp-5892	178	21	tp53	tp53	PROPN
fnp-5892	178	22	was	be	AUX
fnp-5892	178	23	inactivated	inactivate	VERB
fnp-5892	178	24	by	by	ADP
fnp-5892	178	25	different	different	ADJ
fnp-5892	178	26	missense	missense	NOUN
fnp-5892	178	27	mutations	mutation	NOUN
fnp-5892	178	28	most	most	ADV
fnp-5892	178	29	likely	likely	ADV
fnp-5892	178	30	targeting	target	VERB
fnp-5892	178	31	both	both	DET
fnp-5892	178	32	alleles	allele	NOUN
fnp-5892	178	33	(	(	PUNCT
fnp-5892	178	34	suppl	suppl	ADJ
fnp-5892	178	35	.	.	PUNCT
fnp-5892	178	36	table	table	NOUN
fnp-5892	178	37	 	 	SPACE
fnp-5892	178	38	1	1	NUM
fnp-5892	178	39	)	)	PUNCT
fnp-5892	178	40	,	,	PUNCT
fnp-5892	178	41	83	83	NUM
fnp-5892	178	42	 	 	SPACE
fnp-5892	178	43	%	%	NOUN
fnp-5892	178	44	of	of	ADP
fnp-5892	178	45	the	the	DET
fnp-5892	178	46	tumors	tumor	NOUN
fnp-5892	178	47	in	in	ADP
fnp-5892	178	48	the	the	DET
fnp-5892	178	49	rest	rest	NOUN
fnp-5892	178	50	of	of	ADP
fnp-5892	178	51	the	the	DET
fnp-5892	178	52	cohort	cohort	NOUN
fnp-5892	178	53	showed	show	VERB
fnp-5892	178	54	only	only	ADV
fnp-5892	178	55	one	one	NUM
fnp-5892	178	56	tp53	tp53	PROPN
fnp-5892	178	57	mutation	mutation	NOUN
fnp-5892	178	58	,	,	PUNCT
fnp-5892	178	59	with	with	ADP
fnp-5892	178	60	the	the	DET
fnp-5892	178	61	second	second	ADJ
fnp-5892	178	62	allele	allele	NOUN
fnp-5892	178	63	inactivated	inactivate	VERB
fnp-5892	178	64	by	by	ADP
fnp-5892	178	65	loss	loss	NOUN
fnp-5892	178	66	or	or	CCONJ
fnp-5892	178	67	neutral	neutral	ADJ
fnp-5892	178	68	loss	loss	NOUN
fnp-5892	178	69	of	of	ADP
fnp-5892	178	70	heterozygosity	heterozygosity	NOUN
fnp-5892	178	71	(	(	PUNCT
fnp-5892	178	72	fig	fig	NOUN
fnp-5892	178	73	.	.	PUNCT
fnp-5892	178	74	 	 	SPACE
fnp-5892	178	75	4f	4f	NUM
fnp-5892	178	76	)	)	PUNCT
fnp-5892	178	77	.	.	PUNCT
fnp-5892	179	1	molecular	molecular	ADJ
fnp-5892	179	2	landscape	landscape	NOUN
fnp-5892	179	3	of	of	ADP
fnp-5892	179	4	the	the	DET
fnp-5892	179	5	g3	g3	PROPN
fnp-5892	179	6	/	/	SYM
fnp-5892	179	7	mmr	mmr	PROPN
fnp-5892	179	8	glioblastoma	glioblastoma	NOUN
fnp-5892	179	9	subgroup	subgroup	NOUN
fnp-5892	179	10	tumors	tumor	NOUN
fnp-5892	179	11	.	.	PUNCT
fnp-5892	180	1	the	the	DET
fnp-5892	180	2	tmb	tmb	PROPN
fnp-5892	180	3	of	of	ADP
fnp-5892	180	4	the	the	DET
fnp-5892	180	5	g3	g3	PROPN
fnp-5892	180	6	/	/	SYM
fnp-5892	180	7	mmr	mmr	PROPN
fnp-5892	180	8	cases	case	NOUN
fnp-5892	180	9	was	be	AUX
fnp-5892	180	10	significantly	significantly	ADV
fnp-5892	180	11	higher	high	ADJ
fnp-5892	180	12	than	than	ADP
fnp-5892	180	13	that	that	PRON
fnp-5892	180	14	of	of	ADP
fnp-5892	180	15	the	the	DET
fnp-5892	180	16	other	other	ADJ
fnp-5892	180	17	glioblastoma	glioblastoma	NOUN
fnp-5892	180	18	cases	case	NOUN
fnp-5892	180	19	,	,	PUNCT
fnp-5892	180	20	with	with	ADP
fnp-5892	180	21	or	or	CCONJ
fnp-5892	180	22	without	without	ADP
fnp-5892	180	23	high	high	ADJ
fnp-5892	180	24	msi	msi	PROPN
fnp-5892	180	25	(	(	PUNCT
fnp-5892	180	26	table	table	NOUN
fnp-5892	180	27	 	 	SPACE
fnp-5892	180	28	1	1	NUM
fnp-5892	180	29	and	and	CCONJ
fnp-5892	180	30	fig	fig	NOUN
fnp-5892	180	31	.	.	PUNCT
fnp-5892	180	32	 	 	SPACE
fnp-5892	180	33	5a	5a	NUM
fnp-5892	180	34	)	)	PUNCT
fnp-5892	180	35	.	.	PUNCT
fnp-5892	181	1	for	for	ADP
fnp-5892	181	2	comparison	comparison	NOUN
fnp-5892	181	3	,	,	PUNCT
fnp-5892	181	4	three	three	NUM
fnp-5892	181	5	additional	additional	ADJ
fnp-5892	181	6	cases	case	NOUN
fnp-5892	181	7	from	from	ADP
fnp-5892	181	8	the	the	DET
fnp-5892	181	9	glioblastoma	glioblastoma	NOUN
fnp-5892	181	10	cohort	cohort	NOUN
fnp-5892	181	11	showed	show	VERB
fnp-5892	181	12	very	very	ADV
fnp-5892	181	13	high	high	ADJ
fnp-5892	181	14	tmb	tmb	X
fnp-5892	181	15	(	(	PUNCT
fnp-5892	181	16	fig	fig	NOUN
fnp-5892	181	17	.	.	PUNCT
fnp-5892	181	18	 	 	SPACE
fnp-5892	181	19	5a	5a	NUM
fnp-5892	181	20	;	;	PUNCT
fnp-5892	181	21	suppl	suppl	ADJ
fnp-5892	181	22	.	.	PUNCT
fnp-5892	181	23	table	table	NOUN
fnp-5892	181	24	 	 	SPACE
fnp-5892	181	25	s2	s2	PROPN
fnp-5892	181	26	)	)	PUNCT
fnp-5892	181	27	.	.	PUNCT
fnp-5892	182	1	one	one	NUM
fnp-5892	182	2	was	be	AUX
fnp-5892	182	3	a	a	DET
fnp-5892	182	4	tumor	tumor	NOUN
fnp-5892	182	5	at	at	ADP
fnp-5892	182	6	initial	initial	ADJ
fnp-5892	182	7	presentation	presentation	NOUN
fnp-5892	182	8	in	in	ADP
fnp-5892	182	9	a	a	DET
fnp-5892	182	10	53	53	NUM
fnp-5892	182	11	-	-	PUNCT
fnp-5892	182	12	years	year	NOUN
fnp-5892	182	13	-	-	PUNCT
fnp-5892	182	14	old	old	ADJ
fnp-5892	182	15	male	male	NOUN
fnp-5892	182	16	(	(	PUNCT
fnp-5892	182	17	m53	m53	PROPN
fnp-5892	182	18	/	/	SYM
fnp-5892	182	19	sc	sc	PROPN
fnp-5892	182	20	)	)	PUNCT
fnp-5892	182	21	that	that	PRON
fnp-5892	182	22	showed	show	VERB
fnp-5892	182	23	clonal	clonal	ADJ
fnp-5892	182	24	vaf	vaf	NOUN
fnp-5892	182	25	in	in	ADP
fnp-5892	182	26	few	few	ADJ
fnp-5892	182	27	mutations	mutation	NOUN
fnp-5892	182	28	common	common	ADJ
fnp-5892	182	29	to	to	ADP
fnp-5892	182	30	g1	g1	VERB
fnp-5892	182	31	/	/	SYM
fnp-5892	182	32	egfr	egfr	NOUN
fnp-5892	182	33	-	-	PUNCT
fnp-5892	182	34	amplified	amplify	VERB
fnp-5892	182	35	tumors	tumor	NOUN
fnp-5892	182	36	,	,	PUNCT
fnp-5892	182	37	and	and	CCONJ
fnp-5892	182	38	subclonal	subclonal	ADJ
fnp-5892	182	39	vaf	vaf	PROPN
fnp-5892	182	40	in	in	ADP
fnp-5892	182	41	a	a	DET
fnp-5892	182	42	multitude	multitude	NOUN
fnp-5892	182	43	of	of	ADP
fnp-5892	182	44	less	less	ADJ
fnp-5892	182	45	common	common	ADJ
fnp-5892	182	46	mutations	mutation	NOUN
fnp-5892	182	47	indicative	indicative	ADJ
fnp-5892	182	48	of	of	ADP
fnp-5892	182	49	a	a	DET
fnp-5892	182	50	subclonal	subclonal	ADJ
fnp-5892	182	51	population	population	NOUN
fnp-5892	182	52	of	of	ADP
fnp-5892	182	53	cells	cell	NOUN
fnp-5892	182	54	with	with	ADP
fnp-5892	182	55	very	very	ADV
fnp-5892	182	56	high	high	ADJ
fnp-5892	182	57	tmb	tmb	PROPN
fnp-5892	182	58	.	.	PUNCT
fnp-5892	183	1	two	two	NUM
fnp-5892	183	2	other	other	ADJ
fnp-5892	183	3	cases	case	NOUN
fnp-5892	183	4	were	be	AUX
fnp-5892	183	5	recurrent	recurrent	ADJ
fnp-5892	183	6	,	,	PUNCT
fnp-5892	183	7	g1	g1	X
fnp-5892	183	8	/	/	SYM
fnp-5892	183	9	egfr	egfr	NOUN
fnp-5892	183	10	-	-	PUNCT
fnp-5892	183	11	amplified	amplify	VERB
fnp-5892	183	12	subgroup	subgroup	NOUN
fnp-5892	183	13	tumors	tumor	NOUN
fnp-5892	183	14	in	in	ADP
fnp-5892	183	15	male	male	ADJ
fnp-5892	183	16	and	and	CCONJ
fnp-5892	183	17	female	female	ADJ
fnp-5892	183	18	patients	patient	NOUN
fnp-5892	183	19	aged	age	VERB
fnp-5892	183	20	66	66	NUM
fnp-5892	183	21	and	and	CCONJ
fnp-5892	183	22	58	58	NUM
fnp-5892	183	23	years	year	NOUN
fnp-5892	183	24	,	,	PUNCT
fnp-5892	183	25	respectively	respectively	ADV
fnp-5892	183	26	(	(	PUNCT
fnp-5892	183	27	m66	m66	PROPN
fnp-5892	183	28	/	/	SYM
fnp-5892	183	29	tmz	tmz	PROPN
fnp-5892	183	30	and	and	CCONJ
fnp-5892	183	31	f58	f58	PROPN
fnp-5892	183	32	/	/	SYM
fnp-5892	183	33	tmz	tmz	PROPN
fnp-5892	183	34	)	)	PUNCT
fnp-5892	183	35	,	,	PUNCT
fnp-5892	183	36	previously	previously	ADV
fnp-5892	183	37	treated	treat	VERB
fnp-5892	183	38	with	with	ADP
fnp-5892	183	39	tmz	tmz	PROPN
fnp-5892	183	40	,	,	PUNCT
fnp-5892	183	41	a	a	DET
fnp-5892	183	42	known	know	VERB
fnp-5892	183	43	hypermutator	hypermutator	NOUN
fnp-5892	183	44	phenotype	phenotype	NOUN
fnp-5892	183	45	inducer	inducer	NOUN
fnp-5892	184	1	[	[	X
fnp-5892	184	2	28	28	NUM
fnp-5892	184	3	]	]	PUNCT
fnp-5892	184	4	.	.	PUNCT
fnp-5892	185	1	interestingly	interestingly	ADV
fnp-5892	185	2	,	,	PUNCT
fnp-5892	185	3	of	of	ADP
fnp-5892	185	4	the	the	DET
fnp-5892	185	5	20	20	NUM
fnp-5892	185	6	post	post	NOUN
fnp-5892	185	7	-	-	ADJ
fnp-5892	185	8	tmz	tmz	NOUN
fnp-5892	185	9	,	,	PUNCT
fnp-5892	185	10	recurrent	recurrent	ADJ
fnp-5892	185	11	tumors	tumor	NOUN
fnp-5892	185	12	subjected	subject	VERB
fnp-5892	185	13	to	to	ADP
fnp-5892	185	14	ngs	ng	NOUN
fnp-5892	185	15	in	in	ADP
fnp-5892	185	16	this	this	DET
fnp-5892	185	17	cohort	cohort	NOUN
fnp-5892	185	18	,	,	PUNCT
fnp-5892	185	19	of	of	ADP
fnp-5892	185	20	which	which	PRON
fnp-5892	185	21	only	only	ADV
fnp-5892	185	22	5	5	NUM
fnp-5892	185	23	mapped	map	VERB
fnp-5892	185	24	to	to	ADP
fnp-5892	185	25	the	the	DET
fnp-5892	185	26	g1	g1	PROPN
fnp-5892	185	27	/	/	SYM
fnp-5892	185	28	egfr	egfr	NOUN
fnp-5892	185	29	-	-	PUNCT
fnp-5892	185	30	amplified	amplify	VERB
fnp-5892	185	31	subgroup	subgroup	NOUN
fnp-5892	185	32	,	,	PUNCT
fnp-5892	185	33	both	both	DET
fnp-5892	185	34	tumors	tumor	NOUN
fnp-5892	185	35	with	with	ADP
fnp-5892	185	36	hypermutator	hypermutator	NOUN
fnp-5892	185	37	phenotype	phenotype	NOUN
fnp-5892	185	38	belonged	belong	VERB
fnp-5892	185	39	to	to	ADP
fnp-5892	185	40	the	the	DET
fnp-5892	185	41	g1	g1	PROPN
fnp-5892	185	42	/	/	SYM
fnp-5892	185	43	egfr	egfr	NOUN
fnp-5892	185	44	-	-	PUNCT
fnp-5892	185	45	amplified	amplify	VERB
fnp-5892	185	46	subgroup	subgroup	NOUN
fnp-5892	185	47	.	.	PUNCT
fnp-5892	186	1	all	all	DET
fnp-5892	186	2	these	these	DET
fnp-5892	186	3	three	three	NUM
fnp-5892	186	4	g1	g1	NOUN
fnp-5892	186	5	/	/	SYM
fnp-5892	186	6	egfr	egfr	NOUN
fnp-5892	186	7	-	-	PUNCT
fnp-5892	186	8	amplified	amplify	VERB
fnp-5892	186	9	tumors	tumor	NOUN
fnp-5892	186	10	harbored	harbor	VERB
fnp-5892	186	11	very	very	ADV
fnp-5892	186	12	high	high	ADJ
fnp-5892	186	13	tmb	tmb	NOUN
fnp-5892	186	14	,	,	PUNCT
fnp-5892	186	15	stable	stable	ADJ
fnp-5892	186	16	msi	msi	NOUN
fnp-5892	186	17	,	,	PUNCT
fnp-5892	186	18	but	but	CCONJ
fnp-5892	186	19	lacked	lack	VERB
fnp-5892	186	20	mgc	mgc	PROPN
fnp-5892	186	21	histology	histology	NOUN
fnp-5892	186	22	.	.	PUNCT
fnp-5892	187	1	their	their	PRON
fnp-5892	187	2	immunohistochemical	immunohistochemical	ADJ
fnp-5892	187	3	profiles	profile	NOUN
fnp-5892	187	4	were	be	AUX
fnp-5892	187	5	undistinguishable	undistinguishable	ADJ
fnp-5892	187	6	from	from	ADP
fnp-5892	187	7	those	those	PRON
fnp-5892	187	8	of	of	ADP
fnp-5892	187	9	g1	g1	NOUN
fnp-5892	187	10	/	/	SYM
fnp-5892	187	11	egfr	egfr	NOUN
fnp-5892	187	12	-	-	PUNCT
fnp-5892	187	13	amplified	amplify	VERB
fnp-5892	187	14	tumors	tumor	NOUN
fnp-5892	187	15	,	,	PUNCT
fnp-5892	187	16	showing	show	VERB
fnp-5892	187	17	negative	negative	ADJ
fnp-5892	187	18	p53	p53	NOUN
fnp-5892	187	19	and	and	CCONJ
fnp-5892	187	20	p16	p16	PROPN
fnp-5892	187	21	ihc	ihc	PROPN
fnp-5892	187	22	.	.	PUNCT
fnp-5892	188	1	figure	figure	VERB
fnp-5892	188	2	5	5	NUM
fnp-5892	188	3	:	:	PUNCT
fnp-5892	188	4	molecular	molecular	ADJ
fnp-5892	188	5	profiling	profiling	NOUN
fnp-5892	188	6	of	of	ADP
fnp-5892	188	7	the	the	DET
fnp-5892	188	8	g3	g3	PROPN
fnp-5892	188	9	/	/	SYM
fnp-5892	188	10	mmr	mmr	PROPN
fnp-5892	188	11	subgroup	subgroup	PROPN
fnp-5892	188	12	a.	a.	PROPN
fnp-5892	188	13	tmb	tmb	PROPN
fnp-5892	188	14	mean±sem	mean±sem	PROPN
fnp-5892	188	15	graph	graph	NOUN
fnp-5892	188	16	of	of	ADP
fnp-5892	188	17	individual	individual	ADJ
fnp-5892	188	18	case	case	NOUN
fnp-5892	188	19	values	value	NOUN
fnp-5892	188	20	from	from	ADP
fnp-5892	188	21	indicated	indicate	VERB
fnp-5892	188	22	cases	case	NOUN
fnp-5892	188	23	.	.	PUNCT
fnp-5892	189	1	post	post	PROPN
fnp-5892	189	2	-	-	ADJ
fnp-5892	189	3	tmz	tmz	NOUN
fnp-5892	189	4	,	,	PUNCT
fnp-5892	189	5	post	post	PROPN
fnp-5892	189	6	tmz	tmz	PROPN
fnp-5892	189	7	chemotherapy	chemotherapy	NOUN
fnp-5892	189	8	;	;	PUNCT
fnp-5892	189	9	total	total	ADJ
fnp-5892	189	10	gbm	gbm	PROPN
fnp-5892	189	11	-	-	PUNCT
fnp-5892	189	12	mmr	mmr	PROPN
fnp-5892	189	13	,	,	PUNCT
fnp-5892	189	14	gbm	gbm	PROPN
fnp-5892	189	15	cases	case	NOUN
fnp-5892	189	16	without	without	ADP
fnp-5892	189	17	the	the	DET
fnp-5892	189	18	g3	g3	PROPN
fnp-5892	189	19	/	/	SYM
fnp-5892	189	20	mmr	mmr	PROPN
fnp-5892	189	21	cases	case	NOUN
fnp-5892	189	22	.	.	PUNCT
fnp-5892	190	1	statistical	statistical	ADJ
fnp-5892	190	2	significance	significance	NOUN
fnp-5892	190	3	:	:	PUNCT
fnp-5892	190	4	*	*	X
fnp-5892	190	5	,	,	PUNCT
fnp-5892	190	6	p	p	X
fnp-5892	190	7	 	 	SPACE
fnp-5892	190	8	<	<	X
fnp-5892	190	9	  	  	SPACE
fnp-5892	190	10	0.05	0.05	NUM
fnp-5892	190	11	.	.	PUNCT
fnp-5892	191	1	b.	b.	NOUN
fnp-5892	191	2	genomic	genomic	NOUN
fnp-5892	191	3	alterations	alteration	NOUN
fnp-5892	191	4	in	in	ADP
fnp-5892	191	5	effectors	effector	NOUN
fnp-5892	191	6	of	of	ADP
fnp-5892	191	7	the	the	DET
fnp-5892	191	8	pathways	pathway	NOUN
fnp-5892	191	9	indicated	indicate	VERB
fnp-5892	191	10	on	on	ADP
fnp-5892	191	11	the	the	DET
fnp-5892	191	12	left	left	NOUN
fnp-5892	191	13	are	be	AUX
fnp-5892	191	14	shown	show	VERB
fnp-5892	191	15	by	by	ADP
fnp-5892	191	16	color	color	NOUN
fnp-5892	191	17	-	-	PUNCT
fnp-5892	191	18	coded	code	VERB
fnp-5892	191	19	squares	square	NOUN
fnp-5892	191	20	.	.	PUNCT
fnp-5892	192	1	telom	telom	NOUN
fnp-5892	192	2	,	,	PUNCT
fnp-5892	192	3	telomere	telomere	NOUN
fnp-5892	192	4	maintenance	maintenance	NOUN
fnp-5892	192	5	;	;	PUNCT
fnp-5892	192	6	cc	cc	NOUN
fnp-5892	192	7	g1	g1	PROPN
fnp-5892	192	8	,	,	PUNCT
fnp-5892	192	9	cell	cell	NOUN
fnp-5892	192	10	cycle	cycle	NOUN
fnp-5892	192	11	g1	g1	NOUN
fnp-5892	192	12	phase	phase	NOUN
fnp-5892	192	13	;	;	PUNCT
fnp-5892	192	14	ddr	ddr	PROPN
fnp-5892	192	15	,	,	PUNCT
fnp-5892	192	16	dna	dna	ADJ
fnp-5892	192	17	damage	damage	NOUN
fnp-5892	192	18	response	response	NOUN
fnp-5892	192	19	;	;	PUNCT
fnp-5892	192	20	chrm	chrm	NOUN
fnp-5892	192	21	,	,	PUNCT
fnp-5892	192	22	chromatin	chromatin	NOUN
fnp-5892	192	23	remodeling	remodeling	NOUN
fnp-5892	192	24	;	;	PUNCT
fnp-5892	192	25	chrom	chrom	NOUN
fnp-5892	192	26	,	,	PUNCT
fnp-5892	192	27	chromosomes	chromosome	NOUN
fnp-5892	192	28	;	;	PUNCT
fnp-5892	192	29	expr	expr	ADJ
fnp-5892	192	30	,	,	PUNCT
fnp-5892	192	31	rna	rna	NOUN
fnp-5892	192	32	expression	expression	NOUN
fnp-5892	192	33	.	.	PUNCT
fnp-5892	193	1	c	c	X
fnp-5892	193	2	–	–	PUNCT
fnp-5892	193	3	d.	d.	NOUN
fnp-5892	193	4	line	line	NOUN
fnp-5892	193	5	graphs	graph	NOUN
fnp-5892	193	6	tracing	trace	VERB
fnp-5892	193	7	the	the	DET
fnp-5892	193	8	incidence	incidence	NOUN
fnp-5892	193	9	of	of	ADP
fnp-5892	193	10	the	the	DET
fnp-5892	193	11	indicated	indicate	VERB
fnp-5892	193	12	alterations	alteration	NOUN
fnp-5892	193	13	in	in	ADP
fnp-5892	193	14	the	the	DET
fnp-5892	193	15	g3	g3	PROPN
fnp-5892	193	16	/	/	SYM
fnp-5892	193	17	mmr	mmr	PROPN
fnp-5892	193	18	subgroup	subgroup	NOUN
fnp-5892	193	19	in	in	ADP
fnp-5892	193	20	comparison	comparison	NOUN
fnp-5892	193	21	with	with	ADP
fnp-5892	193	22	the	the	DET
fnp-5892	193	23	rest	rest	NOUN
fnp-5892	193	24	of	of	ADP
fnp-5892	193	25	the	the	DET
fnp-5892	193	26	g1	g1	NOUN
fnp-5892	193	27	–	–	PUNCT
fnp-5892	193	28	g7	g7	PROPN
fnp-5892	193	29	molecular	molecular	ADJ
fnp-5892	193	30	subgroups	subgroup	NOUN
fnp-5892	193	31	.	.	PUNCT
fnp-5892	194	1	e.	e.	PROPN
fnp-5892	194	2	rna	rna	PROPN
fnp-5892	194	3	expression	expression	NOUN
fnp-5892	194	4	heatmaps	heatmap	NOUN
fnp-5892	194	5	for	for	ADP
fnp-5892	194	6	the	the	DET
fnp-5892	194	7	indicated	indicate	VERB
fnp-5892	194	8	rtks	rtks	NOUN
fnp-5892	194	9	,	,	PUNCT
fnp-5892	194	10	transcription	transcription	NOUN
fnp-5892	194	11	factor	factor	NOUN
fnp-5892	194	12	ap-1	ap-1	NOUN
fnp-5892	194	13	complex	complex	ADJ
fnp-5892	194	14	and	and	CCONJ
fnp-5892	194	15	mapk	mapk	NOUN
fnp-5892	194	16	pathway	pathway	NOUN
fnp-5892	194	17	feedback	feedback	NOUN
fnp-5892	194	18	effectors	effector	NOUN
fnp-5892	194	19	.	.	PUNCT
fnp-5892	195	1	a	a	DET
fnp-5892	195	2	comparison	comparison	NOUN
fnp-5892	195	3	of	of	ADP
fnp-5892	195	4	the	the	DET
fnp-5892	195	5	molecular	molecular	ADJ
fnp-5892	195	6	landscape	landscape	NOUN
fnp-5892	195	7	of	of	ADP
fnp-5892	195	8	the	the	DET
fnp-5892	195	9	g3	g3	PROPN
fnp-5892	195	10	/	/	SYM
fnp-5892	195	11	mmr	mmr	PROPN
fnp-5892	195	12	cases	case	NOUN
fnp-5892	195	13	with	with	ADP
fnp-5892	195	14	the	the	DET
fnp-5892	195	15	3	3	NUM
fnp-5892	195	16	cases	case	NOUN
fnp-5892	195	17	with	with	ADP
fnp-5892	195	18	very	very	ADV
fnp-5892	195	19	high	high	ADJ
fnp-5892	195	20	tmb	tmb	NOUN
fnp-5892	195	21	and	and	CCONJ
fnp-5892	195	22	,	,	PUNCT
fnp-5892	195	23	in	in	ADP
fnp-5892	195	24	general	general	ADJ
fnp-5892	195	25	,	,	PUNCT
fnp-5892	195	26	with	with	ADP
fnp-5892	195	27	the	the	DET
fnp-5892	195	28	distribution	distribution	NOUN
fnp-5892	195	29	of	of	ADP
fnp-5892	195	30	mutations	mutation	NOUN
fnp-5892	195	31	from	from	ADP
fnp-5892	195	32	the	the	DET
fnp-5892	195	33	rest	rest	NOUN
fnp-5892	195	34	of	of	ADP
fnp-5892	195	35	the	the	DET
fnp-5892	195	36	g1	g1	NOUN
fnp-5892	195	37	–	–	PUNCT
fnp-5892	195	38	g7	g7	PROPN
fnp-5892	195	39	molecular	molecular	ADJ
fnp-5892	195	40	subgroups	subgroup	NOUN
fnp-5892	195	41	(	(	PUNCT
fnp-5892	195	42	suppl	suppl	ADJ
fnp-5892	195	43	.	.	PUNCT
fnp-5892	196	1	tables	tables	PROPN
fnp-5892	196	2	s2	s2	PROPN
fnp-5892	196	3	-	-	PUNCT
fnp-5892	196	4	s3	s3	NOUN
fnp-5892	196	5	)	)	PUNCT
fnp-5892	196	6	,	,	PUNCT
fnp-5892	196	7	showed	show	VERB
fnp-5892	196	8	distinctive	distinctive	ADJ
fnp-5892	196	9	features	feature	NOUN
fnp-5892	196	10	for	for	ADP
fnp-5892	196	11	the	the	DET
fnp-5892	196	12	g3	g3	PROPN
fnp-5892	196	13	/	/	SYM
fnp-5892	196	14	mmr	mmr	PROPN
fnp-5892	196	15	subgroup	subgroup	NOUN
fnp-5892	196	16	(	(	PUNCT
fnp-5892	196	17	table	table	NOUN
fnp-5892	196	18	 	 	SPACE
fnp-5892	196	19	1	1	NUM
fnp-5892	196	20	;	;	PUNCT
fnp-5892	196	21	fig	fig	NOUN
fnp-5892	196	22	.	.	PUNCT
fnp-5892	196	23	 	 	SPACE
fnp-5892	197	1	5b	5b	NUM
fnp-5892	197	2	–	–	PUNCT
fnp-5892	197	3	d	d	NOUN
fnp-5892	197	4	;	;	PUNCT
fnp-5892	197	5	suppl	suppl	ADJ
fnp-5892	197	6	.	.	PUNCT
fnp-5892	197	7	table	table	NOUN
fnp-5892	197	8	 	 	SPACE
fnp-5892	197	9	s1	s1	NOUN
fnp-5892	197	10	)	)	PUNCT
fnp-5892	197	11	.	.	PUNCT
fnp-5892	198	1	germline	germline	NOUN
fnp-5892	198	2	pathogenic	pathogenic	ADJ
fnp-5892	198	3	alterations	alteration	NOUN
fnp-5892	198	4	in	in	ADP
fnp-5892	198	5	msh2	msh2	NOUN
fnp-5892	198	6	or	or	CCONJ
fnp-5892	198	7	msh6	msh6	VERB
fnp-5892	198	8	mmr	mmr	PROPN
fnp-5892	198	9	genes	gene	NOUN
fnp-5892	198	10	were	be	AUX
fnp-5892	198	11	present	present	ADJ
fnp-5892	198	12	in	in	ADP
fnp-5892	198	13	all	all	DET
fnp-5892	198	14	g3	g3	PROPN
fnp-5892	198	15	/	/	SYM
fnp-5892	198	16	mmr	mmr	NOUN
fnp-5892	198	17	cases	case	NOUN
fnp-5892	198	18	but	but	CCONJ
fnp-5892	198	19	absent	absent	ADJ
fnp-5892	198	20	in	in	ADP
fnp-5892	198	21	the	the	DET
fnp-5892	198	22	rest	rest	NOUN
fnp-5892	198	23	of	of	ADP
fnp-5892	198	24	the	the	DET
fnp-5892	198	25	cohort	cohort	NOUN
fnp-5892	198	26	.	.	PUNCT
fnp-5892	199	1	these	these	PRON
fnp-5892	199	2	were	be	AUX
fnp-5892	199	3	either	either	CCONJ
fnp-5892	199	4	splice	splice	NOUN
fnp-5892	199	5	site	site	NOUN
fnp-5892	199	6	or	or	CCONJ
fnp-5892	199	7	frameshift	frameshift	ADJ
fnp-5892	199	8	mutations	mutation	NOUN
fnp-5892	199	9	,	,	PUNCT
fnp-5892	199	10	resulting	result	VERB
fnp-5892	199	11	in	in	ADP
fnp-5892	199	12	truncation	truncation	NOUN
fnp-5892	199	13	of	of	ADP
fnp-5892	199	14	the	the	DET
fnp-5892	199	15	protein	protein	NOUN
fnp-5892	199	16	,	,	PUNCT
fnp-5892	199	17	or	or	CCONJ
fnp-5892	199	18	loss	loss	NOUN
fnp-5892	199	19	of	of	ADP
fnp-5892	199	20	the	the	DET
fnp-5892	199	21	msh2	msh2	NOUN
fnp-5892	199	22	/	/	SYM
fnp-5892	199	23	msh6	msh6	NOUN
fnp-5892	199	24	locus	locus	NOUN
fnp-5892	199	25	on	on	ADP
fnp-5892	199	26	chromosome	chromosome	NOUN
fnp-5892	199	27	2p16.3	2p16.3	NUM
fnp-5892	199	28	,	,	PUNCT
fnp-5892	199	29	an	an	DET
fnp-5892	199	30	exceedingly	exceedingly	ADV
fnp-5892	199	31	rare	rare	ADJ
fnp-5892	199	32	event	event	NOUN
fnp-5892	199	33	in	in	ADP
fnp-5892	199	34	glioblastoma	glioblastoma	NOUN
fnp-5892	199	35	present	present	ADJ
fnp-5892	199	36	only	only	ADV
fnp-5892	199	37	in	in	ADP
fnp-5892	199	38	the	the	DET
fnp-5892	199	39	m79	m79	NOUN
fnp-5892	199	40	g3	g3	PROPN
fnp-5892	199	41	/	/	SYM
fnp-5892	199	42	mmr	mmr	PROPN
fnp-5892	199	43	case	case	NOUN
fnp-5892	199	44	from	from	ADP
fnp-5892	199	45	the	the	DET
fnp-5892	199	46	entire	entire	ADJ
fnp-5892	199	47	cohort	cohort	NOUN
fnp-5892	199	48	.	.	PUNCT
fnp-5892	200	1	interestingly	interestingly	ADV
fnp-5892	200	2	,	,	PUNCT
fnp-5892	200	3	the	the	DET
fnp-5892	200	4	msh6	msh6	NOUN
fnp-5892	200	5	p.f1088fs	p.f1088f	VERB
fnp-5892	200	6	mutation	mutation	NOUN
fnp-5892	200	7	was	be	AUX
fnp-5892	200	8	recurrent	recurrent	ADJ
fnp-5892	200	9	,	,	PUNCT
fnp-5892	200	10	either	either	CCONJ
fnp-5892	200	11	as	as	ADP
fnp-5892	200	12	germline	germline	NOUN
fnp-5892	200	13	or	or	CCONJ
fnp-5892	200	14	as	as	ADP
fnp-5892	200	15	second	second	ADJ
fnp-5892	200	16	hit	hit	VERB
fnp-5892	200	17	somatic	somatic	ADJ
fnp-5892	200	18	mutation	mutation	NOUN
fnp-5892	200	19	(	(	PUNCT
fnp-5892	200	20	suppl	suppl	ADJ
fnp-5892	200	21	.	.	PUNCT
fnp-5892	200	22	table	table	NOUN
fnp-5892	200	23	 	 	SPACE
fnp-5892	200	24	s1	s1	NOUN
fnp-5892	200	25	)	)	PUNCT
fnp-5892	200	26	.	.	PUNCT
fnp-5892	201	1	in	in	ADP
fnp-5892	201	2	comparison	comparison	NOUN
fnp-5892	201	3	,	,	PUNCT
fnp-5892	201	4	the	the	DET
fnp-5892	201	5	3	3	NUM
fnp-5892	201	6	cases	case	NOUN
fnp-5892	201	7	with	with	ADP
fnp-5892	201	8	very	very	ADV
fnp-5892	201	9	high	high	ADJ
fnp-5892	201	10	tmb	tmb	NOUN
fnp-5892	201	11	showed	show	VERB
fnp-5892	201	12	pathogenic	pathogenic	ADJ
fnp-5892	201	13	or	or	CCONJ
fnp-5892	201	14	likely	likely	ADJ
fnp-5892	201	15	pathogenic	pathogenic	ADJ
fnp-5892	201	16	msh2	msh2	NOUN
fnp-5892	201	17	or	or	CCONJ
fnp-5892	201	18	msh6	msh6	VERB
fnp-5892	201	19	mutations	mutation	NOUN
fnp-5892	201	20	with	with	ADP
fnp-5892	201	21	vaf	vaf	PROPN
fnp-5892	201	22	in	in	ADP
fnp-5892	201	23	the	the	DET
fnp-5892	201	24	somatic	somatic	ADJ
fnp-5892	201	25	range	range	NOUN
fnp-5892	201	26	,	,	PUNCT
fnp-5892	201	27	of	of	ADP
fnp-5892	201	28	which	which	PRON
fnp-5892	201	29	only	only	ADV
fnp-5892	201	30	one	one	NUM
fnp-5892	201	31	resulted	result	VERB
fnp-5892	201	32	in	in	ADP
fnp-5892	201	33	protein	protein	NOUN
fnp-5892	201	34	truncation	truncation	NOUN
fnp-5892	201	35	,	,	PUNCT
fnp-5892	201	36	in	in	ADP
fnp-5892	201	37	m66	m66	PROPN
fnp-5892	201	38	/	/	SYM
fnp-5892	201	39	tmz	tmz	PROPN
fnp-5892	201	40	,	,	PUNCT
fnp-5892	201	41	the	the	DET
fnp-5892	201	42	other	other	ADJ
fnp-5892	201	43	being	be	AUX
fnp-5892	201	44	missense	missense	NOUN
fnp-5892	201	45	mutations	mutation	NOUN
fnp-5892	201	46	,	,	PUNCT
fnp-5892	201	47	with	with	ADP
fnp-5892	201	48	subclonal	subclonal	ADJ
fnp-5892	201	49	vaf	vaf	PROPN
fnp-5892	201	50	in	in	ADP
fnp-5892	201	51	the	the	DET
fnp-5892	201	52	m53	m53	PROPN
fnp-5892	201	53	/	/	SYM
fnp-5892	201	54	sc	sc	PROPN
fnp-5892	201	55	tumor	tumor	NOUN
fnp-5892	201	56	(	(	PUNCT
fnp-5892	201	57	suppl	suppl	ADJ
fnp-5892	201	58	.	.	PUNCT
fnp-5892	201	59	table	table	NOUN
fnp-5892	201	60	 	 	SPACE
fnp-5892	201	61	s2	s2	PROPN
fnp-5892	201	62	)	)	PUNCT
fnp-5892	201	63	.	.	PUNCT
fnp-5892	202	1	in	in	ADP
fnp-5892	202	2	comparison	comparison	NOUN
fnp-5892	202	3	,	,	PUNCT
fnp-5892	202	4	a	a	DET
fnp-5892	202	5	paucity	paucity	NOUN
fnp-5892	202	6	of	of	ADP
fnp-5892	202	7	pathogenic	pathogenic	ADJ
fnp-5892	202	8	mutations	mutation	NOUN
fnp-5892	202	9	in	in	ADP
fnp-5892	202	10	mmr	mmr	PROPN
fnp-5892	202	11	,	,	PUNCT
fnp-5892	202	12	pole	pole	NOUN
fnp-5892	202	13	and	and	CCONJ
fnp-5892	202	14	mutyh	mutyh	NOUN
fnp-5892	202	15	genes	gene	NOUN
fnp-5892	202	16	,	,	PUNCT
fnp-5892	202	17	the	the	DET
fnp-5892	202	18	latter	latter	ADJ
fnp-5892	202	19	two	two	NUM
fnp-5892	202	20	also	also	ADV
fnp-5892	202	21	known	know	VERB
fnp-5892	202	22	to	to	PART
fnp-5892	202	23	induce	induce	VERB
fnp-5892	202	24	hypermutator	hypermutator	NOUN
fnp-5892	202	25	phenotype	phenotype	NOUN
fnp-5892	203	1	[	[	X
fnp-5892	203	2	29,30	29,30	NUM
fnp-5892	203	3	]	]	PUNCT
fnp-5892	203	4	,	,	PUNCT
fnp-5892	203	5	was	be	AUX
fnp-5892	203	6	apparent	apparent	ADJ
fnp-5892	203	7	in	in	ADP
fnp-5892	203	8	the	the	DET
fnp-5892	203	9	cohort	cohort	NOUN
fnp-5892	203	10	,	,	PUNCT
fnp-5892	203	11	without	without	ADP
fnp-5892	203	12	high	high	ADJ
fnp-5892	203	13	tmb	tmb	NOUN
fnp-5892	203	14	in	in	ADP
fnp-5892	203	15	any	any	PRON
fnp-5892	203	16	of	of	ADP
fnp-5892	203	17	these	these	DET
fnp-5892	203	18	mutant	mutant	ADJ
fnp-5892	203	19	cases	case	NOUN
fnp-5892	203	20	(	(	PUNCT
fnp-5892	203	21	suppl	suppl	ADJ
fnp-5892	203	22	.	.	PUNCT
fnp-5892	203	23	table	table	NOUN
fnp-5892	203	24	 	 	SPACE
fnp-5892	203	25	s2	s2	PROPN
fnp-5892	203	26	)	)	PUNCT
fnp-5892	203	27	.	.	PUNCT
fnp-5892	204	1	in	in	ADP
fnp-5892	204	2	particular	particular	ADJ
fnp-5892	204	3	,	,	PUNCT
fnp-5892	204	4	the	the	DET
fnp-5892	204	5	g2	g2	PROPN
fnp-5892	204	6	/	/	SYM
fnp-5892	204	7	fgfr3	fgfr3	PROPN
fnp-5892	204	8	molecular	molecular	ADJ
fnp-5892	204	9	subgroup	subgroup	NOUN
fnp-5892	204	10	displayed	display	VERB
fnp-5892	204	11	higher	high	ADJ
fnp-5892	204	12	incidence	incidence	NOUN
fnp-5892	204	13	of	of	ADP
fnp-5892	204	14	mmr	mmr	PROPN
fnp-5892	204	15	/	/	SYM
fnp-5892	204	16	mutyh	mutyh	NOUN
fnp-5892	204	17	mutations	mutation	NOUN
fnp-5892	204	18	,	,	PUNCT
fnp-5892	204	19	with	with	ADP
fnp-5892	204	20	the	the	DET
fnp-5892	204	21	m60	m60	NOUN
fnp-5892	204	22	case	case	NOUN
fnp-5892	204	23	showing	show	VERB
fnp-5892	204	24	the	the	DET
fnp-5892	204	25	only	only	ADJ
fnp-5892	204	26	msh6	msh6	NOUN
fnp-5892	204	27	truncating	truncate	VERB
fnp-5892	204	28	mutation	mutation	NOUN
fnp-5892	204	29	with	with	ADP
fnp-5892	204	30	vaf	vaf	PROPN
fnp-5892	204	31	in	in	ADP
fnp-5892	204	32	the	the	DET
fnp-5892	204	33	somatic	somatic	ADJ
fnp-5892	204	34	range	range	NOUN
fnp-5892	204	35	from	from	ADP
fnp-5892	204	36	the	the	DET
fnp-5892	204	37	cohort	cohort	NOUN
fnp-5892	204	38	.	.	PUNCT
fnp-5892	205	1	as	as	SCONJ
fnp-5892	205	2	previously	previously	ADV
fnp-5892	205	3	described	describe	VERB
fnp-5892	205	4	,	,	PUNCT
fnp-5892	205	5	this	this	DET
fnp-5892	205	6	tumor	tumor	NOUN
fnp-5892	205	7	showed	show	VERB
fnp-5892	205	8	a	a	DET
fnp-5892	205	9	typical	typical	ADJ
fnp-5892	205	10	g2	g2	PROPN
fnp-5892	205	11	/	/	SYM
fnp-5892	205	12	fgfr3	fgfr3	PROPN
fnp-5892	205	13	molecular	molecular	ADJ
fnp-5892	205	14	profile	profile	NOUN
fnp-5892	205	15	and	and	CCONJ
fnp-5892	205	16	lacked	lack	VERB
fnp-5892	205	17	mgcs	mgcs	NOUN
fnp-5892	205	18	[	[	X
fnp-5892	205	19	15	15	NUM
fnp-5892	205	20	]	]	X
fnp-5892	205	21	(	(	PUNCT
fnp-5892	205	22	suppl	suppl	ADJ
fnp-5892	205	23	.	.	PUNCT
fnp-5892	205	24	table	table	NOUN
fnp-5892	205	25	 	 	SPACE
fnp-5892	205	26	s2	s2	PROPN
fnp-5892	205	27	)	)	PUNCT
fnp-5892	205	28	.	.	PUNCT
fnp-5892	206	1	a	a	DET
fnp-5892	206	2	truncating	truncate	VERB
fnp-5892	206	3	mutation	mutation	NOUN
fnp-5892	206	4	in	in	ADP
fnp-5892	206	5	mlh3	mlh3	PROPN
fnp-5892	206	6	,	,	PUNCT
fnp-5892	206	7	a	a	DET
fnp-5892	206	8	paralog	paralog	NOUN
fnp-5892	206	9	of	of	ADP
fnp-5892	206	10	mlh1	mlh1	PROPN
fnp-5892	206	11	,	,	PUNCT
fnp-5892	206	12	with	with	ADP
fnp-5892	206	13	vaf	vaf	PROPN
fnp-5892	206	14	in	in	ADP
fnp-5892	206	15	the	the	DET
fnp-5892	206	16	germline	germline	NOUN
fnp-5892	206	17	range	range	NOUN
fnp-5892	206	18	,	,	PUNCT
fnp-5892	206	19	in	in	ADP
fnp-5892	206	20	the	the	DET
fnp-5892	206	21	g1	g1	PROPN
fnp-5892	206	22	/	/	SYM
fnp-5892	206	23	egfr	egfr	NOUN
fnp-5892	206	24	-	-	PUNCT
fnp-5892	206	25	amplified	amplify	VERB
fnp-5892	206	26	m31	m31	NOUN
fnp-5892	206	27	tumor	tumor	NOUN
fnp-5892	206	28	,	,	PUNCT
fnp-5892	206	29	was	be	AUX
fnp-5892	206	30	the	the	DET
fnp-5892	206	31	only	only	ADJ
fnp-5892	206	32	other	other	ADJ
fnp-5892	206	33	germline	germline	NOUN
fnp-5892	206	34	mmr	mmr	PROPN
fnp-5892	206	35	truncating	truncate	VERB
fnp-5892	206	36	mutation	mutation	NOUN
fnp-5892	206	37	from	from	ADP
fnp-5892	206	38	the	the	DET
fnp-5892	206	39	cohort	cohort	NOUN
fnp-5892	206	40	,	,	PUNCT
fnp-5892	206	41	and	and	CCONJ
fnp-5892	206	42	did	do	AUX
fnp-5892	206	43	not	not	PART
fnp-5892	206	44	show	show	VERB
fnp-5892	206	45	high	high	ADJ
fnp-5892	206	46	tmb	tmb	NOUN
fnp-5892	206	47	,	,	PUNCT
fnp-5892	206	48	most	most	ADV
fnp-5892	206	49	likely	likely	ADJ
fnp-5892	206	50	due	due	ADP
fnp-5892	206	51	to	to	ADP
fnp-5892	206	52	compensation	compensation	NOUN
fnp-5892	206	53	by	by	ADP
fnp-5892	206	54	the	the	DET
fnp-5892	206	55	mlh1	mlh1	PROPN
fnp-5892	206	56	-	-	PUNCT
fnp-5892	206	57	pms2	pms2	PROPN
fnp-5892	206	58	mmr	mmr	PROPN
fnp-5892	206	59	pair	pair	PROPN
fnp-5892	206	60	.	.	PUNCT
fnp-5892	207	1	the	the	DET
fnp-5892	207	2	only	only	ADJ
fnp-5892	207	3	two	two	NUM
fnp-5892	207	4	tumors	tumor	NOUN
fnp-5892	207	5	that	that	PRON
fnp-5892	207	6	showed	show	VERB
fnp-5892	207	7	concomitant	concomitant	ADJ
fnp-5892	207	8	mgcs	mgcs	NOUN
fnp-5892	207	9	,	,	PUNCT
fnp-5892	207	10	tp53	tp53	PROPN
fnp-5892	207	11	mutations	mutation	NOUN
fnp-5892	207	12	and	and	CCONJ
fnp-5892	207	13	mutations	mutation	NOUN
fnp-5892	207	14	in	in	ADP
fnp-5892	207	15	either	either	CCONJ
fnp-5892	207	16	mutyh	mutyh	PROPN
fnp-5892	207	17	or	or	CCONJ
fnp-5892	207	18	msh3	msh3	PROPN
fnp-5892	207	19	but	but	CCONJ
fnp-5892	207	20	without	without	ADP
fnp-5892	207	21	hypermutator	hypermutator	NOUN
fnp-5892	207	22	phenotype	phenotype	NOUN
fnp-5892	207	23	belonged	belong	VERB
fnp-5892	207	24	to	to	ADP
fnp-5892	207	25	the	the	DET
fnp-5892	207	26	g5	g5	PROPN
fnp-5892	207	27	/	/	SYM
fnp-5892	207	28	pdgfra	pdgfra	PROPN
fnp-5892	207	29	subgroup	subgroup	NOUN
fnp-5892	207	30	(	(	PUNCT
fnp-5892	207	31	suppl	suppl	PROPN
fnp-5892	207	32	.	.	PUNCT
fnp-5892	207	33	table	table	NOUN
fnp-5892	207	34	 	 	SPACE
fnp-5892	207	35	s2	s2	PROPN
fnp-5892	207	36	)	)	PUNCT
fnp-5892	207	37	.	.	PUNCT
fnp-5892	208	1	it	it	PRON
fnp-5892	208	2	has	have	AUX
fnp-5892	208	3	been	be	AUX
fnp-5892	208	4	shown	show	VERB
fnp-5892	208	5	that	that	DET
fnp-5892	208	6	deficiency	deficiency	NOUN
fnp-5892	208	7	in	in	ADP
fnp-5892	208	8	dna	dna	PROPN
fnp-5892	208	9	repair	repair	NOUN
fnp-5892	208	10	results	result	NOUN
fnp-5892	208	11	in	in	ADP
fnp-5892	208	12	a	a	DET
fnp-5892	208	13	specific	specific	ADJ
fnp-5892	208	14	dna	dna	NOUN
fnp-5892	208	15	mutation	mutation	NOUN
fnp-5892	208	16	signature	signature	NOUN
fnp-5892	208	17	in	in	ADP
fnp-5892	208	18	tumors	tumor	NOUN
fnp-5892	208	19	,	,	PUNCT
fnp-5892	208	20	represented	represent	VERB
fnp-5892	208	21	by	by	ADP
fnp-5892	208	22	predominance	predominance	NOUN
fnp-5892	208	23	of	of	ADP
fnp-5892	208	24	c	c	NOUN
fnp-5892	208	25	:	:	PUNCT
fnp-5892	208	26	g	g	NOUN
fnp-5892	208	27	to	to	ADP
fnp-5892	208	28	t	t	PROPN
fnp-5892	208	29	:	:	PUNCT
fnp-5892	208	30	a	a	DET
fnp-5892	208	31	transitions	transition	NOUN
fnp-5892	208	32	in	in	ADP
fnp-5892	208	33	mmr	mmr	PROPN
fnp-5892	208	34	-	-	ADJ
fnp-5892	208	35	deficient	deficient	ADJ
fnp-5892	208	36	tumors	tumor	NOUN
fnp-5892	208	37	,	,	PUNCT
fnp-5892	208	38	and	and	CCONJ
fnp-5892	208	39	c	c	X
fnp-5892	208	40	:	:	PUNCT
fnp-5892	208	41	g	g	NOUN
fnp-5892	208	42	to	to	ADP
fnp-5892	208	43	a	a	DET
fnp-5892	208	44	:	:	PUNCT
fnp-5892	208	45	t	t	NOUN
fnp-5892	208	46	transversions	transversion	NOUN
fnp-5892	208	47	in	in	ADP
fnp-5892	208	48	pole	pole	NOUN
fnp-5892	208	49	,	,	PUNCT
fnp-5892	208	50	pold1	pold1	ADJ
fnp-5892	208	51	and	and	CCONJ
fnp-5892	208	52	mutyh	mutyh	PROPN
fnp-5892	208	53	mutant	mutant	ADJ
fnp-5892	208	54	tumors	tumor	NOUN
fnp-5892	209	1	[	[	X
fnp-5892	209	2	31,32	31,32	NUM
fnp-5892	209	3	]	]	PUNCT
fnp-5892	209	4	.	.	PUNCT
fnp-5892	210	1	all	all	DET
fnp-5892	210	2	g3	g3	PROPN
fnp-5892	210	3	/	/	SYM
fnp-5892	210	4	mmr	mmr	PROPN
fnp-5892	210	5	tumors	tumor	NOUN
fnp-5892	210	6	,	,	PUNCT
fnp-5892	210	7	as	as	ADV
fnp-5892	210	8	well	well	ADV
fnp-5892	210	9	as	as	ADP
fnp-5892	210	10	the	the	DET
fnp-5892	210	11	m66	m66	PROPN
fnp-5892	210	12	/	/	SYM
fnp-5892	210	13	tmz	tmz	PROPN
fnp-5892	210	14	and	and	CCONJ
fnp-5892	210	15	f58	f58	PROPN
fnp-5892	210	16	/	/	SYM
fnp-5892	210	17	tmz	tmz	NOUN
fnp-5892	210	18	tumors	tumor	NOUN
fnp-5892	210	19	,	,	PUNCT
fnp-5892	210	20	showed	show	VERB
fnp-5892	210	21	an	an	DET
fnp-5892	210	22	mmr	mmr	PROPN
fnp-5892	210	23	-	-	PUNCT
fnp-5892	210	24	type	type	ADJ
fnp-5892	210	25	dna	dna	PROPN
fnp-5892	210	26	mutation	mutation	NOUN
fnp-5892	210	27	signature	signature	NOUN
fnp-5892	210	28	(	(	PUNCT
fnp-5892	210	29	table	table	NOUN
fnp-5892	210	30	 	 	SPACE
fnp-5892	210	31	1	1	NUM
fnp-5892	210	32	)	)	PUNCT
fnp-5892	210	33	.	.	PUNCT
fnp-5892	211	1	surprisingly	surprisingly	ADV
fnp-5892	211	2	,	,	PUNCT
fnp-5892	211	3	the	the	DET
fnp-5892	211	4	m53	m53	NOUN
fnp-5892	211	5	/	/	SYM
fnp-5892	211	6	sc	sc	PROPN
fnp-5892	211	7	tumor	tumor	NOUN
fnp-5892	211	8	showed	show	VERB
fnp-5892	211	9	a	a	DET
fnp-5892	211	10	pole	pole	ADJ
fnp-5892	211	11	-	-	PUNCT
fnp-5892	211	12	type	type	NOUN
fnp-5892	211	13	dna	dna	PROPN
fnp-5892	211	14	mutation	mutation	NOUN
fnp-5892	211	15	signature	signature	NOUN
fnp-5892	211	16	,	,	PUNCT
fnp-5892	211	17	and	and	CCONJ
fnp-5892	211	18	mutation	mutation	NOUN
fnp-5892	211	19	analysis	analysis	NOUN
fnp-5892	211	20	revealed	reveal	VERB
fnp-5892	211	21	two	two	NUM
fnp-5892	211	22	subclonal	subclonal	ADJ
fnp-5892	211	23	polh	polh	ADJ
fnp-5892	211	24	mutations	mutation	NOUN
fnp-5892	211	25	,	,	PUNCT
fnp-5892	211	26	including	include	VERB
fnp-5892	211	27	one	one	NUM
fnp-5892	211	28	pathogenic	pathogenic	ADJ
fnp-5892	211	29	(	(	PUNCT
fnp-5892	211	30	fig	fig	NOUN
fnp-5892	211	31	.	.	PUNCT
fnp-5892	211	32	 	 	SPACE
fnp-5892	211	33	5b	5b	NUM
fnp-5892	211	34	,	,	PUNCT
fnp-5892	211	35	suppl	suppl	ADJ
fnp-5892	211	36	.	.	PUNCT
fnp-5892	211	37	table	table	NOUN
fnp-5892	211	38	 	 	SPACE
fnp-5892	211	39	s2	s2	PROPN
fnp-5892	211	40	)	)	PUNCT
fnp-5892	211	41	.	.	PUNCT
fnp-5892	212	1	since	since	SCONJ
fnp-5892	212	2	no	no	DET
fnp-5892	212	3	report	report	NOUN
fnp-5892	212	4	is	be	AUX
fnp-5892	212	5	available	available	ADJ
fnp-5892	212	6	in	in	ADP
fnp-5892	212	7	the	the	DET
fnp-5892	212	8	literature	literature	NOUN
fnp-5892	212	9	for	for	ADP
fnp-5892	212	10	association	association	NOUN
fnp-5892	212	11	of	of	ADP
fnp-5892	212	12	polh	polh	ADJ
fnp-5892	212	13	mutations	mutation	NOUN
fnp-5892	212	14	with	with	ADP
fnp-5892	212	15	high	high	ADJ
fnp-5892	212	16	tmb	tmb	PROPN
fnp-5892	212	17	,	,	PUNCT
fnp-5892	212	18	the	the	DET
fnp-5892	212	19	latter	latter	ADJ
fnp-5892	212	20	may	may	AUX
fnp-5892	212	21	be	be	AUX
fnp-5892	212	22	due	due	ADJ
fnp-5892	212	23	to	to	ADP
fnp-5892	212	24	the	the	DET
fnp-5892	212	25	msh2	msh2	ADJ
fnp-5892	212	26	subclonal	subclonal	ADJ
fnp-5892	212	27	mutations	mutation	NOUN
fnp-5892	212	28	but	but	CCONJ
fnp-5892	212	29	possibly	possibly	ADV
fnp-5892	212	30	fine	fine	ADV
fnp-5892	212	31	-	-	PUNCT
fnp-5892	212	32	tuned	tune	VERB
fnp-5892	212	33	by	by	ADP
fnp-5892	212	34	the	the	DET
fnp-5892	212	35	polh	polh	ADJ
fnp-5892	212	36	deficiency	deficiency	NOUN
fnp-5892	212	37	.	.	PUNCT
fnp-5892	213	1	the	the	DET
fnp-5892	213	2	g3	g3	PROPN
fnp-5892	213	3	/	/	SYM
fnp-5892	213	4	mmr	mmr	PROPN
fnp-5892	213	5	subgroup	subgroup	PROPN
fnp-5892	213	6	tumors	tumor	NOUN
fnp-5892	213	7	lacked	lack	VERB
fnp-5892	213	8	or	or	CCONJ
fnp-5892	213	9	showed	show	VERB
fnp-5892	213	10	low	low	ADJ
fnp-5892	213	11	incidence	incidence	NOUN
fnp-5892	213	12	for	for	ADP
fnp-5892	213	13	many	many	ADJ
fnp-5892	213	14	of	of	ADP
fnp-5892	213	15	the	the	DET
fnp-5892	213	16	common	common	ADJ
fnp-5892	213	17	glioblastoma	glioblastoma	NOUN
fnp-5892	213	18	molecular	molecular	ADJ
fnp-5892	213	19	alterations	alteration	NOUN
fnp-5892	213	20	,	,	PUNCT
fnp-5892	213	21	such	such	ADJ
fnp-5892	213	22	as	as	ADP
fnp-5892	213	23	simultaneous	simultaneous	ADJ
fnp-5892	213	24	chromosome	chromosome	NOUN
fnp-5892	213	25	7	7	NUM
fnp-5892	213	26	gain	gain	NOUN
fnp-5892	213	27	and	and	CCONJ
fnp-5892	213	28	10	10	NUM
fnp-5892	213	29	loss	loss	NOUN
fnp-5892	213	30	(	(	PUNCT
fnp-5892	213	31	see	see	VERB
fnp-5892	213	32	also	also	ADV
fnp-5892	213	33	[	[	X
fnp-5892	213	34	5	5	NUM
fnp-5892	213	35	]	]	NUM
fnp-5892	213	36	)	)	PUNCT
fnp-5892	213	37	,	,	PUNCT
fnp-5892	213	38	tert	tert	NOUN
fnp-5892	213	39	promoter	promoter	NOUN
fnp-5892	213	40	mutations	mutation	NOUN
fnp-5892	213	41	and	and	CCONJ
fnp-5892	213	42	cdkn2a	cdkn2a	VERB
fnp-5892	213	43	homozygous	homozygous	ADJ
fnp-5892	213	44	loss	loss	NOUN
fnp-5892	213	45	(	(	PUNCT
fnp-5892	213	46	fig	fig	NOUN
fnp-5892	213	47	.	.	PUNCT
fnp-5892	213	48	 	 	SPACE
fnp-5892	214	1	5b	5b	NUM
fnp-5892	214	2	–	–	PUNCT
fnp-5892	214	3	c	c	NOUN
fnp-5892	214	4	,	,	PUNCT
fnp-5892	214	5	suppl	suppl	ADJ
fnp-5892	214	6	.	.	PUNCT
fnp-5892	214	7	table	table	NOUN
fnp-5892	214	8	 	 	SPACE
fnp-5892	214	9	s3	s3	PROPN
fnp-5892	214	10	)	)	PUNCT
fnp-5892	214	11	.	.	PUNCT
fnp-5892	215	1	conversely	conversely	ADV
fnp-5892	215	2	,	,	PUNCT
fnp-5892	215	3	they	they	PRON
fnp-5892	215	4	showed	show	VERB
fnp-5892	215	5	100	100	NUM
fnp-5892	215	6	 	 	SPACE
fnp-5892	215	7	%	%	NOUN
fnp-5892	215	8	tp53	tp53	PROPN
fnp-5892	215	9	mutation	mutation	NOUN
fnp-5892	215	10	rate	rate	NOUN
fnp-5892	215	11	and	and	CCONJ
fnp-5892	215	12	high	high	ADJ
fnp-5892	215	13	incidence	incidence	NOUN
fnp-5892	215	14	of	of	ADP
fnp-5892	215	15	mutations	mutation	NOUN
fnp-5892	215	16	in	in	ADP
fnp-5892	215	17	genes	gene	NOUN
fnp-5892	215	18	from	from	ADP
fnp-5892	215	19	dna	dna	PROPN
fnp-5892	215	20	damage	damage	NOUN
fnp-5892	215	21	response	response	NOUN
fnp-5892	215	22	(	(	PUNCT
fnp-5892	215	23	ddr	ddr	NOUN
fnp-5892	215	24	)	)	PUNCT
fnp-5892	215	25	and	and	CCONJ
fnp-5892	215	26	chromatin	chromatin	NOUN
fnp-5892	215	27	remodeling	remodeling	NOUN
fnp-5892	215	28	pathways	pathway	NOUN
fnp-5892	215	29	,	,	PUNCT
fnp-5892	215	30	especially	especially	ADV
fnp-5892	215	31	from	from	ADP
fnp-5892	215	32	the	the	PRON
fnp-5892	215	33	swi	swi	PROPN
fnp-5892	215	34	/	/	SYM
fnp-5892	215	35	snf	snf	PROPN
fnp-5892	215	36	complex	complex	NOUN
fnp-5892	215	37	(	(	PUNCT
fnp-5892	215	38	fig	fig	NOUN
fnp-5892	215	39	5b	5b	NUM
fnp-5892	215	40	–	–	PUNCT
fnp-5892	215	41	c	c	NOUN
fnp-5892	215	42	,	,	PUNCT
fnp-5892	215	43	suppl	suppl	ADJ
fnp-5892	215	44	.	.	PUNCT
fnp-5892	216	1	tables	table	NOUN
fnp-5892	217	1	s1	s1	PROPN
fnp-5892	217	2	,	,	PUNCT
fnp-5892	217	3	s3	s3	PROPN
fnp-5892	217	4	)	)	PUNCT
fnp-5892	217	5	.	.	PUNCT
fnp-5892	218	1	interestingly	interestingly	ADV
fnp-5892	218	2	,	,	PUNCT
fnp-5892	218	3	likely	likely	ADV
fnp-5892	218	4	pathogenic	pathogenic	ADJ
fnp-5892	218	5	notch1	notch1	NOUN
fnp-5892	218	6	missense	missense	NOUN
fnp-5892	218	7	mutations	mutation	NOUN
fnp-5892	218	8	were	be	AUX
fnp-5892	218	9	detected	detect	VERB
fnp-5892	218	10	in	in	ADP
fnp-5892	218	11	three	three	NUM
fnp-5892	218	12	of	of	ADP
fnp-5892	218	13	the	the	DET
fnp-5892	218	14	five	five	NUM
fnp-5892	218	15	g3	g3	PROPN
fnp-5892	218	16	/	/	SYM
fnp-5892	218	17	mmr	mmr	PROPN
fnp-5892	218	18	cases	case	NOUN
fnp-5892	218	19	.	.	PUNCT
fnp-5892	219	1	100	100	NUM
fnp-5892	219	2	 	 	SPACE
fnp-5892	219	3	%	%	NOUN
fnp-5892	219	4	of	of	ADP
fnp-5892	219	5	g3	g3	PROPN
fnp-5892	219	6	/	/	SYM
fnp-5892	219	7	mmr	mmr	PROPN
fnp-5892	219	8	tp53	tp53	PROPN
fnp-5892	219	9	mutations	mutation	NOUN
fnp-5892	219	10	were	be	AUX
fnp-5892	219	11	biallelic	biallelic	ADJ
fnp-5892	219	12	(	(	PUNCT
fnp-5892	219	13	fig	fig	NOUN
fnp-5892	219	14	.	.	PUNCT
fnp-5892	219	15	 	 	SPACE
fnp-5892	219	16	4f	4f	NOUN
fnp-5892	219	17	)	)	PUNCT
fnp-5892	219	18	and	and	CCONJ
fnp-5892	219	19	targeted	target	VERB
fnp-5892	219	20	arg	arg	NOUN
fnp-5892	219	21	residues	residue	NOUN
fnp-5892	219	22	(	(	PUNCT
fnp-5892	219	23	suppl	suppl	ADJ
fnp-5892	219	24	.	.	PUNCT
fnp-5892	219	25	table	table	NOUN
fnp-5892	219	26	 	 	SPACE
fnp-5892	219	27	s3	s3	PROPN
fnp-5892	219	28	)	)	PUNCT
fnp-5892	219	29	.	.	PUNCT
fnp-5892	220	1	in	in	ADP
fnp-5892	220	2	the	the	DET
fnp-5892	220	3	rest	rest	NOUN
fnp-5892	220	4	of	of	ADP
fnp-5892	220	5	the	the	DET
fnp-5892	220	6	cohort	cohort	NOUN
fnp-5892	220	7	,	,	PUNCT
fnp-5892	220	8	tp53	tp53	PROPN
fnp-5892	220	9	arg	arg	NOUN
fnp-5892	220	10	mutations	mutation	NOUN
fnp-5892	220	11	were	be	AUX
fnp-5892	220	12	seen	see	VERB
fnp-5892	220	13	in	in	ADP
fnp-5892	220	14	a	a	DET
fnp-5892	220	15	quarter	quarter	NOUN
fnp-5892	220	16	of	of	ADP
fnp-5892	220	17	cases	case	NOUN
fnp-5892	220	18	,	,	PUNCT
fnp-5892	220	19	the	the	DET
fnp-5892	220	20	highest	high	ADJ
fnp-5892	220	21	rate	rate	NOUN
fnp-5892	220	22	of	of	ADP
fnp-5892	220	23	40	40	NUM
fnp-5892	220	24	 	 	SPACE
fnp-5892	220	25	%	%	NOUN
fnp-5892	220	26	being	be	AUX
fnp-5892	220	27	noted	note	VERB
fnp-5892	220	28	in	in	ADP
fnp-5892	220	29	the	the	DET
fnp-5892	220	30	g7	g7	PROPN
fnp-5892	220	31	 	 	SPACE
fnp-5892	220	32	/	/	SYM
fnp-5892	220	33	 	 	SPACE
fnp-5892	220	34	other	other	ADJ
fnp-5892	220	35	subgroup	subgroup	NOUN
fnp-5892	220	36	.	.	PUNCT
fnp-5892	221	1	the	the	DET
fnp-5892	221	2	pi3k	pi3k	PROPN
fnp-5892	221	3	pathway	pathway	NOUN
fnp-5892	221	4	was	be	AUX
fnp-5892	221	5	strongly	strongly	ADV
fnp-5892	221	6	activated	activate	VERB
fnp-5892	221	7	by	by	ADP
fnp-5892	221	8	mutations	mutation	NOUN
fnp-5892	221	9	in	in	ADP
fnp-5892	221	10	pik3ca	pik3ca	NOUN
fnp-5892	221	11	and	and	CCONJ
fnp-5892	221	12	pten	pten	VERB
fnp-5892	221	13	upstream	upstream	ADJ
fnp-5892	221	14	effectors	effector	NOUN
fnp-5892	221	15	,	,	PUNCT
fnp-5892	221	16	but	but	CCONJ
fnp-5892	221	17	also	also	ADV
fnp-5892	221	18	by	by	ADP
fnp-5892	221	19	tsc2	tsc2	PROPN
fnp-5892	221	20	mutations	mutation	NOUN
fnp-5892	221	21	(	(	PUNCT
fnp-5892	221	22	fig	fig	NOUN
fnp-5892	221	23	.	.	PUNCT
fnp-5892	221	24	 	 	SPACE
fnp-5892	222	1	5b	5b	NUM
fnp-5892	222	2	–	–	PUNCT
fnp-5892	222	3	d	d	NOUN
fnp-5892	222	4	,	,	PUNCT
fnp-5892	222	5	suppl	suppl	ADJ
fnp-5892	222	6	.	.	PUNCT
fnp-5892	222	7	table	table	NOUN
fnp-5892	222	8	 	 	SPACE
fnp-5892	222	9	s1	s1	NOUN
fnp-5892	222	10	)	)	PUNCT
fnp-5892	222	11	.	.	PUNCT
fnp-5892	223	1	the	the	DET
fnp-5892	223	2	80	80	NUM
fnp-5892	223	3	 	 	SPACE
fnp-5892	223	4	%	%	NOUN
fnp-5892	223	5	mutation	mutation	NOUN
fnp-5892	223	6	rates	rate	NOUN
fnp-5892	223	7	for	for	ADP
fnp-5892	223	8	pik3ca	pik3ca	PRON
fnp-5892	223	9	and	and	CCONJ
fnp-5892	223	10	pten	pten	NOUN
fnp-5892	223	11	were	be	AUX
fnp-5892	223	12	the	the	DET
fnp-5892	223	13	highest	high	ADJ
fnp-5892	223	14	in	in	ADP
fnp-5892	223	15	the	the	DET
fnp-5892	223	16	cohort	cohort	NOUN
fnp-5892	223	17	,	,	PUNCT
fnp-5892	223	18	the	the	DET
fnp-5892	223	19	pik3ca	pik3ca	NOUN
fnp-5892	223	20	mutation	mutation	NOUN
fnp-5892	223	21	rate	rate	NOUN
fnp-5892	223	22	being	be	AUX
fnp-5892	223	23	three	three	NUM
fnp-5892	223	24	-	-	NOUN
fnp-5892	223	25	fold	fold	VERB
fnp-5892	223	26	higher	high	ADJ
fnp-5892	223	27	than	than	ADP
fnp-5892	223	28	the	the	DET
fnp-5892	223	29	next	next	ADJ
fnp-5892	223	30	highest	high	ADJ
fnp-5892	223	31	rate	rate	NOUN
fnp-5892	223	32	from	from	ADP
fnp-5892	223	33	the	the	DET
fnp-5892	223	34	g5	g5	PROPN
fnp-5892	223	35	/	/	SYM
fnp-5892	223	36	pdgfra	pdgfra	PROPN
fnp-5892	223	37	subgroup	subgroup	NOUN
fnp-5892	223	38	(	(	PUNCT
fnp-5892	223	39	suppl	suppl	PROPN
fnp-5892	223	40	.	.	PUNCT
fnp-5892	223	41	table	table	NOUN
fnp-5892	223	42	 	 	SPACE
fnp-5892	223	43	s3	s3	PROPN
fnp-5892	223	44	)	)	PUNCT
fnp-5892	223	45	.	.	PUNCT
fnp-5892	224	1	three	three	NUM
fnp-5892	224	2	g3	g3	PROPN
fnp-5892	224	3	/	/	SYM
fnp-5892	224	4	mmr	mmr	PROPN
fnp-5892	224	5	cases	case	NOUN
fnp-5892	224	6	showed	show	VERB
fnp-5892	224	7	overlapping	overlap	VERB
fnp-5892	224	8	pik3ca	pik3ca	NOUN
fnp-5892	224	9	and	and	CCONJ
fnp-5892	224	10	pten	pten	VERB
fnp-5892	224	11	mutations	mutation	NOUN
fnp-5892	224	12	,	,	PUNCT
fnp-5892	224	13	and	and	CCONJ
fnp-5892	224	14	one	one	NUM
fnp-5892	224	15	of	of	ADP
fnp-5892	224	16	these	these	PRON
fnp-5892	224	17	showed	show	VERB
fnp-5892	224	18	additional	additional	ADJ
fnp-5892	224	19	pik3r1	pik3r1	ADJ
fnp-5892	224	20	subclonal	subclonal	ADJ
fnp-5892	224	21	mutation	mutation	NOUN
fnp-5892	224	22	(	(	PUNCT
fnp-5892	224	23	fig	fig	NOUN
fnp-5892	224	24	.	.	PUNCT
fnp-5892	224	25	 	 	SPACE
fnp-5892	224	26	5b	5b	NUM
fnp-5892	224	27	)	)	PUNCT
fnp-5892	224	28	.	.	PUNCT
fnp-5892	225	1	the	the	DET
fnp-5892	225	2	g3	g3	PROPN
fnp-5892	225	3	/	/	SYM
fnp-5892	225	4	mmr	mmr	PROPN
fnp-5892	225	5	60	60	NUM
fnp-5892	225	6	 	 	SPACE
fnp-5892	225	7	%	%	NOUN
fnp-5892	225	8	rate	rate	NOUN
fnp-5892	225	9	of	of	ADP
fnp-5892	225	10	overlapping	overlap	VERB
fnp-5892	225	11	mutations	mutation	NOUN
fnp-5892	225	12	in	in	ADP
fnp-5892	225	13	pi3k	pi3k	PROPN
fnp-5892	225	14	pathway	pathway	NOUN
fnp-5892	225	15	upstream	upstream	ADJ
fnp-5892	225	16	effectors	effector	NOUN
fnp-5892	225	17	was	be	AUX
fnp-5892	225	18	10	10	NUM
fnp-5892	225	19	-	-	ADJ
fnp-5892	225	20	fold	fold	VERB
fnp-5892	225	21	higher	high	ADJ
fnp-5892	225	22	than	than	ADP
fnp-5892	225	23	the	the	DET
fnp-5892	225	24	5.6	5.6	NUM
fnp-5892	225	25	 	 	SPACE
fnp-5892	225	26	%	%	NOUN
fnp-5892	225	27	rate	rate	NOUN
fnp-5892	225	28	in	in	ADP
fnp-5892	225	29	the	the	DET
fnp-5892	225	30	rest	rest	NOUN
fnp-5892	225	31	of	of	ADP
fnp-5892	225	32	the	the	DET
fnp-5892	225	33	cohort	cohort	NOUN
fnp-5892	225	34	(	(	PUNCT
fnp-5892	225	35	fig	fig	NOUN
fnp-5892	225	36	.	.	PUNCT
fnp-5892	225	37	 	 	SPACE
fnp-5892	225	38	5d	5d	NUM
fnp-5892	225	39	)	)	PUNCT
fnp-5892	225	40	.	.	PUNCT
fnp-5892	226	1	strikingly	strikingly	ADV
fnp-5892	226	2	,	,	PUNCT
fnp-5892	226	3	pik3ca	pik3ca	PROPN
fnp-5892	226	4	p.r88q	p.r88q	PROPN
fnp-5892	226	5	was	be	AUX
fnp-5892	226	6	the	the	DET
fnp-5892	226	7	activating	activate	VERB
fnp-5892	226	8	mutation	mutation	NOUN
fnp-5892	226	9	in	in	ADP
fnp-5892	226	10	all	all	DET
fnp-5892	226	11	four	four	NUM
fnp-5892	226	12	g3	g3	PROPN
fnp-5892	226	13	/	/	SYM
fnp-5892	226	14	mmr	mmr	PROPN
fnp-5892	226	15	mutant	mutant	ADJ
fnp-5892	226	16	cases	case	NOUN
fnp-5892	226	17	,	,	PUNCT
fnp-5892	226	18	whereas	whereas	SCONJ
fnp-5892	226	19	it	it	PRON
fnp-5892	226	20	was	be	AUX
fnp-5892	226	21	a	a	DET
fnp-5892	226	22	single	single	ADJ
fnp-5892	226	23	event	event	NOUN
fnp-5892	226	24	in	in	ADP
fnp-5892	226	25	the	the	DET
fnp-5892	226	26	34	34	NUM
fnp-5892	226	27	pik3ca	pik3ca	NOUN
fnp-5892	226	28	-	-	PUNCT
fnp-5892	226	29	mutant	mutant	ADJ
fnp-5892	226	30	cases	case	NOUN
fnp-5892	226	31	from	from	ADP
fnp-5892	226	32	the	the	DET
fnp-5892	226	33	rest	rest	NOUN
fnp-5892	226	34	of	of	ADP
fnp-5892	226	35	the	the	DET
fnp-5892	226	36	cohort	cohort	NOUN
fnp-5892	226	37	(	(	PUNCT
fnp-5892	226	38	fig	fig	NOUN
fnp-5892	226	39	.	.	PUNCT
fnp-5892	226	40	 	 	SPACE
fnp-5892	227	1	5b	5b	NUM
fnp-5892	227	2	,	,	PUNCT
fnp-5892	227	3	d	d	NOUN
fnp-5892	227	4	;	;	PUNCT
fnp-5892	227	5	suppl	suppl	ADJ
fnp-5892	227	6	.	.	PUNCT
fnp-5892	227	7	table	table	NOUN
fnp-5892	227	8	 	 	SPACE
fnp-5892	227	9	s3	s3	PROPN
fnp-5892	227	10	)	)	PUNCT
fnp-5892	227	11	.	.	PUNCT
fnp-5892	228	1	similar	similar	ADJ
fnp-5892	228	2	to	to	ADP
fnp-5892	228	3	tp53	tp53	PROPN
fnp-5892	228	4	,	,	PUNCT
fnp-5892	228	5	pik3ca	pik3ca	VERB
fnp-5892	228	6	mutations	mutation	NOUN
fnp-5892	228	7	on	on	ADP
fnp-5892	228	8	arg	arg	NOUN
fnp-5892	228	9	residues	residue	NOUN
fnp-5892	228	10	were	be	AUX
fnp-5892	228	11	scarce	scarce	ADJ
fnp-5892	228	12	in	in	ADP
fnp-5892	228	13	the	the	DET
fnp-5892	228	14	rest	rest	NOUN
fnp-5892	228	15	of	of	ADP
fnp-5892	228	16	the	the	DET
fnp-5892	228	17	cohort	cohort	NOUN
fnp-5892	228	18	,	,	PUNCT
fnp-5892	228	19	numbering	number	VERB
fnp-5892	228	20	one	one	NUM
fnp-5892	228	21	p.r88q	p.r88q	NOUN
fnp-5892	228	22	and	and	CCONJ
fnp-5892	228	23	one	one	NUM
fnp-5892	228	24	p.r38l	p.r38l	PROPN
fnp-5892	228	25	in	in	ADP
fnp-5892	228	26	the	the	DET
fnp-5892	228	27	g7	g7	PROPN
fnp-5892	228	28	 	 	SPACE
fnp-5892	228	29	/	/	SYM
fnp-5892	228	30	 	 	SPACE
fnp-5892	228	31	other	other	ADJ
fnp-5892	228	32	and	and	CCONJ
fnp-5892	228	33	g3	g3	PROPN
fnp-5892	228	34	/	/	SYM
fnp-5892	228	35	nf1	nf1	NOUN
fnp-5892	228	36	subgroups	subgroup	NOUN
fnp-5892	228	37	,	,	PUNCT
fnp-5892	228	38	respectively	respectively	ADV
fnp-5892	228	39	.	.	PUNCT
fnp-5892	229	1	pten	pten	ADJ
fnp-5892	229	2	mutations	mutation	NOUN
fnp-5892	229	3	were	be	AUX
fnp-5892	229	4	biallelic	biallelic	ADJ
fnp-5892	229	5	in	in	ADP
fnp-5892	229	6	two	two	NUM
fnp-5892	229	7	g3	g3	PROPN
fnp-5892	229	8	/	/	SYM
fnp-5892	229	9	mmr	mmr	PROPN
fnp-5892	229	10	cases	case	NOUN
fnp-5892	229	11	(	(	PUNCT
fnp-5892	229	12	40	40	NUM
fnp-5892	229	13	 	 	SPACE
fnp-5892	229	14	%	%	NOUN
fnp-5892	229	15	)	)	PUNCT
fnp-5892	229	16	,	,	PUNCT
fnp-5892	229	17	whereas	whereas	SCONJ
fnp-5892	229	18	two	two	NUM
fnp-5892	229	19	concomitant	concomitant	ADJ
fnp-5892	229	20	pten	pten	ADJ
fnp-5892	229	21	mutations	mutation	NOUN
fnp-5892	229	22	were	be	AUX
fnp-5892	229	23	noted	note	VERB
fnp-5892	229	24	only	only	ADV
fnp-5892	229	25	in	in	ADP
fnp-5892	229	26	3	3	NUM
fnp-5892	229	27	cases	case	NOUN
fnp-5892	229	28	in	in	ADP
fnp-5892	229	29	the	the	DET
fnp-5892	229	30	rest	rest	NOUN
fnp-5892	229	31	of	of	ADP
fnp-5892	229	32	the	the	DET
fnp-5892	229	33	cohort	cohort	NOUN
fnp-5892	229	34	(	(	PUNCT
fnp-5892	229	35	2.5	2.5	NUM
fnp-5892	229	36	 	 	SPACE
fnp-5892	229	37	%	%	NOUN
fnp-5892	229	38	)	)	PUNCT
fnp-5892	229	39	,	,	PUNCT
fnp-5892	229	40	all	all	PRON
fnp-5892	229	41	showing	show	VERB
fnp-5892	229	42	subclonal	subclonal	ADJ
fnp-5892	229	43	vaf	vaf	NOUN
fnp-5892	229	44	,	,	PUNCT
fnp-5892	229	45	suggestive	suggestive	ADJ
fnp-5892	229	46	of	of	ADP
fnp-5892	229	47	heterogeneity	heterogeneity	NOUN
fnp-5892	229	48	rather	rather	ADV
fnp-5892	229	49	than	than	ADP
fnp-5892	229	50	of	of	ADP
fnp-5892	229	51	biallelic	biallelic	ADJ
fnp-5892	229	52	hit	hit	NOUN
fnp-5892	229	53	.	.	PUNCT
fnp-5892	230	1	double	double	ADJ
fnp-5892	230	2	hit	hit	VERB
fnp-5892	230	3	mutations	mutation	NOUN
fnp-5892	230	4	were	be	AUX
fnp-5892	230	5	also	also	ADV
fnp-5892	230	6	detected	detect	VERB
fnp-5892	230	7	in	in	ADP
fnp-5892	230	8	tsc2	tsc2	PROPN
fnp-5892	230	9	tumor	tumor	PROPN
fnp-5892	230	10	suppressor	suppressor	NOUN
fnp-5892	230	11	gene	gene	NOUN
fnp-5892	230	12	,	,	PUNCT
fnp-5892	230	13	in	in	ADP
fnp-5892	230	14	two	two	NUM
fnp-5892	230	15	out	out	ADP
fnp-5892	230	16	of	of	ADP
fnp-5892	230	17	three	three	NUM
fnp-5892	230	18	mutant	mutant	ADJ
fnp-5892	230	19	g3	g3	NOUN
fnp-5892	230	20	/	/	SYM
fnp-5892	230	21	mmr	mmr	PROPN
fnp-5892	230	22	cases	case	NOUN
fnp-5892	230	23	(	(	PUNCT
fnp-5892	230	24	fig	fig	NOUN
fnp-5892	230	25	.	.	PUNCT
fnp-5892	230	26	 	 	SPACE
fnp-5892	231	1	5b	5b	NUM
fnp-5892	231	2	,	,	PUNCT
fnp-5892	231	3	suppl	suppl	ADJ
fnp-5892	231	4	.	.	PUNCT
fnp-5892	231	5	table	table	NOUN
fnp-5892	231	6	 	 	SPACE
fnp-5892	231	7	s1	s1	NOUN
fnp-5892	231	8	)	)	PUNCT
fnp-5892	231	9	.	.	PUNCT
fnp-5892	232	1	tsc1/2	tsc1/2	PROPN
fnp-5892	233	1	mutations	mutation	NOUN
fnp-5892	233	2	are	be	AUX
fnp-5892	233	3	relatively	relatively	ADV
fnp-5892	233	4	uncommon	uncommon	ADJ
fnp-5892	233	5	in	in	ADP
fnp-5892	233	6	glioblastoma	glioblastoma	NOUN
fnp-5892	233	7	,	,	PUNCT
fnp-5892	233	8	numbering	number	VERB
fnp-5892	233	9	8	8	NUM
fnp-5892	233	10	cases	case	NOUN
fnp-5892	233	11	in	in	ADP
fnp-5892	233	12	the	the	DET
fnp-5892	233	13	rest	rest	NOUN
fnp-5892	233	14	of	of	ADP
fnp-5892	233	15	the	the	DET
fnp-5892	233	16	cohort	cohort	NOUN
fnp-5892	233	17	(	(	PUNCT
fnp-5892	233	18	3.8	3.8	NUM
fnp-5892	233	19	 	 	SPACE
fnp-5892	233	20	%	%	NOUN
fnp-5892	233	21	)	)	PUNCT
fnp-5892	233	22	,	,	PUNCT
fnp-5892	233	23	without	without	ADP
fnp-5892	233	24	double	double	ADJ
fnp-5892	233	25	hit	hit	NOUN
fnp-5892	233	26	(	(	PUNCT
fnp-5892	233	27	fig	fig	NOUN
fnp-5892	233	28	.	.	PUNCT
fnp-5892	233	29	 	 	SPACE
fnp-5892	233	30	5d	5d	NUM
fnp-5892	233	31	)	)	PUNCT
fnp-5892	233	32	.	.	PUNCT
fnp-5892	234	1	the	the	DET
fnp-5892	234	2	mapk	mapk	PROPN
fnp-5892	234	3	pathways	pathway	NOUN
fnp-5892	234	4	was	be	AUX
fnp-5892	234	5	activated	activate	VERB
fnp-5892	234	6	by	by	ADP
fnp-5892	234	7	mutations	mutation	NOUN
fnp-5892	234	8	in	in	ADP
fnp-5892	234	9	many	many	ADJ
fnp-5892	234	10	effectors	effector	NOUN
fnp-5892	234	11	,	,	PUNCT
fnp-5892	234	12	some	some	DET
fnp-5892	234	13	overlapping	overlap	VERB
fnp-5892	234	14	,	,	PUNCT
fnp-5892	234	15	such	such	ADJ
fnp-5892	234	16	as	as	ADP
fnp-5892	234	17	ptpn11	ptpn11	NOUN
fnp-5892	234	18	and	and	CCONJ
fnp-5892	234	19	nf1	nf1	NOUN
fnp-5892	234	20	or	or	CCONJ
fnp-5892	234	21	kras	kras	PROPN
fnp-5892	234	22	(	(	PUNCT
fnp-5892	234	23	fig	fig	NOUN
fnp-5892	234	24	.	.	PUNCT
fnp-5892	234	25	 	 	SPACE
fnp-5892	234	26	5b	5b	NUM
fnp-5892	234	27	)	)	PUNCT
fnp-5892	234	28	.	.	PUNCT
fnp-5892	235	1	none	none	NOUN
fnp-5892	235	2	of	of	ADP
fnp-5892	235	3	the	the	DET
fnp-5892	235	4	major	major	ADJ
fnp-5892	235	5	rtks	rtks	NOUN
fnp-5892	235	6	defining	define	VERB
fnp-5892	235	7	the	the	DET
fnp-5892	235	8	g1	g1	NOUN
fnp-5892	235	9	/	/	SYM
fnp-5892	235	10	egfr	egfr	NOUN
fnp-5892	235	11	,	,	PUNCT
fnp-5892	235	12	g2	g2	PROPN
fnp-5892	235	13	/	/	SYM
fnp-5892	235	14	fgfr3	fgfr3	PROPN
fnp-5892	235	15	,	,	PUNCT
fnp-5892	235	16	g5	g5	NOUN
fnp-5892	235	17	/	/	SYM
fnp-5892	235	18	pdgfra	pdgfra	NOUN
fnp-5892	235	19	or	or	CCONJ
fnp-5892	235	20	g6	g6	ADJ
fnp-5892	235	21	/	/	SYM
fnp-5892	235	22	multi	multi	ADJ
fnp-5892	235	23	-	-	ADJ
fnp-5892	235	24	rtk	rtk	ADJ
fnp-5892	235	25	subgroups	subgroup	NOUN
fnp-5892	235	26	was	be	AUX
fnp-5892	235	27	amplified	amplify	VERB
fnp-5892	235	28	or	or	CCONJ
fnp-5892	235	29	mutated	mutate	VERB
fnp-5892	235	30	.	.	PUNCT
fnp-5892	236	1	likely	likely	ADJ
fnp-5892	236	2	pathogenic	pathogenic	ADJ
fnp-5892	236	3	missense	missense	NOUN
fnp-5892	236	4	mutations	mutation	NOUN
fnp-5892	236	5	in	in	ADP
fnp-5892	236	6	ret	ret	NOUN
fnp-5892	236	7	in	in	ADP
fnp-5892	236	8	two	two	NUM
fnp-5892	236	9	cases	case	NOUN
fnp-5892	236	10	,	,	PUNCT
fnp-5892	236	11	and	and	CCONJ
fnp-5892	236	12	flt1	flt1	PROPN
fnp-5892	236	13	and	and	CCONJ
fnp-5892	236	14	csf1r	csf1r	PROPN
fnp-5892	236	15	in	in	ADP
fnp-5892	236	16	one	one	NUM
fnp-5892	236	17	case	case	NOUN
fnp-5892	236	18	each	each	PRON
fnp-5892	236	19	,	,	PUNCT
fnp-5892	236	20	were	be	AUX
fnp-5892	236	21	detected	detect	VERB
fnp-5892	236	22	(	(	PUNCT
fnp-5892	236	23	suppl	suppl	ADJ
fnp-5892	236	24	.	.	PUNCT
fnp-5892	236	25	table	table	NOUN
fnp-5892	236	26	 	 	SPACE
fnp-5892	236	27	s1	s1	NOUN
fnp-5892	236	28	)	)	PUNCT
fnp-5892	236	29	,	,	PUNCT
fnp-5892	236	30	of	of	ADP
fnp-5892	236	31	which	which	PRON
fnp-5892	236	32	the	the	DET
fnp-5892	236	33	ret	ret	PROPN
fnp-5892	236	34	mutation	mutation	NOUN
fnp-5892	236	35	in	in	ADP
fnp-5892	236	36	case	case	NOUN
fnp-5892	236	37	f70	f70	PROPN
fnp-5892	236	38	was	be	AUX
fnp-5892	236	39	accompanied	accompany	VERB
fnp-5892	236	40	by	by	ADP
fnp-5892	236	41	overexpression	overexpression	NOUN
fnp-5892	236	42	(	(	PUNCT
fnp-5892	236	43	fig	fig	NOUN
fnp-5892	236	44	.	.	PUNCT
fnp-5892	236	45	 	 	SPACE
fnp-5892	236	46	5e	5e	NOUN
fnp-5892	236	47	,	,	PUNCT
fnp-5892	236	48	suppl	suppl	PROPN
fnp-5892	236	49	.	.	PUNCT
fnp-5892	236	50	table	table	NOUN
fnp-5892	236	51	 	 	SPACE
fnp-5892	236	52	s4	s4	PROPN
fnp-5892	236	53	)	)	PUNCT
fnp-5892	236	54	.	.	PUNCT
fnp-5892	237	1	virtually	virtually	ADV
fnp-5892	237	2	all	all	DET
fnp-5892	237	3	the	the	DET
fnp-5892	237	4	g3	g3	PROPN
fnp-5892	237	5	/	/	SYM
fnp-5892	237	6	mmr	mmr	PROPN
fnp-5892	237	7	cases	case	NOUN
fnp-5892	237	8	showed	show	VERB
fnp-5892	237	9	moderate	moderate	ADJ
fnp-5892	237	10	overexpression	overexpression	NOUN
fnp-5892	237	11	of	of	ADP
fnp-5892	237	12	at	at	ADV
fnp-5892	237	13	least	least	ADV
fnp-5892	237	14	one	one	NUM
fnp-5892	237	15	rtk	rtk	NOUN
fnp-5892	237	16	except	except	SCONJ
fnp-5892	237	17	for	for	ADP
fnp-5892	237	18	egfr	egfr	NOUN
fnp-5892	237	19	,	,	PUNCT
fnp-5892	237	20	and	and	CCONJ
fnp-5892	237	21	the	the	DET
fnp-5892	237	22	m72	m72	ADJ
fnp-5892	237	23	tumor	tumor	NOUN
fnp-5892	237	24	showed	show	VERB
fnp-5892	237	25	high	high	ADJ
fnp-5892	237	26	met	meet	VERB
fnp-5892	237	27	overexpression	overexpression	NOUN
fnp-5892	237	28	close	close	ADV
fnp-5892	237	29	to	to	ADP
fnp-5892	237	30	the	the	DET
fnp-5892	237	31	range	range	NOUN
fnp-5892	237	32	of	of	ADP
fnp-5892	237	33	the	the	DET
fnp-5892	237	34	met	meet	VERB
fnp-5892	237	35	-	-	PUNCT
fnp-5892	237	36	amplified	amplify	VERB
fnp-5892	237	37	tumors	tumor	NOUN
fnp-5892	237	38	from	from	ADP
fnp-5892	237	39	g6	g6	ADJ
fnp-5892	237	40	/	/	SYM
fnp-5892	237	41	multi	multi	ADJ
fnp-5892	237	42	-	-	ADJ
fnp-5892	237	43	rtk	rtk	ADJ
fnp-5892	237	44	subgroup	subgroup	NOUN
fnp-5892	237	45	(	(	PUNCT
fnp-5892	237	46	fig	fig	NOUN
fnp-5892	237	47	.	.	PUNCT
fnp-5892	237	48	 	 	SPACE
fnp-5892	237	49	5e	5e	NOUN
fnp-5892	237	50	,	,	PUNCT
fnp-5892	237	51	suppl	suppl	PROPN
fnp-5892	237	52	.	.	PUNCT
fnp-5892	237	53	table	table	NOUN
fnp-5892	237	54	 	 	SPACE
fnp-5892	237	55	s4	s4	PROPN
fnp-5892	237	56	)	)	PUNCT
fnp-5892	237	57	.	.	PUNCT
fnp-5892	238	1	fos	fos	PROPN
fnp-5892	238	2	and	and	CCONJ
fnp-5892	238	3	jun	jun	PROPN
fnp-5892	238	4	families	family	NOUN
fnp-5892	238	5	of	of	ADP
fnp-5892	238	6	transcription	transcription	NOUN
fnp-5892	238	7	factors	factor	NOUN
fnp-5892	238	8	heterodimerize	heterodimerize	VERB
fnp-5892	238	9	to	to	PART
fnp-5892	238	10	form	form	VERB
fnp-5892	238	11	the	the	DET
fnp-5892	238	12	activator	activator	NOUN
fnp-5892	238	13	protein-1	protein-1	PROPN
fnp-5892	238	14	(	(	PUNCT
fnp-5892	238	15	ap-1	ap-1	NOUN
fnp-5892	238	16	)	)	PUNCT
fnp-5892	238	17	complex	complex	NOUN
fnp-5892	238	18	that	that	PRON
fnp-5892	238	19	is	be	AUX
fnp-5892	238	20	phosphorylated	phosphorylate	VERB
fnp-5892	238	21	and	and	CCONJ
fnp-5892	238	22	activated	activate	VERB
fnp-5892	238	23	by	by	ADP
fnp-5892	238	24	mapk	mapk	NOUN
fnp-5892	238	25	[	[	X
fnp-5892	238	26	33	33	NUM
fnp-5892	238	27	]	]	PUNCT
fnp-5892	238	28	.	.	PUNCT
fnp-5892	239	1	the	the	DET
fnp-5892	239	2	four	four	NUM
fnp-5892	239	3	members	member	NOUN
fnp-5892	239	4	of	of	ADP
fnp-5892	239	5	the	the	DET
fnp-5892	239	6	fos	fos	NOUN
fnp-5892	239	7	family	family	NOUN
fnp-5892	239	8	are	be	AUX
fnp-5892	239	9	transcription	transcription	NOUN
fnp-5892	239	10	activators	activator	NOUN
fnp-5892	239	11	,	,	PUNCT
fnp-5892	239	12	whereas	whereas	SCONJ
fnp-5892	239	13	jund	jund	NOUN
fnp-5892	239	14	from	from	ADP
fnp-5892	239	15	the	the	DET
fnp-5892	239	16	jun	jun	PROPN
fnp-5892	239	17	family	family	NOUN
fnp-5892	239	18	acts	act	VERB
fnp-5892	239	19	mostly	mostly	ADV
fnp-5892	239	20	as	as	ADP
fnp-5892	239	21	repressor	repressor	NOUN
fnp-5892	239	22	.	.	PUNCT
fnp-5892	240	1	the	the	DET
fnp-5892	240	2	expression	expression	NOUN
fnp-5892	240	3	of	of	ADP
fnp-5892	240	4	the	the	DET
fnp-5892	240	5	ap-1	ap-1	ADV
fnp-5892	240	6	complex	complex	ADJ
fnp-5892	240	7	transcription	transcription	NOUN
fnp-5892	240	8	factors	factor	NOUN
fnp-5892	240	9	in	in	ADP
fnp-5892	240	10	g3	g3	PROPN
fnp-5892	240	11	/	/	SYM
fnp-5892	240	12	mmr	mmr	PROPN
fnp-5892	240	13	cases	case	NOUN
fnp-5892	240	14	showed	show	VERB
fnp-5892	240	15	overexpression	overexpression	NOUN
fnp-5892	240	16	of	of	ADP
fnp-5892	240	17	one	one	NUM
fnp-5892	240	18	or	or	CCONJ
fnp-5892	240	19	more	more	ADV
fnp-5892	240	20	activating	activate	VERB
fnp-5892	240	21	transcription	transcription	NOUN
fnp-5892	240	22	factors	factor	NOUN
fnp-5892	240	23	,	,	PUNCT
fnp-5892	240	24	with	with	ADP
fnp-5892	240	25	the	the	DET
fnp-5892	240	26	m72	m72	PROPN
fnp-5892	240	27	and	and	CCONJ
fnp-5892	240	28	m79	m79	NOUN
fnp-5892	240	29	tumors	tumor	NOUN
fnp-5892	240	30	highly	highly	ADV
fnp-5892	240	31	overexpressing	overexpresse	VERB
fnp-5892	240	32	fosb	fosb	NOUN
fnp-5892	240	33	,	,	PUNCT
fnp-5892	240	34	and	and	CCONJ
fnp-5892	240	35	additionally	additionally	ADV
fnp-5892	240	36	fosl1	fosl1	NOUN
fnp-5892	240	37	for	for	ADP
fnp-5892	240	38	m72	m72	NOUN
fnp-5892	240	39	(	(	PUNCT
fnp-5892	240	40	fig	fig	NOUN
fnp-5892	240	41	.	.	PUNCT
fnp-5892	240	42	 	 	SPACE
fnp-5892	240	43	5e	5e	NOUN
fnp-5892	240	44	,	,	PUNCT
fnp-5892	240	45	suppl	suppl	PROPN
fnp-5892	240	46	.	.	PUNCT
fnp-5892	240	47	table	table	NOUN
fnp-5892	240	48	 	 	SPACE
fnp-5892	240	49	s5	s5	NOUN
fnp-5892	240	50	)	)	PUNCT
fnp-5892	240	51	.	.	PUNCT
fnp-5892	241	1	consistent	consistent	ADJ
fnp-5892	241	2	with	with	ADP
fnp-5892	241	3	its	its	PRON
fnp-5892	241	4	role	role	NOUN
fnp-5892	241	5	as	as	ADP
fnp-5892	241	6	suppressor	suppressor	NOUN
fnp-5892	241	7	,	,	PUNCT
fnp-5892	241	8	jund	jund	PROPN
fnp-5892	241	9	showed	show	VERB
fnp-5892	241	10	no	no	DET
fnp-5892	241	11	overexpression	overexpression	NOUN
fnp-5892	241	12	and	and	CCONJ
fnp-5892	241	13	was	be	AUX
fnp-5892	241	14	decreased	decrease	VERB
fnp-5892	241	15	in	in	ADP
fnp-5892	241	16	the	the	DET
fnp-5892	241	17	m68	m68	PROPN
fnp-5892	241	18	and	and	CCONJ
fnp-5892	241	19	f70	f70	PROPN
fnp-5892	241	20	tumors	tumor	NOUN
fnp-5892	241	21	that	that	PRON
fnp-5892	241	22	showed	show	VERB
fnp-5892	241	23	lesser	less	ADJ
fnp-5892	241	24	overexpression	overexpression	NOUN
fnp-5892	241	25	of	of	ADP
fnp-5892	241	26	the	the	DET
fnp-5892	241	27	transcription	transcription	NOUN
fnp-5892	241	28	activator	activator	NOUN
fnp-5892	241	29	family	family	NOUN
fnp-5892	241	30	members	member	NOUN
fnp-5892	241	31	(	(	PUNCT
fnp-5892	241	32	suppl	suppl	ADJ
fnp-5892	241	33	.	.	PUNCT
fnp-5892	241	34	table	table	NOUN
fnp-5892	241	35	 	 	SPACE
fnp-5892	241	36	s5	s5	NOUN
fnp-5892	241	37	)	)	PUNCT
fnp-5892	241	38	.	.	PUNCT
fnp-5892	242	1	the	the	DET
fnp-5892	242	2	activation	activation	NOUN
fnp-5892	242	3	of	of	ADP
fnp-5892	242	4	the	the	DET
fnp-5892	242	5	mapk	mapk	NOUN
fnp-5892	242	6	and	and	CCONJ
fnp-5892	242	7	pi3k	pi3k	NOUN
fnp-5892	242	8	canonical	canonical	ADJ
fnp-5892	242	9	growth	growth	NOUN
fnp-5892	242	10	pathways	pathway	NOUN
fnp-5892	242	11	has	have	AUX
fnp-5892	242	12	been	be	AUX
fnp-5892	242	13	shown	show	VERB
fnp-5892	242	14	to	to	PART
fnp-5892	242	15	result	result	VERB
fnp-5892	242	16	in	in	ADP
fnp-5892	242	17	an	an	DET
fnp-5892	242	18	inhibitory	inhibitory	ADJ
fnp-5892	242	19	feedback	feedback	NOUN
fnp-5892	242	20	response	response	NOUN
fnp-5892	242	21	in	in	ADP
fnp-5892	242	22	glioblastoma	glioblastoma	NOUN
fnp-5892	242	23	[	[	X
fnp-5892	242	24	15	15	NUM
fnp-5892	242	25	]	]	PUNCT
fnp-5892	242	26	.	.	PUNCT
fnp-5892	243	1	the	the	DET
fnp-5892	243	2	dual	dual	ADJ
fnp-5892	243	3	-	-	PUNCT
fnp-5892	243	4	specificity	specificity	NOUN
fnp-5892	243	5	phosphatases	phosphatase	NOUN
fnp-5892	243	6	(	(	PUNCT
fnp-5892	243	7	dusp	dusp	PROPN
fnp-5892	243	8	)	)	PUNCT
fnp-5892	243	9	directly	directly	ADV
fnp-5892	243	10	dephosphorylate	dephosphorylate	VERB
fnp-5892	243	11	and	and	CCONJ
fnp-5892	243	12	inactivate	inactivate	VERB
fnp-5892	243	13	mapk	mapk	NOUN
fnp-5892	243	14	,	,	PUNCT
fnp-5892	243	15	with	with	ADP
fnp-5892	243	16	dusp5	dusp5	NOUN
fnp-5892	243	17	and	and	CCONJ
fnp-5892	243	18	dusp1/6	dusp1/6	AUX
fnp-5892	243	19	specifically	specifically	ADV
fnp-5892	243	20	dephosphorylating	dephosphorylate	VERB
fnp-5892	243	21	erk1	erk1	PROPN
fnp-5892	243	22	and	and	CCONJ
fnp-5892	243	23	erk2	erk2	PROPN
fnp-5892	243	24	,	,	PUNCT
fnp-5892	243	25	respectively	respectively	ADV
fnp-5892	243	26	,	,	PUNCT
fnp-5892	243	27	and	and	CCONJ
fnp-5892	243	28	dusp4	dusp4	NOUN
fnp-5892	243	29	dephosphorylating	dephosphorylate	VERB
fnp-5892	243	30	erk1	erk1	PROPN
fnp-5892	243	31	,	,	PUNCT
fnp-5892	243	32	erk2	erk2	NOUN
fnp-5892	243	33	and	and	CCONJ
fnp-5892	243	34	junk	junk	NOUN
fnp-5892	244	1	[	[	X
fnp-5892	244	2	34	34	NUM
fnp-5892	244	3	]	]	PUNCT
fnp-5892	244	4	.	.	PUNCT
fnp-5892	245	1	of	of	ADP
fnp-5892	245	2	these	these	PRON
fnp-5892	245	3	,	,	PUNCT
fnp-5892	245	4	dusp5	dusp5	PROPN
fnp-5892	245	5	was	be	AUX
fnp-5892	245	6	upregulated	upregulate	VERB
fnp-5892	245	7	in	in	ADP
fnp-5892	245	8	all	all	DET
fnp-5892	245	9	five	five	NUM
fnp-5892	245	10	g3	g3	PROPN
fnp-5892	245	11	/	/	SYM
fnp-5892	245	12	mmr	mmr	PROPN
fnp-5892	245	13	tumors	tumor	NOUN
fnp-5892	245	14	,	,	PUNCT
fnp-5892	245	15	and	and	CCONJ
fnp-5892	245	16	dusp1	dusp1	VERB
fnp-5892	245	17	in	in	ADP
fnp-5892	245	18	three	three	NUM
fnp-5892	245	19	tumors	tumor	NOUN
fnp-5892	245	20	(	(	PUNCT
fnp-5892	245	21	fig	fig	NOUN
fnp-5892	245	22	.	.	PUNCT
fnp-5892	245	23	 	 	SPACE
fnp-5892	245	24	5e	5e	NOUN
fnp-5892	245	25	and	and	CCONJ
fnp-5892	245	26	suppl	suppl	ADJ
fnp-5892	245	27	.	.	PUNCT
fnp-5892	245	28	table	table	NOUN
fnp-5892	245	29	 	 	SPACE
fnp-5892	245	30	s6	s6	PROPN
fnp-5892	245	31	)	)	PUNCT
fnp-5892	245	32	,	,	PUNCT
fnp-5892	245	33	suggesting	suggest	VERB
fnp-5892	245	34	mapk	mapk	NOUN
fnp-5892	245	35	activation	activation	NOUN
fnp-5892	245	36	in	in	ADP
fnp-5892	245	37	all	all	DET
fnp-5892	245	38	tumors	tumor	NOUN
fnp-5892	245	39	.	.	PUNCT
fnp-5892	246	1	moreover	moreover	ADV
fnp-5892	246	2	,	,	PUNCT
fnp-5892	246	3	the	the	DET
fnp-5892	246	4	more	more	ADV
fnp-5892	246	5	specific	specific	ADJ
fnp-5892	246	6	inhibitors	inhibitor	NOUN
fnp-5892	246	7	errfi1	errfi1	ADV
fnp-5892	246	8	and	and	CCONJ
fnp-5892	246	9	spry1/4	spry1/4	VERB
fnp-5892	246	10	targeting	target	VERB
fnp-5892	246	11	downregulation	downregulation	NOUN
fnp-5892	246	12	of	of	ADP
fnp-5892	246	13	growth	growth	NOUN
fnp-5892	246	14	signaling	signal	VERB
fnp-5892	246	15	from	from	ADP
fnp-5892	246	16	the	the	DET
fnp-5892	246	17	egfr	egfr	NOUN
fnp-5892	246	18	and	and	CCONJ
fnp-5892	246	19	fgfr	fgfr	ADJ
fnp-5892	246	20	rtk	rtk	PROPN
fnp-5892	246	21	families	family	NOUN
fnp-5892	246	22	,	,	PUNCT
fnp-5892	246	23	respectively	respectively	ADV
fnp-5892	246	24	[	[	X
fnp-5892	246	25	35,36	35,36	NUM
fnp-5892	246	26	]	]	PUNCT
fnp-5892	246	27	,	,	PUNCT
fnp-5892	246	28	were	be	AUX
fnp-5892	246	29	strongly	strongly	ADV
fnp-5892	246	30	upregulated	upregulate	VERB
fnp-5892	246	31	in	in	ADP
fnp-5892	246	32	m72	m72	NOUN
fnp-5892	246	33	and	and	CCONJ
fnp-5892	246	34	f70	f70	PROPN
fnp-5892	246	35	tumors	tumor	NOUN
fnp-5892	246	36	,	,	PUNCT
fnp-5892	246	37	respectively	respectively	ADV
fnp-5892	246	38	(	(	PUNCT
fnp-5892	246	39	fig	fig	NOUN
fnp-5892	246	40	.	.	PUNCT
fnp-5892	246	41	 	 	SPACE
fnp-5892	246	42	5e	5e	NOUN
fnp-5892	246	43	and	and	CCONJ
fnp-5892	246	44	suppl	suppl	ADJ
fnp-5892	246	45	.	.	PUNCT
fnp-5892	246	46	table	table	NOUN
fnp-5892	246	47	 	 	SPACE
fnp-5892	246	48	s6	s6	PROPN
fnp-5892	246	49	)	)	PUNCT
fnp-5892	246	50	.	.	PUNCT
fnp-5892	247	1	discussion	discussion	NOUN
fnp-5892	247	2	the	the	DET
fnp-5892	247	3	identification	identification	NOUN
fnp-5892	247	4	of	of	ADP
fnp-5892	247	5	molecular	molecular	ADJ
fnp-5892	247	6	subgroups	subgroup	NOUN
fnp-5892	247	7	susceptible	susceptible	ADJ
fnp-5892	247	8	to	to	ADP
fnp-5892	247	9	targeted	target	VERB
fnp-5892	247	10	therapies	therapy	NOUN
fnp-5892	247	11	is	be	AUX
fnp-5892	247	12	the	the	DET
fnp-5892	247	13	ultimate	ultimate	ADJ
fnp-5892	247	14	goal	goal	NOUN
fnp-5892	247	15	of	of	ADP
fnp-5892	247	16	tumor	tumor	NOUN
fnp-5892	247	17	classifications	classification	NOUN
fnp-5892	247	18	.	.	PUNCT
fnp-5892	248	1	the	the	DET
fnp-5892	248	2	mapk	mapk	NOUN
fnp-5892	248	3	pathway	pathway	NOUN
fnp-5892	248	4	-	-	PUNCT
fnp-5892	248	5	based	base	VERB
fnp-5892	248	6	g1	g1	NOUN
fnp-5892	248	7	–	–	PUNCT
fnp-5892	248	8	g7	g7	NOUN
fnp-5892	248	9	molecular	molecular	ADJ
fnp-5892	248	10	classification	classification	NOUN
fnp-5892	248	11	of	of	ADP
fnp-5892	248	12	glioblastoma	glioblastoma	NOUN
fnp-5892	248	13	allowed	allow	VERB
fnp-5892	248	14	subclassification	subclassification	NOUN
fnp-5892	248	15	of	of	ADP
fnp-5892	248	16	the	the	DET
fnp-5892	248	17	small	small	ADJ
fnp-5892	248	18	number	number	NOUN
fnp-5892	248	19	of	of	ADP
fnp-5892	248	20	cases	case	NOUN
fnp-5892	248	21	with	with	ADP
fnp-5892	248	22	genetic	genetic	ADJ
fnp-5892	248	23	mmr	mmr	PROPN
fnp-5892	248	24	deficiency	deficiency	NOUN
fnp-5892	248	25	in	in	ADP
fnp-5892	248	26	the	the	DET
fnp-5892	248	27	g3	g3	PROPN
fnp-5892	248	28	/	/	SYM
fnp-5892	248	29	mmr	mmr	PROPN
fnp-5892	248	30	molecular	molecular	ADJ
fnp-5892	248	31	subgroup	subgroup	NOUN
fnp-5892	248	32	[	[	X
fnp-5892	248	33	5	5	NUM
fnp-5892	248	34	]	]	PUNCT
fnp-5892	248	35	.	.	PUNCT
fnp-5892	249	1	the	the	DET
fnp-5892	249	2	incidence	incidence	NOUN
fnp-5892	249	3	of	of	ADP
fnp-5892	249	4	these	these	DET
fnp-5892	249	5	tumors	tumor	NOUN
fnp-5892	249	6	in	in	ADP
fnp-5892	249	7	the	the	DET
fnp-5892	249	8	prospective	prospective	ADJ
fnp-5892	249	9	cohort	cohort	NOUN
fnp-5892	249	10	of	of	ADP
fnp-5892	249	11	218	218	NUM
fnp-5892	249	12	glioblastoma	glioblastoma	NOUN
fnp-5892	249	13	cases	case	NOUN
fnp-5892	249	14	is	be	AUX
fnp-5892	249	15	low	low	ADJ
fnp-5892	249	16	,	,	PUNCT
fnp-5892	249	17	approximately	approximately	ADV
fnp-5892	249	18	2	2	NUM
fnp-5892	249	19	 	 	SPACE
fnp-5892	249	20	%	%	NOUN
fnp-5892	249	21	.	.	PUNCT
fnp-5892	250	1	unlike	unlike	ADP
fnp-5892	250	2	three	three	NUM
fnp-5892	250	3	recent	recent	ADJ
fnp-5892	250	4	studies	study	NOUN
fnp-5892	250	5	that	that	PRON
fnp-5892	250	6	have	have	AUX
fnp-5892	250	7	characterized	characterize	VERB
fnp-5892	250	8	few	few	ADJ
fnp-5892	250	9	glioblastoma	glioblastoma	NOUN
fnp-5892	250	10	cases	case	NOUN
fnp-5892	250	11	with	with	ADP
fnp-5892	250	12	mmr	mmr	NOUN
fnp-5892	250	13	deficiency	deficiency	NOUN
fnp-5892	250	14	mainly	mainly	ADV
fnp-5892	250	15	in	in	ADP
fnp-5892	250	16	younger	young	ADJ
fnp-5892	250	17	adults	adult	NOUN
fnp-5892	251	1	[	[	X
fnp-5892	251	2	13,14,37	13,14,37	X
fnp-5892	251	3	]	]	X
fnp-5892	251	4	,	,	PUNCT
fnp-5892	251	5	this	this	PRON
fnp-5892	251	6	is	be	AUX
fnp-5892	251	7	the	the	DET
fnp-5892	251	8	first	first	ADJ
fnp-5892	251	9	study	study	NOUN
fnp-5892	251	10	assembling	assemble	VERB
fnp-5892	251	11	five	five	NUM
fnp-5892	251	12	cases	case	NOUN
fnp-5892	251	13	of	of	ADP
fnp-5892	251	14	glioblastoma	glioblastoma	NOUN
fnp-5892	251	15	with	with	ADP
fnp-5892	251	16	germline	germline	NOUN
fnp-5892	251	17	mmr	mmr	PROPN
fnp-5892	251	18	deficiency	deficiency	NOUN
fnp-5892	251	19	in	in	ADP
fnp-5892	251	20	adults	adult	NOUN
fnp-5892	251	21	over	over	ADP
fnp-5892	251	22	60	60	NUM
fnp-5892	251	23	years	year	NOUN
fnp-5892	251	24	of	of	ADP
fnp-5892	251	25	age	age	NOUN
fnp-5892	251	26	,	,	PUNCT
fnp-5892	251	27	who	who	PRON
fnp-5892	251	28	represent	represent	VERB
fnp-5892	251	29	the	the	DET
fnp-5892	251	30	large	large	ADJ
fnp-5892	251	31	majority	majority	NOUN
fnp-5892	251	32	of	of	ADP
fnp-5892	251	33	patients	patient	NOUN
fnp-5892	251	34	with	with	ADP
fnp-5892	251	35	glioblastoma	glioblastoma	NOUN
fnp-5892	251	36	.	.	PUNCT
fnp-5892	252	1	of	of	ADP
fnp-5892	252	2	the	the	DET
fnp-5892	252	3	studies	study	NOUN
fnp-5892	252	4	in	in	ADP
fnp-5892	252	5	younger	young	ADJ
fnp-5892	252	6	mmr	mmr	PROPN
fnp-5892	252	7	patients	patient	NOUN
fnp-5892	252	8	,	,	PUNCT
fnp-5892	252	9	the	the	DET
fnp-5892	252	10	only	only	ADJ
fnp-5892	252	11	one	one	NUM
fnp-5892	252	12	showing	show	VERB
fnp-5892	252	13	survival	survival	NOUN
fnp-5892	252	14	data	datum	NOUN
fnp-5892	252	15	concluded	conclude	VERB
fnp-5892	252	16	that	that	SCONJ
fnp-5892	252	17	these	these	DET
fnp-5892	252	18	mmr	mmr	PROPN
fnp-5892	252	19	patients	patient	NOUN
fnp-5892	252	20	exhibit	exhibit	VERB
fnp-5892	252	21	better	well	ADJ
fnp-5892	252	22	survival	survival	NOUN
fnp-5892	252	23	by	by	ADP
fnp-5892	252	24	comparing	compare	VERB
fnp-5892	252	25	them	they	PRON
fnp-5892	252	26	to	to	ADP
fnp-5892	252	27	a	a	DET
fnp-5892	252	28	standard	standard	ADJ
fnp-5892	252	29	glioblastoma	glioblastoma	NOUN
fnp-5892	252	30	cohort	cohort	NOUN
fnp-5892	252	31	significantly	significantly	ADV
fnp-5892	252	32	much	much	ADV
fnp-5892	252	33	older	old	ADJ
fnp-5892	252	34	,	,	PUNCT
fnp-5892	252	35	with	with	ADP
fnp-5892	252	36	a	a	DET
fnp-5892	252	37	difference	difference	NOUN
fnp-5892	252	38	of	of	ADP
fnp-5892	252	39	13	13	NUM
fnp-5892	252	40	years	year	NOUN
fnp-5892	252	41	in	in	ADP
fnp-5892	252	42	median	median	ADJ
fnp-5892	252	43	age	age	NOUN
fnp-5892	253	1	[	[	X
fnp-5892	253	2	13	13	NUM
fnp-5892	253	3	]	]	PUNCT
fnp-5892	253	4	.	.	PUNCT
fnp-5892	254	1	studies	study	NOUN
fnp-5892	254	2	,	,	PUNCT
fnp-5892	254	3	including	include	VERB
fnp-5892	254	4	the	the	DET
fnp-5892	254	5	current	current	ADJ
fnp-5892	254	6	one	one	NOUN
fnp-5892	254	7	,	,	PUNCT
fnp-5892	254	8	have	have	AUX
fnp-5892	254	9	clearly	clearly	ADV
fnp-5892	254	10	shown	show	VERB
fnp-5892	254	11	significant	significant	ADJ
fnp-5892	254	12	age	age	NOUN
fnp-5892	254	13	-	-	PUNCT
fnp-5892	254	14	dependent	dependent	ADJ
fnp-5892	254	15	differences	difference	NOUN
fnp-5892	254	16	for	for	ADP
fnp-5892	254	17	glioblastoma	glioblastoma	NOUN
fnp-5892	254	18	patient	patient	ADJ
fnp-5892	254	19	survival	survival	NOUN
fnp-5892	254	20	[	[	X
fnp-5892	254	21	20,21	20,21	NUM
fnp-5892	254	22	]	]	PUNCT
fnp-5892	254	23	,	,	PUNCT
fnp-5892	254	24	and	and	CCONJ
fnp-5892	254	25	therefore	therefore	ADV
fnp-5892	254	26	the	the	DET
fnp-5892	254	27	conclusion	conclusion	NOUN
fnp-5892	254	28	of	of	ADP
fnp-5892	254	29	a	a	DET
fnp-5892	254	30	longer	long	ADJ
fnp-5892	254	31	survival	survival	NOUN
fnp-5892	254	32	even	even	ADV
fnp-5892	254	33	for	for	ADP
fnp-5892	254	34	younger	young	ADJ
fnp-5892	254	35	adult	adult	NOUN
fnp-5892	254	36	mmr	mmr	PROPN
fnp-5892	254	37	patients	patient	NOUN
fnp-5892	254	38	is	be	AUX
fnp-5892	254	39	inaccurate	inaccurate	ADJ
fnp-5892	254	40	methodologically	methodologically	ADV
fnp-5892	254	41	in	in	ADP
fnp-5892	254	42	the	the	DET
fnp-5892	254	43	afore	afore	ADV
fnp-5892	254	44	mentioned	mention	VERB
fnp-5892	254	45	study	study	NOUN
fnp-5892	254	46	[	[	X
fnp-5892	254	47	13	13	NUM
fnp-5892	254	48	]	]	PUNCT
fnp-5892	254	49	.	.	PUNCT
fnp-5892	255	1	the	the	DET
fnp-5892	255	2	current	current	ADJ
fnp-5892	255	3	study	study	NOUN
fnp-5892	255	4	unequivocally	unequivocally	ADV
fnp-5892	255	5	showed	show	VERB
fnp-5892	255	6	dismal	dismal	ADJ
fnp-5892	255	7	survival	survival	NOUN
fnp-5892	255	8	for	for	ADP
fnp-5892	255	9	the	the	DET
fnp-5892	255	10	adult	adult	NOUN
fnp-5892	255	11	g3	g3	PROPN
fnp-5892	255	12	/	/	SYM
fnp-5892	255	13	mmr	mmr	PROPN
fnp-5892	255	14	glioblastoma	glioblastoma	NOUN
fnp-5892	255	15	patients	patient	NOUN
fnp-5892	255	16	,	,	PUNCT
fnp-5892	255	17	significantly	significantly	ADV
fnp-5892	255	18	shorter	short	ADJ
fnp-5892	255	19	than	than	ADP
fnp-5892	255	20	for	for	ADP
fnp-5892	255	21	the	the	DET
fnp-5892	255	22	rest	rest	NOUN
fnp-5892	255	23	of	of	ADP
fnp-5892	255	24	the	the	DET
fnp-5892	255	25	glioblastoma	glioblastoma	NOUN
fnp-5892	255	26	cohort	cohort	NOUN
fnp-5892	255	27	adjusted	adjust	VERB
fnp-5892	255	28	for	for	ADP
fnp-5892	255	29	age	age	NOUN
fnp-5892	255	30	.	.	PUNCT
fnp-5892	256	1	this	this	DET
fnp-5892	256	2	finding	finding	NOUN
fnp-5892	256	3	stratifies	stratify	VERB
fnp-5892	256	4	the	the	DET
fnp-5892	256	5	g3	g3	PROPN
fnp-5892	256	6	/	/	SYM
fnp-5892	256	7	mmr	mmr	PROPN
fnp-5892	256	8	as	as	ADP
fnp-5892	256	9	a	a	DET
fnp-5892	256	10	high	high	ADJ
fnp-5892	256	11	-	-	PUNCT
fnp-5892	256	12	risk	risk	NOUN
fnp-5892	256	13	glioblastoma	glioblastoma	NOUN
fnp-5892	256	14	subgroup	subgroup	NOUN
fnp-5892	256	15	and	and	CCONJ
fnp-5892	256	16	aligns	align	VERB
fnp-5892	256	17	it	it	PRON
fnp-5892	256	18	with	with	ADP
fnp-5892	256	19	a	a	DET
fnp-5892	256	20	recent	recent	ADJ
fnp-5892	256	21	study	study	NOUN
fnp-5892	256	22	reporting	report	VERB
fnp-5892	256	23	poor	poor	ADJ
fnp-5892	256	24	prognosis	prognosis	NOUN
fnp-5892	256	25	for	for	ADP
fnp-5892	256	26	lynch	lynch	NOUN
fnp-5892	256	27	-	-	PUNCT
fnp-5892	256	28	syndrome	syndrome	NOUN
fnp-5892	256	29	patients	patient	NOUN
fnp-5892	256	30	with	with	ADP
fnp-5892	256	31	idh	idh	NOUN
fnp-5892	256	32	-	-	PUNCT
fnp-5892	256	33	mutant	mutant	NOUN
fnp-5892	256	34	astrocytoma	astrocytoma	NOUN
fnp-5892	257	1	[	[	X
fnp-5892	257	2	38	38	NUM
fnp-5892	257	3	]	]	PUNCT
fnp-5892	257	4	.	.	PUNCT
fnp-5892	258	1	the	the	DET
fnp-5892	258	2	speedy	speedy	ADJ
fnp-5892	258	3	identification	identification	NOUN
fnp-5892	258	4	of	of	ADP
fnp-5892	258	5	the	the	DET
fnp-5892	258	6	g3	g3	PROPN
fnp-5892	258	7	/	/	SYM
fnp-5892	258	8	mmr	mmr	PROPN
fnp-5892	258	9	patients	patient	NOUN
fnp-5892	258	10	is	be	AUX
fnp-5892	258	11	peremptory	peremptory	ADJ
fnp-5892	258	12	for	for	ADP
fnp-5892	258	13	prompt	prompt	ADJ
fnp-5892	258	14	therapy	therapy	NOUN
fnp-5892	258	15	with	with	ADP
fnp-5892	258	16	immune	immune	ADJ
fnp-5892	258	17	checkpoint	checkpoint	NOUN
fnp-5892	258	18	inhibitors	inhibitor	NOUN
fnp-5892	258	19	.	.	PUNCT
fnp-5892	259	1	the	the	DET
fnp-5892	259	2	only	only	ADJ
fnp-5892	259	3	controlled	control	VERB
fnp-5892	259	4	study	study	NOUN
fnp-5892	259	5	to	to	ADP
fnp-5892	259	6	date	date	NOUN
fnp-5892	259	7	of	of	ADP
fnp-5892	259	8	immune	immune	ADJ
fnp-5892	259	9	checkpoint	checkpoint	NOUN
fnp-5892	259	10	therapy	therapy	NOUN
fnp-5892	259	11	for	for	ADP
fnp-5892	259	12	recurrent	recurrent	ADJ
fnp-5892	259	13	mmr	mmr	PROPN
fnp-5892	259	14	-	-	ADJ
fnp-5892	259	15	deficient	deficient	ADJ
fnp-5892	259	16	glioblastoma	glioblastoma	NOUN
fnp-5892	259	17	has	have	AUX
fnp-5892	259	18	not	not	PART
fnp-5892	259	19	found	find	VERB
fnp-5892	259	20	a	a	DET
fnp-5892	259	21	significant	significant	ADJ
fnp-5892	259	22	difference	difference	NOUN
fnp-5892	259	23	to	to	PART
fnp-5892	259	24	control	control	VERB
fnp-5892	259	25	when	when	SCONJ
fnp-5892	259	26	using	use	VERB
fnp-5892	259	27	pembrolizumab	pembrolizumab	NOUN
fnp-5892	259	28	,	,	PUNCT
fnp-5892	259	29	a	a	DET
fnp-5892	259	30	pd-1	pd-1	ADJ
fnp-5892	259	31	inhibitor	inhibitor	NOUN
fnp-5892	259	32	[	[	X
fnp-5892	259	33	39	39	NUM
fnp-5892	259	34	]	]	PUNCT
fnp-5892	259	35	.	.	PUNCT
fnp-5892	260	1	in	in	ADP
fnp-5892	260	2	addition	addition	NOUN
fnp-5892	260	3	,	,	PUNCT
fnp-5892	260	4	a	a	DET
fnp-5892	260	5	recent	recent	ADJ
fnp-5892	260	6	case	case	NOUN
fnp-5892	260	7	report	report	NOUN
fnp-5892	260	8	has	have	AUX
fnp-5892	260	9	shown	show	VERB
fnp-5892	260	10	lack	lack	NOUN
fnp-5892	260	11	of	of	ADP
fnp-5892	260	12	effectiveness	effectiveness	NOUN
fnp-5892	260	13	of	of	ADP
fnp-5892	260	14	pembrolizumab	pembrolizumab	NOUN
fnp-5892	260	15	for	for	ADP
fnp-5892	260	16	controlling	control	VERB
fnp-5892	260	17	lynch	lynch	NOUN
fnp-5892	260	18	-	-	PUNCT
fnp-5892	260	19	syndrome	syndrome	NOUN
fnp-5892	260	20	-	-	PUNCT
fnp-5892	260	21	associated	associate	VERB
fnp-5892	260	22	glioblastoma	glioblastoma	NOUN
fnp-5892	260	23	in	in	ADP
fnp-5892	260	24	a	a	DET
fnp-5892	260	25	young	young	ADJ
fnp-5892	260	26	adult	adult	NOUN
fnp-5892	260	27	patient	patient	NOUN
fnp-5892	260	28	[	[	X
fnp-5892	260	29	40	40	NUM
fnp-5892	260	30	]	]	PUNCT
fnp-5892	260	31	.	.	PUNCT
fnp-5892	261	1	in	in	ADP
fnp-5892	261	2	agreement	agreement	NOUN
fnp-5892	261	3	with	with	ADP
fnp-5892	261	4	these	these	DET
fnp-5892	261	5	data	datum	NOUN
fnp-5892	261	6	,	,	PUNCT
fnp-5892	261	7	the	the	DET
fnp-5892	261	8	m68	m68	PROPN
fnp-5892	261	9	patient	patient	NOUN
fnp-5892	261	10	from	from	ADP
fnp-5892	261	11	the	the	DET
fnp-5892	261	12	g3	g3	PROPN
fnp-5892	261	13	/	/	SYM
fnp-5892	261	14	mmr	mmr	PROPN
fnp-5892	261	15	subgroup	subgroup	NOUN
fnp-5892	261	16	was	be	AUX
fnp-5892	261	17	briefly	briefly	ADV
fnp-5892	261	18	treated	treat	VERB
fnp-5892	261	19	with	with	ADP
fnp-5892	261	20	pembrolizumab	pembrolizumab	NOUN
fnp-5892	261	21	without	without	ADP
fnp-5892	261	22	response	response	NOUN
fnp-5892	261	23	,	,	PUNCT
fnp-5892	261	24	although	although	SCONJ
fnp-5892	261	25	it	it	PRON
fnp-5892	261	26	is	be	AUX
fnp-5892	261	27	not	not	PART
fnp-5892	261	28	clear	clear	ADJ
fnp-5892	261	29	if	if	SCONJ
fnp-5892	261	30	the	the	DET
fnp-5892	261	31	lack	lack	NOUN
fnp-5892	261	32	of	of	ADP
fnp-5892	261	33	immune	immune	ADJ
fnp-5892	261	34	checkpoint	checkpoint	NOUN
fnp-5892	261	35	marker	marker	NOUN
fnp-5892	261	36	expression	expression	NOUN
fnp-5892	261	37	may	may	AUX
fnp-5892	261	38	have	have	AUX
fnp-5892	261	39	contributed	contribute	VERB
fnp-5892	261	40	to	to	ADP
fnp-5892	261	41	the	the	DET
fnp-5892	261	42	inhibitor	inhibitor	NOUN
fnp-5892	261	43	resistance	resistance	NOUN
fnp-5892	261	44	.	.	PUNCT
fnp-5892	262	1	in	in	ADP
fnp-5892	262	2	contrast	contrast	NOUN
fnp-5892	262	3	,	,	PUNCT
fnp-5892	262	4	the	the	DET
fnp-5892	262	5	f70	f70	PROPN
fnp-5892	262	6	patient	patient	NOUN
fnp-5892	262	7	who	who	PRON
fnp-5892	262	8	was	be	AUX
fnp-5892	262	9	treated	treat	VERB
fnp-5892	262	10	with	with	ADP
fnp-5892	262	11	the	the	DET
fnp-5892	262	12	dual	dual	ADJ
fnp-5892	262	13	regimen	regiman	NOUN
fnp-5892	262	14	of	of	ADP
fnp-5892	262	15	nivolumab	nivolumab	NOUN
fnp-5892	262	16	-	-	PUNCT
fnp-5892	262	17	ipilimumab	ipilimumab	NOUN
fnp-5892	262	18	after	after	ADP
fnp-5892	262	19	standard	standard	ADJ
fnp-5892	262	20	concurrent	concurrent	ADJ
fnp-5892	262	21	radiation	radiation	NOUN
fnp-5892	262	22	-	-	PUNCT
fnp-5892	262	23	tmz	tmz	NOUN
fnp-5892	262	24	adjuvant	adjuvant	PROPN
fnp-5892	262	25	therapy	therapy	NOUN
fnp-5892	262	26	,	,	PUNCT
fnp-5892	262	27	showed	show	VERB
fnp-5892	262	28	much	much	ADV
fnp-5892	262	29	better	well	ADJ
fnp-5892	262	30	survival	survival	NOUN
fnp-5892	262	31	than	than	ADP
fnp-5892	262	32	the	the	DET
fnp-5892	262	33	other	other	ADJ
fnp-5892	262	34	patients	patient	NOUN
fnp-5892	262	35	from	from	ADP
fnp-5892	262	36	the	the	DET
fnp-5892	262	37	g3	g3	PROPN
fnp-5892	262	38	/	/	SYM
fnp-5892	262	39	mmr	mmr	PROPN
fnp-5892	262	40	subgroup	subgroup	NOUN
fnp-5892	262	41	.	.	PUNCT
fnp-5892	263	1	this	this	DET
fnp-5892	263	2	result	result	NOUN
fnp-5892	263	3	,	,	PUNCT
fnp-5892	263	4	even	even	ADV
fnp-5892	263	5	if	if	SCONJ
fnp-5892	263	6	unique	unique	ADJ
fnp-5892	263	7	to	to	ADP
fnp-5892	263	8	this	this	DET
fnp-5892	263	9	adult	adult	NOUN
fnp-5892	263	10	g3	g3	NOUN
fnp-5892	263	11	/	/	SYM
fnp-5892	263	12	mmr	mmr	PROPN
fnp-5892	263	13	patient	patient	NOUN
fnp-5892	263	14	,	,	PUNCT
fnp-5892	263	15	shows	show	VERB
fnp-5892	263	16	that	that	SCONJ
fnp-5892	263	17	the	the	DET
fnp-5892	263	18	combination	combination	NOUN
fnp-5892	263	19	nivolumab	nivolumab	NOUN
fnp-5892	263	20	-	-	PUNCT
fnp-5892	263	21	ipilimumab	ipilimumab	NOUN
fnp-5892	263	22	targeting	target	VERB
fnp-5892	263	23	both	both	PRON
fnp-5892	263	24	pd-1	pd-1	ADJ
fnp-5892	263	25	and	and	CCONJ
fnp-5892	263	26	ctla-4	ctla-4	NOUN
fnp-5892	263	27	,	,	PUNCT
fnp-5892	263	28	respectively	respectively	ADV
fnp-5892	263	29	,	,	PUNCT
fnp-5892	263	30	may	may	AUX
fnp-5892	263	31	be	be	AUX
fnp-5892	263	32	effective	effective	ADJ
fnp-5892	263	33	on	on	ADP
fnp-5892	263	34	adult	adult	NOUN
fnp-5892	263	35	g3	g3	NOUN
fnp-5892	263	36	/	/	SYM
fnp-5892	263	37	mmr	mmr	PROPN
fnp-5892	263	38	glioblastoma	glioblastoma	NOUN
fnp-5892	263	39	.	.	PUNCT
fnp-5892	264	1	few	few	ADJ
fnp-5892	264	2	pediatric	pediatric	ADJ
fnp-5892	264	3	examples	example	NOUN
fnp-5892	264	4	of	of	ADP
fnp-5892	264	5	mmr	mmr	PROPN
fnp-5892	264	6	/	/	SYM
fnp-5892	264	7	lynch	lynch	PROPN
fnp-5892	264	8	syndrome	syndrome	PROPN
fnp-5892	264	9	glioblastoma	glioblastoma	NOUN
fnp-5892	264	10	were	be	AUX
fnp-5892	264	11	successfully	successfully	ADV
fnp-5892	264	12	treated	treat	VERB
fnp-5892	264	13	with	with	ADP
fnp-5892	264	14	pd-1	pd-1	ADJ
fnp-5892	264	15	inhibitors	inhibitor	NOUN
fnp-5892	264	16	[	[	X
fnp-5892	264	17	41,42	41,42	NOUN
fnp-5892	264	18	]	]	PUNCT
fnp-5892	264	19	,	,	PUNCT
fnp-5892	264	20	but	but	CCONJ
fnp-5892	264	21	in	in	ADP
fnp-5892	264	22	one	one	NUM
fnp-5892	264	23	case	case	NOUN
fnp-5892	264	24	,	,	PUNCT
fnp-5892	264	25	a	a	DET
fnp-5892	264	26	sustained	sustained	ADJ
fnp-5892	264	27	response	response	NOUN
fnp-5892	264	28	could	could	AUX
fnp-5892	264	29	only	only	ADV
fnp-5892	264	30	be	be	AUX
fnp-5892	264	31	achieved	achieve	VERB
fnp-5892	264	32	after	after	ADP
fnp-5892	264	33	addition	addition	NOUN
fnp-5892	264	34	of	of	ADP
fnp-5892	264	35	anti	anti	ADJ
fnp-5892	264	36	-	-	ADJ
fnp-5892	264	37	ctla-4	ctla-4	NOUN
fnp-5892	264	38	ipilimumab	ipilimumab	NOUN
fnp-5892	264	39	to	to	ADP
fnp-5892	264	40	the	the	DET
fnp-5892	264	41	initial	initial	ADJ
fnp-5892	264	42	anti	anti	ADJ
fnp-5892	264	43	-	-	ADJ
fnp-5892	264	44	pd-1	pd-1	ADJ
fnp-5892	264	45	nivolumab	nivolumab	NOUN
fnp-5892	264	46	regimen	regiman	NOUN
fnp-5892	265	1	[	[	X
fnp-5892	265	2	43	43	NUM
fnp-5892	265	3	]	]	PUNCT
fnp-5892	265	4	.	.	PUNCT
fnp-5892	266	1	this	this	DET
fnp-5892	266	2	dual	dual	ADJ
fnp-5892	266	3	regimen	regimen	NOUN
fnp-5892	266	4	is	be	AUX
fnp-5892	266	5	also	also	ADV
fnp-5892	266	6	used	use	VERB
fnp-5892	266	7	in	in	ADP
fnp-5892	266	8	metastatic	metastatic	ADJ
fnp-5892	266	9	crc	crc	NOUN
fnp-5892	266	10	associated	associate	VERB
fnp-5892	266	11	to	to	ADP
fnp-5892	266	12	lynch	lynch	PROPN
fnp-5892	266	13	syndrome	syndrome	PROPN
fnp-5892	267	1	[	[	X
fnp-5892	267	2	44	44	NUM
fnp-5892	267	3	]	]	PUNCT
fnp-5892	267	4	,	,	PUNCT
fnp-5892	267	5	and	and	CCONJ
fnp-5892	267	6	as	as	ADP
fnp-5892	267	7	first	first	ADJ
fnp-5892	267	8	-	-	PUNCT
fnp-5892	267	9	line	line	NOUN
fnp-5892	267	10	therapy	therapy	NOUN
fnp-5892	267	11	for	for	ADP
fnp-5892	267	12	metastatic	metastatic	ADJ
fnp-5892	267	13	or	or	CCONJ
fnp-5892	267	14	advanced	advanced	ADJ
fnp-5892	267	15	nsclc	nsclc	NOUN
fnp-5892	267	16	with	with	ADP
fnp-5892	267	17	tmb	tmb	PROPN
fnp-5892	267	18	 	 	SPACE
fnp-5892	267	19	≥	≥	NUM
fnp-5892	267	20	  	  	SPACE
fnp-5892	267	21	10	10	NUM
fnp-5892	267	22	mutations	mutation	NOUN
fnp-5892	267	23	 	 	SPACE
fnp-5892	267	24	/	/	SYM
fnp-5892	267	25	 	 	SPACE
fnp-5892	267	26	mb	mb	NOUN
fnp-5892	267	27	,	,	PUNCT
fnp-5892	267	28	regardless	regardless	ADV
fnp-5892	267	29	of	of	ADP
fnp-5892	267	30	the	the	DET
fnp-5892	267	31	pd	pd	PROPN
fnp-5892	267	32	-	-	PUNCT
fnp-5892	267	33	l1	l1	PROPN
fnp-5892	267	34	expression	expression	NOUN
fnp-5892	267	35	levels	level	NOUN
fnp-5892	268	1	[	[	X
fnp-5892	268	2	22,45,46	22,45,46	NUM
fnp-5892	268	3	]	]	PUNCT
fnp-5892	268	4	.	.	PUNCT
fnp-5892	269	1	the	the	DET
fnp-5892	269	2	identification	identification	NOUN
fnp-5892	269	3	of	of	ADP
fnp-5892	269	4	the	the	DET
fnp-5892	269	5	g3	g3	PROPN
fnp-5892	269	6	/	/	SYM
fnp-5892	269	7	mmr	mmr	PROPN
fnp-5892	269	8	patients	patient	NOUN
fnp-5892	269	9	relies	rely	VERB
fnp-5892	269	10	on	on	ADP
fnp-5892	269	11	clinical	clinical	ADJ
fnp-5892	269	12	,	,	PUNCT
fnp-5892	269	13	histologic	histologic	ADJ
fnp-5892	269	14	and	and	CCONJ
fnp-5892	269	15	molecular	molecular	ADJ
fnp-5892	269	16	clues	clue	NOUN
fnp-5892	269	17	.	.	PUNCT
fnp-5892	270	1	a	a	DET
fnp-5892	270	2	review	review	NOUN
fnp-5892	270	3	of	of	ADP
fnp-5892	270	4	the	the	DET
fnp-5892	270	5	literature	literature	NOUN
fnp-5892	270	6	identified	identify	VERB
fnp-5892	270	7	5	5	NUM
fnp-5892	270	8	additional	additional	ADJ
fnp-5892	270	9	adult	adult	NOUN
fnp-5892	270	10	(	(	PUNCT
fnp-5892	270	11	≥	≥	NOUN
fnp-5892	270	12	 	 	SPACE
fnp-5892	270	13	50	50	NUM
fnp-5892	270	14	-	-	PUNCT
fnp-5892	270	15	years	year	NOUN
fnp-5892	270	16	)	)	PUNCT
fnp-5892	270	17	g3	g3	PROPN
fnp-5892	270	18	/	/	SYM
fnp-5892	270	19	mmr	mmr	PROPN
fnp-5892	270	20	cases	case	NOUN
fnp-5892	270	21	with	with	ADP
fnp-5892	270	22	clinical	clinical	ADJ
fnp-5892	270	23	,	,	PUNCT
fnp-5892	270	24	histologic	histologic	ADJ
fnp-5892	270	25	and	and	CCONJ
fnp-5892	270	26	molecular	molecular	ADJ
fnp-5892	270	27	data	datum	NOUN
fnp-5892	270	28	[	[	X
fnp-5892	270	29	13,14	13,14	NUM
fnp-5892	270	30	]	]	PUNCT
fnp-5892	270	31	,	,	PUNCT
fnp-5892	270	32	and	and	CCONJ
fnp-5892	270	33	the	the	DET
fnp-5892	270	34	integrated	integrate	VERB
fnp-5892	270	35	findings	finding	NOUN
fnp-5892	270	36	from	from	ADP
fnp-5892	270	37	the	the	DET
fnp-5892	270	38	total	total	NOUN
fnp-5892	270	39	of	of	ADP
fnp-5892	270	40	10	10	NUM
fnp-5892	270	41	g3	g3	PROPN
fnp-5892	270	42	/	/	SYM
fnp-5892	270	43	mmr	mmr	PROPN
fnp-5892	270	44	adult	adult	NOUN
fnp-5892	270	45	glioblastoma	glioblastoma	NOUN
fnp-5892	270	46	patients	patient	NOUN
fnp-5892	270	47	is	be	AUX
fnp-5892	270	48	summarized	summarize	VERB
fnp-5892	270	49	in	in	ADP
fnp-5892	270	50	table	table	NOUN
fnp-5892	270	51	 	 	SPACE
fnp-5892	270	52	2	2	NUM
fnp-5892	270	53	.	.	PUNCT
fnp-5892	270	54	clinical	clinical	ADJ
fnp-5892	270	55	history	history	NOUN
fnp-5892	270	56	of	of	ADP
fnp-5892	270	57	prior	prior	ADJ
fnp-5892	270	58	cancers	cancer	NOUN
fnp-5892	270	59	pertains	pertain	VERB
fnp-5892	270	60	to	to	ADP
fnp-5892	270	61	half	half	NOUN
fnp-5892	270	62	of	of	ADP
fnp-5892	270	63	the	the	DET
fnp-5892	270	64	patients	patient	NOUN
fnp-5892	270	65	,	,	PUNCT
fnp-5892	270	66	with	with	ADP
fnp-5892	270	67	highest	high	ADJ
fnp-5892	270	68	frequency	frequency	NOUN
fnp-5892	270	69	of	of	ADP
fnp-5892	270	70	crc	crc	NOUN
fnp-5892	270	71	,	,	PUNCT
fnp-5892	270	72	in	in	ADP
fnp-5892	270	73	4	4	NUM
fnp-5892	270	74	of	of	ADP
fnp-5892	270	75	the	the	DET
fnp-5892	270	76	10	10	NUM
fnp-5892	270	77	cases	case	NOUN
fnp-5892	270	78	.	.	PUNCT
fnp-5892	271	1	older	old	ADJ
fnp-5892	271	2	g3	g3	PROPN
fnp-5892	271	3	/	/	SYM
fnp-5892	271	4	mmr	mmr	PROPN
fnp-5892	271	5	patients	patient	NOUN
fnp-5892	271	6	appear	appear	VERB
fnp-5892	271	7	to	to	PART
fnp-5892	271	8	be	be	AUX
fnp-5892	271	9	prone	prone	ADJ
fnp-5892	271	10	to	to	ADP
fnp-5892	271	11	multifocal	multifocal	ADJ
fnp-5892	271	12	or	or	CCONJ
fnp-5892	271	13	deep	deep	ADV
fnp-5892	271	14	-	-	PUNCT
fnp-5892	271	15	seated	seat	VERB
fnp-5892	271	16	tumors	tumor	NOUN
fnp-5892	271	17	that	that	PRON
fnp-5892	271	18	warrant	warrant	VERB
fnp-5892	271	19	subtotal	subtotal	ADJ
fnp-5892	271	20	resections	resection	NOUN
fnp-5892	271	21	or	or	CCONJ
fnp-5892	271	22	only	only	ADV
fnp-5892	271	23	biopsies	biopsy	NOUN
fnp-5892	271	24	.	.	PUNCT
fnp-5892	272	1	histologically	histologically	ADV
fnp-5892	272	2	,	,	PUNCT
fnp-5892	272	3	100	100	NUM
fnp-5892	272	4	 	 	SPACE
fnp-5892	272	5	%	%	NOUN
fnp-5892	272	6	of	of	ADP
fnp-5892	272	7	these	these	DET
fnp-5892	272	8	tumors	tumor	NOUN
fnp-5892	272	9	contain	contain	VERB
fnp-5892	272	10	mgcs	mgcs	NOUN
fnp-5892	272	11	.	.	PUNCT
fnp-5892	273	1	as	as	SCONJ
fnp-5892	273	2	shown	show	VERB
fnp-5892	273	3	in	in	ADP
fnp-5892	273	4	this	this	DET
fnp-5892	273	5	study	study	NOUN
fnp-5892	273	6	,	,	PUNCT
fnp-5892	273	7	mgcs	mgcs	PROPN
fnp-5892	273	8	are	be	AUX
fnp-5892	273	9	not	not	PART
fnp-5892	273	10	specific	specific	ADJ
fnp-5892	273	11	for	for	ADP
fnp-5892	273	12	g3	g3	PROPN
fnp-5892	273	13	/	/	SYM
fnp-5892	273	14	mmr	mmr	PROPN
fnp-5892	273	15	tumors	tumor	NOUN
fnp-5892	273	16	,	,	PUNCT
fnp-5892	273	17	and	and	CCONJ
fnp-5892	273	18	other	other	ADJ
fnp-5892	273	19	g1	g1	PROPN
fnp-5892	273	20	–	–	PUNCT
fnp-5892	273	21	g7	g7	PROPN
fnp-5892	273	22	subgroups	subgroup	NOUN
fnp-5892	273	23	,	,	PUNCT
fnp-5892	273	24	especially	especially	ADV
fnp-5892	273	25	the	the	DET
fnp-5892	273	26	ones	one	NOUN
fnp-5892	273	27	with	with	ADP
fnp-5892	273	28	tumors	tumor	NOUN
fnp-5892	273	29	displaying	display	VERB
fnp-5892	273	30	morphology	morphology	NOUN
fnp-5892	273	31	classified	classify	VERB
fnp-5892	273	32	in	in	ADP
fnp-5892	273	33	the	the	DET
fnp-5892	273	34	anaplastic	anaplastic	ADJ
fnp-5892	273	35	and	and	CCONJ
fnp-5892	273	36	epithelioid	epithelioid	NOUN
fnp-5892	273	37	clusters	cluster	NOUN
fnp-5892	273	38	,	,	PUNCT
fnp-5892	273	39	may	may	AUX
fnp-5892	273	40	show	show	VERB
fnp-5892	273	41	a	a	DET
fnp-5892	273	42	variable	variable	ADJ
fnp-5892	273	43	number	number	NOUN
fnp-5892	273	44	of	of	ADP
fnp-5892	273	45	tumors	tumor	NOUN
fnp-5892	273	46	with	with	ADP
fnp-5892	273	47	mgcs	mgcs	PROPN
fnp-5892	273	48	(	(	PUNCT
fnp-5892	273	49	see	see	VERB
fnp-5892	273	50	fig	fig	NOUN
fnp-5892	273	51	.	.	PUNCT
fnp-5892	273	52	 	 	SPACE
fnp-5892	273	53	4	4	NUM
fnp-5892	273	54	)	)	PUNCT
fnp-5892	273	55	.	.	PUNCT
fnp-5892	274	1	in	in	ADP
fnp-5892	274	2	addition	addition	NOUN
fnp-5892	274	3	to	to	ADP
fnp-5892	274	4	mgcs	mgcs	NOUN
fnp-5892	274	5	,	,	PUNCT
fnp-5892	274	6	all	all	DET
fnp-5892	274	7	the	the	DET
fnp-5892	274	8	g3	g3	PROPN
fnp-5892	274	9	/	/	SYM
fnp-5892	274	10	mmr	mmr	PROPN
fnp-5892	274	11	tumors	tumor	NOUN
fnp-5892	274	12	also	also	ADV
fnp-5892	274	13	show	show	VERB
fnp-5892	274	14	positive	positive	ADJ
fnp-5892	274	15	p53	p53	NOUN
fnp-5892	274	16	ihc	ihc	NOUN
fnp-5892	274	17	.	.	PUNCT
fnp-5892	275	1	however	however	ADV
fnp-5892	275	2	,	,	PUNCT
fnp-5892	275	3	as	as	SCONJ
fnp-5892	275	4	shown	show	VERB
fnp-5892	275	5	in	in	ADP
fnp-5892	275	6	this	this	DET
fnp-5892	275	7	study	study	NOUN
fnp-5892	275	8	,	,	PUNCT
fnp-5892	275	9	nearly	nearly	ADV
fnp-5892	275	10	80	80	NUM
fnp-5892	275	11	 	 	SPACE
fnp-5892	275	12	%	%	NOUN
fnp-5892	275	13	of	of	ADP
fnp-5892	275	14	the	the	DET
fnp-5892	275	15	tumors	tumor	NOUN
fnp-5892	275	16	with	with	ADP
fnp-5892	275	17	mgcs	mgcs	PROPN
fnp-5892	275	18	showed	show	VERB
fnp-5892	275	19	p53	p53	NOUN
fnp-5892	275	20	immunopositivity	immunopositivity	NOUN
fnp-5892	275	21	,	,	PUNCT
fnp-5892	275	22	with	with	ADP
fnp-5892	275	23	the	the	DET
fnp-5892	275	24	g1	g1	PROPN
fnp-5892	275	25	/	/	SYM
fnp-5892	275	26	egfr	egfr	ADJ
fnp-5892	275	27	-	-	PUNCT
fnp-5892	275	28	mutant	mutant	NOUN
fnp-5892	275	29	molecular	molecular	ADJ
fnp-5892	275	30	subgroup	subgroup	NOUN
fnp-5892	275	31	mimicking	mimic	VERB
fnp-5892	275	32	the	the	DET
fnp-5892	275	33	closest	close	ADJ
fnp-5892	275	34	the	the	DET
fnp-5892	275	35	g3	g3	PROPN
fnp-5892	275	36	/	/	SYM
fnp-5892	275	37	mmr	mmr	PROPN
fnp-5892	275	38	subgroup	subgroup	NOUN
fnp-5892	275	39	in	in	ADP
fnp-5892	275	40	terms	term	NOUN
fnp-5892	275	41	of	of	ADP
fnp-5892	275	42	morphology	morphology	NOUN
fnp-5892	275	43	and	and	CCONJ
fnp-5892	275	44	p53	p53	NOUN
fnp-5892	275	45	immunopositivity	immunopositivity	NOUN
fnp-5892	275	46	(	(	PUNCT
fnp-5892	275	47	see	see	VERB
fnp-5892	275	48	fig	fig	NOUN
fnp-5892	275	49	.	.	PUNCT
fnp-5892	275	50	 	 	SPACE
fnp-5892	275	51	4	4	NUM
fnp-5892	275	52	)	)	PUNCT
fnp-5892	275	53	.	.	PUNCT
fnp-5892	276	1	overall	overall	ADV
fnp-5892	276	2	,	,	PUNCT
fnp-5892	276	3	the	the	DET
fnp-5892	276	4	g3	g3	PROPN
fnp-5892	276	5	/	/	SYM
fnp-5892	276	6	mmr	mmr	PROPN
fnp-5892	276	7	subgroup	subgroup	PROPN
fnp-5892	276	8	cases	case	NOUN
fnp-5892	276	9	represented	represent	VERB
fnp-5892	276	10	14.3	14.3	NUM
fnp-5892	276	11	 	 	SPACE
fnp-5892	276	12	%	%	NOUN
fnp-5892	276	13	(	(	PUNCT
fnp-5892	276	14	one	one	NUM
fnp-5892	276	15	seventh	seventh	NOUN
fnp-5892	276	16	)	)	PUNCT
fnp-5892	276	17	of	of	ADP
fnp-5892	276	18	the	the	DET
fnp-5892	276	19	total	total	ADJ
fnp-5892	276	20	glioblastoma	glioblastoma	NOUN
fnp-5892	276	21	cases	case	NOUN
fnp-5892	276	22	showing	show	VERB
fnp-5892	276	23	both	both	PRON
fnp-5892	276	24	mgcs	mgcs	NOUN
fnp-5892	276	25	and	and	CCONJ
fnp-5892	276	26	p53	p53	NOUN
fnp-5892	276	27	immunopositivity	immunopositivity	NOUN
fnp-5892	276	28	.	.	PUNCT
fnp-5892	277	1	the	the	DET
fnp-5892	277	2	ihc	ihc	PROPN
fnp-5892	277	3	with	with	ADP
fnp-5892	277	4	the	the	DET
fnp-5892	277	5	mmr	mmr	PROPN
fnp-5892	277	6	panel	panel	NOUN
fnp-5892	277	7	appears	appear	VERB
fnp-5892	277	8	to	to	PART
fnp-5892	277	9	be	be	AUX
fnp-5892	277	10	specific	specific	ADJ
fnp-5892	277	11	for	for	ADP
fnp-5892	277	12	g3	g3	PROPN
fnp-5892	277	13	/	/	SYM
fnp-5892	277	14	mmr	mmr	PROPN
fnp-5892	277	15	cases	case	NOUN
fnp-5892	277	16	(	(	PUNCT
fnp-5892	277	17	table	table	NOUN
fnp-5892	277	18	 	 	SPACE
fnp-5892	277	19	2	2	NUM
fnp-5892	277	20	)	)	PUNCT
fnp-5892	277	21	,	,	PUNCT
fnp-5892	277	22	but	but	CCONJ
fnp-5892	277	23	will	will	AUX
fnp-5892	277	24	only	only	ADV
fnp-5892	277	25	be	be	AUX
fnp-5892	277	26	yielding	yield	VERB
fnp-5892	277	27	positive	positive	ADJ
fnp-5892	277	28	results	result	NOUN
fnp-5892	277	29	in	in	ADP
fnp-5892	277	30	1	1	NUM
fnp-5892	277	31	out	out	ADP
fnp-5892	277	32	of	of	ADP
fnp-5892	277	33	7	7	NUM
fnp-5892	277	34	glioblastoma	glioblastoma	NOUN
fnp-5892	277	35	cases	case	NOUN
fnp-5892	277	36	with	with	ADP
fnp-5892	277	37	concomitant	concomitant	ADJ
fnp-5892	277	38	mgcs	mgcs	NOUN
fnp-5892	277	39	and	and	CCONJ
fnp-5892	277	40	p53	p53	NOUN
fnp-5892	277	41	immunopositivity	immunopositivity	NOUN
fnp-5892	277	42	.	.	PUNCT
fnp-5892	278	1	current	current	ADJ
fnp-5892	278	2	study	study	NOUN
fnp-5892	278	3	kim	kim	PROPN
fnp-5892	278	4	et	et	PROPN
fnp-5892	278	5	al	al	PROPN
fnp-5892	278	6	.	.	PUNCT
fnp-5892	279	1	[	[	X
fnp-5892	279	2	14	14	NUM
fnp-5892	279	3	]	]	X
fnp-5892	279	4	hadad	hadad	PROPN
fnp-5892	279	5	et	et	PROPN
fnp-5892	279	6	al	al	PROPN
fnp-5892	279	7	.	.	PUNCT
fnp-5892	280	1	[	[	X
fnp-5892	280	2	13	13	NUM
fnp-5892	280	3	]	]	SYM
fnp-5892	280	4	total	total	ADJ
fnp-5892	280	5	3	3	NUM
fnp-5892	280	6	studies	study	NOUN
fnp-5892	280	7	number	number	NOUN
fnp-5892	280	8	of	of	ADP
fnp-5892	280	9	patients	patient	NOUN
fnp-5892	280	10	5	5	NUM
fnp-5892	280	11	3	3	NUM
fnp-5892	280	12	2	2	NUM
fnp-5892	280	13	10	10	NUM
fnp-5892	280	14	median	median	ADJ
fnp-5892	280	15	age	age	NOUN
fnp-5892	280	16	(	(	PUNCT
fnp-5892	280	17	range	range	NOUN
fnp-5892	280	18	)	)	PUNCT
fnp-5892	280	19	in	in	ADP
fnp-5892	280	20	years	year	NOUN
fnp-5892	280	21	70	70	NUM
fnp-5892	280	22	(	(	PUNCT
fnp-5892	280	23	62	62	NUM
fnp-5892	280	24	to	to	PART
fnp-5892	280	25	79	79	NUM
fnp-5892	280	26	)	)	PUNCT
fnp-5892	280	27	69	69	NUM
fnp-5892	280	28	(	(	PUNCT
fnp-5892	280	29	50	50	NUM
fnp-5892	280	30	,	,	PUNCT
fnp-5892	280	31	69	69	NUM
fnp-5892	280	32	and	and	CCONJ
fnp-5892	280	33	75	75	NUM
fnp-5892	280	34	)	)	PUNCT
fnp-5892	280	35	53.5	53.5	NUM
fnp-5892	280	36	(	(	PUNCT
fnp-5892	280	37	50	50	NUM
fnp-5892	280	38	and	and	CCONJ
fnp-5892	280	39	57	57	NUM
fnp-5892	280	40	)	)	PUNCT
fnp-5892	280	41	68.5	68.5	NUM
fnp-5892	280	42	(	(	PUNCT
fnp-5892	280	43	50	50	NUM
fnp-5892	280	44	to	to	PART
fnp-5892	280	45	79	79	NUM
fnp-5892	280	46	)	)	PUNCT
fnp-5892	280	47	sex	sex	NOUN
fnp-5892	280	48	m	m	NOUN
fnp-5892	280	49	:	:	PUNCT
fnp-5892	280	50	f	f	PROPN
fnp-5892	280	51	ratio	ratio	NOUN
fnp-5892	280	52	4	4	NUM
fnp-5892	280	53	 	 	SPACE
fnp-5892	280	54	:	:	PUNCT
fnp-5892	280	55	 	 	SPACE
fnp-5892	280	56	1	1	NUM
fnp-5892	280	57	1	1	NUM
fnp-5892	280	58	 	 	SPACE
fnp-5892	280	59	:	:	PUNCT
fnp-5892	280	60	 	 	SPACE
fnp-5892	280	61	2	2	NUM
fnp-5892	280	62	1	1	NUM
fnp-5892	280	63	 	 	SPACE
fnp-5892	280	64	:	:	PUNCT
fnp-5892	280	65	 	 	SPACE
fnp-5892	280	66	1	1	NUM
fnp-5892	280	67	1.5	1.5	NUM
fnp-5892	280	68	 	 	SPACE
fnp-5892	280	69	:	:	PUNCT
fnp-5892	280	70	 	 	SPACE
fnp-5892	280	71	1	1	NUM
fnp-5892	280	72	history	history	NOUN
fnp-5892	280	73	of	of	ADP
fnp-5892	280	74	prior	prior	ADJ
fnp-5892	280	75	cancer	cancer	NOUN
fnp-5892	280	76	60	60	NUM
fnp-5892	280	77	 	 	SPACE
fnp-5892	280	78	%	%	NOUN
fnp-5892	280	79	67	67	NUM
fnp-5892	280	80	 	 	SPACE
fnp-5892	280	81	%	%	NOUN
fnp-5892	280	82	0	0	NUM
fnp-5892	280	83	 	 	SPACE
fnp-5892	280	84	%	%	NOUN
fnp-5892	280	85	50	50	NUM
fnp-5892	280	86	 	 	SPACE
fnp-5892	280	87	%	%	NOUN
fnp-5892	280	88	location	location	NOUN
fnp-5892	280	89	:	:	PUNCT
fnp-5892	280	90	multifocal	multifocal	ADJ
fnp-5892	280	91	or	or	CCONJ
fnp-5892	280	92	midline	midline	VERB
fnp-5892	280	93	60	60	NUM
fnp-5892	280	94	 	 	SPACE
fnp-5892	280	95	%	%	NOUN
fnp-5892	280	96	67	67	NUM
fnp-5892	280	97	 	 	SPACE
fnp-5892	280	98	%	%	NOUN
fnp-5892	280	99	0	0	NUM
fnp-5892	280	100	 	 	SPACE
fnp-5892	280	101	%	%	NOUN
fnp-5892	280	102	50	50	NUM
fnp-5892	280	103	 	 	SPACE
fnp-5892	280	104	%	%	NOUN
fnp-5892	280	105	survival	survival	NOUN
fnp-5892	280	106	:	:	PUNCT
fnp-5892	280	107	months	month	NOUN
fnp-5892	280	108	3.25	3.25	NUM
fnp-5892	280	109	(	(	PUNCT
fnp-5892	280	110	median	median	NOUN
fnp-5892	280	111	)	)	PUNCT
fnp-5892	280	112	nd	nd	ADP
fnp-5892	280	113	6.4	6.4	NUM
fnp-5892	280	114	and	and	CCONJ
fnp-5892	280	115	50.5	50.5	NUM
fnp-5892	280	116	4.5	4.5	NUM
fnp-5892	280	117	(	(	PUNCT
fnp-5892	280	118	median	median	ADJ
fnp-5892	280	119	)	)	PUNCT
fnp-5892	280	120	surgery	surgery	NOUN
fnp-5892	280	121	40	40	NUM
fnp-5892	280	122	 	 	SPACE
fnp-5892	280	123	%	%	NOUN
fnp-5892	280	124	biopsy	biopsy	VERB
fnp-5892	280	125	100	100	NUM
fnp-5892	280	126	 	 	SPACE
fnp-5892	280	127	%	%	NOUN
fnp-5892	280	128	gtr	gtr	NOUN
fnp-5892	280	129	100	100	NUM
fnp-5892	280	130	 	 	SPACE
fnp-5892	280	131	%	%	NOUN
fnp-5892	280	132	gtr	gtr	NOUN
fnp-5892	280	133	60	60	NUM
fnp-5892	280	134	 	 	SPACE
fnp-5892	280	135	%	%	NOUN
fnp-5892	280	136	gtr	gtr	NOUN
fnp-5892	280	137	adjuvant	adjuvant	ADJ
fnp-5892	280	138	treatment	treatment	NOUN
fnp-5892	280	139	(	(	PUNCT
fnp-5892	280	140	rt	rt	PROPN
fnp-5892	280	141	/	/	SYM
fnp-5892	280	142	tmz	tmz	PROPN
fnp-5892	280	143	)	)	PUNCT
fnp-5892	280	144	67	67	NUM
fnp-5892	280	145	 	 	SPACE
fnp-5892	280	146	%	%	NOUN
fnp-5892	280	147	100	100	NUM
fnp-5892	280	148	 	 	SPACE
fnp-5892	280	149	%	%	NOUN
fnp-5892	280	150	100	100	NUM
fnp-5892	280	151	 	 	SPACE
fnp-5892	280	152	%	%	NOUN
fnp-5892	280	153	80	80	NUM
fnp-5892	280	154	 	 	SPACE
fnp-5892	280	155	%	%	NOUN
fnp-5892	280	156	multinucleated	multinucleate	VERB
fnp-5892	280	157	giant	giant	ADJ
fnp-5892	280	158	cells	cell	NOUN
fnp-5892	280	159	100	100	NUM
fnp-5892	280	160	 	 	SPACE
fnp-5892	280	161	%	%	NOUN
fnp-5892	280	162	100	100	NUM
fnp-5892	280	163	 	 	SPACE
fnp-5892	280	164	%	%	NOUN
fnp-5892	280	165	100	100	NUM
fnp-5892	280	166	 	 	SPACE
fnp-5892	280	167	%	%	NOUN
fnp-5892	280	168	100	100	NUM
fnp-5892	280	169	 	 	SPACE
fnp-5892	280	170	%	%	NOUN
fnp-5892	280	171	ihc	ihc	PROPN
fnp-5892	280	172	msh2	msh2	PROPN
fnp-5892	280	173	/	/	PUNCT
fnp-5892	280	174	msh6	msh6	VERB
fnp-5892	280	175	100	100	NUM
fnp-5892	280	176	 	 	SPACE
fnp-5892	280	177	%	%	NOUN
fnp-5892	280	178	100	100	NUM
fnp-5892	280	179	 	 	SPACE
fnp-5892	280	180	%	%	NOUN
fnp-5892	280	181	100	100	NUM
fnp-5892	280	182	 	 	SPACE
fnp-5892	280	183	%	%	NOUN
fnp-5892	280	184	100	100	NUM
fnp-5892	280	185	 	 	SPACE
fnp-5892	280	186	%	%	NOUN
fnp-5892	280	187	mmr	mmr	PROPN
fnp-5892	280	188	mutation	mutation	NOUN
fnp-5892	280	189	frequency	frequency	NOUN
fnp-5892	280	190	msh6	msh6	NOUN
fnp-5892	280	191	 	 	SPACE
fnp-5892	280	192	>	>	SYM
fnp-5892	280	193	 	 	SPACE
fnp-5892	280	194	msh2	msh2	NOUN
fnp-5892	280	195	msh6	msh6	NOUN
fnp-5892	280	196	 	 	SPACE
fnp-5892	280	197	>	>	SYM
fnp-5892	280	198	 	 	SPACE
fnp-5892	280	199	msh2	msh2	ADJ
fnp-5892	280	200	msh2	msh2	NOUN
fnp-5892	280	201	msh6	msh6	NOUN
fnp-5892	280	202	 	 	SPACE
fnp-5892	280	203	≥	≥	NOUN
fnp-5892	280	204	 	 	SPACE
fnp-5892	280	205	msh2	msh2	PROPN
fnp-5892	280	206	ihc	ihc	PROPN
fnp-5892	280	207	p53	p53	PROPN
fnp-5892	280	208	100	100	NUM
fnp-5892	280	209	 	 	SPACE
fnp-5892	280	210	%	%	NOUN
fnp-5892	280	211	100	100	NUM
fnp-5892	280	212	 	 	SPACE
fnp-5892	280	213	%	%	NOUN
fnp-5892	280	214	100	100	NUM
fnp-5892	280	215	 	 	SPACE
fnp-5892	280	216	%	%	NOUN
fnp-5892	280	217	100	100	NUM
fnp-5892	280	218	 	 	SPACE
fnp-5892	280	219	%	%	NOUN
fnp-5892	280	220	tp53	tp53	PROPN
fnp-5892	280	221	mutations	mutation	NOUN
fnp-5892	280	222	(	(	PUNCT
fnp-5892	280	223	biallelic	biallelic	ADJ
fnp-5892	280	224	/	/	SYM
fnp-5892	280	225	r	r	NOUN
fnp-5892	280	226	mutations	mutation	NOUN
fnp-5892	280	227	 	 	SPACE
fnp-5892	280	228	%	%	NOUN
fnp-5892	280	229	)	)	PUNCT
fnp-5892	280	230	100	100	NUM
fnp-5892	280	231	 	 	SPACE
fnp-5892	280	232	%	%	NOUN
fnp-5892	280	233	(	(	PUNCT
fnp-5892	280	234	100/100	100/100	NUM
fnp-5892	280	235	)	)	PUNCT
fnp-5892	280	236	100	100	NUM
fnp-5892	280	237	 	 	SPACE
fnp-5892	280	238	%	%	NOUN
fnp-5892	280	239	(	(	PUNCT
fnp-5892	280	240	67/100	67/100	NUM
fnp-5892	280	241	)	)	PUNCT
fnp-5892	280	242	100	100	NUM
fnp-5892	280	243	 	 	SPACE
fnp-5892	280	244	%	%	NOUN
fnp-5892	280	245	(	(	PUNCT
fnp-5892	280	246	50/100	50/100	NUM
fnp-5892	280	247	)	)	PUNCT
fnp-5892	280	248	100	100	NUM
fnp-5892	280	249	 	 	SPACE
fnp-5892	280	250	%	%	NOUN
fnp-5892	280	251	(	(	PUNCT
fnp-5892	280	252	80/100	80/100	NUM
fnp-5892	280	253	)	)	PUNCT
fnp-5892	280	254	mapk	mapk	NOUN
fnp-5892	280	255	pathway	pathway	NOUN
fnp-5892	280	256	(	(	PUNCT
fnp-5892	280	257	ptpn11	ptpn11	NOUN
fnp-5892	280	258	/	/	SYM
fnp-5892	280	259	ras	ras	NOUN
fnp-5892	280	260	/	/	SYM
fnp-5892	280	261	nf1	nf1	NOUN
fnp-5892	280	262	 	 	SPACE
fnp-5892	280	263	%	%	NOUN
fnp-5892	280	264	)	)	PUNCT
fnp-5892	280	265	60	60	NUM
fnp-5892	280	266	 	 	SPACE
fnp-5892	280	267	%	%	NOUN
fnp-5892	280	268	(	(	PUNCT
fnp-5892	280	269	40/20/40	40/20/40	PROPN
fnp-5892	280	270	)	)	PUNCT
fnp-5892	280	271	100	100	NUM
fnp-5892	280	272	 	 	SPACE
fnp-5892	280	273	%	%	NOUN
fnp-5892	280	274	(	(	PUNCT
fnp-5892	280	275	67/0//67	67/0//67	NOUN
fnp-5892	280	276	)	)	PUNCT
fnp-5892	280	277	100	100	NUM
fnp-5892	280	278	 	 	SPACE
fnp-5892	280	279	%	%	NOUN
fnp-5892	280	280	(	(	PUNCT
fnp-5892	280	281	0/0/100	0/0/100	NUM
fnp-5892	280	282	)	)	PUNCT
fnp-5892	280	283	80	80	NUM
fnp-5892	280	284	 	 	SPACE
fnp-5892	280	285	%	%	NOUN
fnp-5892	280	286	(	(	PUNCT
fnp-5892	280	287	40/10/60	40/10/60	NUM
fnp-5892	280	288	)	)	PUNCT
fnp-5892	280	289	pi3k	pi3k	NOUN
fnp-5892	280	290	pathway	pathway	NOUN
fnp-5892	280	291	(	(	PUNCT
fnp-5892	280	292	pik3ca	pik3ca	PROPN
fnp-5892	280	293	/	/	SYM
fnp-5892	280	294	pik3ca	pik3ca	PROPN
fnp-5892	280	295	r88q	r88q	PRON
fnp-5892	280	296	/	/	SYM
fnp-5892	280	297	pten	pten	ADJ
fnp-5892	280	298	 	 	SPACE
fnp-5892	280	299	%	%	NOUN
fnp-5892	280	300	)	)	PUNCT
fnp-5892	280	301	100	100	NUM
fnp-5892	280	302	 	 	SPACE
fnp-5892	280	303	%	%	NOUN
fnp-5892	280	304	(	(	PUNCT
fnp-5892	280	305	80/100/80	80/100/80	NUM
fnp-5892	280	306	)	)	PUNCT
fnp-5892	280	307	100	100	NUM
fnp-5892	280	308	 	 	SPACE
fnp-5892	280	309	%	%	NOUN
fnp-5892	280	310	(	(	PUNCT
fnp-5892	280	311	67/0/33	67/0/33	NUM
fnp-5892	280	312	)	)	PUNCT
fnp-5892	280	313	100	100	NUM
fnp-5892	280	314	 	 	SPACE
fnp-5892	280	315	%	%	NOUN
fnp-5892	280	316	(	(	PUNCT
fnp-5892	280	317	50/100/100	50/100/100	NOUN
fnp-5892	280	318	)	)	PUNCT
fnp-5892	280	319	100	100	NUM
fnp-5892	280	320	 	 	SPACE
fnp-5892	280	321	%	%	NOUN
fnp-5892	280	322	(	(	PUNCT
fnp-5892	280	323	70/71/70	70/71/70	NOUN
fnp-5892	280	324	)	)	PUNCT
fnp-5892	280	325	ddr	ddr	NOUN
fnp-5892	280	326	pathway	pathway	NOUN
fnp-5892	280	327	80	80	NUM
fnp-5892	280	328	 	 	SPACE
fnp-5892	280	329	%	%	NOUN
fnp-5892	280	330	67	67	NUM
fnp-5892	280	331	 	 	SPACE
fnp-5892	280	332	%	%	NOUN
fnp-5892	280	333	50	50	NUM
fnp-5892	280	334	 	 	SPACE
fnp-5892	280	335	%	%	NOUN
fnp-5892	280	336	70	70	NUM
fnp-5892	280	337	 	 	SPACE
fnp-5892	280	338	%	%	NOUN
fnp-5892	280	339	chromatin	chromatin	NOUN
fnp-5892	280	340	remodeling	remodeling	NOUN
fnp-5892	280	341	(	(	PUNCT
fnp-5892	280	342	dnmt3a/	dnmt3a/	NOUN
fnp-5892	280	343	setd2/	setd2/	PROPN
fnp-5892	280	344	swi	swi	PROPN
fnp-5892	280	345	/	/	SYM
fnp-5892	280	346	snf	snf	PROPN
fnp-5892	280	347	 	 	SPACE
fnp-5892	280	348	%	%	NOUN
fnp-5892	280	349	)	)	PUNCT
fnp-5892	280	350	100	100	NUM
fnp-5892	280	351	 	 	SPACE
fnp-5892	280	352	%	%	NOUN
fnp-5892	280	353	(	(	PUNCT
fnp-5892	280	354	40/20/80	40/20/80	NOUN
fnp-5892	280	355	)	)	PUNCT
fnp-5892	280	356	100	100	NUM
fnp-5892	280	357	 	 	SPACE
fnp-5892	280	358	%	%	NOUN
fnp-5892	280	359	(	(	PUNCT
fnp-5892	280	360	0/33/100	0/33/100	NOUN
fnp-5892	280	361	)	)	PUNCT
fnp-5892	280	362	100	100	NUM
fnp-5892	280	363	 	 	SPACE
fnp-5892	280	364	%	%	NOUN
fnp-5892	280	365	(	(	PUNCT
fnp-5892	280	366	100/100/100	100/100/100	NUM
fnp-5892	280	367	)	)	SYM
fnp-5892	280	368	100	100	NUM
fnp-5892	280	369	 	 	SPACE
fnp-5892	280	370	%	%	NOUN
fnp-5892	280	371	(	(	PUNCT
fnp-5892	280	372	40/40/90	40/40/90	NOUN
fnp-5892	280	373	)	)	PUNCT
fnp-5892	280	374	common	common	ADJ
fnp-5892	280	375	gbm	gbm	NOUN
fnp-5892	280	376	alterations	alteration	NOUN
fnp-5892	280	377	(	(	PUNCT
fnp-5892	280	378	tert	tert	NOUN
fnp-5892	280	379	;	;	PUNCT
fnp-5892	280	380	chr	chr	PROPN
fnp-5892	280	381	7gain&10	7gain&10	PROPN
fnp-5892	280	382	loss	loss	NOUN
fnp-5892	280	383	)	)	PUNCT
fnp-5892	280	384	0	0	NUM
fnp-5892	280	385	 	 	SPACE
fnp-5892	280	386	%	%	NOUN
fnp-5892	280	387	0	0	NUM
fnp-5892	280	388	 	 	SPACE
fnp-5892	280	389	%	%	NOUN
fnp-5892	280	390	0	0	NUM
fnp-5892	280	391	 	 	SPACE
fnp-5892	280	392	%	%	NOUN
fnp-5892	280	393	0	0	NUM
fnp-5892	280	394	 	 	SPACE
fnp-5892	280	395	%	%	NOUN
fnp-5892	280	396	average	average	ADJ
fnp-5892	280	397	tmb	tmb	X
fnp-5892	280	398	(	(	PUNCT
fnp-5892	280	399	mutations	mutation	NOUN
fnp-5892	280	400	/	/	SYM
fnp-5892	280	401	mb	mb	NOUN
fnp-5892	280	402	)	)	PUNCT
fnp-5892	280	403	24.3	24.3	NUM
fnp-5892	280	404	23	23	NUM
fnp-5892	280	405	35	35	NUM
fnp-5892	280	406	27.3	27.3	NUM
fnp-5892	280	407	msi	msi	NOUN
fnp-5892	280	408	-	-	ADJ
fnp-5892	280	409	high	high	ADJ
fnp-5892	280	410	25	25	NUM
fnp-5892	280	411	 	 	SPACE
fnp-5892	280	412	%	%	NOUN
fnp-5892	280	413	100	100	NUM
fnp-5892	280	414	 	 	SPACE
fnp-5892	280	415	%	%	NOUN
fnp-5892	280	416	100	100	NUM
fnp-5892	280	417	 	 	SPACE
fnp-5892	280	418	%	%	NOUN
fnp-5892	280	419	67	67	NUM
fnp-5892	280	420	 	 	SPACE
fnp-5892	280	421	%	%	NOUN
fnp-5892	280	422	table	table	NOUN
fnp-5892	280	423	2	2	NUM
fnp-5892	280	424	:	:	PUNCT
fnp-5892	280	425	review	review	NOUN
fnp-5892	280	426	:	:	PUNCT
fnp-5892	280	427	integrated	integrated	ADJ
fnp-5892	280	428	characteristics	characteristic	NOUN
fnp-5892	280	429	of	of	ADP
fnp-5892	280	430	g3	g3	PROPN
fnp-5892	280	431	/	/	SYM
fnp-5892	280	432	mmr	mmr	PROPN
fnp-5892	280	433	subgroup	subgroup	NOUN
fnp-5892	280	434	glioblastoma	glioblastoma	NOUN
fnp-5892	280	435	in	in	ADP
fnp-5892	280	436	≥	≥	NOUN
fnp-5892	280	437	 	 	SPACE
fnp-5892	280	438	50	50	NUM
fnp-5892	280	439	-	-	PUNCT
fnp-5892	280	440	year	year	NOUN
fnp-5892	280	441	-	-	PUNCT
fnp-5892	280	442	old	old	ADJ
fnp-5892	280	443	patients	patient	NOUN
fnp-5892	280	444	.	.	PUNCT
fnp-5892	281	1	gbm	gbm	NOUN
fnp-5892	281	2	,	,	PUNCT
fnp-5892	281	3	glioblastoma	glioblastoma	NOUN
fnp-5892	281	4	;	;	PUNCT
fnp-5892	281	5	m	m	NOUN
fnp-5892	281	6	,	,	PUNCT
fnp-5892	281	7	male	male	NOUN
fnp-5892	281	8	;	;	PUNCT
fnp-5892	281	9	f	f	X
fnp-5892	281	10	,	,	PUNCT
fnp-5892	281	11	female	female	NOUN
fnp-5892	281	12	;	;	PUNCT
fnp-5892	281	13	gtr	gtr	NOUN
fnp-5892	281	14	,	,	PUNCT
fnp-5892	281	15	gross	gross	ADJ
fnp-5892	281	16	total	total	ADJ
fnp-5892	281	17	resection	resection	NOUN
fnp-5892	281	18	;	;	PUNCT
fnp-5892	281	19	str	str	NUM
fnp-5892	281	20	,	,	PUNCT
fnp-5892	281	21	subtotal	subtotal	ADJ
fnp-5892	281	22	resection	resection	NOUN
fnp-5892	281	23	;	;	PUNCT
fnp-5892	281	24	rt	rt	PROPN
fnp-5892	281	25	/	/	SYM
fnp-5892	281	26	tmz	tmz	PROPN
fnp-5892	281	27	,	,	PUNCT
fnp-5892	281	28	radiation	radiation	NOUN
fnp-5892	281	29	/	/	SYM
fnp-5892	281	30	temozolomide	temozolomide	NOUN
fnp-5892	281	31	;	;	PUNCT
fnp-5892	281	32	nd	nd	NUM
fnp-5892	281	33	,	,	PUNCT
fnp-5892	281	34	not	not	PART
fnp-5892	281	35	determined	determine	VERB
fnp-5892	281	36	;	;	PUNCT
fnp-5892	281	37	chr	chr	NOUN
fnp-5892	281	38	,	,	PUNCT
fnp-5892	281	39	chromosome	chromosome	VERB
fnp-5892	281	40	.	.	PUNCT
fnp-5892	282	1	the	the	DET
fnp-5892	282	2	ngs	ng	NOUN
fnp-5892	282	3	molecular	molecular	ADJ
fnp-5892	282	4	analysis	analysis	NOUN
fnp-5892	282	5	with	with	ADP
fnp-5892	282	6	tmb	tmb	PROPN
fnp-5892	282	7	inclusion	inclusion	NOUN
fnp-5892	282	8	is	be	AUX
fnp-5892	282	9	necessary	necessary	ADJ
fnp-5892	282	10	for	for	ADP
fnp-5892	282	11	detecting	detect	VERB
fnp-5892	282	12	and/or	and/or	CCONJ
fnp-5892	282	13	confirming	confirm	VERB
fnp-5892	282	14	the	the	DET
fnp-5892	282	15	presence	presence	NOUN
fnp-5892	282	16	of	of	ADP
fnp-5892	282	17	g3	g3	PROPN
fnp-5892	282	18	/	/	SYM
fnp-5892	282	19	mmr	mmr	PROPN
fnp-5892	282	20	cases	case	NOUN
fnp-5892	282	21	.	.	PUNCT
fnp-5892	283	1	in	in	ADP
fnp-5892	283	2	general	general	ADJ
fnp-5892	283	3	,	,	PUNCT
fnp-5892	283	4	high	high	ADJ
fnp-5892	283	5	tmb	tmb	PROPN
fnp-5892	283	6	is	be	AUX
fnp-5892	283	7	a	a	DET
fnp-5892	283	8	relatively	relatively	ADV
fnp-5892	283	9	rare	rare	ADJ
fnp-5892	283	10	occurrence	occurrence	NOUN
fnp-5892	283	11	in	in	ADP
fnp-5892	283	12	untreated	untreated	ADJ
fnp-5892	283	13	,	,	PUNCT
fnp-5892	283	14	first	first	ADJ
fnp-5892	283	15	-	-	PUNCT
fnp-5892	283	16	presentation	presentation	NOUN
fnp-5892	283	17	glioblastoma	glioblastoma	NOUN
fnp-5892	283	18	,	,	PUNCT
fnp-5892	283	19	and	and	CCONJ
fnp-5892	283	20	is	be	AUX
fnp-5892	283	21	more	more	ADV
fnp-5892	283	22	often	often	ADV
fnp-5892	283	23	seen	see	VERB
fnp-5892	283	24	in	in	ADP
fnp-5892	283	25	recurrences	recurrence	NOUN
fnp-5892	283	26	with	with	ADP
fnp-5892	283	27	tmz	tmz	NOUN
fnp-5892	283	28	-	-	PUNCT
fnp-5892	283	29	related	relate	VERB
fnp-5892	283	30	hypermutator	hypermutator	NOUN
fnp-5892	283	31	phenotype	phenotype	NOUN
fnp-5892	284	1	[	[	X
fnp-5892	284	2	28	28	NUM
fnp-5892	284	3	]	]	PUNCT
fnp-5892	284	4	.	.	PUNCT
fnp-5892	285	1	noteworthy	noteworthy	ADJ
fnp-5892	285	2	,	,	PUNCT
fnp-5892	285	3	both	both	CCONJ
fnp-5892	285	4	post	post	ADJ
fnp-5892	285	5	-	-	ADJ
fnp-5892	285	6	tmz	tmz	NOUN
fnp-5892	285	7	recurrences	recurrence	NOUN
fnp-5892	285	8	described	describe	VERB
fnp-5892	285	9	here	here	ADV
fnp-5892	285	10	mapped	map	VERB
fnp-5892	285	11	to	to	ADP
fnp-5892	285	12	the	the	DET
fnp-5892	285	13	g1	g1	PROPN
fnp-5892	285	14	/	/	SYM
fnp-5892	285	15	egfr	egfr	NOUN
fnp-5892	285	16	-	-	PUNCT
fnp-5892	285	17	amplified	amplify	VERB
fnp-5892	285	18	subgroup	subgroup	NOUN
fnp-5892	285	19	,	,	PUNCT
fnp-5892	285	20	suggesting	suggest	VERB
fnp-5892	285	21	an	an	DET
fnp-5892	285	22	association	association	NOUN
fnp-5892	285	23	worth	worth	ADJ
fnp-5892	285	24	looking	look	VERB
fnp-5892	285	25	into	into	ADP
fnp-5892	285	26	.	.	PUNCT
fnp-5892	286	1	a	a	DET
fnp-5892	286	2	hypermutator	hypermutator	NOUN
fnp-5892	286	3	phenotype	phenotype	NOUN
fnp-5892	286	4	in	in	ADP
fnp-5892	286	5	untreated	untreated	ADJ
fnp-5892	286	6	tumors	tumor	NOUN
fnp-5892	286	7	may	may	AUX
fnp-5892	286	8	be	be	AUX
fnp-5892	286	9	the	the	DET
fnp-5892	286	10	result	result	NOUN
fnp-5892	286	11	of	of	ADP
fnp-5892	286	12	germline	germline	NOUN
fnp-5892	286	13	and/or	and/or	CCONJ
fnp-5892	286	14	somatic	somatic	ADJ
fnp-5892	286	15	mutations	mutation	NOUN
fnp-5892	286	16	in	in	ADP
fnp-5892	286	17	mmr	mmr	PROPN
fnp-5892	286	18	,	,	PUNCT
fnp-5892	286	19	pole	pole	NOUN
fnp-5892	286	20	or	or	CCONJ
fnp-5892	286	21	mutyh	mutyh	NOUN
fnp-5892	286	22	genes	gene	NOUN
fnp-5892	286	23	.	.	PUNCT
fnp-5892	287	1	germline	germline	NOUN
fnp-5892	287	2	mmr	mmr	PROPN
fnp-5892	287	3	mutations	mutation	NOUN
fnp-5892	287	4	were	be	AUX
fnp-5892	287	5	found	find	VERB
fnp-5892	287	6	only	only	ADV
fnp-5892	287	7	in	in	ADP
fnp-5892	287	8	msh2	msh2	NOUN
fnp-5892	287	9	or	or	CCONJ
fnp-5892	287	10	msh6	msh6	NOUN
fnp-5892	287	11	,	,	PUNCT
fnp-5892	287	12	with	with	ADP
fnp-5892	287	13	the	the	DET
fnp-5892	287	14	msh6	msh6	PROPN
fnp-5892	287	15	p.f1088fs	p.f1088f	VERB
fnp-5892	287	16	mutation	mutation	NOUN
fnp-5892	287	17	recurrent	recurrent	NOUN
fnp-5892	287	18	in	in	ADP
fnp-5892	287	19	2	2	NUM
fnp-5892	287	20	studies	study	NOUN
fnp-5892	287	21	,	,	PUNCT
fnp-5892	287	22	the	the	DET
fnp-5892	287	23	current	current	ADJ
fnp-5892	287	24	one	one	NUM
fnp-5892	287	25	and	and	CCONJ
fnp-5892	287	26	that	that	SCONJ
fnp-5892	287	27	by	by	ADP
fnp-5892	287	28	kim	kim	PROPN
fnp-5892	287	29	et	et	PROPN
fnp-5892	287	30	al	al	PROPN
fnp-5892	287	31	.	.	PUNCT
fnp-5892	288	1	[	[	X
fnp-5892	288	2	14	14	NUM
fnp-5892	288	3	]	]	PUNCT
fnp-5892	288	4	.	.	PUNCT
fnp-5892	289	1	in	in	ADP
fnp-5892	289	2	the	the	DET
fnp-5892	289	3	current	current	ADJ
fnp-5892	289	4	study	study	NOUN
fnp-5892	289	5	,	,	PUNCT
fnp-5892	289	6	somatic	somatic	ADJ
fnp-5892	289	7	mmr	mmr	PROPN
fnp-5892	289	8	mutations	mutation	NOUN
fnp-5892	289	9	did	do	AUX
fnp-5892	289	10	not	not	PART
fnp-5892	289	11	result	result	VERB
fnp-5892	289	12	in	in	ADP
fnp-5892	289	13	hypermutator	hypermutator	NOUN
fnp-5892	289	14	phenotype	phenotype	NOUN
fnp-5892	289	15	in	in	ADP
fnp-5892	289	16	untreated	untreated	ADJ
fnp-5892	289	17	,	,	PUNCT
fnp-5892	289	18	first	first	ADJ
fnp-5892	289	19	-	-	PUNCT
fnp-5892	289	20	presentation	presentation	NOUN
fnp-5892	289	21	glioblastomas	glioblastoma	NOUN
fnp-5892	289	22	(	(	PUNCT
fnp-5892	289	23	see	see	VERB
fnp-5892	289	24	suppl	suppl	ADJ
fnp-5892	289	25	.	.	PUNCT
fnp-5892	289	26	table	table	NOUN
fnp-5892	289	27	 	 	SPACE
fnp-5892	289	28	s2	s2	PROPN
fnp-5892	289	29	)	)	PUNCT
fnp-5892	289	30	.	.	PUNCT
fnp-5892	290	1	however	however	ADV
fnp-5892	290	2	,	,	PUNCT
fnp-5892	290	3	at	at	ADV
fnp-5892	290	4	least	least	ADV
fnp-5892	290	5	three	three	NUM
fnp-5892	290	6	≥	≥	NUM
fnp-5892	290	7	 	 	SPACE
fnp-5892	290	8	50	50	NUM
fnp-5892	290	9	-	-	PUNCT
fnp-5892	290	10	year	year	NOUN
fnp-5892	290	11	-	-	PUNCT
fnp-5892	290	12	old	old	ADJ
fnp-5892	290	13	patients	patient	NOUN
fnp-5892	290	14	in	in	ADP
fnp-5892	290	15	the	the	DET
fnp-5892	290	16	studies	study	NOUN
fnp-5892	290	17	by	by	ADP
fnp-5892	290	18	hadad	hadad	PROPN
fnp-5892	290	19	et	et	PROPN
fnp-5892	290	20	al	al	PROPN
fnp-5892	290	21	.	.	PROPN
fnp-5892	290	22	and	and	CCONJ
fnp-5892	290	23	kim	kim	PROPN
fnp-5892	290	24	et	et	PROPN
fnp-5892	290	25	al	al	PROPN
fnp-5892	290	26	.	.	PROPN
fnp-5892	290	27	presented	present	VERB
fnp-5892	290	28	with	with	ADP
fnp-5892	290	29	hypermutator	hypermutator	NOUN
fnp-5892	290	30	phenotype	phenotype	NOUN
fnp-5892	290	31	in	in	ADP
fnp-5892	290	32	sporadic	sporadic	ADJ
fnp-5892	290	33	glioblastomas	glioblastoma	NOUN
fnp-5892	290	34	with	with	ADP
fnp-5892	290	35	somatic	somatic	ADJ
fnp-5892	290	36	mmr	mmr	PROPN
fnp-5892	290	37	alterations	alteration	NOUN
fnp-5892	290	38	[	[	X
fnp-5892	290	39	13,14	13,14	NUM
fnp-5892	290	40	]	]	PUNCT
fnp-5892	290	41	.	.	PUNCT
fnp-5892	291	1	the	the	DET
fnp-5892	291	2	question	question	NOUN
fnp-5892	291	3	arises	arise	VERB
fnp-5892	291	4	if	if	SCONJ
fnp-5892	291	5	these	these	DET
fnp-5892	291	6	tumors	tumor	NOUN
fnp-5892	291	7	should	should	AUX
fnp-5892	291	8	be	be	AUX
fnp-5892	291	9	included	include	VERB
fnp-5892	291	10	in	in	ADP
fnp-5892	291	11	the	the	DET
fnp-5892	291	12	g3	g3	PROPN
fnp-5892	291	13	/	/	SYM
fnp-5892	291	14	mmr	mmr	PROPN
fnp-5892	291	15	high	high	ADJ
fnp-5892	291	16	-	-	PUNCT
fnp-5892	291	17	risk	risk	NOUN
fnp-5892	291	18	subgroup	subgroup	NOUN
fnp-5892	291	19	where	where	SCONJ
fnp-5892	291	20	mmr	mmr	PROPN
fnp-5892	291	21	mutations	mutation	NOUN
fnp-5892	291	22	are	be	AUX
fnp-5892	291	23	causative	causative	ADJ
fnp-5892	291	24	,	,	PUNCT
fnp-5892	291	25	or	or	CCONJ
fnp-5892	291	26	if	if	SCONJ
fnp-5892	291	27	their	their	PRON
fnp-5892	291	28	tumors	tumor	NOUN
fnp-5892	291	29	,	,	PUNCT
fnp-5892	291	30	like	like	ADP
fnp-5892	291	31	the	the	DET
fnp-5892	291	32	m53	m53	NOUN
fnp-5892	291	33	/	/	SYM
fnp-5892	291	34	sc	sc	NOUN
fnp-5892	291	35	case	case	NOUN
fnp-5892	291	36	,	,	PUNCT
fnp-5892	291	37	show	show	VERB
fnp-5892	291	38	only	only	ADV
fnp-5892	291	39	added	add	VERB
fnp-5892	291	40	hypermutator	hypermutator	NOUN
fnp-5892	291	41	phenotype	phenotype	NOUN
fnp-5892	291	42	to	to	ADP
fnp-5892	291	43	a	a	DET
fnp-5892	291	44	baseline	baseline	ADJ
fnp-5892	291	45	mutation	mutation	NOUN
fnp-5892	291	46	core	core	NOUN
fnp-5892	291	47	that	that	PRON
fnp-5892	291	48	fits	fit	VERB
fnp-5892	291	49	another	another	DET
fnp-5892	291	50	g1	g1	NOUN
fnp-5892	291	51	–	–	PUNCT
fnp-5892	291	52	g7	g7	PROPN
fnp-5892	291	53	subgroup	subgroup	NOUN
fnp-5892	291	54	and	and	CCONJ
fnp-5892	291	55	show	show	VERB
fnp-5892	291	56	therefore	therefore	ADV
fnp-5892	291	57	better	well	ADJ
fnp-5892	291	58	prognosis	prognosis	NOUN
fnp-5892	291	59	.	.	PUNCT
fnp-5892	292	1	more	more	ADJ
fnp-5892	292	2	studies	study	NOUN
fnp-5892	292	3	are	be	AUX
fnp-5892	292	4	necessary	necessary	ADJ
fnp-5892	292	5	to	to	PART
fnp-5892	292	6	clarify	clarify	VERB
fnp-5892	292	7	this	this	DET
fnp-5892	292	8	issue	issue	NOUN
fnp-5892	292	9	,	,	PUNCT
fnp-5892	292	10	and	and	CCONJ
fnp-5892	292	11	treatment	treatment	NOUN
fnp-5892	292	12	with	with	ADP
fnp-5892	292	13	immune	immune	ADJ
fnp-5892	292	14	checkpoint	checkpoint	NOUN
fnp-5892	292	15	inhibitors	inhibitor	NOUN
fnp-5892	292	16	may	may	AUX
fnp-5892	292	17	prove	prove	VERB
fnp-5892	292	18	beneficial	beneficial	ADJ
fnp-5892	292	19	in	in	ADP
fnp-5892	292	20	glioblastomas	glioblastoma	NOUN
fnp-5892	292	21	with	with	ADP
fnp-5892	292	22	both	both	DET
fnp-5892	292	23	germline	germline	NOUN
fnp-5892	292	24	and	and	CCONJ
fnp-5892	292	25	somatic	somatic	ADJ
fnp-5892	292	26	mmr	mmr	PROPN
fnp-5892	292	27	mutations	mutation	NOUN
fnp-5892	292	28	.	.	PUNCT
fnp-5892	293	1	for	for	ADP
fnp-5892	293	2	mutyh	mutyh	PROPN
fnp-5892	293	3	,	,	PUNCT
fnp-5892	293	4	a	a	DET
fnp-5892	293	5	pan	pan	ADJ
fnp-5892	293	6	-	-	ADJ
fnp-5892	293	7	cancer	cancer	ADJ
fnp-5892	293	8	recent	recent	ADJ
fnp-5892	293	9	study	study	NOUN
fnp-5892	293	10	has	have	AUX
fnp-5892	293	11	shown	show	VERB
fnp-5892	293	12	that	that	SCONJ
fnp-5892	293	13	biallelic	biallelic	ADJ
fnp-5892	293	14	mutations	mutation	NOUN
fnp-5892	293	15	and	and	CCONJ
fnp-5892	293	16	not	not	PART
fnp-5892	293	17	heterozygous	heterozygous	ADJ
fnp-5892	293	18	germline	germline	NOUN
fnp-5892	293	19	variants	variant	NOUN
fnp-5892	293	20	result	result	VERB
fnp-5892	293	21	in	in	ADP
fnp-5892	293	22	high	high	ADJ
fnp-5892	293	23	tmb	tmb	PROPN
fnp-5892	294	1	[	[	X
fnp-5892	294	2	30	30	NUM
fnp-5892	294	3	]	]	PUNCT
fnp-5892	294	4	.	.	PUNCT
fnp-5892	295	1	glioblastoma	glioblastoma	NOUN
fnp-5892	295	2	cases	case	NOUN
fnp-5892	295	3	with	with	ADP
fnp-5892	295	4	high	high	ADJ
fnp-5892	295	5	tmb	tmb	NOUN
fnp-5892	295	6	due	due	ADP
fnp-5892	295	7	to	to	ADP
fnp-5892	295	8	mutyh	mutyh	PROPN
fnp-5892	295	9	mutations	mutation	NOUN
fnp-5892	295	10	have	have	AUX
fnp-5892	295	11	not	not	PART
fnp-5892	295	12	been	be	AUX
fnp-5892	295	13	reported	report	VERB
fnp-5892	295	14	in	in	ADP
fnp-5892	295	15	the	the	DET
fnp-5892	295	16	literature	literature	NOUN
fnp-5892	295	17	,	,	PUNCT
fnp-5892	295	18	and	and	CCONJ
fnp-5892	295	19	in	in	ADP
fnp-5892	295	20	our	our	PRON
fnp-5892	295	21	series	series	NOUN
fnp-5892	295	22	,	,	PUNCT
fnp-5892	295	23	the	the	DET
fnp-5892	295	24	two	two	NUM
fnp-5892	295	25	tumors	tumor	NOUN
fnp-5892	295	26	with	with	ADP
fnp-5892	295	27	heterozygous	heterozygous	ADJ
fnp-5892	295	28	germline	germline	NOUN
fnp-5892	295	29	mutyh	mutyh	PROPN
fnp-5892	295	30	mutations	mutation	NOUN
fnp-5892	295	31	did	do	AUX
fnp-5892	295	32	not	not	PART
fnp-5892	295	33	show	show	VERB
fnp-5892	295	34	high	high	ADJ
fnp-5892	295	35	tmb	tmb	NOUN
fnp-5892	295	36	(	(	PUNCT
fnp-5892	295	37	see	see	VERB
fnp-5892	295	38	suppl	suppl	ADJ
fnp-5892	295	39	.	.	PUNCT
fnp-5892	295	40	table	table	NOUN
fnp-5892	295	41	 	 	SPACE
fnp-5892	295	42	s2	s2	PROPN
fnp-5892	295	43	)	)	PUNCT
fnp-5892	295	44	.	.	PUNCT
fnp-5892	296	1	pole	pole	NOUN
fnp-5892	296	2	mutations	mutation	NOUN
fnp-5892	296	3	in	in	ADP
fnp-5892	296	4	glioblastoma	glioblastoma	NOUN
fnp-5892	296	5	are	be	AUX
fnp-5892	296	6	equally	equally	ADV
fnp-5892	296	7	rare	rare	ADJ
fnp-5892	296	8	,	,	PUNCT
fnp-5892	296	9	with	with	ADP
fnp-5892	296	10	only	only	ADV
fnp-5892	296	11	one	one	NUM
fnp-5892	296	12	in	in	ADP
fnp-5892	296	13	this	this	DET
fnp-5892	296	14	cohort	cohort	NOUN
fnp-5892	296	15	,	,	PUNCT
fnp-5892	296	16	without	without	ADP
fnp-5892	296	17	high	high	ADJ
fnp-5892	296	18	tmb	tmb	PROPN
fnp-5892	296	19	.	.	PUNCT
fnp-5892	297	1	however	however	ADV
fnp-5892	297	2	,	,	PUNCT
fnp-5892	297	3	pole	pole	ADJ
fnp-5892	297	4	somatic	somatic	ADJ
fnp-5892	297	5	mutations	mutation	NOUN
fnp-5892	297	6	with	with	ADP
fnp-5892	297	7	hypermutator	hypermutator	NOUN
fnp-5892	297	8	phenotype	phenotype	NOUN
fnp-5892	297	9	and	and	CCONJ
fnp-5892	297	10	usually	usually	ADV
fnp-5892	297	11	accompanied	accompany	VERB
fnp-5892	297	12	by	by	ADP
fnp-5892	297	13	germline	germline	NOUN
fnp-5892	297	14	or	or	CCONJ
fnp-5892	297	15	somatic	somatic	ADJ
fnp-5892	297	16	mmr	mmr	PROPN
fnp-5892	297	17	mutations	mutation	NOUN
fnp-5892	297	18	have	have	AUX
fnp-5892	297	19	been	be	AUX
fnp-5892	297	20	reported	report	VERB
fnp-5892	297	21	mainly	mainly	ADV
fnp-5892	297	22	in	in	ADP
fnp-5892	297	23	young	young	ADJ
fnp-5892	297	24	glioblastoma	glioblastoma	NOUN
fnp-5892	297	25	patients	patient	NOUN
fnp-5892	297	26	[	[	X
fnp-5892	297	27	13,29	13,29	NUM
fnp-5892	297	28	]	]	PUNCT
fnp-5892	297	29	.	.	PUNCT
fnp-5892	298	1	beside	beside	ADP
fnp-5892	298	2	high	high	PROPN
fnp-5892	298	3	tmb	tmb	PROPN
fnp-5892	298	4	,	,	PUNCT
fnp-5892	298	5	the	the	DET
fnp-5892	298	6	g3	g3	PROPN
fnp-5892	298	7	/	/	SYM
fnp-5892	298	8	mmr	mmr	PROPN
fnp-5892	298	9	subgroup	subgroup	NOUN
fnp-5892	298	10	tumors	tumor	NOUN
fnp-5892	298	11	showed	show	VERB
fnp-5892	298	12	a	a	DET
fnp-5892	298	13	common	common	ADJ
fnp-5892	298	14	signature	signature	NOUN
fnp-5892	298	15	represented	represent	VERB
fnp-5892	298	16	by	by	ADP
fnp-5892	298	17	mutations	mutation	NOUN
fnp-5892	298	18	resulting	result	VERB
fnp-5892	298	19	in	in	ADP
fnp-5892	298	20	ras	ras	NOUN
fnp-5892	298	21	activation	activation	NOUN
fnp-5892	298	22	,	,	PUNCT
fnp-5892	298	23	with	with	ADP
fnp-5892	298	24	high	high	ADJ
fnp-5892	298	25	incidence	incidence	NOUN
fnp-5892	298	26	of	of	ADP
fnp-5892	298	27	ptpn11	ptpn11	NOUN
fnp-5892	298	28	and	and	CCONJ
fnp-5892	298	29	nf1	nf1	NOUN
fnp-5892	298	30	mutations	mutation	NOUN
fnp-5892	298	31	(	(	PUNCT
fnp-5892	298	32	table	table	NOUN
fnp-5892	298	33	 	 	SPACE
fnp-5892	298	34	2	2	NUM
fnp-5892	298	35	)	)	PUNCT
fnp-5892	298	36	,	,	PUNCT
fnp-5892	298	37	an	an	DET
fnp-5892	298	38	association	association	NOUN
fnp-5892	298	39	also	also	ADV
fnp-5892	298	40	noted	note	VERB
fnp-5892	298	41	in	in	ADP
fnp-5892	298	42	the	the	DET
fnp-5892	298	43	g3	g3	PROPN
fnp-5892	298	44	/	/	SYM
fnp-5892	298	45	nf1	nf1	NOUN
fnp-5892	298	46	subgroup	subgroup	NOUN
fnp-5892	298	47	[	[	X
fnp-5892	298	48	4	4	NUM
fnp-5892	298	49	]	]	PUNCT
fnp-5892	298	50	.	.	PUNCT
fnp-5892	299	1	the	the	DET
fnp-5892	299	2	resulting	result	VERB
fnp-5892	299	3	mapk	mapk	NOUN
fnp-5892	299	4	activation	activation	NOUN
fnp-5892	299	5	was	be	AUX
fnp-5892	299	6	accompanied	accompany	VERB
fnp-5892	299	7	by	by	ADP
fnp-5892	299	8	high	high	ADJ
fnp-5892	299	9	levels	level	NOUN
fnp-5892	299	10	of	of	ADP
fnp-5892	299	11	the	the	DET
fnp-5892	299	12	transcription	transcription	NOUN
fnp-5892	299	13	factors	factor	NOUN
fnp-5892	299	14	from	from	ADP
fnp-5892	299	15	the	the	DET
fnp-5892	299	16	ap-1	ap-1	NOUN
fnp-5892	299	17	effector	effector	NOUN
fnp-5892	299	18	complex	complex	NOUN
fnp-5892	299	19	and	and	CCONJ
fnp-5892	299	20	by	by	ADP
fnp-5892	299	21	upregulation	upregulation	NOUN
fnp-5892	299	22	of	of	ADP
fnp-5892	299	23	a	a	DET
fnp-5892	299	24	negative	negative	ADJ
fnp-5892	299	25	feedback	feedback	NOUN
fnp-5892	299	26	,	,	PUNCT
fnp-5892	299	27	of	of	ADP
fnp-5892	299	28	which	which	DET
fnp-5892	299	29	dusp5	dusp5	NOUN
fnp-5892	299	30	was	be	AUX
fnp-5892	299	31	the	the	DET
fnp-5892	299	32	most	most	ADV
fnp-5892	299	33	consistently	consistently	ADV
fnp-5892	299	34	upregulated	upregulate	VERB
fnp-5892	299	35	.	.	PUNCT
fnp-5892	300	1	the	the	DET
fnp-5892	300	2	activation	activation	NOUN
fnp-5892	300	3	of	of	ADP
fnp-5892	300	4	the	the	DET
fnp-5892	300	5	pi3k	pi3k	PROPN
fnp-5892	300	6	pathway	pathway	NOUN
fnp-5892	300	7	was	be	AUX
fnp-5892	300	8	present	present	ADJ
fnp-5892	300	9	in	in	ADP
fnp-5892	300	10	all	all	DET
fnp-5892	300	11	the	the	DET
fnp-5892	300	12	cases	case	NOUN
fnp-5892	300	13	,	,	PUNCT
fnp-5892	300	14	with	with	ADP
fnp-5892	300	15	high	high	ADJ
fnp-5892	300	16	incidence	incidence	NOUN
fnp-5892	300	17	of	of	ADP
fnp-5892	300	18	pik3ca	pik3ca	NOUN
fnp-5892	300	19	mutations	mutation	NOUN
fnp-5892	300	20	,	,	PUNCT
fnp-5892	300	21	especially	especially	ADV
fnp-5892	300	22	of	of	ADP
fnp-5892	300	23	p.r88q	p.r88q	PROPN
fnp-5892	300	24	,	,	PUNCT
fnp-5892	300	25	of	of	ADP
fnp-5892	300	26	overlapping	overlap	VERB
fnp-5892	300	27	pik3ca	pik3ca	NOUN
fnp-5892	300	28	and	and	CCONJ
fnp-5892	300	29	pten	pten	VERB
fnp-5892	300	30	mutations	mutation	NOUN
fnp-5892	300	31	,	,	PUNCT
fnp-5892	300	32	and	and	CCONJ
fnp-5892	300	33	of	of	ADP
fnp-5892	300	34	tsc2	tsc2	PROPN
fnp-5892	300	35	mutations	mutation	NOUN
fnp-5892	300	36	(	(	PUNCT
fnp-5892	300	37	table	table	NOUN
fnp-5892	300	38	 	 	SPACE
fnp-5892	300	39	2	2	NUM
fnp-5892	300	40	and	and	CCONJ
fnp-5892	300	41	fig	fig	NOUN
fnp-5892	300	42	.	.	PUNCT
fnp-5892	300	43	 	 	SPACE
fnp-5892	300	44	5d	5d	NUM
fnp-5892	300	45	)	)	PUNCT
fnp-5892	300	46	.	.	PUNCT
fnp-5892	301	1	as	as	SCONJ
fnp-5892	301	2	shown	show	VERB
fnp-5892	301	3	,	,	PUNCT
fnp-5892	301	4	tp53	tp53	PROPN
fnp-5892	301	5	was	be	AUX
fnp-5892	301	6	mutant	mutant	ADJ
fnp-5892	301	7	in	in	ADP
fnp-5892	301	8	all	all	DET
fnp-5892	301	9	the	the	DET
fnp-5892	301	10	cases	case	NOUN
fnp-5892	301	11	,	,	PUNCT
fnp-5892	301	12	with	with	ADP
fnp-5892	301	13	predominance	predominance	NOUN
fnp-5892	301	14	of	of	ADP
fnp-5892	301	15	biallelic	biallelic	ADJ
fnp-5892	301	16	arg	arg	NOUN
fnp-5892	301	17	mutations	mutation	NOUN
fnp-5892	301	18	.	.	PUNCT
fnp-5892	302	1	very	very	ADV
fnp-5892	302	2	high	high	ADJ
fnp-5892	302	3	incidence	incidence	NOUN
fnp-5892	302	4	of	of	ADP
fnp-5892	302	5	mutations	mutation	NOUN
fnp-5892	302	6	in	in	ADP
fnp-5892	302	7	the	the	DET
fnp-5892	302	8	ddr	ddr	NOUN
fnp-5892	302	9	and	and	CCONJ
fnp-5892	302	10	chromatin	chromatin	NOUN
fnp-5892	302	11	remodeling	remodeling	NOUN
fnp-5892	302	12	pathways	pathway	NOUN
fnp-5892	302	13	,	,	PUNCT
fnp-5892	302	14	particularly	particularly	ADV
fnp-5892	302	15	in	in	ADP
fnp-5892	302	16	dnmt3a	dnmt3a	PROPN
fnp-5892	302	17	,	,	PUNCT
fnp-5892	302	18	setd2	setd2	PROPN
fnp-5892	302	19	and	and	CCONJ
fnp-5892	302	20	the	the	DET
fnp-5892	302	21	swi	swi	PROPN
fnp-5892	302	22	/	/	SYM
fnp-5892	302	23	snf	snf	PROPN
fnp-5892	302	24	complex	complex	NOUN
fnp-5892	302	25	,	,	PUNCT
fnp-5892	302	26	coupled	couple	VERB
fnp-5892	302	27	to	to	ADP
fnp-5892	302	28	absence	absence	NOUN
fnp-5892	302	29	of	of	ADP
fnp-5892	302	30	the	the	DET
fnp-5892	302	31	characteristic	characteristic	ADJ
fnp-5892	302	32	tert	tert	NOUN
fnp-5892	302	33	promoter	promoter	NOUN
fnp-5892	302	34	mutations	mutation	NOUN
fnp-5892	302	35	or	or	CCONJ
fnp-5892	302	36	concomitant	concomitant	ADJ
fnp-5892	302	37	chromosome	chromosome	NOUN
fnp-5892	302	38	7	7	NUM
fnp-5892	302	39	gain	gain	NOUN
fnp-5892	302	40	and	and	CCONJ
fnp-5892	302	41	10	10	NUM
fnp-5892	302	42	loss	loss	NOUN
fnp-5892	302	43	,	,	PUNCT
fnp-5892	302	44	distinguished	distinguish	VERB
fnp-5892	302	45	the	the	DET
fnp-5892	302	46	g3	g3	PROPN
fnp-5892	302	47	/	/	SYM
fnp-5892	302	48	mmr	mmr	PROPN
fnp-5892	302	49	subgroup	subgroup	NOUN
fnp-5892	302	50	from	from	ADP
fnp-5892	302	51	the	the	DET
fnp-5892	302	52	other	other	ADJ
fnp-5892	302	53	g1	g1	NOUN
fnp-5892	302	54	–	–	PUNCT
fnp-5892	302	55	g7	g7	PROPN
fnp-5892	302	56	subgroups	subgroup	NOUN
fnp-5892	302	57	(	(	PUNCT
fnp-5892	302	58	table	table	NOUN
fnp-5892	302	59	 	 	SPACE
fnp-5892	302	60	2	2	NUM
fnp-5892	302	61	and	and	CCONJ
fnp-5892	302	62	fig	fig	NOUN
fnp-5892	302	63	.	.	PUNCT
fnp-5892	302	64	 	 	SPACE
fnp-5892	302	65	5c	5c	NUM
fnp-5892	302	66	)	)	PUNCT
fnp-5892	303	1	[	[	X
fnp-5892	303	2	5	5	NUM
fnp-5892	303	3	]	]	PUNCT
fnp-5892	303	4	.	.	PUNCT
fnp-5892	304	1	mutations	mutation	NOUN
fnp-5892	304	2	in	in	ADP
fnp-5892	304	3	apc	apc	PROPN
fnp-5892	304	4	and	and	CCONJ
fnp-5892	304	5	notch1/2	notch1/2	PROPN
fnp-5892	304	6	genes	gene	NOUN
fnp-5892	304	7	were	be	AUX
fnp-5892	304	8	also	also	ADV
fnp-5892	304	9	overrepresented	overrepresente	VERB
fnp-5892	304	10	in	in	ADP
fnp-5892	304	11	g3	g3	PROPN
fnp-5892	304	12	/	/	SYM
fnp-5892	304	13	mmr	mmr	PROPN
fnp-5892	304	14	patients	patient	NOUN
fnp-5892	304	15	from	from	ADP
fnp-5892	304	16	this	this	DET
fnp-5892	304	17	study	study	NOUN
fnp-5892	304	18	and	and	CCONJ
fnp-5892	304	19	that	that	SCONJ
fnp-5892	304	20	by	by	ADP
fnp-5892	304	21	kim	kim	PROPN
fnp-5892	304	22	et	et	PROPN
fnp-5892	304	23	al	al	PROPN
fnp-5892	304	24	.	.	PUNCT
fnp-5892	305	1	[	[	X
fnp-5892	305	2	14	14	NUM
fnp-5892	305	3	]	]	PUNCT
fnp-5892	305	4	.	.	PUNCT
fnp-5892	306	1	in	in	ADP
fnp-5892	306	2	general	general	ADJ
fnp-5892	306	3	,	,	PUNCT
fnp-5892	306	4	the	the	DET
fnp-5892	306	5	g3	g3	PROPN
fnp-5892	306	6	/	/	SYM
fnp-5892	306	7	mmr	mmr	PROPN
fnp-5892	306	8	molecular	molecular	ADJ
fnp-5892	306	9	profile	profile	NOUN
fnp-5892	306	10	resembled	resemble	VERB
fnp-5892	306	11	closer	close	ADV
fnp-5892	306	12	the	the	DET
fnp-5892	306	13	profiles	profile	NOUN
fnp-5892	306	14	of	of	ADP
fnp-5892	306	15	other	other	ADJ
fnp-5892	306	16	solid	solid	ADJ
fnp-5892	306	17	cancers	cancer	NOUN
fnp-5892	306	18	and	and	CCONJ
fnp-5892	306	19	was	be	AUX
fnp-5892	306	20	highly	highly	ADV
fnp-5892	306	21	divergent	divergent	ADJ
fnp-5892	306	22	from	from	ADP
fnp-5892	306	23	that	that	PRON
fnp-5892	306	24	of	of	ADP
fnp-5892	306	25	non	non	ADJ
fnp-5892	306	26	-	-	ADJ
fnp-5892	306	27	mmr	mmr	ADJ
fnp-5892	306	28	glioblastoma	glioblastoma	NOUN
fnp-5892	306	29	[	[	X
fnp-5892	306	30	47	47	NUM
fnp-5892	306	31	]	]	PUNCT
fnp-5892	306	32	.	.	PUNCT
fnp-5892	307	1	conclusions	conclusion	NOUN
fnp-5892	307	2	in	in	ADP
fnp-5892	307	3	conclusion	conclusion	NOUN
fnp-5892	307	4	,	,	PUNCT
fnp-5892	307	5	this	this	DET
fnp-5892	307	6	study	study	NOUN
fnp-5892	307	7	characterizes	characterize	VERB
fnp-5892	307	8	rare	rare	ADJ
fnp-5892	307	9	cases	case	NOUN
fnp-5892	307	10	of	of	ADP
fnp-5892	307	11	adult	adult	NOUN
fnp-5892	307	12	glioblastoma	glioblastoma	NOUN
fnp-5892	307	13	associated	associate	VERB
fnp-5892	307	14	to	to	ADP
fnp-5892	307	15	lynch	lynch	PROPN
fnp-5892	307	16	syndrome	syndrome	PROPN
fnp-5892	307	17	that	that	PRON
fnp-5892	307	18	appear	appear	VERB
fnp-5892	307	19	to	to	PART
fnp-5892	307	20	represent	represent	VERB
fnp-5892	307	21	a	a	DET
fnp-5892	307	22	high	high	ADJ
fnp-5892	307	23	-	-	PUNCT
fnp-5892	307	24	risk	risk	NOUN
fnp-5892	307	25	g3	g3	NOUN
fnp-5892	307	26	/	/	SYM
fnp-5892	307	27	mmr	mmr	PROPN
fnp-5892	307	28	subgroup	subgroup	NOUN
fnp-5892	307	29	showing	show	VERB
fnp-5892	307	30	distinctive	distinctive	ADJ
fnp-5892	307	31	clinical	clinical	ADJ
fnp-5892	307	32	,	,	PUNCT
fnp-5892	307	33	histologic	histologic	ADJ
fnp-5892	307	34	and	and	CCONJ
fnp-5892	307	35	molecular	molecular	ADJ
fnp-5892	307	36	characteristics	characteristic	NOUN
fnp-5892	307	37	.	.	PUNCT
fnp-5892	308	1	it	it	PRON
fnp-5892	308	2	reviews	review	VERB
fnp-5892	308	3	the	the	DET
fnp-5892	308	4	available	available	ADJ
fnp-5892	308	5	cases	case	NOUN
fnp-5892	308	6	in	in	ADP
fnp-5892	308	7	the	the	DET
fnp-5892	308	8	literature	literature	NOUN
fnp-5892	308	9	,	,	PUNCT
fnp-5892	308	10	and	and	CCONJ
fnp-5892	308	11	proposes	propose	VERB
fnp-5892	308	12	immune	immune	ADJ
fnp-5892	308	13	checkpoint	checkpoint	NOUN
fnp-5892	308	14	inhibitors	inhibitor	NOUN
fnp-5892	308	15	as	as	ADP
fnp-5892	308	16	adjuvant	adjuvant	ADJ
fnp-5892	308	17	treatment	treatment	NOUN
fnp-5892	308	18	,	,	PUNCT
fnp-5892	308	19	particularly	particularly	ADV
fnp-5892	308	20	the	the	DET
fnp-5892	308	21	dual	dual	ADJ
fnp-5892	308	22	nivolumab	nivolumab	NOUN
fnp-5892	308	23	-	-	PUNCT
fnp-5892	308	24	ipilimumab	ipilimumab	NOUN
fnp-5892	308	25	regimen	regiman	NOUN
fnp-5892	308	26	that	that	PRON
fnp-5892	308	27	showed	show	VERB
fnp-5892	308	28	net	net	ADJ
fnp-5892	308	29	survival	survival	NOUN
fnp-5892	308	30	benefit	benefit	NOUN
fnp-5892	308	31	in	in	ADP
fnp-5892	308	32	the	the	DET
fnp-5892	308	33	g3	g3	PROPN
fnp-5892	308	34	/	/	SYM
fnp-5892	308	35	mmr	mmr	PROPN
fnp-5892	308	36	patient	patient	NOUN
fnp-5892	308	37	receiving	receive	VERB
fnp-5892	308	38	it	it	PRON
fnp-5892	308	39	.	.	PUNCT
fnp-5892	309	1	more	more	ADJ
fnp-5892	309	2	studies	study	NOUN
fnp-5892	309	3	are	be	AUX
fnp-5892	309	4	necessary	necessary	ADJ
fnp-5892	309	5	to	to	PART
fnp-5892	309	6	validate	validate	VERB
fnp-5892	309	7	this	this	DET
fnp-5892	309	8	regimen	regiman	NOUN
fnp-5892	309	9	and	and	CCONJ
fnp-5892	309	10	correlate	correlate	VERB
fnp-5892	309	11	it	it	PRON
fnp-5892	309	12	with	with	ADP
fnp-5892	309	13	the	the	DET
fnp-5892	309	14	molecular	molecular	ADJ
fnp-5892	309	15	parameters	parameter	NOUN
fnp-5892	309	16	usually	usually	ADV
fnp-5892	309	17	used	use	VERB
fnp-5892	309	18	in	in	ADP
fnp-5892	309	19	crc	crc	NOUN
fnp-5892	309	20	associated	associate	VERB
fnp-5892	309	21	to	to	ADP
fnp-5892	309	22	lynch	lynch	PROPN
fnp-5892	309	23	syndrome	syndrome	PROPN
fnp-5892	309	24	,	,	PUNCT
fnp-5892	309	25	such	such	ADJ
fnp-5892	309	26	as	as	ADP
fnp-5892	309	27	tmb	tmb	PROPN
fnp-5892	309	28	,	,	PUNCT
fnp-5892	309	29	msi	msi	PROPN
fnp-5892	309	30	status	status	PROPN
fnp-5892	309	31	and	and	CCONJ
fnp-5892	309	32	immune	immune	ADJ
fnp-5892	309	33	checkpoint	checkpoint	NOUN
fnp-5892	309	34	markers	marker	NOUN
fnp-5892	309	35	expression	expression	NOUN
fnp-5892	309	36	levels	level	NOUN
fnp-5892	309	37	.	.	PUNCT
fnp-5892	310	1	ethics	ethic	NOUN
fnp-5892	310	2	,	,	PUNCT
fnp-5892	310	3	consent	consent	NOUN
fnp-5892	310	4	and	and	CCONJ
fnp-5892	310	5	permissions	permission	NOUN
fnp-5892	310	6	this	this	DET
fnp-5892	310	7	study	study	NOUN
fnp-5892	310	8	was	be	AUX
fnp-5892	310	9	conducted	conduct	VERB
fnp-5892	310	10	in	in	ADP
fnp-5892	310	11	accordance	accordance	NOUN
fnp-5892	310	12	to	to	ADP
fnp-5892	310	13	the	the	DET
fnp-5892	310	14	declaration	declaration	NOUN
fnp-5892	310	15	of	of	ADP
fnp-5892	310	16	helsinki	helsinki	PROPN
fnp-5892	310	17	,	,	PUNCT
fnp-5892	310	18	and	and	CCONJ
fnp-5892	310	19	approved	approve	VERB
fnp-5892	310	20	by	by	ADP
fnp-5892	310	21	the	the	DET
fnp-5892	310	22	ethics	ethic	NOUN
fnp-5892	310	23	committee	committee	PROPN
fnp-5892	310	24	of	of	ADP
fnp-5892	310	25	neuromarkers	neuromarker	NOUN
fnp-5892	310	26	(	(	PUNCT
fnp-5892	310	27	protocol	protocol	PROPN
fnp-5892	310	28	code	code	NOUN
fnp-5892	310	29	nm	nm	NOUN
fnp-5892	310	30	-	-	PUNCT
fnp-5892	310	31	rec-2	rec-2	NOUN
fnp-5892	310	32	on	on	ADP
fnp-5892	310	33	9	9	NUM
fnp-5892	310	34	january	january	NOUN
fnp-5892	310	35	2020	2020	NUM
fnp-5892	310	36	and	and	CCONJ
fnp-5892	310	37	30	30	NUM
fnp-5892	310	38	january	january	NOUN
fnp-5892	310	39	2023	2023	NUM
fnp-5892	310	40	)	)	PUNCT
fnp-5892	310	41	for	for	ADP
fnp-5892	310	42	studies	study	NOUN
fnp-5892	310	43	involving	involve	VERB
fnp-5892	310	44	human	human	ADJ
fnp-5892	310	45	subjects	subject	NOUN
fnp-5892	310	46	.	.	PUNCT
fnp-5892	311	1	informed	informed	ADJ
fnp-5892	311	2	consent	consent	NOUN
fnp-5892	311	3	was	be	AUX
fnp-5892	311	4	obtained	obtain	VERB
fnp-5892	311	5	for	for	ADP
fnp-5892	311	6	all	all	DET
fnp-5892	311	7	subjects	subject	NOUN
fnp-5892	311	8	.	.	PUNCT
fnp-5892	312	1	consent	consent	NOUN
fnp-5892	312	2	for	for	ADP
fnp-5892	312	3	publication	publication	NOUN
fnp-5892	312	4	patient	patient	ADJ
fnp-5892	312	5	consent	consent	NOUN
fnp-5892	312	6	for	for	ADP
fnp-5892	312	7	publication	publication	NOUN
fnp-5892	312	8	was	be	AUX
fnp-5892	312	9	waived	waive	VERB
fnp-5892	312	10	due	due	ADP
fnp-5892	312	11	to	to	ADP
fnp-5892	312	12	the	the	DET
fnp-5892	312	13	study	study	NOUN
fnp-5892	312	14	not	not	PART
fnp-5892	312	15	identifying	identify	VERB
fnp-5892	312	16	the	the	DET
fnp-5892	312	17	patients	patient	NOUN
fnp-5892	312	18	.	.	PUNCT
fnp-5892	313	1	availability	availability	NOUN
fnp-5892	313	2	of	of	ADP
fnp-5892	313	3	data	datum	NOUN
fnp-5892	313	4	and	and	CCONJ
fnp-5892	313	5	materials	material	NOUN
fnp-5892	313	6	the	the	DET
fnp-5892	313	7	genomic	genomic	NOUN
fnp-5892	313	8	and	and	CCONJ
fnp-5892	313	9	transcriptomic	transcriptomic	ADJ
fnp-5892	313	10	datasets	dataset	NOUN
fnp-5892	313	11	supporting	support	VERB
fnp-5892	313	12	the	the	DET
fnp-5892	313	13	conclusions	conclusion	NOUN
fnp-5892	313	14	of	of	ADP
fnp-5892	313	15	this	this	DET
fnp-5892	313	16	article	article	NOUN
fnp-5892	313	17	are	be	AUX
fnp-5892	313	18	de	de	ADJ
fnp-5892	313	19	-	-	VERB
fnp-5892	313	20	posited	posit	VERB
fnp-5892	313	21	in	in	ADP
fnp-5892	313	22	the	the	DET
fnp-5892	313	23	public	public	ADJ
fnp-5892	313	24	repository	repository	NOUN
fnp-5892	313	25	neuromarkers	neuromarker	NOUN
fnp-5892	313	26	open	open	ADJ
fnp-5892	313	27	research	research	NOUN
fnp-5892	313	28	database	database	NOUN
fnp-5892	313	29	https://neuromarkers.org/database	https://neuromarkers.org/database	X
fnp-5892	313	30	under	under	ADP
fnp-5892	313	31	the	the	DET
fnp-5892	313	32	accession	accession	NOUN
fnp-5892	313	33	numbers	number	NOUN
fnp-5892	313	34	g	g	PROPN
fnp-5892	313	35	-	-	PUNCT
fnp-5892	313	36	nm/24	nm/24	NOUN
fnp-5892	313	37	-	-	PUNCT
fnp-5892	313	38	1	1	NUM
fnp-5892	313	39	and	and	CCONJ
fnp-5892	313	40	t	t	PROPN
fnp-5892	313	41	-	-	PUNCT
fnp-5892	313	42	nm/24	nm/24	NOUN
fnp-5892	313	43	-	-	PUNCT
fnp-5892	313	44	1	1	NUM
fnp-5892	313	45	,	,	PUNCT
fnp-5892	313	46	respectively	respectively	ADV
fnp-5892	313	47	.	.	PUNCT
fnp-5892	314	1	conflicts	conflict	NOUN
fnp-5892	314	2	of	of	ADP
fnp-5892	314	3	interest	interest	NOUN
fnp-5892	314	4	statement	statement	NOUN
fnp-5892	314	5	the	the	DET
fnp-5892	314	6	author	author	NOUN
fnp-5892	314	7	declares	declare	VERB
fnp-5892	314	8	no	no	DET
fnp-5892	314	9	conflicts	conflict	NOUN
fnp-5892	314	10	of	of	ADP
fnp-5892	314	11	interest	interest	NOUN
fnp-5892	314	12	.	.	PUNCT
fnp-5892	315	1	funding	funding	NOUN
fnp-5892	315	2	statement	statement	NOUN
fnp-5892	315	3	this	this	DET
fnp-5892	315	4	work	work	NOUN
fnp-5892	315	5	was	be	AUX
fnp-5892	315	6	supported	support	VERB
fnp-5892	315	7	by	by	ADP
fnp-5892	315	8	an	an	DET
fnp-5892	315	9	award	award	NOUN
fnp-5892	315	10	from	from	ADP
fnp-5892	315	11	neuromarkers	neuromarker	NOUN
fnp-5892	315	12	[	[	X
fnp-5892	315	13	nm2024	nm2024	NOUN
fnp-5892	315	14	-	-	PUNCT
fnp-5892	315	15	1	1	NUM
fnp-5892	315	16	]	]	PUNCT
fnp-5892	315	17	to	to	ADP
fnp-5892	315	18	m.-m.g	m.-m.g	PROPN
fnp-5892	315	19	.	.	PUNCT
fnp-5892	316	1	acknowledgements	acknowledgement	NOUN
fnp-5892	316	2	this	this	DET
fnp-5892	316	3	paper	paper	NOUN
fnp-5892	316	4	is	be	AUX
fnp-5892	316	5	dedicated	dedicate	VERB
fnp-5892	316	6	to	to	ADP
fnp-5892	316	7	the	the	DET
fnp-5892	316	8	patients	patient	NOUN
fnp-5892	316	9	and	and	CCONJ
fnp-5892	316	10	their	their	PRON
fnp-5892	316	11	families	family	NOUN
fnp-5892	316	12	.	.	PUNCT
fnp-5892	317	1	references	reference	NOUN
fnp-5892	317	2	1	1	NUM
fnp-5892	317	3	.	.	PUNCT
fnp-5892	318	1	ostrom	ostrom	NOUN
fnp-5892	318	2	,	,	PUNCT
fnp-5892	318	3	q.t	q.t	PROPN
fnp-5892	318	4	.	.	PROPN
fnp-5892	318	5	;	;	PUNCT
fnp-5892	318	6	truitt	truitt	PROPN
fnp-5892	318	7	,	,	PUNCT
fnp-5892	318	8	g.	g.	PROPN
fnp-5892	318	9	;	;	PUNCT
fnp-5892	318	10	gittleman	gittleman	NOUN
fnp-5892	318	11	,	,	PUNCT
fnp-5892	318	12	h.	h.	PROPN
fnp-5892	318	13	;	;	PUNCT
fnp-5892	318	14	brat	brat	NOUN
fnp-5892	318	15	,	,	PUNCT
fnp-5892	318	16	d.j	d.j	PROPN
fnp-5892	318	17	.	.	PROPN
fnp-5892	318	18	;	;	PUNCT
fnp-5892	318	19	kruchko	kruchko	VERB
fnp-5892	318	20	,	,	PUNCT
fnp-5892	318	21	c.	c.	PROPN
fnp-5892	318	22	;	;	PUNCT
fnp-5892	318	23	wilson	wilson	PROPN
fnp-5892	318	24	,	,	PUNCT
fnp-5892	318	25	r.	r.	PROPN
fnp-5892	318	26	;	;	PUNCT
fnp-5892	318	27	barnholtz	barnholtz	NOUN
fnp-5892	318	28	-	-	PUNCT
fnp-5892	318	29	sloan	sloan	PROPN
fnp-5892	318	30	,	,	PUNCT
fnp-5892	318	31	j.s	j.s	PROPN
fnp-5892	318	32	.	.	PROPN
fnp-5892	318	33	relative	relative	ADJ
fnp-5892	318	34	survival	survival	NOUN
fnp-5892	318	35	after	after	ADP
fnp-5892	318	36	diagnosis	diagnosis	NOUN
fnp-5892	318	37	with	with	ADP
fnp-5892	318	38	a	a	DET
fnp-5892	318	39	primary	primary	ADJ
fnp-5892	318	40	brain	brain	NOUN
fnp-5892	318	41	or	or	CCONJ
fnp-5892	318	42	other	other	ADJ
fnp-5892	318	43	central	central	ADJ
fnp-5892	318	44	nervous	nervous	ADJ
fnp-5892	318	45	system	system	NOUN
fnp-5892	318	46	tumor	tumor	NOUN
fnp-5892	318	47	in	in	ADP
fnp-5892	318	48	the	the	DET
fnp-5892	318	49	national	national	ADJ
fnp-5892	318	50	program	program	NOUN
fnp-5892	318	51	of	of	ADP
fnp-5892	318	52	cancer	cancer	NOUN
fnp-5892	318	53	registries	registry	NOUN
fnp-5892	318	54	,	,	PUNCT
fnp-5892	318	55	2004	2004	NUM
fnp-5892	318	56	to	to	ADP
fnp-5892	318	57	2014	2014	NUM
fnp-5892	318	58	.	.	PUNCT
fnp-5892	319	1	neurooncol	neurooncol	ADJ
fnp-5892	319	2	pract	pract	PROPN
fnp-5892	319	3	2020	2020	NUM
fnp-5892	319	4	,	,	PUNCT
fnp-5892	319	5	7	7	NUM
fnp-5892	319	6	,	,	PUNCT
fnp-5892	319	7	306	306	NUM
fnp-5892	319	8	-	-	SYM
fnp-5892	319	9	312	312	NUM
fnp-5892	319	10	.	.	PUNCT
fnp-5892	320	1	https://doi.org/10.1093/nop/npz059	https://doi.org/10.1093/nop/npz059	PROPN
fnp-5892	320	2	2	2	NUM
fnp-5892	320	3	.	.	PUNCT
fnp-5892	320	4	who	who	PRON
fnp-5892	320	5	classification	classification	NOUN
fnp-5892	320	6	of	of	ADP
fnp-5892	320	7	tumors	tumor	NOUN
fnp-5892	320	8	editorial	editorial	PROPN
fnp-5892	320	9	board	board	PROPN
fnp-5892	320	10	.	.	PUNCT
fnp-5892	321	1	central	central	ADJ
fnp-5892	321	2	nervous	nervous	ADJ
fnp-5892	321	3	system	system	NOUN
fnp-5892	321	4	tumors	tumor	NOUN
fnp-5892	321	5	,	,	PUNCT
fnp-5892	321	6	5th	5th	ADJ
fnp-5892	321	7	ed	ed	NOUN
fnp-5892	321	8	.	.	PROPN
fnp-5892	321	9	,	,	PUNCT
fnp-5892	321	10	international	international	ADJ
fnp-5892	321	11	agency	agency	NOUN
fnp-5892	321	12	for	for	ADP
fnp-5892	321	13	research	research	NOUN
fnp-5892	321	14	on	on	ADP
fnp-5892	321	15	cancer	cancer	NOUN
fnp-5892	321	16	,	,	PUNCT
fnp-5892	321	17	lyon	lyon	PROPN
fnp-5892	321	18	(	(	PUNCT
fnp-5892	321	19	france	france	PROPN
fnp-5892	321	20	)	)	PUNCT
fnp-5892	321	21	,	,	PUNCT
fnp-5892	321	22	2021	2021	NUM
fnp-5892	321	23	.	.	PUNCT
fnp-5892	322	1	https://doi.org/10.1093/neuonc/noab106	https://doi.org/10.1093/neuonc/noab106	NOUN
fnp-5892	323	1	3	3	X
fnp-5892	323	2	.	.	X
fnp-5892	323	3	georgescu	georgescu	PROPN
fnp-5892	323	4	,	,	PUNCT
fnp-5892	323	5	m.m	m.m	PROPN
fnp-5892	323	6	.	.	PROPN
fnp-5892	323	7	pten	pten	PROPN
fnp-5892	323	8	tumor	tumor	NOUN
fnp-5892	323	9	suppressor	suppressor	NOUN
fnp-5892	323	10	network	network	NOUN
fnp-5892	323	11	in	in	ADP
fnp-5892	323	12	pi3k	pi3k	PROPN
fnp-5892	323	13	-	-	PUNCT
fnp-5892	323	14	akt	akt	PROPN
fnp-5892	323	15	pathway	pathway	NOUN
fnp-5892	323	16	control	control	PROPN
fnp-5892	323	17	.	.	PUNCT
fnp-5892	324	1	genes	gene	NOUN
fnp-5892	324	2	&	&	CCONJ
fnp-5892	324	3	cancer	cancer	NOUN
fnp-5892	324	4	2010	2010	NUM
fnp-5892	324	5	,	,	PUNCT
fnp-5892	324	6	1	1	NUM
fnp-5892	324	7	,	,	PUNCT
fnp-5892	324	8	1170	1170	NUM
fnp-5892	324	9	-	-	SYM
fnp-5892	324	10	1177	1177	NUM
fnp-5892	324	11	.	.	PUNCT
fnp-5892	325	1	https://doi.org/10.1177/1947601911407325	https://doi.org/10.1177/1947601911407325	PROPN
fnp-5892	325	2	4	4	X
fnp-5892	325	3	.	.	X
fnp-5892	325	4	georgescu	georgescu	PROPN
fnp-5892	325	5	,	,	PUNCT
fnp-5892	325	6	m.m	m.m	PROPN
fnp-5892	325	7	.	.	PROPN
fnp-5892	325	8	multi	multi	ADJ
fnp-5892	325	9	-	-	ADJ
fnp-5892	325	10	platform	platform	ADJ
fnp-5892	325	11	classification	classification	NOUN
fnp-5892	325	12	of	of	ADP
fnp-5892	325	13	idh	idh	NOUN
fnp-5892	325	14	-	-	PUNCT
fnp-5892	325	15	wild	wild	ADJ
fnp-5892	325	16	-	-	PUNCT
fnp-5892	325	17	type	type	NOUN
fnp-5892	325	18	glioblastoma	glioblastoma	NOUN
fnp-5892	325	19	based	base	VERB
fnp-5892	325	20	on	on	ADP
fnp-5892	325	21	erk	erk	PROPN
fnp-5892	325	22	/	/	SYM
fnp-5892	325	23	mapk	mapk	NOUN
fnp-5892	325	24	pathway	pathway	NOUN
fnp-5892	325	25	:	:	PUNCT
fnp-5892	326	1	diagnostic	diagnostic	ADJ
fnp-5892	326	2	,	,	PUNCT
fnp-5892	326	3	prognostic	prognostic	ADJ
fnp-5892	326	4	and	and	CCONJ
fnp-5892	326	5	therapeutic	therapeutic	ADJ
fnp-5892	326	6	implications	implication	NOUN
fnp-5892	326	7	.	.	PUNCT
fnp-5892	327	1	cancers	cancer	NOUN
fnp-5892	327	2	(	(	PUNCT
fnp-5892	327	3	basel	basel	PROPN
fnp-5892	327	4	)	)	PUNCT
fnp-5892	327	5	2021	2021	NUM
fnp-5892	327	6	,	,	PUNCT
fnp-5892	327	7	13	13	NUM
fnp-5892	327	8	.	.	X
fnp-5892	327	9	https://doi.org/10.3390/cancers13184532	https://doi.org/10.3390/cancers13184532	PROPN
fnp-5892	327	10	5	5	NUM
fnp-5892	327	11	.	.	PUNCT
fnp-5892	327	12	georgescu	georgescu	PROPN
fnp-5892	327	13	,	,	PUNCT
fnp-5892	327	14	m.m	m.m	PROPN
fnp-5892	327	15	.	.	PROPN
fnp-5892	327	16	translation	translation	NOUN
fnp-5892	327	17	into	into	ADP
fnp-5892	327	18	clinical	clinical	ADJ
fnp-5892	327	19	practice	practice	NOUN
fnp-5892	327	20	of	of	ADP
fnp-5892	327	21	the	the	DET
fnp-5892	327	22	g1	g1	NOUN
fnp-5892	327	23	–	–	PUNCT
fnp-5892	327	24	g7	g7	PROPN
fnp-5892	327	25	molecular	molecular	ADJ
fnp-5892	327	26	subgroup	subgroup	NOUN
fnp-5892	327	27	classification	classification	NOUN
fnp-5892	327	28	of	of	ADP
fnp-5892	327	29	glioblastoma	glioblastoma	NOUN
fnp-5892	327	30	:	:	PUNCT
fnp-5892	327	31	comprehensive	comprehensive	ADJ
fnp-5892	327	32	demographic	demographic	ADJ
fnp-5892	327	33	and	and	CCONJ
fnp-5892	327	34	molecular	molecular	ADJ
fnp-5892	327	35	pathway	pathway	NOUN
fnp-5892	327	36	profiling	profiling	NOUN
fnp-5892	327	37	.	.	PUNCT
fnp-5892	328	1	cancers	cancer	NOUN
fnp-5892	328	2	(	(	PUNCT
fnp-5892	328	3	basel	basel	PROPN
fnp-5892	328	4	)	)	PUNCT
fnp-5892	328	5	2024	2024	NUM
fnp-5892	328	6	,	,	PUNCT
fnp-5892	328	7	16	16	NUM
fnp-5892	328	8	.	.	PUNCT
fnp-5892	328	9	https://doi.org/10.3390/cancers16020361	https://doi.org/10.3390/cancers16020361	NOUN
fnp-5892	328	10	6	6	NUM
fnp-5892	328	11	.	.	PUNCT
fnp-5892	329	1	li	li	PROPN
fnp-5892	329	2	,	,	PUNCT
fnp-5892	329	3	y.m	y.m	PROPN
fnp-5892	329	4	.	.	PROPN
fnp-5892	329	5	;	;	PUNCT
fnp-5892	329	6	suki	suki	PROPN
fnp-5892	329	7	,	,	PUNCT
fnp-5892	329	8	d.	d.	PROPN
fnp-5892	329	9	;	;	PUNCT
fnp-5892	329	10	hess	hess	PROPN
fnp-5892	329	11	,	,	PUNCT
fnp-5892	329	12	k.	k.	PROPN
fnp-5892	329	13	;	;	PUNCT
fnp-5892	329	14	sawaya	sawaya	PROPN
fnp-5892	329	15	,	,	PUNCT
fnp-5892	329	16	r.	r.	VERB
fnp-5892	329	17	the	the	DET
fnp-5892	329	18	influence	influence	NOUN
fnp-5892	329	19	of	of	ADP
fnp-5892	329	20	maximum	maximum	ADJ
fnp-5892	329	21	safe	safe	ADJ
fnp-5892	329	22	resection	resection	NOUN
fnp-5892	329	23	of	of	ADP
fnp-5892	329	24	glioblastoma	glioblastoma	NOUN
fnp-5892	329	25	on	on	ADP
fnp-5892	329	26	survival	survival	NOUN
fnp-5892	329	27	in	in	ADP
fnp-5892	329	28	1229	1229	NUM
fnp-5892	329	29	patients	patient	NOUN
fnp-5892	329	30	:	:	PUNCT
fnp-5892	329	31	can	can	AUX
fnp-5892	329	32	we	we	PRON
fnp-5892	329	33	do	do	VERB
fnp-5892	329	34	better	well	ADV
fnp-5892	329	35	than	than	ADP
fnp-5892	329	36	gross	gross	ADJ
fnp-5892	329	37	-	-	PUNCT
fnp-5892	329	38	total	total	NOUN
fnp-5892	329	39	resection	resection	NOUN
fnp-5892	329	40	?	?	PUNCT
fnp-5892	330	1	j	j	PROPN
fnp-5892	330	2	neurosurg	neurosurg	PROPN
fnp-5892	330	3	2016	2016	NUM
fnp-5892	330	4	,	,	PUNCT
fnp-5892	330	5	124	124	NUM
fnp-5892	330	6	,	,	PUNCT
fnp-5892	330	7	977	977	NUM
fnp-5892	330	8	-	-	SYM
fnp-5892	330	9	988	988	NUM
fnp-5892	330	10	.	.	PUNCT
fnp-5892	331	1	https://doi.org/10.3171/2015.5.jns142087	https://doi.org/10.3171/2015.5.jns142087	ADJ
fnp-5892	331	2	7	7	NUM
fnp-5892	331	3	.	.	PUNCT
fnp-5892	331	4	stupp	stupp	NOUN
fnp-5892	331	5	,	,	PUNCT
fnp-5892	331	6	r.	r.	PROPN
fnp-5892	331	7	;	;	PUNCT
fnp-5892	331	8	mason	mason	PROPN
fnp-5892	331	9	,	,	PUNCT
fnp-5892	331	10	w.p	w.p	PROPN
fnp-5892	331	11	.	.	PROPN
fnp-5892	331	12	;	;	PUNCT
fnp-5892	331	13	van	van	PROPN
fnp-5892	331	14	den	den	PROPN
fnp-5892	331	15	bent	bent	ADJ
fnp-5892	331	16	,	,	PUNCT
fnp-5892	331	17	m.j	m.j	PROPN
fnp-5892	331	18	.	.	PROPN
fnp-5892	331	19	;	;	PUNCT
fnp-5892	331	20	weller	weller	NOUN
fnp-5892	331	21	,	,	PUNCT
fnp-5892	331	22	m.	m.	NOUN
fnp-5892	331	23	;	;	PUNCT
fnp-5892	331	24	fisher	fisher	PROPN
fnp-5892	331	25	,	,	PUNCT
fnp-5892	331	26	b.	b.	PROPN
fnp-5892	331	27	;	;	PUNCT
fnp-5892	331	28	taphoorn	taphoorn	VERB
fnp-5892	331	29	,	,	PUNCT
fnp-5892	331	30	m.j	m.j	PROPN
fnp-5892	331	31	.	.	PROPN
fnp-5892	331	32	;	;	PUNCT
fnp-5892	331	33	belanger	belanger	PROPN
fnp-5892	331	34	,	,	PUNCT
fnp-5892	331	35	k.	k.	PROPN
fnp-5892	331	36	;	;	PUNCT
fnp-5892	331	37	brandes	brandes	PROPN
fnp-5892	331	38	,	,	PUNCT
fnp-5892	331	39	a.a	a.a	PROPN
fnp-5892	331	40	.	.	PROPN
fnp-5892	331	41	;	;	PUNCT
fnp-5892	331	42	marosi	marosi	PROPN
fnp-5892	331	43	,	,	PUNCT
fnp-5892	331	44	c.	c.	NOUN
fnp-5892	331	45	;	;	PUNCT
fnp-5892	331	46	bogdahn	bogdahn	NOUN
fnp-5892	331	47	,	,	PUNCT
fnp-5892	331	48	u.	u.	PROPN
fnp-5892	331	49	,	,	PUNCT
fnp-5892	331	50	et	et	PROPN
fnp-5892	331	51	al	al	PROPN
fnp-5892	331	52	.	.	PROPN
fnp-5892	331	53	radiotherapy	radiotherapy	PROPN
fnp-5892	331	54	plus	plus	CCONJ
fnp-5892	331	55	concomitant	concomitant	ADJ
fnp-5892	331	56	and	and	CCONJ
fnp-5892	331	57	adjuvant	adjuvant	ADJ
fnp-5892	331	58	temozolomide	temozolomide	NOUN
fnp-5892	331	59	for	for	ADP
fnp-5892	331	60	glioblastoma	glioblastoma	NOUN
fnp-5892	331	61	.	.	PUNCT
fnp-5892	332	1	n	n	PROPN
fnp-5892	332	2	engl	engl	PROPN
fnp-5892	332	3	j	j	PROPN
fnp-5892	332	4	med	med	PROPN
fnp-5892	332	5	2005	2005	NUM
fnp-5892	332	6	,	,	PUNCT
fnp-5892	332	7	352	352	NUM
fnp-5892	332	8	,	,	PUNCT
fnp-5892	332	9	987	987	NUM
fnp-5892	332	10	-	-	SYM
fnp-5892	332	11	996	996	NUM
fnp-5892	332	12	.	.	PUNCT
fnp-5892	332	13	https://doi.org/10.1056/nejmoa043330	https://doi.org/10.1056/nejmoa043330	PROPN
fnp-5892	332	14	8	8	NUM
fnp-5892	332	15	.	.	PUNCT
fnp-5892	333	1	oster	oster	PROPN
fnp-5892	333	2	,	,	PUNCT
fnp-5892	333	3	c.	c.	PROPN
fnp-5892	333	4	;	;	PUNCT
fnp-5892	333	5	schmidt	schmidt	PROPN
fnp-5892	333	6	,	,	PUNCT
fnp-5892	333	7	t.	t.	PROPN
fnp-5892	333	8	;	;	PUNCT
fnp-5892	333	9	agkatsev	agkatsev	PROPN
fnp-5892	333	10	,	,	PUNCT
fnp-5892	333	11	s.	s.	PROPN
fnp-5892	333	12	;	;	PUNCT
fnp-5892	333	13	lazaridis	lazaridis	PROPN
fnp-5892	333	14	,	,	PUNCT
fnp-5892	333	15	l.	l.	PROPN
fnp-5892	333	16	;	;	PUNCT
fnp-5892	333	17	kleinschnitz	kleinschnitz	PROPN
fnp-5892	333	18	,	,	PUNCT
fnp-5892	333	19	c.	c.	PROPN
fnp-5892	333	20	;	;	PUNCT
fnp-5892	333	21	sure	sure	ADJ
fnp-5892	333	22	,	,	PUNCT
fnp-5892	333	23	u.	u.	PROPN
fnp-5892	333	24	;	;	PUNCT
fnp-5892	333	25	scheffler	scheffler	PROPN
fnp-5892	333	26	,	,	PUNCT
fnp-5892	333	27	b.	b.	PROPN
fnp-5892	333	28	;	;	PUNCT
fnp-5892	333	29	kebir	kebir	PROPN
fnp-5892	333	30	,	,	PUNCT
fnp-5892	333	31	s.	s.	PROPN
fnp-5892	333	32	;	;	PUNCT
fnp-5892	333	33	glas	glas	PROPN
fnp-5892	333	34	,	,	PUNCT
fnp-5892	333	35	m.	m.	NOUN
fnp-5892	333	36	are	be	AUX
fnp-5892	333	37	we	we	PRON
fnp-5892	333	38	providing	provide	VERB
fnp-5892	333	39	best	well	ADV
fnp-5892	333	40	-	-	PUNCT
fnp-5892	333	41	available	available	ADJ
fnp-5892	333	42	care	care	NOUN
fnp-5892	333	43	to	to	ADP
fnp-5892	333	44	newly	newly	ADV
fnp-5892	333	45	diagnosed	diagnose	VERB
fnp-5892	333	46	glioblastoma	glioblastoma	NOUN
fnp-5892	333	47	patients	patient	NOUN
fnp-5892	333	48	?	?	PUNCT
fnp-5892	334	1	systematic	systematic	ADJ
fnp-5892	334	2	review	review	NOUN
fnp-5892	334	3	of	of	ADP
fnp-5892	334	4	phase	phase	NOUN
fnp-5892	334	5	iii	iii	NUM
fnp-5892	334	6	trials	trial	NOUN
fnp-5892	334	7	in	in	ADP
fnp-5892	334	8	newly	newly	ADV
fnp-5892	334	9	diagnosed	diagnose	VERB
fnp-5892	334	10	glioblastoma	glioblastoma	NOUN
fnp-5892	334	11	2005	2005	NUM
fnp-5892	334	12	-	-	SYM
fnp-5892	334	13	2022	2022	NUM
fnp-5892	334	14	.	.	PUNCT
fnp-5892	335	1	neurooncol	neurooncol	PROPN
fnp-5892	335	2	adv	adv	PROPN
fnp-5892	335	3	2023	2023	NUM
fnp-5892	335	4	,	,	PUNCT
fnp-5892	335	5	5	5	NUM
fnp-5892	335	6	,	,	PUNCT
fnp-5892	335	7	vdad105	vdad105	PROPN
fnp-5892	335	8	.	.	PUNCT
fnp-5892	336	1	https://doi.org/10.1093/noajnl/vdad105	https://doi.org/10.1093/noajnl/vdad105	NOUN
fnp-5892	336	2	9	9	NUM
fnp-5892	336	3	.	.	PUNCT
fnp-5892	336	4	cruz	cruz	PROPN
fnp-5892	336	5	da	da	PROPN
fnp-5892	336	6	silva	silva	PROPN
fnp-5892	336	7	,	,	PUNCT
fnp-5892	336	8	e.	e.	PROPN
fnp-5892	336	9	;	;	PUNCT
fnp-5892	336	10	mercier	mercier	PROPN
fnp-5892	336	11	,	,	PUNCT
fnp-5892	336	12	m.c	m.c	PROPN
fnp-5892	336	13	.	.	PROPN
fnp-5892	336	14	;	;	PUNCT
fnp-5892	336	15	etienne	etienne	PROPN
fnp-5892	336	16	-	-	PUNCT
fnp-5892	336	17	selloum	selloum	PROPN
fnp-5892	336	18	,	,	PUNCT
fnp-5892	336	19	n.	n.	NOUN
fnp-5892	336	20	;	;	PUNCT
fnp-5892	336	21	dontenwill	dontenwill	NOUN
fnp-5892	336	22	,	,	PUNCT
fnp-5892	336	23	m.	m.	NOUN
fnp-5892	336	24	;	;	PUNCT
fnp-5892	336	25	choulier	choulier	NOUN
fnp-5892	336	26	,	,	PUNCT
fnp-5892	336	27	l.	l.	PROPN
fnp-5892	336	28	a	a	DET
fnp-5892	336	29	systematic	systematic	ADJ
fnp-5892	336	30	review	review	NOUN
fnp-5892	336	31	of	of	ADP
fnp-5892	336	32	glioblastoma	glioblastoma	NOUN
fnp-5892	336	33	-	-	PUNCT
fnp-5892	336	34	targeted	target	VERB
fnp-5892	336	35	therapies	therapy	NOUN
fnp-5892	336	36	in	in	ADP
fnp-5892	336	37	phases	phase	NOUN
fnp-5892	336	38	ii	ii	PROPN
fnp-5892	336	39	,	,	PUNCT
fnp-5892	336	40	iii	iii	PROPN
fnp-5892	336	41	,	,	PUNCT
fnp-5892	336	42	iv	iv	NUM
fnp-5892	336	43	clinical	clinical	ADJ
fnp-5892	336	44	trials	trial	NOUN
fnp-5892	336	45	.	.	PUNCT
fnp-5892	337	1	cancers	cancer	NOUN
fnp-5892	337	2	(	(	PUNCT
fnp-5892	337	3	basel	basel	PROPN
fnp-5892	337	4	)	)	PUNCT
fnp-5892	337	5	2021	2021	NUM
fnp-5892	337	6	,	,	PUNCT
fnp-5892	337	7	13	13	NUM
fnp-5892	337	8	.	.	PUNCT
fnp-5892	338	1	https://doi.org/10.3390/cancers13081795	https://doi.org/10.3390/cancers13081795	ADV
fnp-5892	338	2	10	10	NUM
fnp-5892	338	3	.	.	PUNCT
fnp-5892	339	1	dunn	dunn	PROPN
fnp-5892	339	2	,	,	PUNCT
fnp-5892	339	3	d.b	d.b	PROPN
fnp-5892	339	4	.	.	PROPN
fnp-5892	339	5	larotrectinib	larotrectinib	NOUN
fnp-5892	339	6	and	and	CCONJ
fnp-5892	339	7	entrectinib	entrectinib	NOUN
fnp-5892	339	8	:	:	PUNCT
fnp-5892	339	9	trk	trk	VERB
fnp-5892	339	10	inhibitors	inhibitor	NOUN
fnp-5892	339	11	for	for	ADP
fnp-5892	339	12	the	the	DET
fnp-5892	339	13	treatment	treatment	NOUN
fnp-5892	339	14	of	of	ADP
fnp-5892	339	15	pediatric	pediatric	ADJ
fnp-5892	339	16	and	and	CCONJ
fnp-5892	339	17	adult	adult	NOUN
fnp-5892	339	18	patients	patient	NOUN
fnp-5892	339	19	with	with	ADP
fnp-5892	339	20	ntrk	ntrk	ADJ
fnp-5892	339	21	gene	gene	NOUN
fnp-5892	339	22	fusion	fusion	NOUN
fnp-5892	339	23	.	.	PUNCT
fnp-5892	340	1	j	j	PROPN
fnp-5892	340	2	adv	adv	PROPN
fnp-5892	340	3	pract	pract	PROPN
fnp-5892	340	4	oncol	oncol	ADJ
fnp-5892	340	5	2020	2020	NUM
fnp-5892	340	6	,	,	PUNCT
fnp-5892	340	7	11	11	NUM
fnp-5892	340	8	,	,	PUNCT
fnp-5892	340	9	418	418	NUM
fnp-5892	340	10	-	-	SYM
fnp-5892	340	11	423	423	NUM
fnp-5892	340	12	.	.	PUNCT
fnp-5892	341	1	https://doi.org/10.6004/jadpro.2020.11.4.9	https://doi.org/10.6004/jadpro.2020.11.4.9	SYM
fnp-5892	341	2	11	11	NUM
fnp-5892	341	3	.	.	PUNCT
fnp-5892	342	1	lynch	lynch	PROPN
fnp-5892	342	2	,	,	PUNCT
fnp-5892	342	3	h.t	h.t	PROPN
fnp-5892	342	4	.	.	PROPN
fnp-5892	342	5	;	;	PUNCT
fnp-5892	342	6	snyder	snyder	PROPN
fnp-5892	342	7	,	,	PUNCT
fnp-5892	342	8	c.l	c.l	PROPN
fnp-5892	342	9	.	.	PROPN
fnp-5892	342	10	;	;	PUNCT
fnp-5892	342	11	shaw	shaw	PROPN
fnp-5892	342	12	,	,	PUNCT
fnp-5892	342	13	t.g	t.g	PROPN
fnp-5892	342	14	.	.	PROPN
fnp-5892	342	15	;	;	PUNCT
fnp-5892	342	16	heinen	heinen	PROPN
fnp-5892	342	17	,	,	PUNCT
fnp-5892	342	18	c.d	c.d	PROPN
fnp-5892	342	19	.	.	PROPN
fnp-5892	342	20	;	;	PUNCT
fnp-5892	342	21	hitchins	hitchin	NOUN
fnp-5892	342	22	,	,	PUNCT
fnp-5892	342	23	m.p	m.p	PROPN
fnp-5892	342	24	.	.	PROPN
fnp-5892	342	25	milestones	milestone	NOUN
fnp-5892	342	26	of	of	ADP
fnp-5892	342	27	lynch	lynch	PROPN
fnp-5892	342	28	syndrome	syndrome	PROPN
fnp-5892	342	29	:	:	PUNCT
fnp-5892	342	30	1895	1895	NUM
fnp-5892	342	31	-	-	SYM
fnp-5892	342	32	2015	2015	NUM
fnp-5892	342	33	.	.	PUNCT
fnp-5892	343	1	nat	nat	PROPN
fnp-5892	343	2	rev	rev	VERB
fnp-5892	343	3	cancer	cancer	NOUN
fnp-5892	343	4	2015	2015	NUM
fnp-5892	343	5	,	,	PUNCT
fnp-5892	343	6	15	15	NUM
fnp-5892	343	7	,	,	PUNCT
fnp-5892	343	8	181	181	NUM
fnp-5892	343	9	-	-	SYM
fnp-5892	343	10	194	194	NUM
fnp-5892	343	11	.	.	PUNCT
fnp-5892	344	1	https://doi.org/10.1038/nrc3878	https://doi.org/10.1038/nrc3878	ADV
fnp-5892	344	2	12	12	NUM
fnp-5892	344	3	.	.	PUNCT
fnp-5892	345	1	therkildsen	therkildsen	PROPN
fnp-5892	345	2	,	,	PUNCT
fnp-5892	345	3	c.	c.	PROPN
fnp-5892	345	4	;	;	PUNCT
fnp-5892	345	5	jensen	jensen	PROPN
fnp-5892	345	6	,	,	PUNCT
fnp-5892	345	7	l.h	l.h	PROPN
fnp-5892	345	8	.	.	PROPN
fnp-5892	345	9	;	;	PUNCT
fnp-5892	345	10	rasmussen	rasmussen	PROPN
fnp-5892	345	11	,	,	PUNCT
fnp-5892	345	12	m.	m.	NOUN
fnp-5892	345	13	;	;	PUNCT
fnp-5892	345	14	bernstein	bernstein	PROPN
fnp-5892	345	15	,	,	PUNCT
fnp-5892	345	16	i.	i.	PROPN
fnp-5892	345	17	an	an	DET
fnp-5892	345	18	update	update	NOUN
fnp-5892	345	19	on	on	ADP
fnp-5892	345	20	immune	immune	ADJ
fnp-5892	345	21	checkpoint	checkpoint	NOUN
fnp-5892	345	22	therapy	therapy	NOUN
fnp-5892	345	23	for	for	ADP
fnp-5892	345	24	the	the	DET
fnp-5892	345	25	treatment	treatment	NOUN
fnp-5892	345	26	of	of	ADP
fnp-5892	345	27	lynch	lynch	PROPN
fnp-5892	345	28	syndrome	syndrome	PROPN
fnp-5892	345	29	.	.	PUNCT
fnp-5892	346	1	clin	clin	PROPN
fnp-5892	346	2	exp	exp	PROPN
fnp-5892	346	3	gastroenterol	gastroenterol	PROPN
fnp-5892	346	4	2021	2021	NUM
fnp-5892	346	5	,	,	PUNCT
fnp-5892	346	6	14	14	NUM
fnp-5892	346	7	,	,	PUNCT
fnp-5892	346	8	181	181	NUM
fnp-5892	346	9	-	-	SYM
fnp-5892	346	10	197	197	NUM
fnp-5892	346	11	.	.	PUNCT
fnp-5892	347	1	https://doi.org/10.2147/ceg.s278054	https://doi.org/10.2147/ceg.s278054	NOUN
fnp-5892	348	1	13	13	NUM
fnp-5892	348	2	.	.	PUNCT
fnp-5892	349	1	hadad	hadad	PROPN
fnp-5892	349	2	,	,	PUNCT
fnp-5892	349	3	s.	s.	PROPN
fnp-5892	349	4	;	;	PUNCT
fnp-5892	349	5	gupta	gupta	PROPN
fnp-5892	349	6	,	,	PUNCT
fnp-5892	349	7	r.	r.	PROPN
fnp-5892	349	8	;	;	PUNCT
fnp-5892	349	9	oberheim	oberheim	PROPN
fnp-5892	349	10	bush	bush	PROPN
fnp-5892	349	11	,	,	PUNCT
fnp-5892	349	12	n.a	n.a	PROPN
fnp-5892	349	13	.	.	PROPN
fnp-5892	349	14	;	;	PUNCT
fnp-5892	349	15	taylor	taylor	PROPN
fnp-5892	349	16	,	,	PUNCT
fnp-5892	349	17	j.w	j.w	PROPN
fnp-5892	349	18	.	.	PROPN
fnp-5892	349	19	;	;	PUNCT
fnp-5892	349	20	villanueva	villanueva	PROPN
fnp-5892	349	21	-	-	PUNCT
fnp-5892	349	22	meyer	meyer	PROPN
fnp-5892	349	23	,	,	PUNCT
fnp-5892	349	24	j.e	j.e	PROPN
fnp-5892	349	25	.	.	PROPN
fnp-5892	349	26	;	;	PUNCT
fnp-5892	349	27	young	young	ADJ
fnp-5892	349	28	,	,	PUNCT
fnp-5892	349	29	j.s	j.s	PROPN
fnp-5892	349	30	.	.	PROPN
fnp-5892	349	31	;	;	PUNCT
fnp-5892	349	32	wu	wu	PROPN
fnp-5892	349	33	,	,	PUNCT
fnp-5892	349	34	j.	j.	PROPN
fnp-5892	349	35	;	;	PUNCT
fnp-5892	349	36	ravindranathan	ravindranathan	PROPN
fnp-5892	349	37	,	,	PUNCT
fnp-5892	349	38	a.	a.	PROPN
fnp-5892	349	39	;	;	PUNCT
fnp-5892	349	40	zhang	zhang	PROPN
fnp-5892	349	41	,	,	PUNCT
fnp-5892	349	42	y.	y.	PROPN
fnp-5892	349	43	;	;	PUNCT
fnp-5892	349	44	warrier	warrier	PROPN
fnp-5892	349	45	,	,	PUNCT
fnp-5892	349	46	g.	g.	PROPN
fnp-5892	349	47	,	,	PUNCT
fnp-5892	349	48	et	et	PROPN
fnp-5892	349	49	al	al	PROPN
fnp-5892	349	50	.	.	PUNCT
fnp-5892	349	51	"	"	PUNCT
fnp-5892	349	52	de	de	X
fnp-5892	349	53	novo	novo	NOUN
fnp-5892	349	54	replication	replication	NOUN
fnp-5892	349	55	repair	repair	NOUN
fnp-5892	349	56	deficient	deficient	ADJ
fnp-5892	349	57	glioblastoma	glioblastoma	NOUN
fnp-5892	349	58	,	,	PUNCT
fnp-5892	349	59	idh	idh	NOUN
fnp-5892	349	60	-	-	PUNCT
fnp-5892	349	61	wildtype	wildtype	NOUN
fnp-5892	349	62	"	"	PUNCT
fnp-5892	349	63	is	be	AUX
fnp-5892	349	64	a	a	DET
fnp-5892	349	65	distinct	distinct	ADJ
fnp-5892	349	66	glioblastoma	glioblastoma	NOUN
fnp-5892	349	67	subtype	subtype	NOUN
fnp-5892	349	68	in	in	ADP
fnp-5892	349	69	adults	adult	NOUN
fnp-5892	349	70	that	that	PRON
fnp-5892	349	71	may	may	AUX
fnp-5892	349	72	benefit	benefit	VERB
fnp-5892	349	73	from	from	ADP
fnp-5892	349	74	immune	immune	ADJ
fnp-5892	349	75	checkpoint	checkpoint	NOUN
fnp-5892	349	76	blockade	blockade	NOUN
fnp-5892	349	77	.	.	PUNCT
fnp-5892	350	1	acta	acta	PROPN
fnp-5892	350	2	neuropathol	neuropathol	PROPN
fnp-5892	350	3	2023	2023	NUM
fnp-5892	350	4	,	,	PUNCT
fnp-5892	350	5	147	147	NUM
fnp-5892	350	6	,	,	PUNCT
fnp-5892	350	7	3	3	NUM
fnp-5892	350	8	.	.	PUNCT
fnp-5892	351	1	https://doi.org/10.1093/neuonc/noad179.0670	https://doi.org/10.1093/neuonc/noad179.0670	PRON
fnp-5892	351	2	14	14	NUM
fnp-5892	351	3	.	.	PUNCT
fnp-5892	352	1	kim	kim	PROPN
fnp-5892	352	2	,	,	PUNCT
fnp-5892	352	3	h.	h.	PROPN
fnp-5892	352	4	;	;	PUNCT
fnp-5892	352	5	lim	lim	PROPN
fnp-5892	352	6	,	,	PUNCT
fnp-5892	352	7	k.y	k.y	PROPN
fnp-5892	352	8	.	.	PROPN
fnp-5892	352	9	;	;	PUNCT
fnp-5892	352	10	park	park	PROPN
fnp-5892	352	11	,	,	PUNCT
fnp-5892	352	12	j.w	j.w	PROPN
fnp-5892	352	13	.	.	PROPN
fnp-5892	352	14	;	;	PUNCT
fnp-5892	352	15	kang	kang	PROPN
fnp-5892	352	16	,	,	PUNCT
fnp-5892	352	17	j.	j.	PROPN
fnp-5892	352	18	;	;	PUNCT
fnp-5892	352	19	won	win	VERB
fnp-5892	352	20	,	,	PUNCT
fnp-5892	352	21	j.k	j.k	PROPN
fnp-5892	352	22	.	.	PROPN
fnp-5892	352	23	;	;	PUNCT
fnp-5892	352	24	lee	lee	PROPN
fnp-5892	352	25	,	,	PUNCT
fnp-5892	352	26	k.	k.	PROPN
fnp-5892	352	27	;	;	PUNCT
fnp-5892	353	1	shim	shim	NOUN
fnp-5892	353	2	,	,	PUNCT
fnp-5892	353	3	y.	y.	PROPN
fnp-5892	353	4	;	;	PUNCT
fnp-5892	353	5	park	park	PROPN
fnp-5892	353	6	,	,	PUNCT
fnp-5892	353	7	c.k	c.k	PROPN
fnp-5892	353	8	.	.	PROPN
fnp-5892	353	9	;	;	PUNCT
fnp-5892	353	10	kim	kim	PROPN
fnp-5892	353	11	,	,	PUNCT
fnp-5892	353	12	s.k	s.k	PROPN
fnp-5892	353	13	.	.	PROPN
fnp-5892	353	14	;	;	PUNCT
fnp-5892	353	15	choi	choi	NOUN
fnp-5892	353	16	,	,	PUNCT
fnp-5892	353	17	s.h	s.h	PROPN
fnp-5892	353	18	.	.	PROPN
fnp-5892	353	19	,	,	PUNCT
fnp-5892	353	20	et	et	PROPN
fnp-5892	353	21	al	al	PROPN
fnp-5892	353	22	.	.	PROPN
fnp-5892	354	1	sporadic	sporadic	ADJ
fnp-5892	354	2	and	and	CCONJ
fnp-5892	354	3	lynch	lynch	PROPN
fnp-5892	354	4	syndrome	syndrome	PROPN
fnp-5892	354	5	-	-	PUNCT
fnp-5892	354	6	associated	associate	VERB
fnp-5892	354	7	mismatch	mismatch	NOUN
fnp-5892	354	8	repair	repair	NOUN
fnp-5892	354	9	-	-	PUNCT
fnp-5892	354	10	deficient	deficient	ADJ
fnp-5892	354	11	brain	brain	NOUN
fnp-5892	354	12	tumors	tumor	NOUN
fnp-5892	354	13	.	.	PUNCT
fnp-5892	355	1	lab	lab	NOUN
fnp-5892	355	2	invest	invest	VERB
fnp-5892	355	3	2022	2022	NUM
fnp-5892	355	4	,	,	PUNCT
fnp-5892	355	5	102	102	NUM
fnp-5892	355	6	,	,	PUNCT
fnp-5892	355	7	160	160	NUM
fnp-5892	355	8	-	-	SYM
fnp-5892	355	9	171	171	NUM
fnp-5892	355	10	.	.	PUNCT
fnp-5892	356	1	https://doi.org/10.1038/s41374-021-00694-3	https://doi.org/10.1038/s41374-021-00694-3	NUM
fnp-5892	356	2	15	15	NUM
fnp-5892	356	3	.	.	PUNCT
fnp-5892	357	1	georgescu	georgescu	PROPN
fnp-5892	357	2	,	,	PUNCT
fnp-5892	357	3	m.m	m.m	PROPN
fnp-5892	357	4	.	.	PROPN
fnp-5892	357	5	;	;	PUNCT
fnp-5892	357	6	islam	islam	PROPN
fnp-5892	357	7	,	,	PUNCT
fnp-5892	357	8	m.z	m.z	PROPN
fnp-5892	357	9	.	.	PROPN
fnp-5892	357	10	;	;	PUNCT
fnp-5892	357	11	li	li	PROPN
fnp-5892	357	12	,	,	PUNCT
fnp-5892	357	13	y.	y.	PROPN
fnp-5892	357	14	;	;	PUNCT
fnp-5892	357	15	traylor	traylor	PROPN
fnp-5892	357	16	,	,	PUNCT
fnp-5892	357	17	j.	j.	PROPN
fnp-5892	357	18	;	;	PUNCT
fnp-5892	357	19	nanda	nanda	ADV
fnp-5892	357	20	,	,	PUNCT
fnp-5892	357	21	a.	a.	NOUN
fnp-5892	357	22	novel	novel	NOUN
fnp-5892	357	23	targetable	targetable	ADJ
fnp-5892	357	24	fgfr2	fgfr2	NOUN
fnp-5892	357	25	and	and	CCONJ
fnp-5892	357	26	fgfr3	fgfr3	NOUN
fnp-5892	357	27	alterations	alteration	NOUN
fnp-5892	357	28	in	in	ADP
fnp-5892	357	29	glioblastoma	glioblastoma	NOUN
fnp-5892	357	30	associate	associate	NOUN
fnp-5892	357	31	with	with	ADP
fnp-5892	357	32	aggressive	aggressive	ADJ
fnp-5892	357	33	phenotype	phenotype	NOUN
fnp-5892	357	34	and	and	CCONJ
fnp-5892	357	35	distinct	distinct	ADJ
fnp-5892	357	36	gene	gene	NOUN
fnp-5892	357	37	expression	expression	NOUN
fnp-5892	357	38	programs	program	NOUN
fnp-5892	357	39	.	.	PUNCT
fnp-5892	358	1	acta	acta	PROPN
fnp-5892	358	2	neuropathol	neuropathol	PROPN
fnp-5892	358	3	commun	commun	PROPN
fnp-5892	358	4	2021	2021	NUM
fnp-5892	358	5	,	,	PUNCT
fnp-5892	358	6	9	9	NUM
fnp-5892	358	7	,	,	PUNCT
fnp-5892	358	8	69	69	NUM
fnp-5892	358	9	.	.	PUNCT
fnp-5892	359	1	https://doi.org/10.1186/s40478-021-01170-1	https://doi.org/10.1186/s40478-021-01170-1	PROPN
fnp-5892	359	2	16	16	NUM
fnp-5892	359	3	.	.	PUNCT
fnp-5892	360	1	georgescu	georgescu	PROPN
fnp-5892	360	2	,	,	PUNCT
fnp-5892	360	3	m.m	m.m	PROPN
fnp-5892	360	4	.	.	PROPN
fnp-5892	360	5	;	;	PUNCT
fnp-5892	360	6	li	li	PROPN
fnp-5892	360	7	,	,	PUNCT
fnp-5892	360	8	y.	y.	PROPN
fnp-5892	360	9	;	;	PUNCT
fnp-5892	360	10	islam	islam	PROPN
fnp-5892	360	11	,	,	PUNCT
fnp-5892	360	12	m.z	m.z	PROPN
fnp-5892	360	13	.	.	PROPN
fnp-5892	360	14	;	;	PUNCT
fnp-5892	360	15	notarianni	notarianni	PROPN
fnp-5892	360	16	,	,	PUNCT
fnp-5892	360	17	c.	c.	PROPN
fnp-5892	360	18	;	;	PUNCT
fnp-5892	360	19	sun	sun	PROPN
fnp-5892	360	20	,	,	PUNCT
fnp-5892	360	21	h.	h.	PROPN
fnp-5892	360	22	;	;	PUNCT
fnp-5892	360	23	olar	olar	ADJ
fnp-5892	360	24	,	,	PUNCT
fnp-5892	360	25	a.	a.	NOUN
fnp-5892	360	26	;	;	PUNCT
fnp-5892	360	27	fuller	full	ADJ
fnp-5892	360	28	,	,	PUNCT
fnp-5892	360	29	g.n	g.n	PROPN
fnp-5892	360	30	.	.	PROPN
fnp-5892	360	31	mutations	mutation	NOUN
fnp-5892	360	32	of	of	ADP
fnp-5892	360	33	the	the	DET
fnp-5892	360	34	mapk	mapk	PROPN
fnp-5892	360	35	/	/	SYM
fnp-5892	360	36	tsc	tsc	PROPN
fnp-5892	360	37	/	/	SYM
fnp-5892	360	38	mtor	mtor	PROPN
fnp-5892	360	39	pathway	pathway	NOUN
fnp-5892	360	40	characterize	characterize	VERB
fnp-5892	360	41	periventricular	periventricular	ADJ
fnp-5892	360	42	glioblastoma	glioblastoma	NOUN
fnp-5892	360	43	with	with	ADP
fnp-5892	360	44	epithelioid	epithelioid	PROPN
fnp-5892	360	45	sega	sega	NOUN
fnp-5892	360	46	-	-	PUNCT
fnp-5892	360	47	like	like	ADJ
fnp-5892	360	48	morphology	morphology	NOUN
fnp-5892	360	49	-	-	PUNCT
fnp-5892	360	50	morphological	morphological	ADJ
fnp-5892	360	51	and	and	CCONJ
fnp-5892	360	52	therapeutic	therapeutic	ADJ
fnp-5892	360	53	implications	implication	NOUN
fnp-5892	360	54	.	.	PUNCT
fnp-5892	361	1	oncotarget	oncotarget	NOUN
fnp-5892	361	2	2019	2019	NUM
fnp-5892	361	3	,	,	PUNCT
fnp-5892	361	4	10	10	NUM
fnp-5892	361	5	,	,	PUNCT
fnp-5892	361	6	4038	4038	NUM
fnp-5892	361	7	-	-	SYM
fnp-5892	361	8	4052	4052	NUM
fnp-5892	361	9	.	.	PUNCT
fnp-5892	362	1	https://doi.org/10.18632/oncotarget.27005	https://doi.org/10.18632/oncotarget.27005	VERB
fnp-5892	363	1	17	17	NUM
fnp-5892	363	2	.	.	PUNCT
fnp-5892	363	3	georgescu	georgescu	PROPN
fnp-5892	363	4	,	,	PUNCT
fnp-5892	363	5	m.m	m.m	PROPN
fnp-5892	363	6	.	.	PROPN
fnp-5892	363	7	;	;	PUNCT
fnp-5892	363	8	olar	olar	ADJ
fnp-5892	363	9	,	,	PUNCT
fnp-5892	363	10	a.	a.	NOUN
fnp-5892	363	11	genetic	genetic	ADJ
fnp-5892	363	12	and	and	CCONJ
fnp-5892	363	13	histologic	histologic	ADJ
fnp-5892	363	14	spatiotemporal	spatiotemporal	ADJ
fnp-5892	363	15	evolution	evolution	NOUN
fnp-5892	363	16	of	of	ADP
fnp-5892	363	17	recurrent	recurrent	ADJ
fnp-5892	363	18	,	,	PUNCT
fnp-5892	363	19	multifocal	multifocal	ADJ
fnp-5892	363	20	,	,	PUNCT
fnp-5892	363	21	multicentric	multicentric	ADJ
fnp-5892	363	22	and	and	CCONJ
fnp-5892	363	23	metastatic	metastatic	ADJ
fnp-5892	363	24	glioblastoma	glioblastoma	NOUN
fnp-5892	363	25	.	.	PUNCT
fnp-5892	364	1	acta	acta	PROPN
fnp-5892	364	2	neuropathol	neuropathol	PROPN
fnp-5892	364	3	commun	commun	PROPN
fnp-5892	364	4	2020	2020	NUM
fnp-5892	364	5	,	,	PUNCT
fnp-5892	364	6	8	8	NUM
fnp-5892	364	7	,	,	PUNCT
fnp-5892	364	8	10	10	NUM
fnp-5892	364	9	.	.	PUNCT
fnp-5892	365	1	https://doi.org/10.1186/s40478-020-0889-x	https://doi.org/10.1186/s40478-020-0889-x	PROPN
fnp-5892	365	2	18	18	NUM
fnp-5892	365	3	.	.	PUNCT
fnp-5892	366	1	georgescu	georgescu	PROPN
fnp-5892	366	2	,	,	PUNCT
fnp-5892	366	3	m.m	m.m	PROPN
fnp-5892	366	4	.	.	PROPN
fnp-5892	366	5	;	;	PUNCT
fnp-5892	366	6	whipple	whipple	PROPN
fnp-5892	366	7	,	,	PUNCT
fnp-5892	366	8	s.g	s.g	PROPN
fnp-5892	366	9	.	.	PROPN
fnp-5892	366	10	;	;	PUNCT
fnp-5892	366	11	notarianni	notarianni	PROPN
fnp-5892	366	12	,	,	PUNCT
fnp-5892	366	13	c.m	c.m	PROPN
fnp-5892	366	14	.	.	PROPN
fnp-5892	366	15	novel	novel	ADJ
fnp-5892	366	16	neoplasms	neoplasm	NOUN
fnp-5892	366	17	associated	associate	VERB
fnp-5892	366	18	with	with	ADP
fnp-5892	366	19	syndromic	syndromic	ADJ
fnp-5892	366	20	pediatric	pediatric	ADJ
fnp-5892	366	21	medulloblastoma	medulloblastoma	NOUN
fnp-5892	366	22	:	:	PUNCT
fnp-5892	366	23	integrated	integrated	ADJ
fnp-5892	366	24	pathway	pathway	NOUN
fnp-5892	366	25	delineation	delineation	NOUN
fnp-5892	366	26	for	for	ADP
fnp-5892	366	27	personalized	personalized	ADJ
fnp-5892	366	28	therapy	therapy	NOUN
fnp-5892	366	29	.	.	PUNCT
fnp-5892	367	1	cell	cell	NOUN
fnp-5892	367	2	commun	commun	PROPN
fnp-5892	367	3	signal	signal	PROPN
fnp-5892	367	4	2022	2022	NUM
fnp-5892	367	5	,	,	PUNCT
fnp-5892	367	6	20	20	NUM
fnp-5892	367	7	,	,	PUNCT
fnp-5892	367	8	123	123	NUM
fnp-5892	367	9	.	.	PUNCT
fnp-5892	368	1	https://doi.org/10.1186/s12964-022-00930-3	https://doi.org/10.1186/s12964-022-00930-3	NUM
fnp-5892	368	2	19	19	NUM
fnp-5892	368	3	.	.	PUNCT
fnp-5892	369	1	georgescu	georgescu	PROPN
fnp-5892	369	2	,	,	PUNCT
fnp-5892	369	3	m.m	m.m	PROPN
fnp-5892	369	4	.	.	PROPN
fnp-5892	369	5	;	;	PUNCT
fnp-5892	369	6	islam	islam	PROPN
fnp-5892	369	7	,	,	PUNCT
fnp-5892	369	8	m.z	m.z	PROPN
fnp-5892	369	9	.	.	PROPN
fnp-5892	369	10	;	;	PUNCT
fnp-5892	369	11	li	li	PROPN
fnp-5892	369	12	,	,	PUNCT
fnp-5892	369	13	y.	y.	PROPN
fnp-5892	369	14	;	;	PUNCT
fnp-5892	369	15	circu	circu	PROPN
fnp-5892	369	16	,	,	PUNCT
fnp-5892	369	17	m.l	m.l	PROPN
fnp-5892	369	18	.	.	PROPN
fnp-5892	369	19	;	;	PUNCT
fnp-5892	369	20	traylor	traylor	PROPN
fnp-5892	369	21	,	,	PUNCT
fnp-5892	369	22	j.	j.	PROPN
fnp-5892	369	23	;	;	PUNCT
fnp-5892	369	24	notarianni	notarianni	PROPN
fnp-5892	369	25	,	,	PUNCT
fnp-5892	369	26	c.m	c.m	PROPN
fnp-5892	369	27	.	.	PROPN
fnp-5892	369	28	;	;	PUNCT
fnp-5892	369	29	kline	kline	PROPN
fnp-5892	369	30	,	,	PUNCT
fnp-5892	369	31	c.n	c.n	PROPN
fnp-5892	369	32	.	.	PROPN
fnp-5892	369	33	;	;	PUNCT
fnp-5892	369	34	burns	burn	NOUN
fnp-5892	369	35	,	,	PUNCT
fnp-5892	369	36	d.k	d.k	PROPN
fnp-5892	369	37	.	.	PROPN
fnp-5892	369	38	global	global	ADJ
fnp-5892	369	39	activation	activation	NOUN
fnp-5892	369	40	of	of	ADP
fnp-5892	369	41	oncogenic	oncogenic	ADJ
fnp-5892	369	42	pathways	pathway	NOUN
fnp-5892	369	43	underlies	underlie	VERB
fnp-5892	369	44	therapy	therapy	NOUN
fnp-5892	369	45	resistance	resistance	NOUN
fnp-5892	369	46	in	in	ADP
fnp-5892	369	47	diffuse	diffuse	ADJ
fnp-5892	369	48	midline	midline	NOUN
fnp-5892	369	49	glioma	glioma	NOUN
fnp-5892	369	50	.	.	PUNCT
fnp-5892	370	1	acta	acta	PROPN
fnp-5892	370	2	neuropathol	neuropathol	PROPN
fnp-5892	370	3	commun	commun	PROPN
fnp-5892	370	4	2020	2020	NUM
fnp-5892	370	5	,	,	PUNCT
fnp-5892	370	6	8	8	NUM
fnp-5892	370	7	,	,	PUNCT
fnp-5892	370	8	111	111	NUM
fnp-5892	370	9	.	.	PUNCT
fnp-5892	371	1	https://doi.org/10.1186/s40478-020-00992-9	https://doi.org/10.1186/s40478-020-00992-9	NOUN
fnp-5892	371	2	20	20	NUM
fnp-5892	371	3	.	.	PUNCT
fnp-5892	371	4	alexopoulos	alexopoulos	PROPN
fnp-5892	371	5	,	,	PUNCT
fnp-5892	371	6	g.	g.	PROPN
fnp-5892	371	7	;	;	PUNCT
fnp-5892	371	8	zhang	zhang	PROPN
fnp-5892	371	9	,	,	PUNCT
fnp-5892	371	10	j.	j.	PROPN
fnp-5892	371	11	;	;	PUNCT
fnp-5892	371	12	karampelas	karampelas	PROPN
fnp-5892	371	13	,	,	PUNCT
fnp-5892	371	14	i.	i.	PROPN
fnp-5892	371	15	;	;	PUNCT
fnp-5892	371	16	patel	patel	PROPN
fnp-5892	371	17	,	,	PUNCT
fnp-5892	371	18	m.	m.	NOUN
fnp-5892	371	19	;	;	PUNCT
fnp-5892	371	20	kemp	kemp	PROPN
fnp-5892	371	21	,	,	PUNCT
fnp-5892	371	22	j.	j.	PROPN
fnp-5892	371	23	;	;	PUNCT
fnp-5892	371	24	coppens	coppens	PROPN
fnp-5892	371	25	,	,	PUNCT
fnp-5892	371	26	j.	j.	PROPN
fnp-5892	371	27	;	;	PUNCT
fnp-5892	371	28	mattei	mattei	PROPN
fnp-5892	371	29	,	,	PUNCT
fnp-5892	371	30	t.a	t.a	PROPN
fnp-5892	371	31	.	.	PROPN
fnp-5892	371	32	;	;	PUNCT
fnp-5892	371	33	mercier	mercier	X
fnp-5892	371	34	,	,	PUNCT
fnp-5892	371	35	p.	p.	NOUN
fnp-5892	371	36	long	long	ADJ
fnp-5892	371	37	-	-	PUNCT
fnp-5892	371	38	term	term	NOUN
fnp-5892	371	39	time	time	NOUN
fnp-5892	371	40	series	series	PROPN
fnp-5892	371	41	forecasting	forecasting	PROPN
fnp-5892	371	42	and	and	CCONJ
fnp-5892	371	43	updates	update	NOUN
fnp-5892	371	44	on	on	ADP
fnp-5892	371	45	survival	survival	NOUN
fnp-5892	371	46	analysis	analysis	NOUN
fnp-5892	371	47	of	of	ADP
fnp-5892	371	48	glioblastoma	glioblastoma	NOUN
fnp-5892	371	49	multiforme	multiforme	NOUN
fnp-5892	371	50	:	:	PUNCT
fnp-5892	371	51	a	a	DET
fnp-5892	371	52	1975	1975	NUM
fnp-5892	371	53	-	-	SYM
fnp-5892	371	54	2018	2018	NUM
fnp-5892	371	55	population	population	NOUN
fnp-5892	371	56	-	-	PUNCT
fnp-5892	371	57	based	base	VERB
fnp-5892	371	58	study	study	NOUN
fnp-5892	371	59	.	.	PUNCT
fnp-5892	372	1	neuroepidemiology	neuroepidemiology	NOUN
fnp-5892	372	2	2022	2022	NUM
fnp-5892	372	3	,	,	PUNCT
fnp-5892	372	4	56	56	NUM
fnp-5892	372	5	,	,	PUNCT
fnp-5892	372	6	75	75	NUM
fnp-5892	372	7	-	-	SYM
fnp-5892	372	8	89	89	NUM
fnp-5892	372	9	.	.	PUNCT
fnp-5892	373	1	https://doi.org/10.1159/000522611	https://doi.org/10.1159/000522611	PROPN
fnp-5892	373	2	21	21	NUM
fnp-5892	373	3	.	.	PUNCT
fnp-5892	374	1	guo	guo	PROPN
fnp-5892	374	2	,	,	PUNCT
fnp-5892	374	3	x.	x.	NOUN
fnp-5892	374	4	;	;	PUNCT
fnp-5892	374	5	gu	gu	PROPN
fnp-5892	374	6	,	,	PUNCT
fnp-5892	374	7	l.	l.	PROPN
fnp-5892	374	8	;	;	PUNCT
fnp-5892	374	9	li	li	PROPN
fnp-5892	374	10	,	,	PUNCT
fnp-5892	374	11	y.	y.	PROPN
fnp-5892	374	12	;	;	PUNCT
fnp-5892	374	13	zheng	zheng	PROPN
fnp-5892	374	14	,	,	PUNCT
fnp-5892	374	15	z.	z.	PROPN
fnp-5892	374	16	;	;	PUNCT
fnp-5892	374	17	chen	chen	PROPN
fnp-5892	374	18	,	,	PUNCT
fnp-5892	374	19	w.	w.	PROPN
fnp-5892	374	20	;	;	PUNCT
fnp-5892	374	21	wang	wang	PROPN
fnp-5892	374	22	,	,	PUNCT
fnp-5892	374	23	y.	y.	PROPN
fnp-5892	374	24	;	;	PUNCT
fnp-5892	374	25	wang	wang	PROPN
fnp-5892	374	26	,	,	PUNCT
fnp-5892	374	27	y.	y.	PROPN
fnp-5892	374	28	;	;	PUNCT
fnp-5892	374	29	xing	xing	PROPN
fnp-5892	374	30	,	,	PUNCT
fnp-5892	374	31	h.	h.	PROPN
fnp-5892	374	32	;	;	PUNCT
fnp-5892	374	33	shi	shi	PROPN
fnp-5892	374	34	,	,	PUNCT
fnp-5892	374	35	y.	y.	PROPN
fnp-5892	374	36	;	;	PUNCT
fnp-5892	374	37	liu	liu	PROPN
fnp-5892	374	38	,	,	PUNCT
fnp-5892	374	39	d.	d.	PROPN
fnp-5892	374	40	,	,	PUNCT
fnp-5892	374	41	et	et	PROPN
fnp-5892	374	42	al	al	PROPN
fnp-5892	374	43	.	.	PROPN
fnp-5892	375	1	histological	histological	ADJ
fnp-5892	375	2	and	and	CCONJ
fnp-5892	375	3	molecular	molecular	ADJ
fnp-5892	375	4	glioblastoma	glioblastoma	NOUN
fnp-5892	375	5	,	,	PUNCT
fnp-5892	375	6	idh	idh	NOUN
fnp-5892	375	7	-	-	PUNCT
fnp-5892	375	8	wildtype	wildtype	NOUN
fnp-5892	375	9	:	:	PUNCT
fnp-5892	375	10	a	a	DET
fnp-5892	375	11	real	real	ADJ
fnp-5892	375	12	-	-	PUNCT
fnp-5892	375	13	world	world	NOUN
fnp-5892	375	14	landscape	landscape	NOUN
fnp-5892	375	15	using	use	VERB
fnp-5892	375	16	the	the	DET
fnp-5892	375	17	2021	2021	NUM
fnp-5892	375	18	who	who	PRON
fnp-5892	375	19	classification	classification	NOUN
fnp-5892	375	20	of	of	ADP
fnp-5892	375	21	central	central	ADJ
fnp-5892	375	22	nervous	nervous	ADJ
fnp-5892	375	23	system	system	NOUN
fnp-5892	375	24	tumors	tumor	NOUN
fnp-5892	375	25	.	.	PUNCT
fnp-5892	376	1	front	front	ADJ
fnp-5892	376	2	oncol	oncol	ADJ
fnp-5892	376	3	2023	2023	NUM
fnp-5892	376	4	,	,	PUNCT
fnp-5892	376	5	13	13	NUM
fnp-5892	376	6	,	,	PUNCT
fnp-5892	376	7	1200815	1200815	NUM
fnp-5892	376	8	.	.	PUNCT
fnp-5892	377	1	https://doi.org/10.3389/fonc.2023.1200815	https://doi.org/10.3389/fonc.2023.1200815	NOUN
fnp-5892	377	2	22	22	NUM
fnp-5892	377	3	.	.	PUNCT
fnp-5892	377	4	reck	reck	PROPN
fnp-5892	377	5	,	,	PUNCT
fnp-5892	377	6	m.	m.	NOUN
fnp-5892	377	7	;	;	PUNCT
fnp-5892	377	8	borghaei	borghaei	PROPN
fnp-5892	377	9	,	,	PUNCT
fnp-5892	377	10	h.	h.	PROPN
fnp-5892	377	11	;	;	PUNCT
fnp-5892	377	12	o'byrne	o'byrne	PROPN
fnp-5892	377	13	,	,	PUNCT
fnp-5892	377	14	k.j	k.j	PROPN
fnp-5892	377	15	.	.	PROPN
fnp-5892	377	16	nivolumab	nivolumab	NOUN
fnp-5892	377	17	plus	plus	CCONJ
fnp-5892	377	18	ipilimumab	ipilimumab	VERB
fnp-5892	377	19	in	in	ADP
fnp-5892	377	20	non	non	ADJ
fnp-5892	377	21	-	-	ADJ
fnp-5892	377	22	small	small	ADJ
fnp-5892	377	23	-	-	PUNCT
fnp-5892	377	24	cell	cell	NOUN
fnp-5892	377	25	lung	lung	NOUN
fnp-5892	377	26	cancer	cancer	NOUN
fnp-5892	377	27	.	.	PUNCT
fnp-5892	378	1	future	future	ADJ
fnp-5892	378	2	oncol	oncol	ADJ
fnp-5892	378	3	2019	2019	NUM
fnp-5892	378	4	,	,	PUNCT
fnp-5892	378	5	15	15	NUM
fnp-5892	378	6	,	,	PUNCT
fnp-5892	378	7	2287	2287	NUM
fnp-5892	378	8	-	-	SYM
fnp-5892	378	9	2302	2302	NUM
fnp-5892	378	10	.	.	PUNCT
fnp-5892	379	1	https://doi.org/10.2217/fon-2019-0031	https://doi.org/10.2217/fon-2019-0031	NOUN
fnp-5892	379	2	23	23	NUM
fnp-5892	379	3	.	.	PUNCT
fnp-5892	380	1	donisi	donisi	PROPN
fnp-5892	380	2	,	,	PUNCT
fnp-5892	380	3	c.	c.	NOUN
fnp-5892	380	4	;	;	PUNCT
fnp-5892	380	5	pretta	pretta	PROPN
fnp-5892	380	6	,	,	PUNCT
fnp-5892	380	7	a.	a.	NOUN
fnp-5892	380	8	;	;	PUNCT
fnp-5892	380	9	pusceddu	pusceddu	NOUN
fnp-5892	380	10	,	,	PUNCT
fnp-5892	380	11	v.	v.	ADP
fnp-5892	380	12	;	;	PUNCT
fnp-5892	380	13	ziranu	ziranu	PROPN
fnp-5892	380	14	,	,	PUNCT
fnp-5892	380	15	p.	p.	PROPN
fnp-5892	380	16	;	;	PUNCT
fnp-5892	380	17	lai	lai	PROPN
fnp-5892	380	18	,	,	PUNCT
fnp-5892	380	19	e.	e.	PROPN
fnp-5892	380	20	;	;	PUNCT
fnp-5892	380	21	puzzoni	puzzoni	ADJ
fnp-5892	380	22	,	,	PUNCT
fnp-5892	380	23	m.	m.	NOUN
fnp-5892	380	24	;	;	PUNCT
fnp-5892	380	25	mariani	mariani	PROPN
fnp-5892	380	26	,	,	PUNCT
fnp-5892	380	27	s.	s.	PROPN
fnp-5892	380	28	;	;	PUNCT
fnp-5892	380	29	massa	massa	PROPN
fnp-5892	380	30	,	,	PUNCT
fnp-5892	380	31	e.	e.	PROPN
fnp-5892	380	32	;	;	PUNCT
fnp-5892	380	33	madeddu	madeddu	PROPN
fnp-5892	380	34	,	,	PUNCT
fnp-5892	380	35	c.	c.	NOUN
fnp-5892	380	36	;	;	PUNCT
fnp-5892	380	37	scartozzi	scartozzi	NOUN
fnp-5892	380	38	,	,	PUNCT
fnp-5892	380	39	m.	m.	NOUN
fnp-5892	380	40	immunotherapy	immunotherapy	NOUN
fnp-5892	380	41	and	and	CCONJ
fnp-5892	380	42	cancer	cancer	NOUN
fnp-5892	380	43	:	:	PUNCT
fnp-5892	380	44	the	the	DET
fnp-5892	380	45	multi	multi	ADJ
fnp-5892	380	46	-	-	ADJ
fnp-5892	380	47	omics	omics	ADJ
fnp-5892	380	48	perspective	perspective	NOUN
fnp-5892	380	49	.	.	PUNCT
fnp-5892	381	1	int	int	PROPN
fnp-5892	381	2	j	j	PROPN
fnp-5892	381	3	mol	mol	ADP
fnp-5892	381	4	sci	sci	PROPN
fnp-5892	381	5	2024	2024	NUM
fnp-5892	381	6	,	,	PUNCT
fnp-5892	381	7	25	25	NUM
fnp-5892	381	8	.	.	PUNCT
fnp-5892	381	9	https://doi.org/10.3390/ijms25063563	https://doi.org/10.3390/ijms25063563	PROPN
fnp-5892	381	10	24	24	NUM
fnp-5892	381	11	.	.	PUNCT
fnp-5892	382	1	ozawa	ozawa	PROPN
fnp-5892	382	2	,	,	PUNCT
fnp-5892	382	3	y.	y.	PROPN
fnp-5892	382	4	;	;	PUNCT
fnp-5892	382	5	yamamuro	yamamuro	PROPN
fnp-5892	382	6	,	,	PUNCT
fnp-5892	382	7	s.	s.	PROPN
fnp-5892	382	8	;	;	PUNCT
fnp-5892	382	9	sano	sano	PROPN
fnp-5892	382	10	,	,	PUNCT
fnp-5892	382	11	e.	e.	PROPN
fnp-5892	382	12	;	;	PUNCT
fnp-5892	382	13	tatsuoka	tatsuoka	PROPN
fnp-5892	382	14	,	,	PUNCT
fnp-5892	382	15	j.	j.	PROPN
fnp-5892	382	16	;	;	PUNCT
fnp-5892	382	17	hanashima	hanashima	VERB
fnp-5892	382	18	,	,	PUNCT
fnp-5892	382	19	y.	y.	PROPN
fnp-5892	382	20	;	;	PUNCT
fnp-5892	382	21	yoshimura	yoshimura	NOUN
fnp-5892	382	22	,	,	PUNCT
fnp-5892	382	23	s.	s.	PROPN
fnp-5892	382	24	;	;	PUNCT
fnp-5892	382	25	sumi	sumi	PROPN
fnp-5892	382	26	,	,	PUNCT
fnp-5892	382	27	k.	k.	PROPN
fnp-5892	382	28	;	;	PUNCT
fnp-5892	382	29	hara	hara	PROPN
fnp-5892	382	30	,	,	PUNCT
fnp-5892	382	31	h.	h.	PROPN
fnp-5892	382	32	;	;	PUNCT
fnp-5892	382	33	nakayama	nakayama	PROPN
fnp-5892	382	34	,	,	PUNCT
fnp-5892	382	35	t.	t.	PROPN
fnp-5892	382	36	;	;	PUNCT
fnp-5892	382	37	suzuki	suzuki	PROPN
fnp-5892	382	38	,	,	PUNCT
fnp-5892	382	39	y.	y.	PROPN
fnp-5892	382	40	,	,	PUNCT
fnp-5892	383	1	et	et	PROPN
fnp-5892	383	2	al	al	PROPN
fnp-5892	383	3	.	.	PROPN
fnp-5892	383	4	indoleamine	indoleamine	PROPN
fnp-5892	383	5	2,3	2,3	NUM
fnp-5892	383	6	-	-	NOUN
fnp-5892	383	7	dioxygenase	dioxygenase	NOUN
fnp-5892	383	8	1	1	NUM
fnp-5892	383	9	is	be	AUX
fnp-5892	383	10	highly	highly	ADV
fnp-5892	383	11	expressed	express	VERB
fnp-5892	383	12	in	in	ADP
fnp-5892	383	13	glioma	glioma	NOUN
fnp-5892	383	14	stem	stem	NOUN
fnp-5892	383	15	cells	cell	NOUN
fnp-5892	383	16	.	.	PUNCT
fnp-5892	384	1	biochem	biochem	PROPN
fnp-5892	384	2	biophys	biophys	PROPN
fnp-5892	384	3	res	res	PROPN
fnp-5892	384	4	commun	commun	PROPN
fnp-5892	384	5	2020	2020	NUM
fnp-5892	384	6	,	,	PUNCT
fnp-5892	384	7	524	524	NUM
fnp-5892	384	8	,	,	PUNCT
fnp-5892	384	9	723	723	NUM
fnp-5892	384	10	-	-	SYM
fnp-5892	384	11	729	729	NUM
fnp-5892	384	12	.	.	PUNCT
fnp-5892	385	1	https://doi.org/10.1016/j.bbrc.2020.01.148	https://doi.org/10.1016/j.bbrc.2020.01.148	NOUN
fnp-5892	385	2	25	25	NUM
fnp-5892	385	3	.	.	PUNCT
fnp-5892	386	1	xing	xing	PROPN
fnp-5892	386	2	,	,	PUNCT
fnp-5892	386	3	z.	z.	PROPN
fnp-5892	386	4	;	;	PUNCT
fnp-5892	386	5	li	li	PROPN
fnp-5892	386	6	,	,	PUNCT
fnp-5892	386	7	x.	x.	PROPN
fnp-5892	386	8	;	;	PUNCT
fnp-5892	386	9	he	he	PRON
fnp-5892	386	10	,	,	PUNCT
fnp-5892	386	11	z.n.t	z.n.t	PROPN
fnp-5892	386	12	.	.	PROPN
fnp-5892	386	13	;	;	PUNCT
fnp-5892	386	14	fang	fang	X
fnp-5892	386	15	,	,	PUNCT
fnp-5892	386	16	x.	x.	NOUN
fnp-5892	386	17	;	;	PUNCT
fnp-5892	386	18	liang	liang	PROPN
fnp-5892	386	19	,	,	PUNCT
fnp-5892	386	20	h.	h.	PROPN
fnp-5892	386	21	;	;	PUNCT
fnp-5892	386	22	kuang	kuang	PROPN
fnp-5892	386	23	,	,	PUNCT
fnp-5892	386	24	c.	c.	PROPN
fnp-5892	386	25	;	;	PUNCT
fnp-5892	386	26	li	li	PROPN
fnp-5892	386	27	,	,	PUNCT
fnp-5892	386	28	a.	a.	PROPN
fnp-5892	386	29	;	;	PUNCT
fnp-5892	386	30	yang	yang	PROPN
fnp-5892	386	31	,	,	PUNCT
fnp-5892	386	32	q.	q.	PROPN
fnp-5892	386	33	ido1	ido1	PROPN
fnp-5892	386	34	inhibitor	inhibitor	NOUN
fnp-5892	386	35	ry103	ry103	PROPN
fnp-5892	386	36	suppresses	suppress	VERB
fnp-5892	386	37	trp	trp	PROPN
fnp-5892	386	38	-	-	PUNCT
fnp-5892	386	39	gcn2	gcn2	NOUN
fnp-5892	386	40	-	-	PUNCT
fnp-5892	386	41	mediated	mediate	VERB
fnp-5892	386	42	angiogenesis	angiogenesis	NOUN
fnp-5892	386	43	and	and	CCONJ
fnp-5892	386	44	counters	counter	VERB
fnp-5892	386	45	immunosuppression	immunosuppression	NOUN
fnp-5892	386	46	in	in	ADP
fnp-5892	386	47	glioblastoma	glioblastoma	NOUN
fnp-5892	386	48	.	.	PUNCT
fnp-5892	387	1	pharmaceutics	pharmaceutic	NOUN
fnp-5892	387	2	2024	2024	NUM
fnp-5892	387	3	,	,	PUNCT
fnp-5892	387	4	16	16	NUM
fnp-5892	387	5	.	.	PUNCT
fnp-5892	387	6	https://doi.org/10.3390/pharmaceutics16070870	https://doi.org/10.3390/pharmaceutics16070870	NOUN
fnp-5892	387	7	26	26	NUM
fnp-5892	387	8	.	.	PUNCT
fnp-5892	388	1	dobbelstein	dobbelstein	PROPN
fnp-5892	388	2	,	,	PUNCT
fnp-5892	388	3	m.	m.	NOUN
fnp-5892	388	4	;	;	PUNCT
fnp-5892	388	5	levine	levine	PROPN
fnp-5892	388	6	,	,	PUNCT
fnp-5892	388	7	a.j	a.j	PROPN
fnp-5892	388	8	.	.	PROPN
fnp-5892	388	9	mdm2	mdm2	PROPN
fnp-5892	388	10	:	:	PUNCT
fnp-5892	388	11	open	open	ADJ
fnp-5892	388	12	questions	question	NOUN
fnp-5892	388	13	.	.	PUNCT
fnp-5892	389	1	cancer	cancer	NOUN
fnp-5892	389	2	sci	sci	PROPN
fnp-5892	389	3	2020	2020	NUM
fnp-5892	389	4	,	,	PUNCT
fnp-5892	389	5	111	111	NUM
fnp-5892	389	6	,	,	PUNCT
fnp-5892	389	7	2203	2203	NUM
fnp-5892	389	8	-	-	SYM
fnp-5892	389	9	2211	2211	NUM
fnp-5892	389	10	.	.	PUNCT
fnp-5892	390	1	https://doi.org/10.1111/cas.14433	https://doi.org/10.1111/cas.14433	PROPN
fnp-5892	390	2	27	27	NUM
fnp-5892	390	3	.	.	PUNCT
fnp-5892	391	1	shen	shen	PROPN
fnp-5892	391	2	,	,	PUNCT
fnp-5892	391	3	a.	a.	PROPN
fnp-5892	391	4	;	;	PUNCT
fnp-5892	391	5	chen	chen	PROPN
fnp-5892	391	6	,	,	PUNCT
fnp-5892	391	7	y.	y.	PROPN
fnp-5892	391	8	;	;	PUNCT
fnp-5892	391	9	liu	liu	PROPN
fnp-5892	391	10	,	,	PUNCT
fnp-5892	391	11	l.	l.	PROPN
fnp-5892	391	12	;	;	PUNCT
fnp-5892	391	13	huang	huang	PROPN
fnp-5892	391	14	,	,	PUNCT
fnp-5892	391	15	y.	y.	PROPN
fnp-5892	391	16	;	;	PUNCT
fnp-5892	391	17	chen	chen	PROPN
fnp-5892	391	18	,	,	PUNCT
fnp-5892	391	19	h.	h.	PROPN
fnp-5892	391	20	;	;	PUNCT
fnp-5892	391	21	qi	qi	PROPN
fnp-5892	391	22	,	,	PUNCT
fnp-5892	391	23	f.	f.	PROPN
fnp-5892	391	24	;	;	PUNCT
fnp-5892	391	25	lin	lin	PROPN
fnp-5892	391	26	,	,	PUNCT
fnp-5892	391	27	j.	j.	PROPN
fnp-5892	391	28	;	;	PUNCT
fnp-5892	391	29	shen	shen	PROPN
fnp-5892	391	30	,	,	PUNCT
fnp-5892	391	31	z.	z.	PROPN
fnp-5892	391	32	;	;	PUNCT
fnp-5892	391	33	wu	wu	PROPN
fnp-5892	391	34	,	,	PUNCT
fnp-5892	391	35	x.	x.	PROPN
fnp-5892	391	36	;	;	PUNCT
fnp-5892	391	37	wu	wu	PROPN
fnp-5892	391	38	,	,	PUNCT
fnp-5892	391	39	m.	m.	NOUN
fnp-5892	391	40	,	,	PUNCT
fnp-5892	391	41	et	et	PROPN
fnp-5892	391	42	al	al	PROPN
fnp-5892	391	43	.	.	PUNCT
fnp-5892	391	44	ebf1	ebf1	PROPN
fnp-5892	391	45	-	-	PUNCT
fnp-5892	391	46	mediated	mediate	VERB
fnp-5892	391	47	upregulation	upregulation	NOUN
fnp-5892	391	48	of	of	ADP
fnp-5892	391	49	ribosome	ribosome	NOUN
fnp-5892	391	50	assembly	assembly	NOUN
fnp-5892	391	51	factor	factor	NOUN
fnp-5892	391	52	pno1	pno1	NOUN
fnp-5892	391	53	contributes	contribute	VERB
fnp-5892	391	54	to	to	ADP
fnp-5892	391	55	cancer	cancer	NOUN
fnp-5892	391	56	progression	progression	NOUN
fnp-5892	391	57	by	by	ADP
fnp-5892	391	58	negatively	negatively	ADV
fnp-5892	391	59	regulating	regulate	VERB
fnp-5892	391	60	the	the	DET
fnp-5892	391	61	p53	p53	NOUN
fnp-5892	391	62	signaling	signal	VERB
fnp-5892	391	63	pathway	pathway	NOUN
fnp-5892	391	64	.	.	PUNCT
fnp-5892	392	1	cancer	cancer	NOUN
fnp-5892	392	2	res	re	NOUN
fnp-5892	392	3	2019	2019	NUM
fnp-5892	392	4	,	,	PUNCT
fnp-5892	392	5	79	79	NUM
fnp-5892	392	6	,	,	PUNCT
fnp-5892	392	7	2257	2257	NUM
fnp-5892	392	8	-	-	SYM
fnp-5892	392	9	2270	2270	NUM
fnp-5892	392	10	.	.	PUNCT
fnp-5892	393	1	https://doi.org/10.1158/0008-5472.can-18-3238	https://doi.org/10.1158/0008-5472.can-18-3238	X
fnp-5892	394	1	28	28	NUM
fnp-5892	394	2	.	.	PUNCT
fnp-5892	395	1	hunter	hunter	NOUN
fnp-5892	395	2	,	,	PUNCT
fnp-5892	395	3	c.	c.	PROPN
fnp-5892	395	4	;	;	PUNCT
fnp-5892	395	5	smith	smith	PROPN
fnp-5892	395	6	,	,	PUNCT
fnp-5892	395	7	r.	r.	PROPN
fnp-5892	395	8	;	;	PUNCT
fnp-5892	395	9	cahill	cahill	PROPN
fnp-5892	395	10	,	,	PUNCT
fnp-5892	395	11	d.p	d.p	PROPN
fnp-5892	395	12	.	.	PROPN
fnp-5892	395	13	;	;	PUNCT
fnp-5892	395	14	stephens	stephen	NOUN
fnp-5892	395	15	,	,	PUNCT
fnp-5892	395	16	p.	p.	NOUN
fnp-5892	395	17	;	;	PUNCT
fnp-5892	395	18	stevens	stevens	PROPN
fnp-5892	395	19	,	,	PUNCT
fnp-5892	395	20	c.	c.	PROPN
fnp-5892	395	21	;	;	PUNCT
fnp-5892	395	22	teague	teague	NOUN
fnp-5892	395	23	,	,	PUNCT
fnp-5892	395	24	j.	j.	PROPN
fnp-5892	395	25	;	;	PUNCT
fnp-5892	395	26	greenman	greenman	NOUN
fnp-5892	395	27	,	,	PUNCT
fnp-5892	395	28	c.	c.	PROPN
fnp-5892	395	29	;	;	PUNCT
fnp-5892	395	30	edkins	edkin	NOUN
fnp-5892	395	31	,	,	PUNCT
fnp-5892	395	32	s.	s.	PROPN
fnp-5892	395	33	;	;	PUNCT
fnp-5892	395	34	bignell	bignell	PROPN
fnp-5892	395	35	,	,	PUNCT
fnp-5892	395	36	g.	g.	PROPN
fnp-5892	395	37	;	;	PUNCT
fnp-5892	395	38	davies	davy	NOUN
fnp-5892	395	39	,	,	PUNCT
fnp-5892	395	40	h.	h.	PROPN
fnp-5892	395	41	,	,	PUNCT
fnp-5892	395	42	et	et	PROPN
fnp-5892	395	43	al	al	PROPN
fnp-5892	395	44	.	.	PUNCT
fnp-5892	396	1	a	a	DET
fnp-5892	396	2	hypermutation	hypermutation	NOUN
fnp-5892	396	3	phenotype	phenotype	NOUN
fnp-5892	396	4	and	and	CCONJ
fnp-5892	396	5	somatic	somatic	ADJ
fnp-5892	396	6	msh6	msh6	NOUN
fnp-5892	396	7	mutations	mutation	NOUN
fnp-5892	396	8	in	in	ADP
fnp-5892	396	9	recurrent	recurrent	ADJ
fnp-5892	396	10	human	human	ADJ
fnp-5892	396	11	malignant	malignant	ADJ
fnp-5892	396	12	gliomas	glioma	NOUN
fnp-5892	396	13	after	after	ADP
fnp-5892	396	14	alkylator	alkylator	NOUN
fnp-5892	396	15	chemotherapy	chemotherapy	NOUN
fnp-5892	396	16	.	.	PUNCT
fnp-5892	397	1	cancer	cancer	NOUN
fnp-5892	397	2	res	re	NOUN
fnp-5892	397	3	2006	2006	NUM
fnp-5892	397	4	,	,	PUNCT
fnp-5892	397	5	66	66	NUM
fnp-5892	397	6	,	,	PUNCT
fnp-5892	397	7	3987	3987	NUM
fnp-5892	397	8	-	-	SYM
fnp-5892	397	9	3991	3991	NUM
fnp-5892	397	10	.	.	PUNCT
fnp-5892	398	1	https://doi.org/10.1158/0008-5472.can-06-0127	https://doi.org/10.1158/0008-5472.can-06-0127	PRON
fnp-5892	398	2	29	29	NUM
fnp-5892	398	3	.	.	PUNCT
fnp-5892	398	4	erson	erson	PROPN
fnp-5892	398	5	-	-	PUNCT
fnp-5892	398	6	omay	omay	PROPN
fnp-5892	398	7	,	,	PUNCT
fnp-5892	398	8	e.z	e.z	PROPN
fnp-5892	398	9	.	.	PROPN
fnp-5892	398	10	;	;	PUNCT
fnp-5892	398	11	caglayan	caglayan	NOUN
fnp-5892	398	12	,	,	PUNCT
fnp-5892	398	13	a.o	a.o	PROPN
fnp-5892	398	14	.	.	PROPN
fnp-5892	398	15	;	;	PUNCT
fnp-5892	398	16	schultz	schultz	PROPN
fnp-5892	398	17	,	,	PUNCT
fnp-5892	398	18	n.	n.	NOUN
fnp-5892	398	19	;	;	PUNCT
fnp-5892	398	20	weinhold	weinhold	ADJ
fnp-5892	398	21	,	,	PUNCT
fnp-5892	398	22	n.	n.	NOUN
fnp-5892	398	23	;	;	PUNCT
fnp-5892	398	24	omay	omay	PROPN
fnp-5892	398	25	,	,	PUNCT
fnp-5892	398	26	s.b	s.b	PROPN
fnp-5892	398	27	.	.	PROPN
fnp-5892	398	28	;	;	PUNCT
fnp-5892	398	29	ozduman	ozduman	NOUN
fnp-5892	398	30	,	,	PUNCT
fnp-5892	398	31	k.	k.	PROPN
fnp-5892	398	32	;	;	PUNCT
fnp-5892	398	33	koksal	koksal	PROPN
fnp-5892	398	34	,	,	PUNCT
fnp-5892	398	35	y.	y.	PROPN
fnp-5892	398	36	;	;	PUNCT
fnp-5892	398	37	li	li	PROPN
fnp-5892	398	38	,	,	PUNCT
fnp-5892	398	39	j.	j.	PROPN
fnp-5892	398	40	;	;	PUNCT
fnp-5892	398	41	serin	serin	PROPN
fnp-5892	398	42	harmanci	harmanci	PROPN
fnp-5892	398	43	,	,	PUNCT
fnp-5892	398	44	a.	a.	NOUN
fnp-5892	398	45	;	;	PUNCT
fnp-5892	398	46	clark	clark	PROPN
fnp-5892	398	47	,	,	PUNCT
fnp-5892	398	48	v.	v.	PROPN
fnp-5892	398	49	,	,	PUNCT
fnp-5892	398	50	et	et	PROPN
fnp-5892	398	51	al	al	PROPN
fnp-5892	398	52	.	.	PROPN
fnp-5892	398	53	somatic	somatic	ADJ
fnp-5892	398	54	pole	pole	NOUN
fnp-5892	398	55	mutations	mutation	NOUN
fnp-5892	398	56	cause	cause	VERB
fnp-5892	398	57	an	an	DET
fnp-5892	398	58	ultramutated	ultramutated	ADJ
fnp-5892	398	59	giant	giant	ADJ
fnp-5892	398	60	cell	cell	NOUN
fnp-5892	398	61	high	high	ADJ
fnp-5892	398	62	-	-	PUNCT
fnp-5892	398	63	grade	grade	NOUN
fnp-5892	398	64	glioma	glioma	NOUN
fnp-5892	398	65	subtype	subtype	NOUN
fnp-5892	398	66	with	with	ADP
fnp-5892	398	67	better	well	ADJ
fnp-5892	398	68	prognosis	prognosis	NOUN
fnp-5892	398	69	.	.	PUNCT
fnp-5892	399	1	neuro	neuro	PROPN
fnp-5892	399	2	oncol	oncol	ADJ
fnp-5892	399	3	2015	2015	NUM
fnp-5892	399	4	,	,	PUNCT
fnp-5892	399	5	17	17	NUM
fnp-5892	399	6	,	,	PUNCT
fnp-5892	399	7	1356	1356	NUM
fnp-5892	399	8	-	-	SYM
fnp-5892	399	9	1364	1364	NUM
fnp-5892	399	10	.	.	PUNCT
fnp-5892	400	1	https://doi.org/10.1093/neuonc/nov027	https://doi.org/10.1093/neuonc/nov027	ADV
fnp-5892	400	2	30	30	NUM
fnp-5892	400	3	.	.	PUNCT
fnp-5892	400	4	paller	paller	NOUN
fnp-5892	400	5	,	,	PUNCT
fnp-5892	400	6	c.j	c.j	PROPN
fnp-5892	400	7	.	.	PROPN
fnp-5892	400	8	;	;	PUNCT
fnp-5892	400	9	tukachinsky	tukachinsky	PROPN
fnp-5892	400	10	,	,	PUNCT
fnp-5892	400	11	h.	h.	PROPN
fnp-5892	400	12	;	;	PUNCT
fnp-5892	400	13	maertens	maertens	PROPN
fnp-5892	400	14	,	,	PUNCT
fnp-5892	400	15	a.	a.	NOUN
fnp-5892	400	16	;	;	PUNCT
fnp-5892	400	17	decker	decker	PROPN
fnp-5892	400	18	,	,	PUNCT
fnp-5892	400	19	b.	b.	PROPN
fnp-5892	400	20	;	;	PUNCT
fnp-5892	400	21	sampson	sampson	PROPN
fnp-5892	400	22	,	,	PUNCT
fnp-5892	400	23	j.r	j.r	PROPN
fnp-5892	400	24	.	.	PROPN
fnp-5892	400	25	;	;	PUNCT
fnp-5892	400	26	cheadle	cheadle	PROPN
fnp-5892	400	27	,	,	PUNCT
fnp-5892	400	28	j.p	j.p	PROPN
fnp-5892	400	29	.	.	PROPN
fnp-5892	400	30	;	;	PUNCT
fnp-5892	400	31	antonarakis	antonarakis	PROPN
fnp-5892	400	32	,	,	PUNCT
fnp-5892	400	33	e.s	e.s	PROPN
fnp-5892	400	34	.	.	PROPN
fnp-5892	400	35	pan	pan	PROPN
fnp-5892	400	36	-	-	ADJ
fnp-5892	400	37	cancer	cancer	ADJ
fnp-5892	400	38	interrogation	interrogation	NOUN
fnp-5892	400	39	of	of	ADP
fnp-5892	400	40	mutyh	mutyh	PROPN
fnp-5892	400	41	variants	variant	NOUN
fnp-5892	400	42	reveals	reveal	VERB
fnp-5892	400	43	biallelic	biallelic	ADJ
fnp-5892	400	44	inactivation	inactivation	NOUN
fnp-5892	400	45	and	and	CCONJ
fnp-5892	400	46	defective	defective	ADJ
fnp-5892	400	47	base	base	NOUN
fnp-5892	400	48	excision	excision	NOUN
fnp-5892	400	49	repair	repair	NOUN
fnp-5892	400	50	across	across	ADP
fnp-5892	400	51	a	a	DET
fnp-5892	400	52	spectrum	spectrum	NOUN
fnp-5892	400	53	of	of	ADP
fnp-5892	400	54	solid	solid	ADJ
fnp-5892	400	55	tumors	tumor	NOUN
fnp-5892	400	56	.	.	PUNCT
fnp-5892	401	1	jco	jco	PROPN
fnp-5892	401	2	precis	precis	PROPN
fnp-5892	401	3	oncol	oncol	PROPN
fnp-5892	401	4	2024	2024	NUM
fnp-5892	401	5	,	,	PUNCT
fnp-5892	401	6	8	8	NUM
fnp-5892	401	7	,	,	PUNCT
fnp-5892	401	8	e2300251	e2300251	NOUN
fnp-5892	401	9	.	.	PUNCT
fnp-5892	402	1	https://doi.org/10.1200/po.23.00251	https://doi.org/10.1200/po.23.00251	PROPN
fnp-5892	403	1	31	31	NUM
fnp-5892	403	2	.	.	PUNCT
fnp-5892	404	1	heitzer	heitzer	PROPN
fnp-5892	404	2	,	,	PUNCT
fnp-5892	404	3	e.	e.	PROPN
fnp-5892	404	4	;	;	PUNCT
fnp-5892	404	5	tomlinson	tomlinson	PROPN
fnp-5892	404	6	,	,	PUNCT
fnp-5892	404	7	i.	i.	PROPN
fnp-5892	404	8	replicative	replicative	PROPN
fnp-5892	404	9	dna	dna	PROPN
fnp-5892	404	10	polymerase	polymerase	NOUN
fnp-5892	404	11	mutations	mutation	NOUN
fnp-5892	404	12	in	in	ADP
fnp-5892	404	13	cancer	cancer	NOUN
fnp-5892	404	14	.	.	PUNCT
fnp-5892	405	1	curr	curr	PROPN
fnp-5892	405	2	opin	opin	PROPN
fnp-5892	405	3	genet	genet	PROPN
fnp-5892	405	4	dev	dev	PROPN
fnp-5892	405	5	2014	2014	NUM
fnp-5892	405	6	,	,	PUNCT
fnp-5892	405	7	24	24	NUM
fnp-5892	405	8	,	,	PUNCT
fnp-5892	405	9	107	107	NUM
fnp-5892	405	10	-	-	SYM
fnp-5892	405	11	113	113	NUM
fnp-5892	405	12	.	.	PUNCT
fnp-5892	406	1	https://doi.org/10.1016/j.gde.2013.12.005	https://doi.org/10.1016/j.gde.2013.12.005	PROPN
fnp-5892	406	2	32	32	NUM
fnp-5892	406	3	.	.	PUNCT
fnp-5892	407	1	mark	mark	PROPN
fnp-5892	407	2	,	,	PUNCT
fnp-5892	407	3	s.c	s.c	PROPN
fnp-5892	407	4	.	.	PROPN
fnp-5892	407	5	;	;	PUNCT
fnp-5892	408	1	sandercock	sandercock	NOUN
fnp-5892	408	2	,	,	PUNCT
fnp-5892	408	3	l.e	l.e	PROPN
fnp-5892	408	4	.	.	PROPN
fnp-5892	408	5	;	;	PUNCT
fnp-5892	408	6	luchman	luchman	PROPN
fnp-5892	408	7	,	,	PUNCT
fnp-5892	408	8	h.a	h.a	PROPN
fnp-5892	408	9	.	.	PROPN
fnp-5892	408	10	;	;	PUNCT
fnp-5892	408	11	baross	baross	PROPN
fnp-5892	408	12	,	,	PUNCT
fnp-5892	408	13	a.	a.	NOUN
fnp-5892	408	14	;	;	PUNCT
fnp-5892	408	15	edelmann	edelmann	PROPN
fnp-5892	408	16	,	,	PUNCT
fnp-5892	408	17	w.	w.	PROPN
fnp-5892	408	18	;	;	PUNCT
fnp-5892	408	19	jirik	jirik	PROPN
fnp-5892	408	20	,	,	PUNCT
fnp-5892	408	21	f.r	f.r	PROPN
fnp-5892	408	22	.	.	PROPN
fnp-5892	408	23	elevated	elevated	ADJ
fnp-5892	408	24	mutant	mutant	ADJ
fnp-5892	408	25	frequencies	frequency	NOUN
fnp-5892	408	26	and	and	CCONJ
fnp-5892	408	27	predominance	predominance	NOUN
fnp-5892	408	28	of	of	ADP
fnp-5892	408	29	g	g	NOUN
fnp-5892	408	30	:	:	PUNCT
fnp-5892	408	31	c	c	NOUN
fnp-5892	408	32	to	to	ADP
fnp-5892	408	33	a	a	DET
fnp-5892	408	34	:	:	PUNCT
fnp-5892	408	35	t	t	NOUN
fnp-5892	408	36	transition	transition	NOUN
fnp-5892	408	37	mutations	mutation	NOUN
fnp-5892	408	38	in	in	ADP
fnp-5892	408	39	msh6(-/-	msh6(-/-	NOUN
fnp-5892	408	40	)	)	PUNCT
fnp-5892	408	41	small	small	ADJ
fnp-5892	408	42	intestinal	intestinal	ADJ
fnp-5892	408	43	epithelium	epithelium	NOUN
fnp-5892	408	44	.	.	PUNCT
fnp-5892	409	1	oncogene	oncogene	NOUN
fnp-5892	409	2	2002	2002	NUM
fnp-5892	409	3	,	,	PUNCT
fnp-5892	409	4	21	21	NUM
fnp-5892	409	5	,	,	PUNCT
fnp-5892	409	6	7126	7126	NUM
fnp-5892	409	7	-	-	SYM
fnp-5892	409	8	7130	7130	NUM
fnp-5892	409	9	.	.	PUNCT
fnp-5892	410	1	https://doi.org/10.1038/sj.onc.1205861	https://doi.org/10.1038/sj.onc.1205861	NOUN
fnp-5892	410	2	33	33	NUM
fnp-5892	410	3	.	.	PUNCT
fnp-5892	410	4	song	song	PROPN
fnp-5892	410	5	,	,	PUNCT
fnp-5892	410	6	d.	d.	PROPN
fnp-5892	410	7	;	;	PUNCT
fnp-5892	410	8	lian	lian	PROPN
fnp-5892	410	9	,	,	PUNCT
fnp-5892	410	10	y.	y.	PROPN
fnp-5892	410	11	;	;	PUNCT
fnp-5892	410	12	zhang	zhang	PROPN
fnp-5892	410	13	,	,	PUNCT
fnp-5892	410	14	l.	l.	PROPN
fnp-5892	410	15	the	the	DET
fnp-5892	410	16	potential	potential	NOUN
fnp-5892	410	17	of	of	ADP
fnp-5892	410	18	activator	activator	NOUN
fnp-5892	410	19	protein	protein	NOUN
fnp-5892	410	20	1	1	NUM
fnp-5892	410	21	(	(	PUNCT
fnp-5892	410	22	ap-1	ap-1	ADV
fnp-5892	410	23	)	)	PUNCT
fnp-5892	410	24	in	in	ADP
fnp-5892	410	25	cancer	cancer	NOUN
fnp-5892	410	26	targeted	target	VERB
fnp-5892	410	27	therapy	therapy	NOUN
fnp-5892	410	28	.	.	PUNCT
fnp-5892	411	1	front	front	ADJ
fnp-5892	411	2	immunol	immunol	NOUN
fnp-5892	411	3	2023	2023	NUM
fnp-5892	411	4	,	,	PUNCT
fnp-5892	411	5	14	14	NUM
fnp-5892	411	6	,	,	PUNCT
fnp-5892	411	7	1224892	1224892	NUM
fnp-5892	411	8	.	.	PUNCT
fnp-5892	412	1	https://doi.org/10.3389/fimmu.2023.1224892	https://doi.org/10.3389/fimmu.2023.1224892	PROPN
fnp-5892	412	2	34	34	NUM
fnp-5892	412	3	.	.	PUNCT
fnp-5892	412	4	caunt	caunt	PROPN
fnp-5892	412	5	,	,	PUNCT
fnp-5892	412	6	c.j	c.j	PROPN
fnp-5892	412	7	.	.	PROPN
fnp-5892	412	8	;	;	PUNCT
fnp-5892	412	9	keyse	keyse	PROPN
fnp-5892	412	10	,	,	PUNCT
fnp-5892	412	11	s.m	s.m	PROPN
fnp-5892	412	12	.	.	PROPN
fnp-5892	412	13	dual	dual	ADJ
fnp-5892	412	14	-	-	PUNCT
fnp-5892	412	15	specificity	specificity	NOUN
fnp-5892	412	16	map	map	NOUN
fnp-5892	412	17	kinase	kinase	PROPN
fnp-5892	412	18	phosphatases	phosphatase	NOUN
fnp-5892	412	19	(	(	PUNCT
fnp-5892	412	20	mkps	mkps	NOUN
fnp-5892	412	21	):	):	PUNCT
fnp-5892	412	22	shaping	shape	VERB
fnp-5892	412	23	the	the	DET
fnp-5892	412	24	outcome	outcome	NOUN
fnp-5892	412	25	of	of	ADP
fnp-5892	412	26	map	map	NOUN
fnp-5892	412	27	kinase	kinase	PROPN
fnp-5892	412	28	signalling	signal	VERB
fnp-5892	412	29	.	.	PUNCT
fnp-5892	413	1	febs	febs	PROPN
fnp-5892	413	2	j	j	PROPN
fnp-5892	413	3	2013	2013	NUM
fnp-5892	413	4	,	,	PUNCT
fnp-5892	413	5	280	280	NUM
fnp-5892	413	6	,	,	PUNCT
fnp-5892	413	7	489	489	NUM
fnp-5892	413	8	-	-	SYM
fnp-5892	413	9	504	504	NUM
fnp-5892	413	10	.	.	PUNCT
fnp-5892	414	1	https://doi.org/10.1111/j.1742-4658.2012.08716.x	https://doi.org/10.1111/j.1742-4658.2012.08716.x	NOUN
fnp-5892	414	2	35	35	NUM
fnp-5892	414	3	.	.	X
fnp-5892	415	1	ornitz	ornitz	PROPN
fnp-5892	415	2	,	,	PUNCT
fnp-5892	415	3	d.m	d.m	PROPN
fnp-5892	415	4	.	.	PUNCT
fnp-5892	415	5	;	;	PUNCT
fnp-5892	415	6	itoh	itoh	ADJ
fnp-5892	415	7	,	,	PUNCT
fnp-5892	415	8	n.	n.	VERB
fnp-5892	415	9	the	the	DET
fnp-5892	415	10	fibroblast	fibroblast	ADJ
fnp-5892	415	11	growth	growth	NOUN
fnp-5892	415	12	factor	factor	NOUN
fnp-5892	415	13	signaling	signal	VERB
fnp-5892	415	14	pathway	pathway	NOUN
fnp-5892	415	15	.	.	PUNCT
fnp-5892	416	1	wiley	wiley	PROPN
fnp-5892	416	2	interdiscip	interdiscip	PROPN
fnp-5892	416	3	rev	rev	VERB
fnp-5892	416	4	dev	dev	PROPN
fnp-5892	416	5	biol	biol	PROPN
fnp-5892	416	6	2015	2015	NUM
fnp-5892	416	7	,	,	PUNCT
fnp-5892	416	8	4	4	NUM
fnp-5892	416	9	,	,	PUNCT
fnp-5892	416	10	215	215	NUM
fnp-5892	416	11	-	-	SYM
fnp-5892	416	12	266	266	NUM
fnp-5892	416	13	.	.	PUNCT
fnp-5892	417	1	https://doi.org/10.1002/wdev.176	https://doi.org/10.1002/wdev.176	X
fnp-5892	418	1	36	36	NUM
fnp-5892	418	2	.	.	PUNCT
fnp-5892	418	3	segatto	segatto	PROPN
fnp-5892	418	4	,	,	PUNCT
fnp-5892	418	5	o.	o.	PROPN
fnp-5892	418	6	;	;	PUNCT
fnp-5892	418	7	anastasi	anastasi	PROPN
fnp-5892	418	8	,	,	PUNCT
fnp-5892	418	9	s.	s.	PROPN
fnp-5892	418	10	;	;	PUNCT
fnp-5892	418	11	alema	alema	PROPN
fnp-5892	418	12	,	,	PUNCT
fnp-5892	418	13	s.	s.	PROPN
fnp-5892	418	14	regulation	regulation	NOUN
fnp-5892	418	15	of	of	ADP
fnp-5892	418	16	epidermal	epidermal	ADJ
fnp-5892	418	17	growth	growth	NOUN
fnp-5892	418	18	factor	factor	NOUN
fnp-5892	418	19	receptor	receptor	NOUN
fnp-5892	418	20	signalling	signal	VERB
fnp-5892	418	21	by	by	ADP
fnp-5892	418	22	inducible	inducible	ADJ
fnp-5892	418	23	feedback	feedback	NOUN
fnp-5892	418	24	inhibitors	inhibitor	NOUN
fnp-5892	418	25	.	.	PUNCT
fnp-5892	419	1	j	j	PROPN
fnp-5892	419	2	cell	cell	NOUN
fnp-5892	419	3	sci	sci	PROPN
fnp-5892	419	4	2011	2011	NUM
fnp-5892	419	5	,	,	PUNCT
fnp-5892	419	6	124	124	NUM
fnp-5892	419	7	,	,	PUNCT
fnp-5892	419	8	1785	1785	NUM
fnp-5892	419	9	-	-	SYM
fnp-5892	419	10	1793	1793	NUM
fnp-5892	419	11	.	.	PUNCT
fnp-5892	420	1	https://doi.org/10.1242/jcs.083303	https://doi.org/10.1242/jcs.083303	VERB
fnp-5892	420	2	37	37	NUM
fnp-5892	420	3	.	.	PUNCT
fnp-5892	421	1	barresi	barresi	NOUN
fnp-5892	421	2	,	,	PUNCT
fnp-5892	421	3	v.	v.	PROPN
fnp-5892	421	4	;	;	PUNCT
fnp-5892	421	5	simbolo	simbolo	ADJ
fnp-5892	421	6	,	,	PUNCT
fnp-5892	421	7	m.	m.	NOUN
fnp-5892	421	8	;	;	PUNCT
fnp-5892	421	9	mafficini	mafficini	PROPN
fnp-5892	421	10	,	,	PUNCT
fnp-5892	421	11	a.	a.	NOUN
fnp-5892	421	12	;	;	PUNCT
fnp-5892	421	13	piredda	piredda	NOUN
fnp-5892	421	14	,	,	PUNCT
fnp-5892	421	15	m.l	m.l	PROPN
fnp-5892	421	16	.	.	PROPN
fnp-5892	421	17	;	;	PUNCT
fnp-5892	421	18	caffo	caffo	NOUN
fnp-5892	421	19	,	,	PUNCT
fnp-5892	421	20	m.	m.	NOUN
fnp-5892	421	21	;	;	PUNCT
fnp-5892	421	22	cardali	cardali	PROPN
fnp-5892	421	23	,	,	PUNCT
fnp-5892	421	24	s.m	s.m	PROPN
fnp-5892	421	25	.	.	PROPN
fnp-5892	421	26	;	;	PUNCT
fnp-5892	422	1	germano	germano	PROPN
fnp-5892	422	2	,	,	PUNCT
fnp-5892	422	3	a.	a.	NOUN
fnp-5892	422	4	;	;	PUNCT
fnp-5892	422	5	cingarlini	cingarlini	PROPN
fnp-5892	422	6	,	,	PUNCT
fnp-5892	422	7	s.	s.	PROPN
fnp-5892	422	8	;	;	PUNCT
fnp-5892	422	9	ghimenton	ghimenton	PROPN
fnp-5892	422	10	,	,	PUNCT
fnp-5892	422	11	c.	c.	PROPN
fnp-5892	422	12	;	;	PUNCT
fnp-5892	422	13	scarpa	scarpa	NOUN
fnp-5892	422	14	,	,	PUNCT
fnp-5892	422	15	a.	a.	NOUN
fnp-5892	422	16	ultra	ultra	NOUN
fnp-5892	422	17	-	-	NOUN
fnp-5892	422	18	mutation	mutation	NOUN
fnp-5892	422	19	in	in	ADP
fnp-5892	422	20	idh	idh	ADJ
fnp-5892	422	21	wild	wild	ADJ
fnp-5892	422	22	-	-	PUNCT
fnp-5892	422	23	type	type	NOUN
fnp-5892	422	24	glioblastomas	glioblastoma	NOUN
fnp-5892	422	25	of	of	ADP
fnp-5892	422	26	patients	patient	NOUN
fnp-5892	422	27	younger	young	ADJ
fnp-5892	422	28	than	than	ADP
fnp-5892	422	29	55	55	NUM
fnp-5892	422	30	years	year	NOUN
fnp-5892	422	31	is	be	AUX
fnp-5892	422	32	associated	associate	VERB
fnp-5892	422	33	with	with	ADP
fnp-5892	422	34	defective	defective	ADJ
fnp-5892	422	35	mismatch	mismatch	NOUN
fnp-5892	422	36	repair	repair	NOUN
fnp-5892	422	37	,	,	PUNCT
fnp-5892	422	38	microsatellite	microsatellite	ADJ
fnp-5892	422	39	instability	instability	NOUN
fnp-5892	422	40	,	,	PUNCT
fnp-5892	422	41	and	and	CCONJ
fnp-5892	422	42	giant	giant	ADJ
fnp-5892	422	43	cell	cell	NOUN
fnp-5892	422	44	enrichment	enrichment	NOUN
fnp-5892	422	45	.	.	PUNCT
fnp-5892	423	1	cancers	cancer	NOUN
fnp-5892	423	2	(	(	PUNCT
fnp-5892	423	3	basel	basel	PROPN
fnp-5892	423	4	)	)	PUNCT
fnp-5892	423	5	2019	2019	NUM
fnp-5892	423	6	,	,	PUNCT
fnp-5892	423	7	11,https://doi.org/10.3390	11,https://doi.org/10.3390	X
fnp-5892	423	8	/	/	SYM
fnp-5892	423	9	cancers11091279	cancers11091279	PROPN
fnp-5892	423	10	38	38	NUM
fnp-5892	423	11	.	.	PUNCT
fnp-5892	424	1	suwala	suwala	NOUN
fnp-5892	424	2	,	,	PUNCT
fnp-5892	424	3	a.k	a.k	PROPN
fnp-5892	424	4	.	.	PROPN
fnp-5892	424	5	;	;	PUNCT
fnp-5892	424	6	stichel	stichel	PROPN
fnp-5892	424	7	,	,	PUNCT
fnp-5892	424	8	d.	d.	PROPN
fnp-5892	424	9	;	;	PUNCT
fnp-5892	424	10	schrimpf	schrimpf	NOUN
fnp-5892	424	11	,	,	PUNCT
fnp-5892	424	12	d.	d.	PROPN
fnp-5892	424	13	;	;	PUNCT
fnp-5892	424	14	kloor	kloor	PROPN
fnp-5892	424	15	,	,	PUNCT
fnp-5892	424	16	m.	m.	NOUN
fnp-5892	424	17	;	;	PUNCT
fnp-5892	424	18	wefers	wefer	NOUN
fnp-5892	424	19	,	,	PUNCT
fnp-5892	424	20	a.k	a.k	PROPN
fnp-5892	424	21	.	.	PROPN
fnp-5892	424	22	;	;	PUNCT
fnp-5892	424	23	reinhardt	reinhardt	PROPN
fnp-5892	424	24	,	,	PUNCT
fnp-5892	424	25	a.	a.	NOUN
fnp-5892	424	26	;	;	PUNCT
fnp-5892	424	27	maas	maas	PROPN
fnp-5892	424	28	,	,	PUNCT
fnp-5892	424	29	s.l.n	s.l.n	PROPN
fnp-5892	424	30	.	.	PROPN
fnp-5892	424	31	;	;	PUNCT
fnp-5892	425	1	kratz	kratz	PROPN
fnp-5892	425	2	,	,	PUNCT
fnp-5892	425	3	c.p	c.p	PROPN
fnp-5892	425	4	.	.	PROPN
fnp-5892	425	5	;	;	PUNCT
fnp-5892	425	6	schweizer	schweizer	PROPN
fnp-5892	425	7	,	,	PUNCT
fnp-5892	425	8	l.	l.	PROPN
fnp-5892	425	9	;	;	PUNCT
fnp-5892	425	10	hasselblatt	hasselblatt	PROPN
fnp-5892	425	11	,	,	PUNCT
fnp-5892	425	12	m.	m.	NOUN
fnp-5892	425	13	,	,	PUNCT
fnp-5892	425	14	et	et	PROPN
fnp-5892	425	15	al	al	PROPN
fnp-5892	425	16	.	.	PROPN
fnp-5892	425	17	primary	primary	ADJ
fnp-5892	425	18	mismatch	mismatch	PROPN
fnp-5892	425	19	repair	repair	NOUN
fnp-5892	425	20	deficient	deficient	ADJ
fnp-5892	425	21	idh	idh	NOUN
fnp-5892	425	22	-	-	PUNCT
fnp-5892	425	23	mutant	mutant	NOUN
fnp-5892	425	24	astrocytoma	astrocytoma	NOUN
fnp-5892	425	25	(	(	PUNCT
fnp-5892	425	26	pmmrdia	pmmrdia	PROPN
fnp-5892	425	27	)	)	PUNCT
fnp-5892	425	28	is	be	AUX
fnp-5892	425	29	a	a	DET
fnp-5892	425	30	distinct	distinct	ADJ
fnp-5892	425	31	type	type	NOUN
fnp-5892	425	32	with	with	ADP
fnp-5892	425	33	a	a	DET
fnp-5892	425	34	poor	poor	ADJ
fnp-5892	425	35	prognosis	prognosis	NOUN
fnp-5892	425	36	.	.	PUNCT
fnp-5892	426	1	acta	acta	PROPN
fnp-5892	426	2	neuropathol	neuropathol	PROPN
fnp-5892	426	3	2021	2021	NUM
fnp-5892	426	4	,	,	PUNCT
fnp-5892	426	5	141	141	NUM
fnp-5892	426	6	,	,	PUNCT
fnp-5892	426	7	85	85	NUM
fnp-5892	426	8	-	-	SYM
fnp-5892	426	9	100	100	NUM
fnp-5892	426	10	.	.	PUNCT
fnp-5892	427	1	https://doi.org/10.1007/s00401-020-02243-6	https://doi.org/10.1007/s00401-020-02243-6	NUM
fnp-5892	427	2	39	39	NUM
fnp-5892	427	3	.	.	PUNCT
fnp-5892	428	1	lombardi	lombardi	PROPN
fnp-5892	428	2	,	,	PUNCT
fnp-5892	428	3	g.	g.	PROPN
fnp-5892	428	4	;	;	PUNCT
fnp-5892	428	5	barresi	barresi	NOUN
fnp-5892	428	6	,	,	PUNCT
fnp-5892	428	7	v.	v.	ADV
fnp-5892	428	8	;	;	PUNCT
fnp-5892	428	9	indraccolo	indraccolo	PROPN
fnp-5892	428	10	,	,	PUNCT
fnp-5892	428	11	s.	s.	PROPN
fnp-5892	428	12	;	;	PUNCT
fnp-5892	428	13	simbolo	simbolo	ADJ
fnp-5892	428	14	,	,	PUNCT
fnp-5892	428	15	m.	m.	NOUN
fnp-5892	428	16	;	;	PUNCT
fnp-5892	428	17	fassan	fassan	ADJ
fnp-5892	428	18	,	,	PUNCT
fnp-5892	428	19	m.	m.	NOUN
fnp-5892	428	20	;	;	PUNCT
fnp-5892	428	21	mandruzzato	mandruzzato	ADJ
fnp-5892	428	22	,	,	PUNCT
fnp-5892	428	23	s.	s.	PROPN
fnp-5892	428	24	;	;	PUNCT
fnp-5892	428	25	simonelli	simonelli	PROPN
fnp-5892	428	26	,	,	PUNCT
fnp-5892	428	27	m.	m.	NOUN
fnp-5892	428	28	;	;	PUNCT
fnp-5892	428	29	caccese	caccese	PROPN
fnp-5892	428	30	,	,	PUNCT
fnp-5892	428	31	m.	m.	NOUN
fnp-5892	428	32	;	;	PUNCT
fnp-5892	428	33	pizzi	pizzi	PROPN
fnp-5892	428	34	,	,	PUNCT
fnp-5892	428	35	m.	m.	NOUN
fnp-5892	428	36	;	;	PUNCT
fnp-5892	428	37	fassina	fassina	PROPN
fnp-5892	428	38	,	,	PUNCT
fnp-5892	428	39	a.	a.	NOUN
fnp-5892	428	40	,	,	PUNCT
fnp-5892	428	41	et	et	PROPN
fnp-5892	428	42	al	al	PROPN
fnp-5892	428	43	.	.	PROPN
fnp-5892	428	44	pembrolizumab	pembrolizumab	NOUN
fnp-5892	428	45	activity	activity	NOUN
fnp-5892	428	46	in	in	ADP
fnp-5892	428	47	recurrent	recurrent	ADJ
fnp-5892	428	48	high	high	ADJ
fnp-5892	428	49	-	-	PUNCT
fnp-5892	428	50	grade	grade	NOUN
fnp-5892	428	51	gliomas	glioma	NOUN
fnp-5892	428	52	with	with	ADP
fnp-5892	428	53	partial	partial	ADJ
fnp-5892	428	54	or	or	CCONJ
fnp-5892	428	55	complete	complete	ADJ
fnp-5892	428	56	loss	loss	NOUN
fnp-5892	428	57	of	of	ADP
fnp-5892	428	58	mismatch	mismatch	ADJ
fnp-5892	428	59	repair	repair	NOUN
fnp-5892	428	60	protein	protein	NOUN
fnp-5892	428	61	expression	expression	NOUN
fnp-5892	428	62	:	:	PUNCT
fnp-5892	428	63	a	a	DET
fnp-5892	428	64	monocentric	monocentric	ADJ
fnp-5892	428	65	,	,	PUNCT
fnp-5892	428	66	observational	observational	ADJ
fnp-5892	428	67	and	and	CCONJ
fnp-5892	428	68	prospective	prospective	ADJ
fnp-5892	428	69	pilot	pilot	NOUN
fnp-5892	428	70	study	study	NOUN
fnp-5892	428	71	.	.	PUNCT
fnp-5892	429	1	cancers	cancer	NOUN
fnp-5892	429	2	(	(	PUNCT
fnp-5892	429	3	basel	basel	PROPN
fnp-5892	429	4	)	)	PUNCT
fnp-5892	429	5	2020	2020	NUM
fnp-5892	429	6	,	,	PUNCT
fnp-5892	429	7	12	12	NUM
fnp-5892	429	8	.	.	PUNCT
fnp-5892	430	1	https://doi.org/10.3390/cancers12082283	https://doi.org/10.3390/cancers12082283	PROPN
fnp-5892	430	2	40	40	NUM
fnp-5892	430	3	.	.	PUNCT
fnp-5892	431	1	nakase	nakase	PROPN
fnp-5892	431	2	,	,	PUNCT
fnp-5892	431	3	k.	k.	PROPN
fnp-5892	431	4	;	;	PUNCT
fnp-5892	431	5	matsuda	matsuda	PROPN
fnp-5892	431	6	,	,	PUNCT
fnp-5892	431	7	r.	r.	PROPN
fnp-5892	431	8	;	;	PUNCT
fnp-5892	431	9	sasaki	sasaki	PROPN
fnp-5892	431	10	,	,	PUNCT
fnp-5892	431	11	s.	s.	PROPN
fnp-5892	431	12	;	;	PUNCT
fnp-5892	431	13	nakagawa	nakagawa	PROPN
fnp-5892	431	14	,	,	PUNCT
fnp-5892	431	15	i.	i.	PROPN
fnp-5892	431	16	lynch	lynch	PROPN
fnp-5892	431	17	syndrome	syndrome	PROPN
fnp-5892	431	18	-	-	PUNCT
fnp-5892	431	19	associated	associate	VERB
fnp-5892	431	20	glioblastoma	glioblastoma	NOUN
fnp-5892	431	21	treated	treat	VERB
fnp-5892	431	22	with	with	ADP
fnp-5892	431	23	concomitant	concomitant	ADJ
fnp-5892	431	24	chemoradiotherapy	chemoradiotherapy	NOUN
fnp-5892	431	25	and	and	CCONJ
fnp-5892	431	26	immune	immune	ADJ
fnp-5892	431	27	checkpoint	checkpoint	NOUN
fnp-5892	431	28	inhibitors	inhibitor	NOUN
fnp-5892	431	29	:	:	PUNCT
fnp-5892	431	30	case	case	NOUN
fnp-5892	431	31	report	report	NOUN
fnp-5892	431	32	and	and	CCONJ
fnp-5892	431	33	review	review	NOUN
fnp-5892	431	34	of	of	ADP
fnp-5892	431	35	literature	literature	NOUN
fnp-5892	431	36	.	.	PUNCT
fnp-5892	432	1	brain	brain	NOUN
fnp-5892	432	2	tumor	tumor	NOUN
fnp-5892	432	3	res	re	NOUN
fnp-5892	432	4	treat	treat	NOUN
fnp-5892	432	5	2024	2024	NUM
fnp-5892	432	6	,	,	PUNCT
fnp-5892	432	7	12	12	NUM
fnp-5892	432	8	,	,	PUNCT
fnp-5892	432	9	70	70	NUM
fnp-5892	432	10	-	-	SYM
fnp-5892	432	11	74	74	NUM
fnp-5892	432	12	.	.	PUNCT
fnp-5892	433	1	https://doi.org/10.14791/btrt.2023.0042	https://doi.org/10.14791/btrt.2023.0042	PROPN
fnp-5892	433	2	41	41	NUM
fnp-5892	433	3	.	.	PUNCT
fnp-5892	433	4	bouffet	bouffet	PROPN
fnp-5892	433	5	,	,	PUNCT
fnp-5892	433	6	e.	e.	PROPN
fnp-5892	433	7	;	;	PUNCT
fnp-5892	433	8	larouche	larouche	PROPN
fnp-5892	433	9	,	,	PUNCT
fnp-5892	433	10	v.	v.	PROPN
fnp-5892	433	11	;	;	PUNCT
fnp-5892	433	12	campbell	campbell	PROPN
fnp-5892	433	13	,	,	PUNCT
fnp-5892	433	14	b.b	b.b	PROPN
fnp-5892	433	15	.	.	PROPN
fnp-5892	433	16	;	;	PUNCT
fnp-5892	433	17	merico	merico	PROPN
fnp-5892	433	18	,	,	PUNCT
fnp-5892	433	19	d.	d.	PROPN
fnp-5892	433	20	;	;	PUNCT
fnp-5892	433	21	de	de	PROPN
fnp-5892	433	22	borja	borja	PROPN
fnp-5892	433	23	,	,	PUNCT
fnp-5892	433	24	r.	r.	PROPN
fnp-5892	433	25	;	;	PUNCT
fnp-5892	433	26	aronson	aronson	PROPN
fnp-5892	433	27	,	,	PUNCT
fnp-5892	433	28	m.	m.	NOUN
fnp-5892	433	29	;	;	PUNCT
fnp-5892	433	30	durno	durno	NOUN
fnp-5892	433	31	,	,	PUNCT
fnp-5892	433	32	c.	c.	PROPN
fnp-5892	433	33	;	;	PUNCT
fnp-5892	433	34	krueger	krueger	PROPN
fnp-5892	433	35	,	,	PUNCT
fnp-5892	433	36	j.	j.	PROPN
fnp-5892	433	37	;	;	PUNCT
fnp-5892	433	38	cabric	cabric	NOUN
fnp-5892	433	39	,	,	PUNCT
fnp-5892	433	40	v.	v.	PROPN
fnp-5892	433	41	;	;	PUNCT
fnp-5892	433	42	ramaswamy	ramaswamy	ADJ
fnp-5892	433	43	,	,	PUNCT
fnp-5892	433	44	v.	v.	ADV
fnp-5892	433	45	,	,	PUNCT
fnp-5892	433	46	et	et	PROPN
fnp-5892	433	47	al	al	PROPN
fnp-5892	433	48	.	.	PROPN
fnp-5892	433	49	immune	immune	ADJ
fnp-5892	433	50	checkpoint	checkpoint	NOUN
fnp-5892	433	51	inhibition	inhibition	NOUN
fnp-5892	433	52	for	for	ADP
fnp-5892	433	53	hypermutant	hypermutant	ADJ
fnp-5892	433	54	glioblastoma	glioblastoma	NOUN
fnp-5892	433	55	multiforme	multiforme	NOUN
fnp-5892	433	56	resulting	result	VERB
fnp-5892	433	57	from	from	ADP
fnp-5892	433	58	germline	germline	PROPN
fnp-5892	433	59	biallelic	biallelic	PROPN
fnp-5892	433	60	mismatch	mismatch	PROPN
fnp-5892	433	61	repair	repair	NOUN
fnp-5892	433	62	deficiency	deficiency	NOUN
fnp-5892	433	63	.	.	PUNCT
fnp-5892	434	1	j	j	PROPN
fnp-5892	434	2	clin	clin	PROPN
fnp-5892	434	3	oncol	oncol	PROPN
fnp-5892	434	4	2016	2016	NUM
fnp-5892	434	5	,	,	PUNCT
fnp-5892	434	6	34	34	NUM
fnp-5892	434	7	,	,	PUNCT
fnp-5892	434	8	2206	2206	NUM
fnp-5892	434	9	-	-	SYM
fnp-5892	434	10	2211	2211	NUM
fnp-5892	434	11	.	.	PUNCT
fnp-5892	435	1	https://doi.org/10.1200/jco.2016.66.6552	https://doi.org/10.1200/jco.2016.66.6552	ADP
fnp-5892	435	2	42	42	NUM
fnp-5892	435	3	.	.	PUNCT
fnp-5892	436	1	le	le	X
fnp-5892	436	2	,	,	PUNCT
fnp-5892	436	3	d.t	d.t	PROPN
fnp-5892	436	4	.	.	PROPN
fnp-5892	436	5	;	;	PUNCT
fnp-5892	436	6	durham	durham	PROPN
fnp-5892	436	7	,	,	PUNCT
fnp-5892	436	8	j.n	j.n	PROPN
fnp-5892	436	9	.	.	PROPN
fnp-5892	436	10	;	;	PUNCT
fnp-5892	437	1	smith	smith	PROPN
fnp-5892	437	2	,	,	PUNCT
fnp-5892	437	3	k.n	k.n	PROPN
fnp-5892	437	4	.	.	PROPN
fnp-5892	437	5	;	;	PUNCT
fnp-5892	437	6	wang	wang	PROPN
fnp-5892	437	7	,	,	PUNCT
fnp-5892	437	8	h.	h.	PROPN
fnp-5892	437	9	;	;	PUNCT
fnp-5892	437	10	bartlett	bartlett	PROPN
fnp-5892	437	11	,	,	PUNCT
fnp-5892	437	12	b.r	b.r	PROPN
fnp-5892	437	13	.	.	PROPN
fnp-5892	437	14	;	;	PUNCT
fnp-5892	437	15	aulakh	aulakh	PROPN
fnp-5892	437	16	,	,	PUNCT
fnp-5892	437	17	l.k	l.k	PROPN
fnp-5892	437	18	.	.	PROPN
fnp-5892	437	19	;	;	PUNCT
fnp-5892	437	20	lu	lu	PROPN
fnp-5892	437	21	,	,	PUNCT
fnp-5892	437	22	s.	s.	PROPN
fnp-5892	437	23	;	;	PUNCT
fnp-5892	437	24	kemberling	kemberle	VERB
fnp-5892	437	25	,	,	PUNCT
fnp-5892	437	26	h.	h.	PROPN
fnp-5892	437	27	;	;	PUNCT
fnp-5892	437	28	wilt	wilt	NOUN
fnp-5892	437	29	,	,	PUNCT
fnp-5892	437	30	c.	c.	PROPN
fnp-5892	437	31	;	;	PUNCT
fnp-5892	437	32	luber	luber	NOUN
fnp-5892	437	33	,	,	PUNCT
fnp-5892	437	34	b.s	b.s	PROPN
fnp-5892	437	35	.	.	PROPN
fnp-5892	437	36	,	,	PUNCT
fnp-5892	437	37	et	et	PROPN
fnp-5892	437	38	al	al	PROPN
fnp-5892	437	39	.	.	PROPN
fnp-5892	437	40	mismatch	mismatch	PROPN
fnp-5892	437	41	repair	repair	NOUN
fnp-5892	437	42	deficiency	deficiency	NOUN
fnp-5892	437	43	predicts	predict	VERB
fnp-5892	437	44	response	response	NOUN
fnp-5892	437	45	of	of	ADP
fnp-5892	437	46	solid	solid	ADJ
fnp-5892	437	47	tumors	tumor	NOUN
fnp-5892	437	48	to	to	ADP
fnp-5892	437	49	pd-1	pd-1	VERB
fnp-5892	437	50	blockade	blockade	NOUN
fnp-5892	437	51	.	.	PUNCT
fnp-5892	438	1	science	science	NOUN
fnp-5892	438	2	2017	2017	NUM
fnp-5892	438	3	,	,	PUNCT
fnp-5892	438	4	357	357	NUM
fnp-5892	438	5	,	,	PUNCT
fnp-5892	438	6	409	409	NUM
fnp-5892	438	7	-	-	SYM
fnp-5892	438	8	413	413	NUM
fnp-5892	438	9	.	.	PUNCT
fnp-5892	439	1	https://doi.org/10.1126/science.aan6733	https://doi.org/10.1126/science.aan6733	ADV
fnp-5892	439	2	43	43	NUM
fnp-5892	439	3	.	.	PUNCT
fnp-5892	440	1	larouche	larouche	PROPN
fnp-5892	440	2	,	,	PUNCT
fnp-5892	440	3	v.	v.	PROPN
fnp-5892	440	4	;	;	PUNCT
fnp-5892	440	5	atkinson	atkinson	PROPN
fnp-5892	440	6	,	,	PUNCT
fnp-5892	440	7	j.	j.	PROPN
fnp-5892	440	8	;	;	PUNCT
fnp-5892	440	9	albrecht	albrecht	PROPN
fnp-5892	440	10	,	,	PUNCT
fnp-5892	440	11	s.	s.	PROPN
fnp-5892	440	12	;	;	PUNCT
fnp-5892	440	13	laframboise	laframboise	PROPN
fnp-5892	440	14	,	,	PUNCT
fnp-5892	440	15	r.	r.	PROPN
fnp-5892	440	16	;	;	PUNCT
fnp-5892	440	17	jabado	jabado	VERB
fnp-5892	440	18	,	,	PUNCT
fnp-5892	440	19	n.	n.	NOUN
fnp-5892	440	20	;	;	PUNCT
fnp-5892	440	21	tabori	tabori	NOUN
fnp-5892	440	22	,	,	PUNCT
fnp-5892	440	23	u.	u.	PROPN
fnp-5892	440	24	;	;	PUNCT
fnp-5892	440	25	bouffet	bouffet	NOUN
fnp-5892	440	26	,	,	PUNCT
fnp-5892	440	27	e.	e.	PROPN
fnp-5892	440	28	;	;	PUNCT
fnp-5892	440	29	international	international	PROPN
fnp-5892	440	30	b	b	PROPN
fnp-5892	440	31	,	,	PUNCT
fnp-5892	440	32	m.c	m.c	PROPN
fnp-5892	440	33	.	.	PROPN
fnp-5892	440	34	sustained	sustain	VERB
fnp-5892	440	35	complete	complete	ADJ
fnp-5892	440	36	response	response	NOUN
fnp-5892	440	37	of	of	ADP
fnp-5892	440	38	recurrent	recurrent	ADJ
fnp-5892	440	39	glioblastoma	glioblastoma	NOUN
fnp-5892	440	40	to	to	ADP
fnp-5892	440	41	combined	combine	VERB
fnp-5892	440	42	checkpoint	checkpoint	NOUN
fnp-5892	440	43	inhibition	inhibition	NOUN
fnp-5892	440	44	in	in	ADP
fnp-5892	440	45	a	a	DET
fnp-5892	440	46	young	young	ADJ
fnp-5892	440	47	patient	patient	NOUN
fnp-5892	440	48	with	with	ADP
fnp-5892	440	49	constitutional	constitutional	ADJ
fnp-5892	440	50	mismatch	mismatch	ADJ
fnp-5892	440	51	repair	repair	NOUN
fnp-5892	440	52	deficiency	deficiency	NOUN
fnp-5892	440	53	.	.	PUNCT
fnp-5892	441	1	pediatr	pediatr	ADJ
fnp-5892	441	2	blood	blood	NOUN
fnp-5892	441	3	cancer	cancer	NOUN
fnp-5892	441	4	2018	2018	NUM
fnp-5892	441	5	,	,	PUNCT
fnp-5892	441	6	65	65	NUM
fnp-5892	441	7	,	,	PUNCT
fnp-5892	441	8	e27389	e27389	PROPN
fnp-5892	441	9	.	.	PUNCT
fnp-5892	442	1	https://doi.org/10.1002/pbc.27389	https://doi.org/10.1002/pbc.27389	PROPN
fnp-5892	442	2	44	44	NUM
fnp-5892	442	3	.	.	PUNCT
fnp-5892	443	1	overman	overman	PROPN
fnp-5892	443	2	,	,	PUNCT
fnp-5892	443	3	m.j	m.j	PROPN
fnp-5892	443	4	.	.	PROPN
fnp-5892	443	5	;	;	PUNCT
fnp-5892	443	6	lonardi	lonardi	PROPN
fnp-5892	443	7	,	,	PUNCT
fnp-5892	443	8	s.	s.	PROPN
fnp-5892	443	9	;	;	PUNCT
fnp-5892	443	10	wong	wong	PROPN
fnp-5892	443	11	,	,	PUNCT
fnp-5892	443	12	k.y.m	k.y.m	PROPN
fnp-5892	443	13	.	.	PUNCT
fnp-5892	443	14	;	;	PUNCT
fnp-5892	443	15	lenz	lenz	PROPN
fnp-5892	443	16	,	,	PUNCT
fnp-5892	443	17	h.j	h.j	PROPN
fnp-5892	443	18	.	.	PROPN
fnp-5892	443	19	;	;	PUNCT
fnp-5892	443	20	gelsomino	gelsomino	PROPN
fnp-5892	443	21	,	,	PUNCT
fnp-5892	443	22	f.	f.	PROPN
fnp-5892	443	23	;	;	PUNCT
fnp-5892	443	24	aglietta	aglietta	ADJ
fnp-5892	443	25	,	,	PUNCT
fnp-5892	443	26	m.	m.	NOUN
fnp-5892	443	27	;	;	PUNCT
fnp-5892	443	28	morse	morse	PROPN
fnp-5892	443	29	,	,	PUNCT
fnp-5892	443	30	m.a	m.a	PROPN
fnp-5892	443	31	.	.	PROPN
fnp-5892	443	32	;	;	PUNCT
fnp-5892	443	33	van	van	PROPN
fnp-5892	443	34	cutsem	cutsem	PROPN
fnp-5892	443	35	,	,	PUNCT
fnp-5892	443	36	e.	e.	PROPN
fnp-5892	443	37	;	;	PUNCT
fnp-5892	443	38	mcdermott	mcdermott	PROPN
fnp-5892	443	39	,	,	PUNCT
fnp-5892	443	40	r.	r.	PROPN
fnp-5892	443	41	;	;	PUNCT
fnp-5892	443	42	hill	hill	PROPN
fnp-5892	443	43	,	,	PUNCT
fnp-5892	443	44	a.	a.	PROPN
fnp-5892	443	45	,	,	PUNCT
fnp-5892	443	46	et	et	PROPN
fnp-5892	443	47	al	al	PROPN
fnp-5892	443	48	.	.	PUNCT
fnp-5892	444	1	durable	durable	ADJ
fnp-5892	444	2	clinical	clinical	ADJ
fnp-5892	444	3	benefit	benefit	NOUN
fnp-5892	444	4	with	with	ADP
fnp-5892	444	5	nivolumab	nivolumab	NOUN
fnp-5892	444	6	plus	plus	CCONJ
fnp-5892	444	7	ipilimumab	ipilimumab	NOUN
fnp-5892	444	8	in	in	ADP
fnp-5892	444	9	dna	dna	PROPN
fnp-5892	444	10	mismatch	mismatch	NOUN
fnp-5892	444	11	repair	repair	NOUN
fnp-5892	444	12	-	-	PUNCT
fnp-5892	444	13	deficient	deficient	ADJ
fnp-5892	444	14	/	/	SYM
fnp-5892	444	15	microsatellite	microsatellite	ADJ
fnp-5892	444	16	instability	instability	NOUN
fnp-5892	444	17	-	-	PUNCT
fnp-5892	444	18	high	high	ADJ
fnp-5892	444	19	metastatic	metastatic	ADJ
fnp-5892	444	20	colorectal	colorectal	ADJ
fnp-5892	444	21	cancer	cancer	NOUN
fnp-5892	444	22	.	.	PUNCT
fnp-5892	445	1	j	j	PROPN
fnp-5892	445	2	clin	clin	PROPN
fnp-5892	445	3	oncol	oncol	PROPN
fnp-5892	445	4	2018	2018	NUM
fnp-5892	445	5	,	,	PUNCT
fnp-5892	445	6	36	36	NUM
fnp-5892	445	7	,	,	PUNCT
fnp-5892	445	8	773	773	NUM
fnp-5892	445	9	-	-	SYM
fnp-5892	445	10	779	779	NUM
fnp-5892	445	11	.	.	PUNCT
fnp-5892	446	1	https://doi.org/10.1200/jco.2017.76.9901	https://doi.org/10.1200/jco.2017.76.9901	PROPN
fnp-5892	446	2	45	45	NUM
fnp-5892	446	3	.	.	PUNCT
fnp-5892	447	1	hellmann	hellmann	PROPN
fnp-5892	447	2	,	,	PUNCT
fnp-5892	447	3	m.d	m.d	PROPN
fnp-5892	447	4	.	.	PROPN
fnp-5892	447	5	;	;	PUNCT
fnp-5892	447	6	paz	paz	NOUN
fnp-5892	447	7	-	-	PUNCT
fnp-5892	447	8	ares	are	NOUN
fnp-5892	447	9	,	,	PUNCT
fnp-5892	447	10	l.	l.	PROPN
fnp-5892	447	11	;	;	PUNCT
fnp-5892	447	12	bernabe	bernabe	ADP
fnp-5892	447	13	caro	caro	PROPN
fnp-5892	447	14	,	,	PUNCT
fnp-5892	447	15	r.	r.	PROPN
fnp-5892	447	16	;	;	PUNCT
fnp-5892	447	17	zurawski	zurawski	PROPN
fnp-5892	447	18	,	,	PUNCT
fnp-5892	447	19	b.	b.	PROPN
fnp-5892	447	20	;	;	PUNCT
fnp-5892	447	21	kim	kim	PROPN
fnp-5892	447	22	,	,	PUNCT
fnp-5892	447	23	s.w	s.w	PROPN
fnp-5892	447	24	.	.	PROPN
fnp-5892	447	25	;	;	PUNCT
fnp-5892	447	26	carcereny	carcereny	PROPN
fnp-5892	447	27	costa	costa	PROPN
fnp-5892	447	28	,	,	PUNCT
fnp-5892	447	29	e.	e.	PROPN
fnp-5892	447	30	;	;	PUNCT
fnp-5892	447	31	park	park	PROPN
fnp-5892	447	32	,	,	PUNCT
fnp-5892	447	33	k.	k.	PROPN
fnp-5892	447	34	;	;	PUNCT
fnp-5892	447	35	alexandru	alexandru	PROPN
fnp-5892	447	36	,	,	PUNCT
fnp-5892	447	37	a.	a.	NOUN
fnp-5892	447	38	;	;	PUNCT
fnp-5892	447	39	lupinacci	lupinacci	PROPN
fnp-5892	447	40	,	,	PUNCT
fnp-5892	447	41	l.	l.	PROPN
fnp-5892	447	42	;	;	PUNCT
fnp-5892	447	43	de	de	X
fnp-5892	447	44	la	la	PROPN
fnp-5892	447	45	mora	mora	PROPN
fnp-5892	447	46	jimenez	jimenez	PROPN
fnp-5892	447	47	,	,	PUNCT
fnp-5892	447	48	e.	e.	PROPN
fnp-5892	447	49	,	,	PUNCT
fnp-5892	447	50	et	et	PROPN
fnp-5892	447	51	al	al	PROPN
fnp-5892	447	52	.	.	PROPN
fnp-5892	447	53	nivolumab	nivolumab	PROPN
fnp-5892	447	54	plus	plus	CCONJ
fnp-5892	447	55	ipilimumab	ipilimumab	VERB
fnp-5892	447	56	in	in	ADP
fnp-5892	447	57	advanced	advanced	ADJ
fnp-5892	447	58	non	non	ADJ
fnp-5892	447	59	-	-	ADJ
fnp-5892	447	60	small	small	ADJ
fnp-5892	447	61	-	-	PUNCT
fnp-5892	447	62	cell	cell	NOUN
fnp-5892	447	63	lung	lung	NOUN
fnp-5892	447	64	cancer	cancer	NOUN
fnp-5892	447	65	.	.	PUNCT
fnp-5892	448	1	n	n	PROPN
fnp-5892	448	2	engl	engl	PROPN
fnp-5892	448	3	j	j	PROPN
fnp-5892	448	4	med	med	PROPN
fnp-5892	448	5	2019	2019	NUM
fnp-5892	448	6	,	,	PUNCT
fnp-5892	448	7	381	381	NUM
fnp-5892	448	8	,	,	PUNCT
fnp-5892	448	9	2020	2020	NUM
fnp-5892	448	10	-	-	SYM
fnp-5892	448	11	2031	2031	NUM
fnp-5892	448	12	.	.	PUNCT
fnp-5892	449	1	https://doi.org/10.1056/nejmoa1910231	https://doi.org/10.1056/nejmoa1910231	PROPN
fnp-5892	449	2	46	46	NUM
fnp-5892	449	3	.	.	PUNCT
fnp-5892	450	1	ready	ready	ADJ
fnp-5892	450	2	,	,	PUNCT
fnp-5892	450	3	n.	n.	NOUN
fnp-5892	450	4	;	;	PUNCT
fnp-5892	450	5	hellmann	hellmann	PROPN
fnp-5892	450	6	,	,	PUNCT
fnp-5892	450	7	m.d	m.d	PROPN
fnp-5892	450	8	.	.	PROPN
fnp-5892	450	9	;	;	PUNCT
fnp-5892	451	1	awad	awad	PROPN
fnp-5892	451	2	,	,	PUNCT
fnp-5892	451	3	m.m	m.m	PROPN
fnp-5892	451	4	.	.	PROPN
fnp-5892	451	5	;	;	PUNCT
fnp-5892	451	6	otterson	otterson	PROPN
fnp-5892	451	7	,	,	PUNCT
fnp-5892	451	8	g.a	g.a	PROPN
fnp-5892	451	9	.	.	PROPN
fnp-5892	451	10	;	;	PUNCT
fnp-5892	452	1	gutierrez	gutierrez	PROPN
fnp-5892	452	2	,	,	PUNCT
fnp-5892	452	3	m.	m.	NOUN
fnp-5892	452	4	;	;	PUNCT
fnp-5892	452	5	gainor	gainor	NOUN
fnp-5892	452	6	,	,	PUNCT
fnp-5892	452	7	j.f	j.f	PROPN
fnp-5892	452	8	.	.	PROPN
fnp-5892	452	9	;	;	PUNCT
fnp-5892	452	10	borghaei	borghaei	PROPN
fnp-5892	452	11	,	,	PUNCT
fnp-5892	452	12	h.	h.	PROPN
fnp-5892	452	13	;	;	PUNCT
fnp-5892	452	14	jolivet	jolivet	PROPN
fnp-5892	452	15	,	,	PUNCT
fnp-5892	452	16	j.	j.	PROPN
fnp-5892	452	17	;	;	PUNCT
fnp-5892	452	18	horn	horn	PROPN
fnp-5892	452	19	,	,	PUNCT
fnp-5892	452	20	l.	l.	PROPN
fnp-5892	452	21	;	;	PUNCT
fnp-5892	452	22	mates	mate	NOUN
fnp-5892	452	23	,	,	PUNCT
fnp-5892	452	24	m.	m.	NOUN
fnp-5892	452	25	,	,	PUNCT
fnp-5892	452	26	et	et	PROPN
fnp-5892	452	27	al	al	PROPN
fnp-5892	452	28	.	.	PUNCT
fnp-5892	453	1	first	first	ADJ
fnp-5892	453	2	-	-	PUNCT
fnp-5892	453	3	line	line	NOUN
fnp-5892	453	4	nivolumab	nivolumab	NOUN
fnp-5892	453	5	plus	plus	CCONJ
fnp-5892	453	6	ipilimumab	ipilimumab	VERB
fnp-5892	453	7	in	in	ADP
fnp-5892	453	8	advanced	advanced	ADJ
fnp-5892	453	9	non	non	ADJ
fnp-5892	453	10	-	-	ADJ
fnp-5892	453	11	small	small	ADJ
fnp-5892	453	12	-	-	PUNCT
fnp-5892	453	13	cell	cell	NOUN
fnp-5892	453	14	lung	lung	NOUN
fnp-5892	453	15	cancer	cancer	NOUN
fnp-5892	453	16	(	(	PUNCT
fnp-5892	453	17	checkmate	checkmate	NOUN
fnp-5892	453	18	568	568	NUM
fnp-5892	453	19	):	):	PUNCT
fnp-5892	453	20	outcomes	outcome	NOUN
fnp-5892	453	21	by	by	ADP
fnp-5892	453	22	programmed	program	VERB
fnp-5892	453	23	death	death	NOUN
fnp-5892	453	24	ligand	ligand	NOUN
fnp-5892	453	25	1	1	NUM
fnp-5892	453	26	and	and	CCONJ
fnp-5892	453	27	tumor	tumor	NOUN
fnp-5892	453	28	mutational	mutational	ADJ
fnp-5892	453	29	burden	burden	NOUN
fnp-5892	453	30	as	as	ADP
fnp-5892	453	31	biomarkers	biomarker	NOUN
fnp-5892	453	32	.	.	PUNCT
fnp-5892	454	1	j	j	PROPN
fnp-5892	454	2	clin	clin	PROPN
fnp-5892	454	3	oncol	oncol	PROPN
fnp-5892	454	4	2019	2019	NUM
fnp-5892	454	5	,	,	PUNCT
fnp-5892	454	6	37	37	NUM
fnp-5892	454	7	,	,	PUNCT
fnp-5892	454	8	992	992	NUM
fnp-5892	454	9	-	-	SYM
fnp-5892	454	10	1000	1000	NUM
fnp-5892	454	11	.	.	PUNCT
fnp-5892	455	1	https://doi.org/10.1200/jco.18.01042	https://doi.org/10.1200/jco.18.01042	ADP
fnp-5892	455	2	47	47	NUM
fnp-5892	455	3	.	.	PUNCT
fnp-5892	456	1	zehir	zehir	PROPN
fnp-5892	456	2	,	,	PUNCT
fnp-5892	456	3	a.	a.	PROPN
fnp-5892	456	4	;	;	PUNCT
fnp-5892	456	5	benayed	benaye	VERB
fnp-5892	456	6	,	,	PUNCT
fnp-5892	456	7	r.	r.	PROPN
fnp-5892	456	8	;	;	PUNCT
fnp-5892	456	9	shah	shah	NOUN
fnp-5892	456	10	,	,	PUNCT
fnp-5892	456	11	r.h	r.h	PROPN
fnp-5892	456	12	.	.	PROPN
fnp-5892	456	13	;	;	PUNCT
fnp-5892	456	14	syed	sye	VERB
fnp-5892	456	15	,	,	PUNCT
fnp-5892	456	16	a.	a.	NOUN
fnp-5892	456	17	;	;	PUNCT
fnp-5892	456	18	middha	middha	PROPN
fnp-5892	456	19	,	,	PUNCT
fnp-5892	456	20	s.	s.	PROPN
fnp-5892	456	21	;	;	PUNCT
fnp-5892	456	22	kim	kim	PROPN
fnp-5892	456	23	,	,	PUNCT
fnp-5892	456	24	h.r	h.r	PROPN
fnp-5892	456	25	.	.	PROPN
fnp-5892	456	26	;	;	PUNCT
fnp-5892	456	27	srinivasan	srinivasan	NOUN
fnp-5892	456	28	,	,	PUNCT
fnp-5892	456	29	p.	p.	PROPN
fnp-5892	456	30	;	;	PUNCT
fnp-5892	456	31	gao	gao	PROPN
fnp-5892	456	32	,	,	PUNCT
fnp-5892	456	33	j.	j.	PROPN
fnp-5892	456	34	;	;	PUNCT
fnp-5892	456	35	chakravarty	chakravarty	PROPN
fnp-5892	456	36	,	,	PUNCT
fnp-5892	456	37	d.	d.	PROPN
fnp-5892	456	38	;	;	PUNCT
fnp-5892	456	39	devlin	devlin	PROPN
fnp-5892	456	40	,	,	PUNCT
fnp-5892	456	41	s.m	s.m	PROPN
fnp-5892	456	42	.	.	PROPN
fnp-5892	456	43	,	,	PUNCT
fnp-5892	456	44	et	et	PROPN
fnp-5892	456	45	al	al	PROPN
fnp-5892	456	46	.	.	PROPN
fnp-5892	456	47	mutational	mutational	ADJ
fnp-5892	456	48	landscape	landscape	NOUN
fnp-5892	456	49	of	of	ADP
fnp-5892	456	50	metastatic	metastatic	ADJ
fnp-5892	456	51	cancer	cancer	NOUN
fnp-5892	456	52	revealed	reveal	VERB
fnp-5892	456	53	from	from	ADP
fnp-5892	456	54	prospective	prospective	ADJ
fnp-5892	456	55	clinical	clinical	ADJ
fnp-5892	456	56	sequencing	sequencing	NOUN
fnp-5892	456	57	of	of	ADP
fnp-5892	456	58	10,000	10,000	NUM
fnp-5892	456	59	patients	patient	NOUN
fnp-5892	456	60	.	.	PUNCT
fnp-5892	457	1	nat	nat	PROPN
fnp-5892	457	2	med	me	VERB
fnp-5892	457	3	2017	2017	NUM
fnp-5892	457	4	,	,	PUNCT
fnp-5892	457	5	23	23	NUM
fnp-5892	457	6	,	,	PUNCT
fnp-5892	457	7	703	703	NUM
fnp-5892	457	8	-	-	SYM
fnp-5892	457	9	713	713	NUM
fnp-5892	457	10	.	.	PUNCT
fnp-5892	458	1	https://doi.org/10.1038/nm.4333	https://doi.org/10.1038/nm.4333	VERB
fnp-5892	458	2	copyright	copyright	NOUN
fnp-5892	458	3	:	:	PUNCT
fnp-5892	458	4	©	©	PROPN
fnp-5892	458	5	2024	2024	NUM
fnp-5892	458	6	the	the	DET
fnp-5892	458	7	author(s	author(s	NOUN
fnp-5892	458	8	)	)	PUNCT
fnp-5892	458	9	.	.	PUNCT
fnp-5892	459	1	this	this	PRON
fnp-5892	459	2	is	be	AUX
fnp-5892	459	3	an	an	DET
fnp-5892	459	4	open	open	ADJ
fnp-5892	459	5	access	access	NOUN
fnp-5892	459	6	article	article	NOUN
fnp-5892	459	7	distributed	distribute	VERB
fnp-5892	459	8	under	under	ADP
fnp-5892	459	9	the	the	DET
fnp-5892	459	10	terms	term	NOUN
fnp-5892	459	11	of	of	ADP
fnp-5892	459	12	the	the	DET
fnp-5892	459	13	creative	creative	ADJ
fnp-5892	459	14	commons	common	NOUN
fnp-5892	459	15	attribution	attribution	NOUN
fnp-5892	459	16	4.0	4.0	NUM
fnp-5892	459	17	international	international	ADJ
fnp-5892	459	18	license	license	NOUN
fnp-5892	459	19	(	(	PUNCT
fnp-5892	459	20	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
fnp-5892	459	21	)	)	PUNCT
fnp-5892	459	22	,	,	PUNCT
fnp-5892	459	23	which	which	PRON
fnp-5892	459	24	permits	permit	VERB
fnp-5892	459	25	unrestricted	unrestricted	ADJ
fnp-5892	459	26	use	use	NOUN
fnp-5892	459	27	,	,	PUNCT
fnp-5892	459	28	distribution	distribution	NOUN
fnp-5892	459	29	,	,	PUNCT
fnp-5892	459	30	and	and	CCONJ
fnp-5892	459	31	reproduction	reproduction	NOUN
fnp-5892	459	32	in	in	ADP
fnp-5892	459	33	any	any	DET
fnp-5892	459	34	medium	medium	NOUN
fnp-5892	459	35	,	,	PUNCT
fnp-5892	459	36	provided	provide	VERB
fnp-5892	459	37	the	the	DET
fnp-5892	459	38	original	original	ADJ
fnp-5892	459	39	author	author	NOUN
fnp-5892	459	40	and	and	CCONJ
fnp-5892	459	41	source	source	NOUN
fnp-5892	459	42	are	be	AUX
fnp-5892	459	43	credited	credit	VERB
fnp-5892	459	44	,	,	PUNCT
fnp-5892	459	45	a	a	DET
fnp-5892	459	46	link	link	NOUN
fnp-5892	459	47	to	to	ADP
fnp-5892	459	48	the	the	DET
fnp-5892	459	49	creative	creative	ADJ
fnp-5892	459	50	commons	common	NOUN
fnp-5892	459	51	license	license	NOUN
fnp-5892	459	52	is	be	AUX
fnp-5892	459	53	provided	provide	VERB
fnp-5892	459	54	,	,	PUNCT
fnp-5892	459	55	and	and	CCONJ
fnp-5892	459	56	any	any	DET
fnp-5892	459	57	changes	change	NOUN
fnp-5892	459	58	are	be	AUX
fnp-5892	459	59	indicated	indicate	VERB
fnp-5892	459	60	.	.	PUNCT
fnp-5892	460	1	the	the	DET
fnp-5892	460	2	creative	creative	ADJ
fnp-5892	460	3	commons	common	NOUN
fnp-5892	460	4	public	public	ADJ
fnp-5892	460	5	domain	domain	NOUN
fnp-5892	460	6	dedication	dedication	NOUN
fnp-5892	460	7	waiver	waiver	NOUN
fnp-5892	460	8	(	(	PUNCT
fnp-5892	460	9	https://creativecommons.org/publicdomain/zero/1.0/	https://creativecommons.org/publicdomain/zero/1.0/	PROPN
fnp-5892	460	10	)	)	PUNCT
fnp-5892	460	11	applies	apply	VERB
fnp-5892	460	12	to	to	ADP
fnp-5892	460	13	the	the	DET
fnp-5892	460	14	data	datum	NOUN
fnp-5892	460	15	made	make	VERB
fnp-5892	460	16	available	available	ADJ
fnp-5892	460	17	in	in	ADP
fnp-5892	460	18	this	this	DET
fnp-5892	460	19	article	article	NOUN
fnp-5892	460	20	,	,	PUNCT
fnp-5892	460	21	unless	unless	SCONJ
fnp-5892	460	22	otherwise	otherwise	ADV
fnp-5892	460	23	stated	state	VERB
fnp-5892	460	24	.	.	PUNCT